id	sid	tid	token	lemma	pos
dpc-3688	1	1	dermatology	dermatology	NOUN
dpc-3688	1	2	:	:	PUNCT
dpc-3688	1	3	practical	practical	ADJ
dpc-3688	1	4	and	and	CCONJ
dpc-3688	1	5	conceptual	conceptual	ADJ
dpc-3688	1	6	review	review	NOUN
dpc-3688	1	7	|	|	ADV
dpc-3688	1	8	dermatol	dermatol	ADJ
dpc-3688	1	9	pract	pract	NOUN
dpc-3688	1	10	concept	concept	NOUN
dpc-3688	1	11	.	.	PUNCT
dpc-3688	2	1	2023;13(3):e2023245	2023;13(3):e2023245	NUM
dpc-3688	2	2	1	1	NUM
dpc-3688	2	3	brodalumab	brodalumab	NOUN
dpc-3688	2	4	in	in	ADP
dpc-3688	2	5	the	the	DET
dpc-3688	2	6	treatment	treatment	NOUN
dpc-3688	2	7	of	of	ADP
dpc-3688	2	8	plaque	plaque	NOUN
dpc-3688	2	9	psoriasis	psoriasis	NOUN
dpc-3688	2	10	localized	localize	VERB
dpc-3688	2	11	in	in	ADP
dpc-3688	2	12	difficult	difficult	ADJ
dpc-3688	2	13	-	-	PUNCT
dpc-3688	2	14	to	to	ADP
dpc-3688	2	15	-	-	PUNCT
dpc-3688	2	16	treat	treat	NOUN
dpc-3688	2	17	areas	area	NOUN
dpc-3688	2	18	:	:	PUNCT
dpc-3688	2	19	a	a	DET
dpc-3688	2	20	 	 	SPACE
dpc-3688	2	21	narrative	narrative	NOUN
dpc-3688	2	22	 	 	SPACE
dpc-3688	2	23	review	review	NOUN
dpc-3688	2	24	maria	maria	PROPN
dpc-3688	2	25	vittoria	vittoria	PROPN
dpc-3688	2	26	cannizzaro1	cannizzaro1	PROPN
dpc-3688	2	27	,	,	PUNCT
dpc-3688	2	28	giulia	giulia	PROPN
dpc-3688	2	29	coscarella1,2	coscarella1,2	PROPN
dpc-3688	2	30	,	,	PUNCT
dpc-3688	2	31	andrea	andrea	PROPN
dpc-3688	2	32	chiricozzi1,2	chiricozzi1,2	PROPN
dpc-3688	2	33	1	1	NUM
dpc-3688	2	34	dermatologia	dermatologia	NOUN
dpc-3688	2	35	,	,	PUNCT
dpc-3688	2	36	dipartimento	dipartimento	ADP
dpc-3688	2	37	universitario	universitario	PROPN
dpc-3688	2	38	di	di	PROPN
dpc-3688	2	39	medicina	medicina	PROPN
dpc-3688	2	40	e	e	PROPN
dpc-3688	2	41	chirurgia	chirurgia	PROPN
dpc-3688	2	42	traslazionale	traslazionale	PROPN
dpc-3688	2	43	,	,	PUNCT
dpc-3688	2	44	università	università	PROPN
dpc-3688	2	45	cattolica	cattolica	PROPN
dpc-3688	2	46	del	del	PROPN
dpc-3688	2	47	sacro	sacro	PROPN
dpc-3688	2	48	cuore	cuore	PROPN
dpc-3688	2	49	,	,	PUNCT
dpc-3688	2	50	rome	rome	PROPN
dpc-3688	2	51	,	,	PUNCT
dpc-3688	2	52	italy	italy	PROPN
dpc-3688	2	53	2	2	NUM
dpc-3688	2	54	dermatologia	dermatologia	NOUN
dpc-3688	2	55	,	,	PUNCT
dpc-3688	2	56	dipartimento	dipartimento	ADP
dpc-3688	2	57	scienze	scienze	PROPN
dpc-3688	2	58	mediche	mediche	PROPN
dpc-3688	2	59	e	e	PROPN
dpc-3688	2	60	chirurgiche	chirurgiche	PROPN
dpc-3688	2	61	,	,	PUNCT
dpc-3688	2	62	fondazione	fondazione	PROPN
dpc-3688	2	63	policlinico	policlinico	PROPN
dpc-3688	2	64	universitario	universitario	PROPN
dpc-3688	2	65	a.	a.	PROPN
dpc-3688	2	66	gemelli	gemelli	PROPN
dpc-3688	2	67	irccs	irccs	PROPN
dpc-3688	2	68	,	,	PUNCT
dpc-3688	2	69	rome	rome	PROPN
dpc-3688	2	70	,	,	PUNCT
dpc-3688	2	71	italy	italy	PROPN
dpc-3688	2	72	key	key	ADJ
dpc-3688	2	73	words	word	NOUN
dpc-3688	2	74	:	:	PUNCT
dpc-3688	2	75	brodalumab	brodalumab	NOUN
dpc-3688	2	76	,	,	PUNCT
dpc-3688	2	77	psoriasis	psoriasis	NOUN
dpc-3688	2	78	,	,	PUNCT
dpc-3688	2	79	pustular	pustular	ADJ
dpc-3688	2	80	psoriasis	psoriasis	NOUN
dpc-3688	2	81	,	,	PUNCT
dpc-3688	2	82	scalp	scalp	NOUN
dpc-3688	2	83	,	,	PUNCT
dpc-3688	2	84	genitals	genital	NOUN
dpc-3688	2	85	citation	citation	NOUN
dpc-3688	2	86	:	:	PUNCT
dpc-3688	2	87	cannizzaro	cannizzaro	VERB
dpc-3688	2	88	mv	mv	PROPN
dpc-3688	2	89	,	,	PUNCT
dpc-3688	2	90	coscarella	coscarella	NOUN
dpc-3688	2	91	g	g	NOUN
dpc-3688	2	92	,	,	PUNCT
dpc-3688	2	93	chiricozzi	chiricozzi	NOUN
dpc-3688	2	94	a.	a.	NOUN
dpc-3688	2	95	brodalumab	brodalumab	NOUN
dpc-3688	2	96	in	in	ADP
dpc-3688	2	97	the	the	DET
dpc-3688	2	98	treatment	treatment	NOUN
dpc-3688	2	99	of	of	ADP
dpc-3688	2	100	plaque	plaque	NOUN
dpc-3688	2	101	psoriasis	psoriasis	NOUN
dpc-3688	2	102	localized	localize	VERB
dpc-3688	2	103	in	in	ADP
dpc-3688	2	104	difficult	difficult	ADJ
dpc-3688	2	105	-	-	PUNCT
dpc-3688	2	106	to	to	ADP
dpc-3688	2	107	-	-	PUNCT
dpc-3688	2	108	treat	treat	NOUN
dpc-3688	2	109	areas	area	NOUN
dpc-3688	2	110	:	:	PUNCT
dpc-3688	2	111	a	a	DET
dpc-3688	2	112	narrative	narrative	NOUN
dpc-3688	2	113	review	review	NOUN
dpc-3688	2	114	.	.	PUNCT
dpc-3688	3	1	dermatol	dermatol	NOUN
dpc-3688	3	2	pract	pract	PROPN
dpc-3688	3	3	concept	concept	NOUN
dpc-3688	3	4	.	.	PUNCT
dpc-3688	4	1	2023;13(3):e2023245	2023;13(3):e2023245	X
dpc-3688	4	2	.	.	PUNCT
dpc-3688	5	1	doi	doi	PROPN
dpc-3688	5	2	:	:	PUNCT
dpc-3688	5	3	https://doi.org/10.5826/dpc.1303a245	https://doi.org/10.5826/dpc.1303a245	PROPN
dpc-3688	5	4	accepted	accept	VERB
dpc-3688	5	5	:	:	PUNCT
dpc-3688	5	6	july	july	PROPN
dpc-3688	5	7	1	1	NUM
dpc-3688	5	8	,	,	PUNCT
dpc-3688	5	9	2023	2023	NUM
dpc-3688	5	10	;	;	PUNCT
dpc-3688	5	11	published	publish	VERB
dpc-3688	5	12	:	:	PUNCT
dpc-3688	6	1	july	july	PROPN
dpc-3688	6	2	2023	2023	NUM
dpc-3688	6	3	copyright	copyright	NOUN
dpc-3688	6	4	:	:	PUNCT
dpc-3688	6	5	©	©	PROPN
dpc-3688	6	6	2023	2023	NUM
dpc-3688	6	7	cannizzaro	cannizzaro	NOUN
dpc-3688	6	8	et	et	PROPN
dpc-3688	6	9	al	al	PROPN
dpc-3688	6	10	.	.	PUNCT
dpc-3688	7	1	this	this	PRON
dpc-3688	7	2	is	be	AUX
dpc-3688	7	3	an	an	DET
dpc-3688	7	4	open	open	ADJ
dpc-3688	7	5	-	-	PUNCT
dpc-3688	7	6	access	access	NOUN
dpc-3688	7	7	article	article	NOUN
dpc-3688	7	8	distributed	distribute	VERB
dpc-3688	7	9	under	under	ADP
dpc-3688	7	10	the	the	DET
dpc-3688	7	11	terms	term	NOUN
dpc-3688	7	12	of	of	ADP
dpc-3688	7	13	the	the	DET
dpc-3688	7	14	creative	creative	ADJ
dpc-3688	7	15	commons	common	NOUN
dpc-3688	7	16	attribution	attribution	NOUN
dpc-3688	7	17	-	-	PUNCT
dpc-3688	7	18	noncommercial	noncommercial	ADJ
dpc-3688	7	19	license	license	NOUN
dpc-3688	7	20	(	(	PUNCT
dpc-3688	7	21	by	by	ADP
dpc-3688	7	22	-	-	PUNCT
dpc-3688	7	23	nc-4.0	nc-4.0	NOUN
dpc-3688	7	24	)	)	PUNCT
dpc-3688	7	25	,	,	PUNCT
dpc-3688	7	26	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-3688	7	27	,	,	PUNCT
dpc-3688	7	28	which	which	PRON
dpc-3688	7	29	permits	permit	VERB
dpc-3688	7	30	unrestricted	unrestricted	ADJ
dpc-3688	7	31	noncommercial	noncommercial	ADJ
dpc-3688	7	32	use	use	NOUN
dpc-3688	7	33	,	,	PUNCT
dpc-3688	7	34	distribution	distribution	NOUN
dpc-3688	7	35	,	,	PUNCT
dpc-3688	7	36	and	and	CCONJ
dpc-3688	7	37	reproduction	reproduction	NOUN
dpc-3688	7	38	in	in	ADP
dpc-3688	7	39	any	any	DET
dpc-3688	7	40	medium	medium	NOUN
dpc-3688	7	41	,	,	PUNCT
dpc-3688	7	42	provided	provide	VERB
dpc-3688	7	43	the	the	DET
dpc-3688	7	44	original	original	ADJ
dpc-3688	7	45	authors	author	NOUN
dpc-3688	7	46	and	and	CCONJ
dpc-3688	7	47	source	source	NOUN
dpc-3688	7	48	are	be	AUX
dpc-3688	7	49	credited	credit	VERB
dpc-3688	7	50	.	.	PUNCT
dpc-3688	8	1	funding	funding	NOUN
dpc-3688	8	2	:	:	PUNCT
dpc-3688	8	3	with	with	ADP
dpc-3688	8	4	the	the	DET
dpc-3688	8	5	unrestricted	unrestricted	ADJ
dpc-3688	8	6	contribution	contribution	NOUN
dpc-3688	8	7	of	of	ADP
dpc-3688	8	8	leo	leo	PROPN
dpc-3688	8	9	pharma	pharma	PROPN
dpc-3688	8	10	.	.	PUNCT
dpc-3688	9	1	competing	compete	VERB
dpc-3688	9	2	interests	interest	NOUN
dpc-3688	9	3	:	:	PUNCT
dpc-3688	9	4	andrea	andrea	PROPN
dpc-3688	9	5	chiricozzi	chiricozzi	PROPN
dpc-3688	9	6	has	have	AUX
dpc-3688	9	7	served	serve	VERB
dpc-3688	9	8	as	as	ADP
dpc-3688	9	9	advisory	advisory	ADJ
dpc-3688	9	10	board	board	NOUN
dpc-3688	9	11	member	member	NOUN
dpc-3688	9	12	and	and	CCONJ
dpc-3688	9	13	consultant	consultant	NOUN
dpc-3688	9	14	and	and	CCONJ
dpc-3688	9	15	has	have	AUX
dpc-3688	9	16	received	receive	VERB
dpc-3688	9	17	fees	fee	NOUN
dpc-3688	9	18	and	and	CCONJ
dpc-3688	9	19	speaker	speaker	NOUN
dpc-3688	9	20	's	's	PART
dpc-3688	9	21	honoraria	honoraria	NOUN
dpc-3688	9	22	or	or	CCONJ
dpc-3688	9	23	has	have	AUX
dpc-3688	9	24	participated	participate	VERB
dpc-3688	9	25	in	in	ADP
dpc-3688	9	26	clinical	clinical	ADJ
dpc-3688	9	27	trials	trial	NOUN
dpc-3688	9	28	for	for	ADP
dpc-3688	9	29	abbvie	abbvie	NOUN
dpc-3688	9	30	,	,	PUNCT
dpc-3688	9	31	almirall	almirall	PROPN
dpc-3688	9	32	,	,	PUNCT
dpc-3688	9	33	bristol	bristol	PROPN
dpc-3688	9	34	myers	myers	PROPN
dpc-3688	9	35	squibb	squibb	PROPN
dpc-3688	9	36	,	,	PUNCT
dpc-3688	9	37	leo	leo	PROPN
dpc-3688	9	38	pharma	pharma	PROPN
dpc-3688	9	39	,	,	PUNCT
dpc-3688	9	40	lilly	lilly	PROPN
dpc-3688	9	41	,	,	PUNCT
dpc-3688	9	42	janssen	janssen	PROPN
dpc-3688	9	43	,	,	PUNCT
dpc-3688	9	44	novartis	novartis	PROPN
dpc-3688	9	45	,	,	PUNCT
dpc-3688	9	46	pfizer	pfizer	NOUN
dpc-3688	9	47	and	and	CCONJ
dpc-3688	9	48	sanofi	sanofi	PROPN
dpc-3688	9	49	genzyme	genzyme	PROPN
dpc-3688	9	50	.	.	PUNCT
dpc-3688	10	1	the	the	DET
dpc-3688	10	2	other	other	ADJ
dpc-3688	10	3	authors	author	NOUN
dpc-3688	10	4	have	have	VERB
dpc-3688	10	5	no	no	DET
dpc-3688	10	6	conflicts	conflict	NOUN
dpc-3688	10	7	of	of	ADP
dpc-3688	10	8	interest	interest	NOUN
dpc-3688	10	9	to	to	PART
dpc-3688	10	10	declare	declare	VERB
dpc-3688	10	11	.	.	PUNCT
dpc-3688	11	1	authorship	authorship	NOUN
dpc-3688	11	2	:	:	PUNCT
dpc-3688	11	3	all	all	DET
dpc-3688	11	4	authors	author	NOUN
dpc-3688	11	5	have	have	AUX
dpc-3688	11	6	contributed	contribute	VERB
dpc-3688	11	7	significantly	significantly	ADV
dpc-3688	11	8	to	to	ADP
dpc-3688	11	9	this	this	DET
dpc-3688	11	10	publication	publication	NOUN
dpc-3688	11	11	.	.	PUNCT
dpc-3688	12	1	corresponding	correspond	VERB
dpc-3688	12	2	author	author	NOUN
dpc-3688	12	3	:	:	PUNCT
dpc-3688	12	4	giulia	giulia	PROPN
dpc-3688	12	5	coscarella	coscarella	PROPN
dpc-3688	12	6	,	,	PUNCT
dpc-3688	12	7	md	md	PROPN
dpc-3688	12	8	,	,	PUNCT
dpc-3688	12	9	dermatologia	dermatologia	PROPN
dpc-3688	12	10	,	,	PUNCT
dpc-3688	12	11	fondazione	fondazione	PROPN
dpc-3688	12	12	policlinico	policlinico	PROPN
dpc-3688	12	13	universitario	universitario	PROPN
dpc-3688	12	14	a.	a.	PROPN
dpc-3688	12	15	gemelli	gemelli	PROPN
dpc-3688	12	16	irccs	irccs	PROPN
dpc-3688	12	17	,	,	PUNCT
dpc-3688	12	18	largo	largo	PROPN
dpc-3688	12	19	agostino	agostino	PROPN
dpc-3688	12	20	gemelli	gemelli	PROPN
dpc-3688	12	21	8	8	NUM
dpc-3688	12	22	,	,	PUNCT
dpc-3688	12	23	00168	00168	NUM
dpc-3688	12	24	rome	rome	PROPN
dpc-3688	12	25	,	,	PUNCT
dpc-3688	12	26	italy	italy	PROPN
dpc-3688	12	27	tel	tel	PROPN
dpc-3688	12	28	.	.	PUNCT
dpc-3688	12	29	:	:	PUNCT
dpc-3688	13	1	+39	+39	PROPN
dpc-3688	13	2	-	-	PUNCT
dpc-3688	13	3	320.6223136	320.6223136	NUM
dpc-3688	13	4	email	email	NOUN
dpc-3688	13	5	:	:	PUNCT
dpc-3688	13	6	giuliacoscarella@gmail.com	giuliacoscarella@gmail.com	X
dpc-3688	13	7	introduction	introduction	NOUN
dpc-3688	13	8	:	:	PUNCT
dpc-3688	13	9	psoriasis	psoriasis	NOUN
dpc-3688	13	10	is	be	AUX
dpc-3688	13	11	a	a	DET
dpc-3688	13	12	common	common	ADJ
dpc-3688	13	13	chronic	chronic	NOUN
dpc-3688	13	14	,	,	PUNCT
dpc-3688	13	15	immune	immune	NOUN
dpc-3688	13	16	-	-	PUNCT
dpc-3688	13	17	mediated	mediate	VERB
dpc-3688	13	18	,	,	PUNCT
dpc-3688	13	19	inflammatory	inflammatory	ADJ
dpc-3688	13	20	skin	skin	NOUN
dpc-3688	13	21	disease	disease	NOUN
dpc-3688	13	22	that	that	SCONJ
dpc-3688	13	23	in	in	ADP
dpc-3688	13	24	certain	certain	ADJ
dpc-3688	13	25	localization	localization	NOUN
dpc-3688	13	26	results	result	VERB
dpc-3688	13	27	difficult	difficult	ADJ
dpc-3688	13	28	to	to	PART
dpc-3688	13	29	treat	treat	VERB
dpc-3688	13	30	.	.	PUNCT
dpc-3688	14	1	psoriatic	psoriatic	ADJ
dpc-3688	14	2	lesions	lesion	NOUN
dpc-3688	14	3	in	in	ADP
dpc-3688	14	4	difficult	difficult	ADJ
dpc-3688	14	5	-	-	PUNCT
dpc-3688	14	6	to	to	ADP
dpc-3688	14	7	-	-	PUNCT
dpc-3688	14	8	treat	treat	NOUN
dpc-3688	14	9	areas	area	NOUN
dpc-3688	14	10	might	might	AUX
dpc-3688	14	11	be	be	AUX
dpc-3688	14	12	hardly	hardly	ADV
dpc-3688	14	13	managed	manage	VERB
dpc-3688	14	14	as	as	ADP
dpc-3688	14	15	no	no	DET
dpc-3688	14	16	standardized	standardized	ADJ
dpc-3688	14	17	therapeutic	therapeutic	ADJ
dpc-3688	14	18	approach	approach	NOUN
dpc-3688	14	19	and	and	CCONJ
dpc-3688	14	20	the	the	DET
dpc-3688	14	21	application	application	NOUN
dpc-3688	14	22	of	of	ADP
dpc-3688	14	23	topical	topical	ADJ
dpc-3688	14	24	treatments	treatment	NOUN
dpc-3688	14	25	might	might	AUX
dpc-3688	14	26	have	have	VERB
dpc-3688	14	27	great	great	ADJ
dpc-3688	14	28	limitations	limitation	NOUN
dpc-3688	14	29	.	.	PUNCT
dpc-3688	15	1	systemic	systemic	ADJ
dpc-3688	15	2	agents	agent	NOUN
dpc-3688	15	3	,	,	PUNCT
dpc-3688	15	4	including	include	VERB
dpc-3688	15	5	biologic	biologic	NOUN
dpc-3688	15	6	therapies	therapy	NOUN
dpc-3688	15	7	,	,	PUNCT
dpc-3688	15	8	have	have	AUX
dpc-3688	15	9	been	be	AUX
dpc-3688	15	10	proven	prove	VERB
dpc-3688	15	11	effective	effective	ADJ
dpc-3688	15	12	in	in	ADP
dpc-3688	15	13	treating	treat	VERB
dpc-3688	15	14	this	this	DET
dpc-3688	15	15	subgroup	subgroup	NOUN
dpc-3688	15	16	of	of	ADP
dpc-3688	15	17	patients	patient	NOUN
dpc-3688	15	18	.	.	PUNCT
dpc-3688	16	1	in	in	ADP
dpc-3688	16	2	particular	particular	ADJ
dpc-3688	16	3	,	,	PUNCT
dpc-3688	16	4	current	current	ADJ
dpc-3688	16	5	evidence	evidence	NOUN
dpc-3688	16	6	has	have	AUX
dpc-3688	16	7	shown	show	VERB
dpc-3688	16	8	beneficial	beneficial	ADJ
dpc-3688	16	9	effects	effect	NOUN
dpc-3688	16	10	with	with	ADP
dpc-3688	16	11	the	the	DET
dpc-3688	16	12	use	use	NOUN
dpc-3688	16	13	of	of	ADP
dpc-3688	16	14	brodalumab	brodalumab	NOUN
dpc-3688	16	15	,	,	PUNCT
dpc-3688	16	16	a	a	DET
dpc-3688	16	17	fully	fully	ADV
dpc-3688	16	18	human	human	ADJ
dpc-3688	16	19	igg2	igg2	ADJ
dpc-3688	16	20	monoclonal	monoclonal	NOUN
dpc-3688	16	21	antibody	antibody	NOUN
dpc-3688	16	22	antagonizing	antagonize	VERB
dpc-3688	16	23	the	the	DET
dpc-3688	16	24	il-17	il-17	NUM
dpc-3688	16	25	receptor	receptor	NOUN
dpc-3688	16	26	a	a	DET
dpc-3688	16	27	subunit	subunit	NOUN
dpc-3688	16	28	(	(	PUNCT
dpc-3688	16	29	il-17ra	il-17ra	PROPN
dpc-3688	16	30	)	)	PUNCT
dpc-3688	16	31	.	.	PUNCT
dpc-3688	17	1	objectives	objective	NOUN
dpc-3688	17	2	:	:	PUNCT
dpc-3688	17	3	the	the	DET
dpc-3688	17	4	aim	aim	NOUN
dpc-3688	17	5	of	of	ADP
dpc-3688	17	6	this	this	DET
dpc-3688	17	7	narrative	narrative	ADJ
dpc-3688	17	8	review	review	NOUN
dpc-3688	17	9	was	be	AUX
dpc-3688	17	10	to	to	PART
dpc-3688	17	11	collect	collect	VERB
dpc-3688	17	12	published	publish	VERB
dpc-3688	17	13	data	datum	NOUN
dpc-3688	17	14	about	about	ADP
dpc-3688	17	15	efficacy	efficacy	NOUN
dpc-3688	17	16	and	and	CCONJ
dpc-3688	17	17	safety	safety	NOUN
dpc-3688	17	18	of	of	ADP
dpc-3688	17	19	brodalumab	brodalumab	NOUN
dpc-3688	17	20	in	in	ADP
dpc-3688	17	21	the	the	DET
dpc-3688	17	22	treatment	treatment	NOUN
dpc-3688	17	23	of	of	ADP
dpc-3688	17	24	psoriasis	psoriasis	NOUN
dpc-3688	17	25	occurring	occur	VERB
dpc-3688	17	26	in	in	ADP
dpc-3688	17	27	difficult	difficult	ADJ
dpc-3688	17	28	-	-	PUNCT
dpc-3688	17	29	to	to	ADP
dpc-3688	17	30	-	-	PUNCT
dpc-3688	17	31	treat	treat	NOUN
dpc-3688	17	32	areas	area	NOUN
dpc-3688	17	33	.	.	PUNCT
dpc-3688	18	1	methods	method	NOUN
dpc-3688	18	2	:	:	PUNCT
dpc-3688	18	3	data	datum	NOUN
dpc-3688	18	4	on	on	ADP
dpc-3688	18	5	brodalumab	brodalumab	NOUN
dpc-3688	18	6	effectiveness	effectiveness	NOUN
dpc-3688	18	7	and	and	CCONJ
dpc-3688	18	8	safety	safety	NOUN
dpc-3688	18	9	deriving	derive	VERB
dpc-3688	18	10	from	from	ADP
dpc-3688	18	11	both	both	DET
dpc-3688	18	12	trials	trial	NOUN
dpc-3688	18	13	and	and	CCONJ
dpc-3688	18	14	real	real	ADJ
dpc-3688	18	15	-	-	PUNCT
dpc-3688	18	16	world	world	NOUN
dpc-3688	18	17	setting	setting	NOUN
dpc-3688	18	18	that	that	PRON
dpc-3688	18	19	had	have	AUX
dpc-3688	18	20	been	be	AUX
dpc-3688	18	21	published	publish	VERB
dpc-3688	18	22	in	in	ADP
dpc-3688	18	23	the	the	DET
dpc-3688	18	24	last	last	ADJ
dpc-3688	18	25	15	15	NUM
dpc-3688	18	26	years	year	NOUN
dpc-3688	18	27	were	be	AUX
dpc-3688	18	28	collected	collect	VERB
dpc-3688	18	29	for	for	ADP
dpc-3688	18	30	this	this	DET
dpc-3688	18	31	review	review	NOUN
dpc-3688	18	32	,	,	PUNCT
dpc-3688	18	33	together	together	ADV
dpc-3688	18	34	with	with	ADP
dpc-3688	18	35	clinical	clinical	ADJ
dpc-3688	18	36	findings	finding	NOUN
dpc-3688	18	37	issued	issue	VERB
dpc-3688	18	38	during	during	ADP
dpc-3688	18	39	international	international	ADJ
dpc-3688	18	40	meetings	meeting	NOUN
dpc-3688	18	41	.	.	PUNCT
dpc-3688	19	1	results	result	NOUN
dpc-3688	19	2	:	:	PUNCT
dpc-3688	19	3	in	in	ADP
dpc-3688	19	4	phase	phase	NOUN
dpc-3688	19	5	3	3	NUM
dpc-3688	19	6	trials	trial	NOUN
dpc-3688	19	7	,	,	PUNCT
dpc-3688	19	8	brodalumab	brodalumab	NOUN
dpc-3688	19	9	demonstrated	demonstrate	VERB
dpc-3688	19	10	to	to	PART
dpc-3688	19	11	be	be	AUX
dpc-3688	19	12	effective	effective	ADJ
dpc-3688	19	13	in	in	ADP
dpc-3688	19	14	promoting	promote	VERB
dpc-3688	19	15	a	a	DET
dpc-3688	19	16	rapid	rapid	ADJ
dpc-3688	19	17	response	response	NOUN
dpc-3688	19	18	in	in	ADP
dpc-3688	19	19	scalp	scalp	NOUN
dpc-3688	19	20	psoriasis	psoriasis	NOUN
dpc-3688	19	21	as	as	ADV
dpc-3688	19	22	well	well	ADV
dpc-3688	19	23	as	as	ADP
dpc-3688	19	24	in	in	ADP
dpc-3688	19	25	generalized	generalized	ADJ
dpc-3688	19	26	pustular	pustular	ADJ
dpc-3688	19	27	psoriasis	psoriasis	NOUN
dpc-3688	19	28	and	and	CCONJ
dpc-3688	19	29	erythrodermic	erythrodermic	ADJ
dpc-3688	19	30	psoriasis	psoriasis	NOUN
dpc-3688	19	31	.	.	PUNCT
dpc-3688	20	1	nail	nail	NOUN
dpc-3688	20	2	psoriasis	psoriasis	NOUN
dpc-3688	20	3	demonstrated	demonstrate	VERB
dpc-3688	20	4	marked	mark	VERB
dpc-3688	20	5	clinical	clinical	ADJ
dpc-3688	20	6	improvement	improvement	NOUN
dpc-3688	20	7	after	after	ADP
dpc-3688	20	8	treatment	treatment	NOUN
dpc-3688	20	9	with	with	ADP
dpc-3688	20	10	brodalumab	brodalumab	NOUN
dpc-3688	20	11	.	.	PUNCT
dpc-3688	21	1	amelioration	amelioration	NOUN
dpc-3688	21	2	of	of	ADP
dpc-3688	21	3	palmoabstract	palmoabstract	ADJ
dpc-3688	21	4	2	2	NUM
dpc-3688	21	5	review	review	NOUN
dpc-3688	21	6	|	|	ADV
dpc-3688	21	7	dermatol	dermatol	ADJ
dpc-3688	21	8	pract	pract	NOUN
dpc-3688	21	9	concept	concept	NOUN
dpc-3688	21	10	.	.	PUNCT
dpc-3688	22	1	2023;13(3):e2023245	2023;13(3):e2023245	NUM
dpc-3688	22	2	introduction	introduction	NOUN
dpc-3688	22	3	psoriasis	psoriasis	NOUN
dpc-3688	22	4	is	be	AUX
dpc-3688	22	5	a	a	DET
dpc-3688	22	6	chronic	chronic	NOUN
dpc-3688	22	7	,	,	PUNCT
dpc-3688	22	8	immune	immune	NOUN
dpc-3688	22	9	-	-	PUNCT
dpc-3688	22	10	mediated	mediate	VERB
dpc-3688	22	11	,	,	PUNCT
dpc-3688	22	12	inflammatory	inflammatory	ADJ
dpc-3688	22	13	skin	skin	NOUN
dpc-3688	22	14	disease	disease	NOUN
dpc-3688	22	15	that	that	PRON
dpc-3688	22	16	is	be	AUX
dpc-3688	22	17	associated	associate	VERB
dpc-3688	22	18	with	with	ADP
dpc-3688	22	19	a	a	DET
dpc-3688	22	20	wide	wide	ADJ
dpc-3688	22	21	array	array	NOUN
dpc-3688	22	22	of	of	ADP
dpc-3688	22	23	comorbidities	comorbiditie	NOUN
dpc-3688	22	24	[	[	X
dpc-3688	22	25	1,2	1,2	NUM
dpc-3688	22	26	]	]	PUNCT
dpc-3688	22	27	,	,	PUNCT
dpc-3688	22	28	as	as	ADV
dpc-3688	22	29	well	well	ADV
dpc-3688	22	30	as	as	ADP
dpc-3688	22	31	with	with	ADP
dpc-3688	22	32	detrimental	detrimental	ADJ
dpc-3688	22	33	physical	physical	ADJ
dpc-3688	22	34	effects	effect	NOUN
dpc-3688	22	35	,	,	PUNCT
dpc-3688	22	36	disability	disability	NOUN
dpc-3688	22	37	,	,	PUNCT
dpc-3688	22	38	reduced	reduce	VERB
dpc-3688	22	39	psychological	psychological	ADJ
dpc-3688	22	40	wellbeing	wellbeing	NOUN
dpc-3688	22	41	and	and	CCONJ
dpc-3688	22	42	impaired	impaired	ADJ
dpc-3688	22	43	quality	quality	NOUN
dpc-3688	22	44	of	of	ADP
dpc-3688	22	45	life	life	NOUN
dpc-3688	22	46	(	(	PUNCT
dpc-3688	22	47	qol	qol	NOUN
dpc-3688	22	48	)	)	PUNCT
dpc-3688	23	1	[	[	X
dpc-3688	23	2	3	3	NUM
dpc-3688	23	3	]	]	PUNCT
dpc-3688	23	4	.	.	PUNCT
dpc-3688	24	1	silvery	silvery	PROPN
dpc-3688	24	2	scales	scale	VERB
dpc-3688	24	3	on	on	ADP
dpc-3688	24	4	an	an	DET
dpc-3688	24	5	erythematous	erythematous	ADJ
dpc-3688	24	6	plaque	plaque	NOUN
dpc-3688	24	7	can	can	AUX
dpc-3688	24	8	affect	affect	VERB
dpc-3688	24	9	any	any	DET
dpc-3688	24	10	body	body	NOUN
dpc-3688	24	11	area	area	NOUN
dpc-3688	24	12	,	,	PUNCT
dpc-3688	24	13	though	though	SCONJ
dpc-3688	24	14	scalp	scalp	NOUN
dpc-3688	24	15	,	,	PUNCT
dpc-3688	24	16	nails	nail	NOUN
dpc-3688	24	17	,	,	PUNCT
dpc-3688	24	18	palm	palm	NOUN
dpc-3688	24	19	and	and	CCONJ
dpc-3688	24	20	soles	sol	NOUN
dpc-3688	24	21	,	,	PUNCT
dpc-3688	24	22	or	or	CCONJ
dpc-3688	24	23	genitalia	genitalia	NOUN
dpc-3688	24	24	may	may	AUX
dpc-3688	24	25	be	be	AUX
dpc-3688	24	26	recalcitrant	recalcitrant	ADJ
dpc-3688	24	27	to	to	ADP
dpc-3688	24	28	therapies	therapy	NOUN
dpc-3688	24	29	,	,	PUNCT
dpc-3688	24	30	hence	hence	ADV
dpc-3688	24	31	are	be	AUX
dpc-3688	24	32	defined	define	VERB
dpc-3688	24	33	difficult	difficult	ADJ
dpc-3688	24	34	-	-	PUNCT
dpc-3688	24	35	to	to	ADP
dpc-3688	24	36	-	-	PUNCT
dpc-3688	24	37	treat	treat	NOUN
dpc-3688	24	38	areas	area	NOUN
dpc-3688	24	39	[	[	X
dpc-3688	24	40	4,5	4,5	NUM
dpc-3688	24	41	]	]	PUNCT
dpc-3688	24	42	.	.	PUNCT
dpc-3688	25	1	patients	patient	NOUN
dpc-3688	25	2	affected	affect	VERB
dpc-3688	25	3	by	by	ADP
dpc-3688	25	4	psoriasis	psoriasis	NOUN
dpc-3688	25	5	in	in	ADP
dpc-3688	25	6	difficult	difficult	ADJ
dpc-3688	25	7	-	-	PUNCT
dpc-3688	25	8	to	to	ADP
dpc-3688	25	9	-	-	PUNCT
dpc-3688	25	10	treat	treat	NOUN
dpc-3688	25	11	areas	area	NOUN
dpc-3688	25	12	might	might	AUX
dpc-3688	25	13	experience	experience	VERB
dpc-3688	25	14	difficulties	difficulty	NOUN
dpc-3688	25	15	in	in	ADP
dpc-3688	25	16	performing	perform	VERB
dpc-3688	25	17	topical	topical	ADJ
dpc-3688	25	18	treatments	treatment	NOUN
dpc-3688	25	19	,	,	PUNCT
dpc-3688	25	20	stigmatization	stigmatization	NOUN
dpc-3688	25	21	of	of	ADP
dpc-3688	25	22	the	the	DET
dpc-3688	25	23	disease	disease	NOUN
dpc-3688	25	24	and	and	CCONJ
dpc-3688	25	25	a	a	DET
dpc-3688	25	26	marked	mark	VERB
dpc-3688	25	27	impact	impact	NOUN
dpc-3688	25	28	on	on	ADP
dpc-3688	25	29	qol	qol	NOUN
dpc-3688	25	30	[	[	X
dpc-3688	25	31	5,6	5,6	NUM
dpc-3688	25	32	]	]	PUNCT
dpc-3688	25	33	.	.	PUNCT
dpc-3688	26	1	albeit	albeit	SCONJ
dpc-3688	26	2	the	the	DET
dpc-3688	26	3	percentage	percentage	NOUN
dpc-3688	26	4	of	of	ADP
dpc-3688	26	5	affected	affected	ADJ
dpc-3688	26	6	body	body	NOUN
dpc-3688	26	7	area	area	NOUN
dpc-3688	26	8	is	be	AUX
dpc-3688	26	9	minimal	minimal	ADJ
dpc-3688	26	10	,	,	PUNCT
dpc-3688	26	11	psoriasis	psoriasis	NOUN
dpc-3688	26	12	localized	localize	VERB
dpc-3688	26	13	in	in	ADP
dpc-3688	26	14	these	these	DET
dpc-3688	26	15	regions	region	NOUN
dpc-3688	26	16	may	may	AUX
dpc-3688	26	17	represent	represent	VERB
dpc-3688	26	18	a	a	DET
dpc-3688	26	19	challenging	challenging	ADJ
dpc-3688	26	20	condition	condition	NOUN
dpc-3688	26	21	for	for	ADP
dpc-3688	26	22	physicians	physician	NOUN
dpc-3688	26	23	.	.	PUNCT
dpc-3688	27	1	the	the	DET
dpc-3688	27	2	scalp	scalp	NOUN
dpc-3688	27	3	is	be	AUX
dpc-3688	27	4	one	one	NUM
dpc-3688	27	5	of	of	ADP
dpc-3688	27	6	the	the	DET
dpc-3688	27	7	first	first	ADJ
dpc-3688	27	8	sites	site	NOUN
dpc-3688	27	9	to	to	PART
dpc-3688	27	10	be	be	AUX
dpc-3688	27	11	affected	affect	VERB
dpc-3688	27	12	,	,	PUNCT
dpc-3688	27	13	and	and	CCONJ
dpc-3688	27	14	its	its	PRON
dpc-3688	27	15	involvement	involvement	NOUN
dpc-3688	27	16	,	,	PUNCT
dpc-3688	27	17	occurring	occur	VERB
dpc-3688	27	18	in	in	ADP
dpc-3688	27	19	about	about	ADV
dpc-3688	27	20	80	80	NUM
dpc-3688	27	21	%	%	NOUN
dpc-3688	27	22	of	of	ADP
dpc-3688	27	23	patients	patient	NOUN
dpc-3688	27	24	,	,	PUNCT
dpc-3688	27	25	increases	increase	VERB
dpc-3688	27	26	with	with	ADP
dpc-3688	27	27	disease	disease	NOUN
dpc-3688	27	28	duration	duration	NOUN
dpc-3688	27	29	.	.	PUNCT
dpc-3688	28	1	scalp	scalp	NOUN
dpc-3688	28	2	psoriasis	psoriasis	NOUN
dpc-3688	28	3	presents	present	VERB
dpc-3688	28	4	with	with	ADP
dpc-3688	28	5	erythema	erythema	ADJ
dpc-3688	28	6	,	,	PUNCT
dpc-3688	28	7	scaling	scaling	NOUN
dpc-3688	28	8	,	,	PUNCT
dpc-3688	28	9	and	and	CCONJ
dpc-3688	28	10	pruritus	pruritus	PROPN
dpc-3688	28	11	,	,	PUNCT
dpc-3688	28	12	often	often	ADV
dpc-3688	28	13	resembling	resemble	VERB
dpc-3688	28	14	seborrheic	seborrheic	ADJ
dpc-3688	28	15	dermatitis	dermatitis	NOUN
dpc-3688	28	16	[	[	X
dpc-3688	28	17	7	7	NUM
dpc-3688	28	18	-	-	SYM
dpc-3688	28	19	9	9	NUM
dpc-3688	28	20	]	]	PUNCT
dpc-3688	28	21	.	.	PUNCT
dpc-3688	29	1	to	to	PART
dpc-3688	29	2	assess	assess	VERB
dpc-3688	29	3	disease	disease	NOUN
dpc-3688	29	4	severity	severity	NOUN
dpc-3688	29	5	and	and	CCONJ
dpc-3688	29	6	treatment	treatment	NOUN
dpc-3688	29	7	response	response	NOUN
dpc-3688	29	8	,	,	PUNCT
dpc-3688	29	9	the	the	DET
dpc-3688	29	10	psoriasis	psoriasis	NOUN
dpc-3688	29	11	scalp	scalp	NOUN
dpc-3688	29	12	severity	severity	NOUN
dpc-3688	29	13	index	index	NOUN
dpc-3688	29	14	(	(	PUNCT
dpc-3688	29	15	pssi	pssi	ADJ
dpc-3688	29	16	)	)	PUNCT
dpc-3688	29	17	is	be	AUX
dpc-3688	29	18	commonly	commonly	ADV
dpc-3688	29	19	used	use	VERB
dpc-3688	29	20	[	[	PUNCT
dpc-3688	29	21	10	10	NUM
dpc-3688	29	22	]	]	PUNCT
dpc-3688	29	23	.	.	PUNCT
dpc-3688	30	1	nail	nail	NOUN
dpc-3688	30	2	psoriasis	psoriasis	NOUN
dpc-3688	30	3	is	be	AUX
dpc-3688	30	4	seen	see	VERB
dpc-3688	30	5	in	in	ADP
dpc-3688	30	6	up	up	ADP
dpc-3688	30	7	to	to	PART
dpc-3688	30	8	80	80	NUM
dpc-3688	30	9	%	%	NOUN
dpc-3688	30	10	of	of	ADP
dpc-3688	30	11	psoriatic	psoriatic	ADJ
dpc-3688	30	12	patients	patient	NOUN
dpc-3688	30	13	,	,	PUNCT
dpc-3688	30	14	being	be	AUX
dpc-3688	30	15	the	the	DET
dpc-3688	30	16	only	only	ADJ
dpc-3688	30	17	psoriatic	psoriatic	ADJ
dpc-3688	30	18	manifestation	manifestation	NOUN
dpc-3688	30	19	in	in	ADP
dpc-3688	30	20	6	6	NUM
dpc-3688	30	21	%	%	NOUN
dpc-3688	30	22	of	of	ADP
dpc-3688	30	23	cases	case	NOUN
dpc-3688	30	24	.	.	PUNCT
dpc-3688	31	1	nail	nail	NOUN
dpc-3688	31	2	psoriasis	psoriasis	NOUN
dpc-3688	31	3	correlates	correlate	VERB
dpc-3688	31	4	with	with	ADP
dpc-3688	31	5	disease	disease	NOUN
dpc-3688	31	6	severity	severity	NOUN
dpc-3688	31	7	and	and	CCONJ
dpc-3688	31	8	its	its	PRON
dpc-3688	31	9	presence	presence	NOUN
dpc-3688	31	10	is	be	AUX
dpc-3688	31	11	associated	associate	VERB
dpc-3688	31	12	with	with	ADP
dpc-3688	31	13	higher	high	ADJ
dpc-3688	31	14	risk	risk	NOUN
dpc-3688	31	15	of	of	ADP
dpc-3688	31	16	developing	develop	VERB
dpc-3688	31	17	psoriatic	psoriatic	ADJ
dpc-3688	31	18	arthritis	arthritis	NOUN
dpc-3688	31	19	.	.	PUNCT
dpc-3688	32	1	clinical	clinical	ADJ
dpc-3688	32	2	manifestations	manifestation	NOUN
dpc-3688	32	3	of	of	ADP
dpc-3688	32	4	nail	nail	NOUN
dpc-3688	32	5	psoriasis	psoriasis	NOUN
dpc-3688	32	6	may	may	AUX
dpc-3688	32	7	vary	vary	VERB
dpc-3688	32	8	whether	whether	SCONJ
dpc-3688	32	9	affecting	affect	VERB
dpc-3688	32	10	nail	nail	NOUN
dpc-3688	32	11	matrix	matrix	NOUN
dpc-3688	32	12	,	,	PUNCT
dpc-3688	32	13	nail	nail	NOUN
dpc-3688	32	14	bed	bed	NOUN
dpc-3688	32	15	,	,	PUNCT
dpc-3688	32	16	the	the	DET
dpc-3688	32	17	proximal	proximal	ADJ
dpc-3688	32	18	nail	nail	NOUN
dpc-3688	32	19	fold	fold	NOUN
dpc-3688	32	20	or	or	CCONJ
dpc-3688	32	21	the	the	DET
dpc-3688	32	22	hyponychium	hyponychium	NOUN
dpc-3688	33	1	[	[	X
dpc-3688	33	2	11,12	11,12	NUM
dpc-3688	33	3	]	]	PUNCT
dpc-3688	33	4	.	.	PUNCT
dpc-3688	34	1	the	the	DET
dpc-3688	34	2	napsi	napsi	NOUN
dpc-3688	34	3	is	be	AUX
dpc-3688	34	4	an	an	DET
dpc-3688	34	5	objective	objective	ADJ
dpc-3688	34	6	assessment	assessment	NOUN
dpc-3688	34	7	instrument	instrument	NOUN
dpc-3688	34	8	that	that	PRON
dpc-3688	34	9	is	be	AUX
dpc-3688	34	10	used	use	VERB
dpc-3688	34	11	to	to	PART
dpc-3688	34	12	assess	assess	VERB
dpc-3688	34	13	the	the	DET
dpc-3688	34	14	severity	severity	NOUN
dpc-3688	34	15	of	of	ADP
dpc-3688	34	16	nail	nail	NOUN
dpc-3688	34	17	psoriasis	psoriasis	NOUN
dpc-3688	34	18	and	and	CCONJ
dpc-3688	34	19	the	the	DET
dpc-3688	34	20	area	area	NOUN
dpc-3688	34	21	of	of	ADP
dpc-3688	34	22	involvement	involvement	NOUN
dpc-3688	34	23	of	of	ADP
dpc-3688	34	24	the	the	DET
dpc-3688	34	25	nail	nail	NOUN
dpc-3688	34	26	unit	unit	NOUN
dpc-3688	34	27	[	[	X
dpc-3688	34	28	10	10	NUM
dpc-3688	34	29	]	]	NUM
dpc-3688	34	30	)	)	PUNCT
dpc-3688	34	31	.	.	PUNCT
dpc-3688	35	1	palmoplantar	palmoplantar	NOUN
dpc-3688	35	2	psoriasis	psoriasis	NOUN
dpc-3688	35	3	(	(	PUNCT
dpc-3688	35	4	ppp	ppp	NOUN
dpc-3688	35	5	)	)	PUNCT
dpc-3688	35	6	can	can	AUX
dpc-3688	35	7	appear	appear	VERB
dpc-3688	35	8	as	as	ADP
dpc-3688	35	9	hyperkeratotic	hyperkeratotic	ADJ
dpc-3688	35	10	,	,	PUNCT
dpc-3688	35	11	pustular	pustular	ADJ
dpc-3688	35	12	,	,	PUNCT
dpc-3688	35	13	or	or	CCONJ
dpc-3688	35	14	with	with	ADP
dpc-3688	35	15	mixed	mixed	ADJ
dpc-3688	35	16	morphologies	morphology	NOUN
dpc-3688	35	17	;	;	PUNCT
dpc-3688	35	18	itching	itching	NOUN
dpc-3688	35	19	,	,	PUNCT
dpc-3688	35	20	pain	pain	NOUN
dpc-3688	35	21	,	,	PUNCT
dpc-3688	35	22	and	and	CCONJ
dpc-3688	35	23	fissuring	fissuring	NOUN
dpc-3688	35	24	are	be	AUX
dpc-3688	35	25	the	the	DET
dpc-3688	35	26	most	most	ADV
dpc-3688	35	27	complained	complain	VERB
dpc-3688	35	28	symptoms	symptom	NOUN
dpc-3688	35	29	[	[	X
dpc-3688	35	30	13	13	NUM
dpc-3688	35	31	]	]	PUNCT
dpc-3688	35	32	.	.	PUNCT
dpc-3688	36	1	palmoplantar	palmoplantar	NOUN
dpc-3688	36	2	psoriasis	psoriasis	NOUN
dpc-3688	36	3	and	and	CCONJ
dpc-3688	36	4	palmoplantar	palmoplantar	NOUN
dpc-3688	36	5	pustolosis	pustolosis	NOUN
dpc-3688	36	6	are	be	AUX
dpc-3688	36	7	monitored	monitor	VERB
dpc-3688	36	8	using	use	VERB
dpc-3688	36	9	the	the	DET
dpc-3688	36	10	palmoplantar	palmoplantar	NOUN
dpc-3688	36	11	psoriasis	psoriasis	NOUN
dpc-3688	36	12	area	area	NOUN
dpc-3688	36	13	and	and	CCONJ
dpc-3688	36	14	severity	severity	NOUN
dpc-3688	36	15	index	index	NOUN
dpc-3688	36	16	(	(	PUNCT
dpc-3688	36	17	ppasi	ppasi	PROPN
dpc-3688	36	18	)	)	PUNCT
dpc-3688	36	19	and	and	CCONJ
dpc-3688	36	20	the	the	DET
dpc-3688	36	21	palmoplantar	palmoplantar	NOUN
dpc-3688	36	22	pustulosis	pustulosis	NOUN
dpc-3688	36	23	psoriasis	psoriasis	NOUN
dpc-3688	36	24	area	area	NOUN
dpc-3688	36	25	and	and	CCONJ
dpc-3688	36	26	severity	severity	NOUN
dpc-3688	36	27	index	index	NOUN
dpc-3688	36	28	(	(	PUNCT
dpc-3688	36	29	pppasi	pppasi	NOUN
dpc-3688	36	30	)	)	PUNCT
dpc-3688	36	31	,	,	PUNCT
dpc-3688	36	32	respectively	respectively	ADV
dpc-3688	36	33	[	[	X
dpc-3688	36	34	10	10	NUM
dpc-3688	36	35	]	]	PUNCT
dpc-3688	36	36	.	.	PUNCT
dpc-3688	37	1	though	though	SCONJ
dpc-3688	37	2	no	no	DET
dpc-3688	37	3	standardized	standardized	ADJ
dpc-3688	37	4	treatment	treatment	NOUN
dpc-3688	37	5	approach	approach	NOUN
dpc-3688	37	6	exists	exist	VERB
dpc-3688	37	7	,	,	PUNCT
dpc-3688	37	8	biologic	biologic	NOUN
dpc-3688	37	9	therapies	therapy	NOUN
dpc-3688	37	10	have	have	AUX
dpc-3688	37	11	been	be	AUX
dpc-3688	37	12	proven	prove	VERB
dpc-3688	37	13	effective	effective	ADJ
dpc-3688	37	14	in	in	ADP
dpc-3688	37	15	treating	treat	VERB
dpc-3688	37	16	patients	patient	NOUN
dpc-3688	37	17	with	with	ADP
dpc-3688	37	18	psoriasis	psoriasis	NOUN
dpc-3688	37	19	in	in	ADP
dpc-3688	37	20	difficult	difficult	ADJ
dpc-3688	37	21	-	-	PUNCT
dpc-3688	37	22	to	to	ADP
dpc-3688	37	23	-	-	PUNCT
dpc-3688	37	24	treat	treat	NOUN
dpc-3688	37	25	areas	area	NOUN
dpc-3688	37	26	.	.	PUNCT
dpc-3688	38	1	mounting	mount	VERB
dpc-3688	38	2	evidence	evidence	NOUN
dpc-3688	38	3	has	have	AUX
dpc-3688	38	4	proven	prove	VERB
dpc-3688	38	5	beneficial	beneficial	ADJ
dpc-3688	38	6	effects	effect	NOUN
dpc-3688	38	7	with	with	ADP
dpc-3688	38	8	the	the	DET
dpc-3688	38	9	use	use	NOUN
dpc-3688	38	10	of	of	ADP
dpc-3688	38	11	brodalumab	brodalumab	NOUN
dpc-3688	38	12	,	,	PUNCT
dpc-3688	38	13	a	a	DET
dpc-3688	38	14	fully	fully	ADV
dpc-3688	38	15	human	human	ADJ
dpc-3688	38	16	igg2	igg2	ADJ
dpc-3688	38	17	monoclonal	monoclonal	NOUN
dpc-3688	38	18	antibody	antibody	NOUN
dpc-3688	38	19	antagonizing	antagonize	VERB
dpc-3688	38	20	the	the	DET
dpc-3688	38	21	il17	il17	PROPN
dpc-3688	38	22	receptor	receptor	NOUN
dpc-3688	38	23	a	a	DET
dpc-3688	38	24	subunit	subunit	NOUN
dpc-3688	38	25	(	(	PUNCT
dpc-3688	38	26	il-17ra	il-17ra	PROPN
dpc-3688	38	27	)	)	PUNCT
dpc-3688	38	28	,	,	PUNCT
dpc-3688	38	29	that	that	PRON
dpc-3688	38	30	has	have	AUX
dpc-3688	38	31	been	be	AUX
dpc-3688	38	32	approved	approve	VERB
dpc-3688	38	33	for	for	ADP
dpc-3688	38	34	the	the	DET
dpc-3688	38	35	treatment	treatment	NOUN
dpc-3688	38	36	of	of	ADP
dpc-3688	38	37	plaque	plaque	NOUN
dpc-3688	38	38	psoriasis	psoriasis	NOUN
dpc-3688	38	39	at	at	ADP
dpc-3688	38	40	the	the	DET
dpc-3688	38	41	induction	induction	NOUN
dpc-3688	38	42	dose	dose	NOUN
dpc-3688	38	43	of	of	ADP
dpc-3688	38	44	210	210	NUM
dpc-3688	38	45	mg	mg	PROPN
dpc-3688	38	46	s.c	s.c	PROPN
dpc-3688	38	47	.	.	PUNCT
dpc-3688	39	1	at	at	ADP
dpc-3688	39	2	weeks	week	NOUN
dpc-3688	39	3	0	0	NUM
dpc-3688	39	4	,	,	PUNCT
dpc-3688	39	5	1	1	NUM
dpc-3688	39	6	,	,	PUNCT
dpc-3688	39	7	and	and	CCONJ
dpc-3688	39	8	2	2	NUM
dpc-3688	39	9	and	and	CCONJ
dpc-3688	39	10	at	at	ADP
dpc-3688	39	11	the	the	DET
dpc-3688	39	12	maintenance	maintenance	NOUN
dpc-3688	39	13	dose	dose	NOUN
dpc-3688	39	14	of	of	ADP
dpc-3688	39	15	210	210	NUM
dpc-3688	39	16	mg	mg	NOUN
dpc-3688	39	17	every	every	DET
dpc-3688	39	18	2	2	NUM
dpc-3688	39	19	weeks	week	NOUN
dpc-3688	40	1	[	[	X
dpc-3688	40	2	14,15	14,15	NUM
dpc-3688	40	3	]	]	PUNCT
dpc-3688	40	4	.	.	PUNCT
dpc-3688	41	1	the	the	DET
dpc-3688	41	2	administration	administration	NOUN
dpc-3688	41	3	of	of	ADP
dpc-3688	41	4	brodalumab	brodalumab	NOUN
dpc-3688	41	5	provides	provide	VERB
dpc-3688	41	6	a	a	DET
dpc-3688	41	7	rapid	rapid	ADJ
dpc-3688	41	8	improvement	improvement	NOUN
dpc-3688	41	9	in	in	ADP
dpc-3688	41	10	disease	disease	NOUN
dpc-3688	41	11	severity	severity	NOUN
dpc-3688	41	12	and	and	CCONJ
dpc-3688	41	13	a	a	DET
dpc-3688	41	14	favorable	favorable	ADJ
dpc-3688	41	15	safety	safety	NOUN
dpc-3688	41	16	profile	profile	NOUN
dpc-3688	41	17	in	in	ADP
dpc-3688	41	18	moderate	moderate	ADJ
dpc-3688	41	19	-	-	PUNCT
dpc-3688	41	20	to	to	ADP
dpc-3688	41	21	-	-	PUNCT
dpc-3688	41	22	severe	severe	ADJ
dpc-3688	41	23	psoriasis	psoriasis	NOUN
dpc-3688	41	24	.	.	PUNCT
dpc-3688	42	1	in	in	ADP
dpc-3688	42	2	addition	addition	NOUN
dpc-3688	42	3	,	,	PUNCT
dpc-3688	42	4	data	datum	NOUN
dpc-3688	42	5	from	from	ADP
dpc-3688	42	6	comparative	comparative	ADJ
dpc-3688	42	7	studies	study	NOUN
dpc-3688	42	8	show	show	VERB
dpc-3688	42	9	a	a	DET
dpc-3688	42	10	faster	fast	ADJ
dpc-3688	42	11	onset	onset	NOUN
dpc-3688	42	12	of	of	ADP
dpc-3688	42	13	action	action	NOUN
dpc-3688	42	14	with	with	ADP
dpc-3688	42	15	brodalumab	brodalumab	NOUN
dpc-3688	42	16	compared	compare	VERB
dpc-3688	42	17	to	to	ADP
dpc-3688	42	18	other	other	ADJ
dpc-3688	42	19	biologic	biologic	NOUN
dpc-3688	42	20	therapies	therapy	NOUN
dpc-3688	42	21	,	,	PUNCT
dpc-3688	42	22	as	as	ADV
dpc-3688	42	23	early	early	ADV
dpc-3688	42	24	as	as	ADP
dpc-3688	42	25	after	after	ADP
dpc-3688	42	26	2	2	NUM
dpc-3688	42	27	weeks	week	NOUN
dpc-3688	42	28	of	of	ADP
dpc-3688	42	29	treatment	treatment	NOUN
dpc-3688	42	30	[	[	X
dpc-3688	42	31	16	16	NUM
dpc-3688	42	32	]	]	PUNCT
dpc-3688	42	33	.	.	PUNCT
dpc-3688	43	1	efficacy	efficacy	NOUN
dpc-3688	43	2	of	of	ADP
dpc-3688	43	3	brodalumab	brodalumab	NOUN
dpc-3688	43	4	on	on	ADP
dpc-3688	43	5	psoriasis	psoriasis	NOUN
dpc-3688	43	6	is	be	AUX
dpc-3688	43	7	well	well	ADV
dpc-3688	43	8	documented	document	VERB
dpc-3688	43	9	from	from	ADP
dpc-3688	43	10	both	both	CCONJ
dpc-3688	43	11	rct	rct	PROPN
dpc-3688	43	12	and	and	CCONJ
dpc-3688	43	13	real	real	ADJ
dpc-3688	43	14	-	-	PUNCT
dpc-3688	43	15	world	world	NOUN
dpc-3688	43	16	data	datum	NOUN
dpc-3688	43	17	showing	show	VERB
dpc-3688	43	18	increasing	increase	VERB
dpc-3688	43	19	percentage	percentage	NOUN
dpc-3688	43	20	of	of	ADP
dpc-3688	43	21	patients	patient	NOUN
dpc-3688	43	22	achieving	achieve	VERB
dpc-3688	43	23	pasi	pasi	NOUN
dpc-3688	43	24	75	75	NUM
dpc-3688	43	25	,	,	PUNCT
dpc-3688	43	26	90	90	NUM
dpc-3688	43	27	and	and	CCONJ
dpc-3688	43	28	100	100	NUM
dpc-3688	43	29	response	response	NOUN
dpc-3688	43	30	rates	rate	NOUN
dpc-3688	43	31	through	through	ADP
dpc-3688	43	32	24	24	NUM
dpc-3688	43	33	weeks	week	NOUN
dpc-3688	43	34	of	of	ADP
dpc-3688	43	35	treatment	treatment	NOUN
dpc-3688	43	36	[	[	X
dpc-3688	43	37	17	17	NUM
dpc-3688	43	38	]	]	PUNCT
dpc-3688	43	39	,	,	PUNCT
dpc-3688	43	40	even	even	ADV
dpc-3688	43	41	in	in	ADP
dpc-3688	43	42	patients	patient	NOUN
dpc-3688	43	43	who	who	PRON
dpc-3688	43	44	failed	fail	VERB
dpc-3688	43	45	previous	previous	ADJ
dpc-3688	43	46	biologics	biologic	NOUN
dpc-3688	43	47	,	,	PUNCT
dpc-3688	43	48	including	include	VERB
dpc-3688	43	49	selective	selective	ADJ
dpc-3688	43	50	anti	anti	ADJ
dpc-3688	43	51	-	-	ADJ
dpc-3688	43	52	interlukin	interlukin	ADJ
dpc-3688	43	53	(	(	PUNCT
dpc-3688	43	54	il)-17	il)-17	PROPN
dpc-3688	43	55	agents	agent	NOUN
dpc-3688	43	56	.	.	PUNCT
dpc-3688	44	1	as	as	SCONJ
dpc-3688	44	2	reported	report	VERB
dpc-3688	44	3	in	in	ADP
dpc-3688	44	4	comparative	comparative	ADJ
dpc-3688	44	5	studies	study	NOUN
dpc-3688	44	6	from	from	ADP
dpc-3688	44	7	rct	rct	PROPN
dpc-3688	44	8	amagine	amagine	PROPN
dpc-3688	44	9	1/2/3	1/2/3	NUM
dpc-3688	44	10	,	,	PUNCT
dpc-3688	44	11	brodalumab	brodalumab	NOUN
dpc-3688	44	12	demonstrated	demonstrate	VERB
dpc-3688	44	13	to	to	PART
dpc-3688	44	14	be	be	AUX
dpc-3688	44	15	effective	effective	ADJ
dpc-3688	44	16	and	and	CCONJ
dpc-3688	44	17	faster	fast	ADV
dpc-3688	44	18	also	also	ADV
dpc-3688	44	19	for	for	ADP
dpc-3688	44	20	patients	patient	NOUN
dpc-3688	44	21	with	with	ADP
dpc-3688	44	22	difficult	difficult	ADJ
dpc-3688	44	23	-	-	PUNCT
dpc-3688	44	24	to	to	ADP
dpc-3688	44	25	-	-	PUNCT
dpc-3688	44	26	treat	treat	NOUN
dpc-3688	44	27	areas	area	NOUN
dpc-3688	44	28	,	,	PUNCT
dpc-3688	44	29	even	even	ADV
dpc-3688	44	30	compared	compare	VERB
dpc-3688	44	31	with	with	ADP
dpc-3688	44	32	other	other	ADJ
dpc-3688	44	33	biologic	biologic	NOUN
dpc-3688	44	34	agents	agent	NOUN
dpc-3688	44	35	[	[	X
dpc-3688	44	36	16,18	16,18	X
dpc-3688	44	37	]	]	PUNCT
dpc-3688	44	38	.	.	PUNCT
dpc-3688	45	1	objectives	objective	VERB
dpc-3688	45	2	the	the	DET
dpc-3688	45	3	aim	aim	NOUN
dpc-3688	45	4	of	of	ADP
dpc-3688	45	5	this	this	DET
dpc-3688	45	6	narrative	narrative	ADJ
dpc-3688	45	7	review	review	NOUN
dpc-3688	45	8	was	be	AUX
dpc-3688	45	9	to	to	PART
dpc-3688	45	10	collect	collect	VERB
dpc-3688	45	11	published	publish	VERB
dpc-3688	45	12	data	datum	NOUN
dpc-3688	45	13	about	about	ADP
dpc-3688	45	14	efficacy	efficacy	NOUN
dpc-3688	45	15	and	and	CCONJ
dpc-3688	45	16	safety	safety	NOUN
dpc-3688	45	17	of	of	ADP
dpc-3688	45	18	brodalumab	brodalumab	NOUN
dpc-3688	45	19	in	in	ADP
dpc-3688	45	20	the	the	DET
dpc-3688	45	21	treatment	treatment	NOUN
dpc-3688	45	22	of	of	ADP
dpc-3688	45	23	psoriasis	psoriasis	NOUN
dpc-3688	45	24	occurring	occur	VERB
dpc-3688	45	25	in	in	ADP
dpc-3688	45	26	difficult	difficult	ADJ
dpc-3688	45	27	-	-	PUNCT
dpc-3688	45	28	to	to	ADP
dpc-3688	45	29	-	-	PUNCT
dpc-3688	45	30	treat	treat	NOUN
dpc-3688	45	31	areas	area	NOUN
dpc-3688	45	32	.	.	PUNCT
dpc-3688	46	1	methods	method	NOUN
dpc-3688	46	2	we	we	PRON
dpc-3688	46	3	carried	carry	VERB
dpc-3688	46	4	out	out	ADP
dpc-3688	46	5	a	a	DET
dpc-3688	46	6	search	search	NOUN
dpc-3688	46	7	of	of	ADP
dpc-3688	46	8	the	the	DET
dpc-3688	46	9	english	english	ADJ
dpc-3688	46	10	-	-	PUNCT
dpc-3688	46	11	language	language	NOUN
dpc-3688	46	12	literature	literature	NOUN
dpc-3688	46	13	regarding	regard	VERB
dpc-3688	46	14	difficult	difficult	ADJ
dpc-3688	46	15	-	-	PUNCT
dpc-3688	46	16	to	to	AUX
dpc-3688	46	17	-	-	PUNCT
dpc-3688	46	18	treat	treat	VERB
dpc-3688	46	19	psoriasis	psoriasis	NOUN
dpc-3688	46	20	and	and	CCONJ
dpc-3688	46	21	treatment	treatment	NOUN
dpc-3688	46	22	,	,	PUNCT
dpc-3688	46	23	with	with	ADP
dpc-3688	46	24	special	special	ADJ
dpc-3688	46	25	focus	focus	NOUN
dpc-3688	46	26	on	on	ADP
dpc-3688	46	27	brodalumab	brodalumab	NOUN
dpc-3688	46	28	effectiveness	effectiveness	NOUN
dpc-3688	46	29	in	in	ADP
dpc-3688	46	30	both	both	PRON
dpc-3688	46	31	trial	trial	NOUN
dpc-3688	46	32	and	and	CCONJ
dpc-3688	46	33	real	real	ADJ
dpc-3688	46	34	world	world	NOUN
dpc-3688	46	35	setting	setting	NOUN
dpc-3688	46	36	.	.	PUNCT
dpc-3688	47	1	we	we	PRON
dpc-3688	47	2	used	use	VERB
dpc-3688	47	3	the	the	DET
dpc-3688	47	4	following	following	ADJ
dpc-3688	47	5	databases	database	NOUN
dpc-3688	47	6	:	:	PUNCT
dpc-3688	47	7	pubmed	pubmed	NOUN
dpc-3688	47	8	,	,	PUNCT
dpc-3688	47	9	embase	embase	NOUN
dpc-3688	47	10	,	,	PUNCT
dpc-3688	47	11	google	google	PROPN
dpc-3688	47	12	scholar	scholar	NOUN
dpc-3688	47	13	,	,	PUNCT
dpc-3688	47	14	researchgate	researchgate	NOUN
dpc-3688	47	15	,	,	PUNCT
dpc-3688	47	16	and	and	CCONJ
dpc-3688	47	17	scopus	scopus	NOUN
dpc-3688	47	18	.	.	PUNCT
dpc-3688	48	1	keywords	keyword	NOUN
dpc-3688	48	2	used	use	VERB
dpc-3688	48	3	were	be	AUX
dpc-3688	48	4	:	:	PUNCT
dpc-3688	48	5	“	"	PUNCT
dpc-3688	48	6	psoriasis	psoriasis	NOUN
dpc-3688	48	7	”	"	PUNCT
dpc-3688	48	8	,	,	PUNCT
dpc-3688	48	9	“	"	PUNCT
dpc-3688	48	10	difficult	difficult	ADJ
dpc-3688	48	11	-	-	PUNCT
dpc-3688	48	12	to	to	ADP
dpc-3688	48	13	-	-	PUNCT
dpc-3688	48	14	treat	treat	VERB
dpc-3688	48	15	psoriasis	psoriasis	NOUN
dpc-3688	48	16	”	"	PUNCT
dpc-3688	48	17	,	,	PUNCT
dpc-3688	48	18	“	"	PUNCT
dpc-3688	48	19	psoriasis	psoriasis	NOUN
dpc-3688	48	20	treatment	treatment	NOUN
dpc-3688	48	21	”	"	PUNCT
dpc-3688	48	22	,	,	PUNCT
dpc-3688	48	23	“	"	PUNCT
dpc-3688	48	24	il-17	il-17	ADP
dpc-3688	48	25	inhibitors	inhibitor	NOUN
dpc-3688	48	26	”	"	PUNCT
dpc-3688	48	27	,	,	PUNCT
dpc-3688	48	28	“	"	PUNCT
dpc-3688	48	29	anti	anti	ADJ
dpc-3688	48	30	-	-	ADJ
dpc-3688	48	31	il-17ra	il-17ra	NOUN
dpc-3688	48	32	”	"	PUNCT
dpc-3688	48	33	,	,	PUNCT
dpc-3688	48	34	“	"	PUNCT
dpc-3688	48	35	brodalumab	brodalumab	NOUN
dpc-3688	48	36	”	"	PUNCT
dpc-3688	48	37	.	.	PUNCT
dpc-3688	49	1	all	all	DET
dpc-3688	49	2	articles	article	NOUN
dpc-3688	49	3	published	publish	VERB
dpc-3688	49	4	in	in	ADP
dpc-3688	49	5	the	the	DET
dpc-3688	49	6	last	last	ADJ
dpc-3688	49	7	15	15	NUM
dpc-3688	49	8	years	year	NOUN
dpc-3688	49	9	and	and	CCONJ
dpc-3688	49	10	data	datum	NOUN
dpc-3688	49	11	from	from	ADP
dpc-3688	49	12	recent	recent	ADJ
dpc-3688	49	13	international	international	ADJ
dpc-3688	49	14	meetings	meeting	NOUN
dpc-3688	49	15	were	be	AUX
dpc-3688	49	16	reviewed	review	VERB
dpc-3688	49	17	.	.	PUNCT
dpc-3688	50	1	plantar	plantar	NOUN
dpc-3688	50	2	psoriasis	psoriasis	NOUN
dpc-3688	50	3	was	be	AUX
dpc-3688	50	4	also	also	ADV
dpc-3688	50	5	described	describe	VERB
dpc-3688	50	6	in	in	ADP
dpc-3688	50	7	brodalumab	brodalumab	NOUN
dpc-3688	50	8	-	-	PUNCT
dpc-3688	50	9	treated	treat	VERB
dpc-3688	50	10	patients	patient	NOUN
dpc-3688	50	11	.	.	PUNCT
dpc-3688	51	1	various	various	ADJ
dpc-3688	51	2	retrospective	retrospective	ADJ
dpc-3688	51	3	real	real	ADJ
dpc-3688	51	4	-	-	PUNCT
dpc-3688	51	5	world	world	NOUN
dpc-3688	51	6	studies	study	NOUN
dpc-3688	51	7	reported	report	VERB
dpc-3688	51	8	a	a	DET
dpc-3688	51	9	complete	complete	ADJ
dpc-3688	51	10	clearance	clearance	NOUN
dpc-3688	51	11	of	of	ADP
dpc-3688	51	12	psoriatic	psoriatic	ADJ
dpc-3688	51	13	lesions	lesion	NOUN
dpc-3688	51	14	in	in	ADP
dpc-3688	51	15	difficult	difficult	ADJ
dpc-3688	51	16	-	-	PUNCT
dpc-3688	51	17	to	to	ADP
dpc-3688	51	18	-	-	PUNCT
dpc-3688	51	19	treat	treat	NOUN
dpc-3688	51	20	areas	area	NOUN
dpc-3688	51	21	,	,	PUNCT
dpc-3688	51	22	including	include	VERB
dpc-3688	51	23	genitalia	genitalia	NOUN
dpc-3688	51	24	,	,	PUNCT
dpc-3688	51	25	through	through	ADP
dpc-3688	51	26	short	short	ADJ
dpc-3688	51	27	-	-	PUNCT
dpc-3688	51	28	term	term	NOUN
dpc-3688	51	29	brodalumab	brodalumab	NOUN
dpc-3688	51	30	treatment	treatment	NOUN
dpc-3688	51	31	.	.	PUNCT
dpc-3688	52	1	conclusions	conclusion	NOUN
dpc-3688	52	2	:	:	PUNCT
dpc-3688	52	3	brodalumab	brodalumab	NOUN
dpc-3688	52	4	,	,	PUNCT
dpc-3688	52	5	combining	combine	VERB
dpc-3688	52	6	rapid	rapid	ADJ
dpc-3688	52	7	and	and	CCONJ
dpc-3688	52	8	sustained	sustained	ADJ
dpc-3688	52	9	efficacy	efficacy	NOUN
dpc-3688	52	10	with	with	ADP
dpc-3688	52	11	a	a	DET
dpc-3688	52	12	favorable	favorable	ADJ
dpc-3688	52	13	safety	safety	NOUN
dpc-3688	52	14	profile	profile	NOUN
dpc-3688	52	15	,	,	PUNCT
dpc-3688	52	16	may	may	AUX
dpc-3688	52	17	be	be	AUX
dpc-3688	52	18	a	a	DET
dpc-3688	52	19	valid	valid	ADJ
dpc-3688	52	20	therapeutic	therapeutic	ADJ
dpc-3688	52	21	option	option	NOUN
dpc-3688	52	22	for	for	ADP
dpc-3688	52	23	severe	severe	ADJ
dpc-3688	52	24	variants	variant	NOUN
dpc-3688	52	25	of	of	ADP
dpc-3688	52	26	psoriasis	psoriasis	NOUN
dpc-3688	52	27	as	as	ADV
dpc-3688	52	28	well	well	ADV
dpc-3688	52	29	as	as	ADP
dpc-3688	52	30	for	for	ADP
dpc-3688	52	31	psoriasis	psoriasis	NOUN
dpc-3688	52	32	localized	localize	VERB
dpc-3688	52	33	in	in	ADP
dpc-3688	52	34	difficult	difficult	ADJ
dpc-3688	52	35	-	-	PUNCT
dpc-3688	52	36	to	to	ADP
dpc-3688	52	37	-	-	PUNCT
dpc-3688	52	38	treat	treat	NOUN
dpc-3688	52	39	areas	area	NOUN
dpc-3688	52	40	.	.	PUNCT
dpc-3688	53	1	review	review	VERB
dpc-3688	53	2	|	|	ADV
dpc-3688	53	3	dermatol	dermatol	ADJ
dpc-3688	53	4	pract	pract	NOUN
dpc-3688	53	5	concept	concept	NOUN
dpc-3688	53	6	.	.	PUNCT
dpc-3688	54	1	2023;13(3):e2023245	2023;13(3):e2023245	NUM
dpc-3688	54	2	3	3	NUM
dpc-3688	54	3	results	result	VERB
dpc-3688	54	4	psoriasis	psoriasis	NOUN
dpc-3688	54	5	pathogenesis	pathogenesis	NOUN
dpc-3688	54	6	and	and	CCONJ
dpc-3688	54	7	druggable	druggable	ADJ
dpc-3688	54	8	targets	target	NOUN
dpc-3688	54	9	psoriasis	psoriasis	NOUN
dpc-3688	54	10	pathogenesis	pathogenesis	NOUN
dpc-3688	54	11	is	be	AUX
dpc-3688	54	12	multifaceted	multifacete	VERB
dpc-3688	54	13	,	,	PUNCT
dpc-3688	54	14	being	be	AUX
dpc-3688	54	15	characterized	characterize	VERB
dpc-3688	54	16	by	by	ADP
dpc-3688	54	17	the	the	DET
dpc-3688	54	18	involvement	involvement	NOUN
dpc-3688	54	19	of	of	ADP
dpc-3688	54	20	a	a	DET
dpc-3688	54	21	wide	wide	ADJ
dpc-3688	54	22	array	array	NOUN
dpc-3688	54	23	of	of	ADP
dpc-3688	54	24	both	both	CCONJ
dpc-3688	54	25	immune	immune	ADJ
dpc-3688	54	26	and	and	CCONJ
dpc-3688	54	27	tissue	tissue	NOUN
dpc-3688	54	28	cells	cell	NOUN
dpc-3688	54	29	and	and	CCONJ
dpc-3688	54	30	by	by	ADP
dpc-3688	54	31	the	the	DET
dpc-3688	54	32	increased	increase	VERB
dpc-3688	54	33	signals	signal	NOUN
dpc-3688	54	34	of	of	ADP
dpc-3688	54	35	different	different	ADJ
dpc-3688	54	36	cytokines	cytokine	NOUN
dpc-3688	54	37	(	(	PUNCT
dpc-3688	54	38	tnf	tnf	PROPN
dpc-3688	54	39	-	-	PUNCT
dpc-3688	54	40	α	α	PROPN
dpc-3688	54	41	,	,	PUNCT
dpc-3688	54	42	il-23	il-23	NOUN
dpc-3688	54	43	,	,	PUNCT
dpc-3688	54	44	il-17a	il-17a	PROPN
dpc-3688	54	45	,	,	PUNCT
dpc-3688	54	46	il-22	il-22	NOUN
dpc-3688	54	47	,	,	PUNCT
dpc-3688	54	48	ifn	ifn	NOUN
dpc-3688	54	49	-γ	-γ	NUM
dpc-3688	54	50	)	)	PUNCT
dpc-3688	55	1	[	[	X
dpc-3688	55	2	19	19	NUM
dpc-3688	55	3	]	]	PUNCT
dpc-3688	55	4	.	.	PUNCT
dpc-3688	56	1	though	though	ADV
dpc-3688	56	2	,	,	PUNCT
dpc-3688	56	3	multiple	multiple	ADJ
dpc-3688	56	4	immune	immune	ADJ
dpc-3688	56	5	pathways	pathway	NOUN
dpc-3688	56	6	contribute	contribute	VERB
dpc-3688	56	7	to	to	ADP
dpc-3688	56	8	the	the	DET
dpc-3688	56	9	inflammatory	inflammatory	ADJ
dpc-3688	56	10	process	process	NOUN
dpc-3688	56	11	,	,	PUNCT
dpc-3688	56	12	the	the	DET
dpc-3688	56	13	il-23	il-23	NOUN
dpc-3688	56	14	/	/	SYM
dpc-3688	56	15	th17	th17	PROPN
dpc-3688	56	16	/	/	SYM
dpc-3688	56	17	il-17a	il-17a	PROPN
dpc-3688	56	18	molecular	molecular	ADJ
dpc-3688	56	19	axis	axis	NOUN
dpc-3688	56	20	is	be	AUX
dpc-3688	56	21	considered	consider	VERB
dpc-3688	56	22	crucial	crucial	ADJ
dpc-3688	56	23	in	in	ADP
dpc-3688	56	24	the	the	DET
dpc-3688	56	25	pathogenesis	pathogenesis	NOUN
dpc-3688	56	26	of	of	ADP
dpc-3688	56	27	psoriasis	psoriasis	NOUN
dpc-3688	56	28	and	and	CCONJ
dpc-3688	56	29	il-17a	il-17a	PROPN
dpc-3688	56	30	is	be	AUX
dpc-3688	56	31	the	the	DET
dpc-3688	56	32	pivotal	pivotal	ADJ
dpc-3688	56	33	effector	effector	NOUN
dpc-3688	56	34	cytokines	cytokine	NOUN
dpc-3688	56	35	in	in	ADP
dpc-3688	56	36	this	this	DET
dpc-3688	56	37	pathogenic	pathogenic	ADJ
dpc-3688	56	38	model	model	NOUN
dpc-3688	57	1	[	[	X
dpc-3688	57	2	20	20	NUM
dpc-3688	57	3	-	-	SYM
dpc-3688	57	4	21	21	NUM
dpc-3688	57	5	]	]	PUNCT
dpc-3688	57	6	.	.	PUNCT
dpc-3688	58	1	il-17a	il-17a	PROPN
dpc-3688	58	2	belongs	belong	VERB
dpc-3688	58	3	to	to	ADP
dpc-3688	58	4	the	the	DET
dpc-3688	58	5	il-17	il-17	NUM
dpc-3688	58	6	cytokine	cytokine	ADJ
dpc-3688	58	7	family	family	NOUN
dpc-3688	58	8	,	,	PUNCT
dpc-3688	58	9	consisting	consist	VERB
dpc-3688	58	10	of	of	ADP
dpc-3688	58	11	six	six	NUM
dpc-3688	58	12	members	member	NOUN
dpc-3688	58	13	(	(	PUNCT
dpc-3688	58	14	il-17a	il-17a	PROPN
dpc-3688	58	15	-	-	PUNCT
dpc-3688	58	16	f	f	PROPN
dpc-3688	58	17	)	)	PUNCT
dpc-3688	58	18	which	which	PRON
dpc-3688	58	19	signal	signal	VERB
dpc-3688	58	20	through	through	ADP
dpc-3688	58	21	dimeric	dimeric	ADJ
dpc-3688	58	22	receptors	receptor	NOUN
dpc-3688	58	23	that	that	PRON
dpc-3688	58	24	included	include	VERB
dpc-3688	58	25	five	five	NUM
dpc-3688	58	26	receptor	receptor	NOUN
dpc-3688	58	27	subunits	subunit	NOUN
dpc-3688	58	28	(	(	PUNCT
dpc-3688	58	29	il-17ra	il-17ra	NOUN
dpc-3688	58	30	to	to	ADP
dpc-3688	58	31	il-17re	il-17re	PROPN
dpc-3688	58	32	)	)	PUNCT
dpc-3688	59	1	[	[	X
dpc-3688	59	2	22,23	22,23	NOUN
dpc-3688	59	3	]	]	PUNCT
dpc-3688	59	4	.	.	PUNCT
dpc-3688	60	1	the	the	DET
dpc-3688	60	2	receptor	receptor	NOUN
dpc-3688	60	3	complex	complex	NOUN
dpc-3688	60	4	binding	bind	VERB
dpc-3688	60	5	to	to	ADP
dpc-3688	60	6	both	both	DET
dpc-3688	60	7	il-17a	il-17a	PROPN
dpc-3688	60	8	and	and	CCONJ
dpc-3688	60	9	il-17f	il-17f	NOUN
dpc-3688	60	10	,	,	PUNCT
dpc-3688	60	11	consists	consist	VERB
dpc-3688	60	12	of	of	ADP
dpc-3688	60	13	two	two	NUM
dpc-3688	60	14	subunits	subunit	NOUN
dpc-3688	60	15	:	:	PUNCT
dpc-3688	60	16	il-17ra	il-17ra	PROPN
dpc-3688	60	17	and	and	CCONJ
dpc-3688	60	18	il-17rc	il-17rc	PROPN
dpc-3688	60	19	,	,	PUNCT
dpc-3688	60	20	while	while	SCONJ
dpc-3688	60	21	il-17c	il-17c	NOUN
dpc-3688	60	22	acts	act	VERB
dpc-3688	60	23	through	through	ADP
dpc-3688	60	24	a	a	DET
dpc-3688	60	25	receptor	receptor	NOUN
dpc-3688	60	26	composed	compose	VERB
dpc-3688	60	27	by	by	ADP
dpc-3688	60	28	the	the	DET
dpc-3688	60	29	subunits	subunit	NOUN
dpc-3688	60	30	il-17ra	il-17ra	PROPN
dpc-3688	60	31	and	and	CCONJ
dpc-3688	60	32	il-17re	il-17re	PROPN
dpc-3688	60	33	.	.	PUNCT
dpc-3688	61	1	il-17e	il-17e	NOUN
dpc-3688	61	2	(	(	PUNCT
dpc-3688	61	3	also	also	ADV
dpc-3688	61	4	called	call	VERB
dpc-3688	61	5	il-25	il-25	NOUN
dpc-3688	61	6	)	)	PUNCT
dpc-3688	61	7	acts	act	VERB
dpc-3688	61	8	through	through	ADP
dpc-3688	61	9	a	a	DET
dpc-3688	61	10	receptor	receptor	NOUN
dpc-3688	61	11	composed	compose	VERB
dpc-3688	61	12	of	of	ADP
dpc-3688	61	13	the	the	DET
dpc-3688	61	14	subunits	subunit	NOUN
dpc-3688	61	15	il-17ra	il-17ra	PROPN
dpc-3688	61	16	and	and	CCONJ
dpc-3688	61	17	il17rb	il17rb	PROPN
dpc-3688	61	18	,	,	PUNCT
dpc-3688	61	19	whereas	whereas	SCONJ
dpc-3688	61	20	il-17b	il-17b	PROPN
dpc-3688	61	21	and	and	CCONJ
dpc-3688	61	22	il-17d	il-17d	PROPN
dpc-3688	61	23	have	have	VERB
dpc-3688	61	24	a	a	DET
dpc-3688	61	25	ligand	ligand	ADJ
dpc-3688	61	26	-	-	PUNCT
dpc-3688	61	27	receptor	receptor	NOUN
dpc-3688	61	28	interaction	interaction	NOUN
dpc-3688	61	29	not	not	PART
dpc-3688	61	30	well	well	ADV
dpc-3688	61	31	-	-	PUNCT
dpc-3688	61	32	defined	define	VERB
dpc-3688	61	33	.	.	PUNCT
dpc-3688	62	1	il-17rd	il-17rd	PROPN
dpc-3688	62	2	acts	act	VERB
dpc-3688	62	3	as	as	ADP
dpc-3688	62	4	an	an	DET
dpc-3688	62	5	alternative	alternative	ADJ
dpc-3688	62	6	heterodimer	heterodimer	NOUN
dpc-3688	62	7	with	with	ADP
dpc-3688	62	8	il-17ra	il-17ra	PROPN
dpc-3688	62	9	and	and	CCONJ
dpc-3688	62	10	is	be	AUX
dpc-3688	62	11	also	also	ADV
dpc-3688	62	12	important	important	ADJ
dpc-3688	62	13	in	in	ADP
dpc-3688	62	14	mediating	mediate	VERB
dpc-3688	62	15	il-17a	il-17a	PROPN
dpc-3688	62	16	signaling	signal	VERB
dpc-3688	62	17	[	[	PUNCT
dpc-3688	62	18	24	24	NUM
dpc-3688	62	19	-	-	SYM
dpc-3688	62	20	25	25	NUM
dpc-3688	62	21	]	]	PUNCT
dpc-3688	62	22	(	(	PUNCT
dpc-3688	62	23	figure	figure	NOUN
dpc-3688	62	24	1	1	NUM
dpc-3688	62	25	)	)	PUNCT
dpc-3688	62	26	.	.	PUNCT
dpc-3688	63	1	the	the	DET
dpc-3688	63	2	expression	expression	NOUN
dpc-3688	63	3	of	of	ADP
dpc-3688	63	4	il-17a	il-17a	PROPN
dpc-3688	63	5	,	,	PUNCT
dpc-3688	63	6	il-17c	il-17c	NOUN
dpc-3688	63	7	,	,	PUNCT
dpc-3688	63	8	and	and	CCONJ
dpc-3688	63	9	il-17f	il-17f	PROPN
dpc-3688	63	10	is	be	AUX
dpc-3688	63	11	increased	increase	VERB
dpc-3688	63	12	up	up	ADP
dpc-3688	63	13	to	to	ADP
dpc-3688	63	14	eightfold	eightfold	ADJ
dpc-3688	63	15	in	in	ADP
dpc-3688	63	16	psoriatic	psoriatic	ADJ
dpc-3688	63	17	lesions	lesion	NOUN
dpc-3688	63	18	compared	compare	VERB
dpc-3688	63	19	to	to	ADP
dpc-3688	63	20	non	non	ADJ
dpc-3688	63	21	-	-	ADJ
dpc-3688	63	22	lesional	lesional	ADJ
dpc-3688	63	23	skin	skin	NOUN
dpc-3688	63	24	with	with	ADP
dpc-3688	63	25	the	the	DET
dpc-3688	63	26	greatest	great	ADJ
dpc-3688	63	27	increase	increase	NOUN
dpc-3688	63	28	being	be	AUX
dpc-3688	63	29	detected	detect	VERB
dpc-3688	63	30	for	for	ADP
dpc-3688	63	31	il-17c	il-17c	NOUN
dpc-3688	63	32	and	and	CCONJ
dpc-3688	63	33	il-17f	il-17f	NOUN
dpc-3688	63	34	,	,	PUNCT
dpc-3688	63	35	though	though	SCONJ
dpc-3688	63	36	il-17a	il-17a	PROPN
dpc-3688	63	37	results	result	VERB
dpc-3688	63	38	the	the	PRON
dpc-3688	63	39	most	most	ADV
dpc-3688	63	40	biologically	biologically	ADV
dpc-3688	63	41	active	active	ADJ
dpc-3688	63	42	(	(	PUNCT
dpc-3688	63	43	up	up	ADP
dpc-3688	63	44	to	to	PART
dpc-3688	63	45	30	30	NUM
dpc-3688	63	46	-	-	NOUN
dpc-3688	63	47	fold	fold	VERB
dpc-3688	63	48	more	more	ADV
dpc-3688	63	49	active	active	ADJ
dpc-3688	63	50	than	than	ADP
dpc-3688	63	51	il-17f	il-17f	NOUN
dpc-3688	63	52	)	)	PUNCT
dpc-3688	64	1	[	[	X
dpc-3688	64	2	22,26,27	22,26,27	NUM
dpc-3688	64	3	]	]	PUNCT
dpc-3688	64	4	.	.	PUNCT
dpc-3688	65	1	mounting	mount	VERB
dpc-3688	65	2	evidence	evidence	NOUN
dpc-3688	65	3	supporting	support	VERB
dpc-3688	65	4	the	the	DET
dpc-3688	65	5	central	central	ADJ
dpc-3688	65	6	role	role	NOUN
dpc-3688	65	7	of	of	ADP
dpc-3688	65	8	il-17a	il-17a	PROPN
dpc-3688	65	9	in	in	ADP
dpc-3688	65	10	psoriasis	psoriasis	NOUN
dpc-3688	65	11	includes	include	VERB
dpc-3688	65	12	the	the	DET
dpc-3688	65	13	upregulation	upregulation	NOUN
dpc-3688	65	14	of	of	ADP
dpc-3688	65	15	both	both	DET
dpc-3688	65	16	il-17a	il-17a	PROPN
dpc-3688	65	17	and	and	CCONJ
dpc-3688	65	18	its	its	PRON
dpc-3688	65	19	related	related	ADJ
dpc-3688	65	20	genes	gene	NOUN
dpc-3688	65	21	in	in	ADP
dpc-3688	65	22	lesional	lesional	ADJ
dpc-3688	65	23	and	and	CCONJ
dpc-3688	65	24	non	non	ADJ
dpc-3688	65	25	-	-	ADJ
dpc-3688	65	26	lesional	lesional	ADJ
dpc-3688	65	27	skin	skin	NOUN
dpc-3688	65	28	of	of	ADP
dpc-3688	65	29	patients	patient	NOUN
dpc-3688	65	30	with	with	ADP
dpc-3688	65	31	psoriasis	psoriasis	NOUN
dpc-3688	65	32	.	.	PUNCT
dpc-3688	66	1	the	the	DET
dpc-3688	66	2	increased	increase	VERB
dpc-3688	66	3	expression	expression	NOUN
dpc-3688	66	4	of	of	ADP
dpc-3688	66	5	il-17a	il-17a	PROPN
dpc-3688	66	6	derives	derive	VERB
dpc-3688	66	7	from	from	ADP
dpc-3688	66	8	immune	immune	ADJ
dpc-3688	66	9	cells	cell	NOUN
dpc-3688	66	10	involved	involve	VERB
dpc-3688	66	11	in	in	ADP
dpc-3688	66	12	psoriasis	psoriasis	NOUN
dpc-3688	66	13	pathogenesis	pathogenesis	NOUN
dpc-3688	66	14	such	such	ADJ
dpc-3688	66	15	as	as	ADP
dpc-3688	66	16	t	t	PROPN
dpc-3688	66	17	helper	helper	NOUN
dpc-3688	66	18	(	(	PUNCT
dpc-3688	66	19	h	h	NOUN
dpc-3688	66	20	)	)	PUNCT
dpc-3688	66	21	cells	cell	NOUN
dpc-3688	66	22	,	,	PUNCT
dpc-3688	66	23	t	t	PROPN
dpc-3688	66	24	cytotoxic	cytotoxic	NOUN
dpc-3688	66	25	(	(	PUNCT
dpc-3688	66	26	c	c	NOUN
dpc-3688	66	27	)	)	PUNCT
dpc-3688	66	28	17	17	NUM
dpc-3688	66	29	,	,	PUNCT
dpc-3688	66	30	innate	innate	ADJ
dpc-3688	66	31	lymphoid	lymphoid	ADJ
dpc-3688	66	32	cells	cell	NOUN
dpc-3688	66	33	(	(	PUNCT
dpc-3688	66	34	ilc)3	ilc)3	PROPN
dpc-3688	66	35	,	,	PUNCT
dpc-3688	66	36	mast	mast	NOUN
dpc-3688	66	37	cells	cell	NOUN
dpc-3688	66	38	,	,	PUNCT
dpc-3688	66	39	and	and	CCONJ
dpc-3688	66	40	neutrophils	neutrophil	NOUN
dpc-3688	66	41	,	,	PUNCT
dpc-3688	66	42	that	that	PRON
dpc-3688	66	43	infiltrate	infiltrate	VERB
dpc-3688	66	44	lesional	lesional	ADJ
dpc-3688	66	45	skin	skin	NOUN
dpc-3688	66	46	and	and	CCONJ
dpc-3688	66	47	contribute	contribute	VERB
dpc-3688	66	48	to	to	ADP
dpc-3688	66	49	its	its	PRON
dpc-3688	66	50	abundant	abundant	ADJ
dpc-3688	66	51	expression	expression	NOUN
dpc-3688	66	52	[	[	X
dpc-3688	66	53	27	27	NUM
dpc-3688	66	54	]	]	PUNCT
dpc-3688	66	55	.	.	PUNCT
dpc-3688	67	1	in	in	ADP
dpc-3688	67	2	vitro	vitro	X
dpc-3688	67	3	,	,	PUNCT
dpc-3688	67	4	il-17	il-17	X
dpc-3688	67	5	affects	affect	VERB
dpc-3688	67	6	the	the	DET
dpc-3688	67	7	expression	expression	NOUN
dpc-3688	67	8	of	of	ADP
dpc-3688	67	9	a	a	DET
dpc-3688	67	10	large	large	ADJ
dpc-3688	67	11	set	set	NOUN
dpc-3688	67	12	of	of	ADP
dpc-3688	67	13	genes	gene	NOUN
dpc-3688	67	14	(	(	PUNCT
dpc-3688	67	15	more	more	ADJ
dpc-3688	67	16	than	than	ADP
dpc-3688	67	17	600	600	NUM
dpc-3688	67	18	upor	upor	ADJ
dpc-3688	67	19	down	down	ADV
dpc-3688	67	20	-	-	PUNCT
dpc-3688	67	21	regulated	regulate	VERB
dpc-3688	67	22	gene	gene	NOUN
dpc-3688	67	23	probes	probe	NOUN
dpc-3688	67	24	)	)	PUNCT
dpc-3688	67	25	in	in	ADP
dpc-3688	67	26	a	a	DET
dpc-3688	67	27	reconstituted	reconstitute	VERB
dpc-3688	67	28	human	human	ADJ
dpc-3688	67	29	epidermis	epidermis	NOUN
dpc-3688	67	30	model	model	NOUN
dpc-3688	67	31	,	,	PUNCT
dpc-3688	67	32	and	and	CCONJ
dpc-3688	67	33	its	its	PRON
dpc-3688	67	34	effects	effect	NOUN
dpc-3688	67	35	are	be	AUX
dpc-3688	67	36	amplified	amplify	VERB
dpc-3688	67	37	by	by	ADP
dpc-3688	67	38	the	the	DET
dpc-3688	67	39	synergism	synergism	NOUN
dpc-3688	67	40	with	with	ADP
dpc-3688	67	41	other	other	ADJ
dpc-3688	67	42	cytokines	cytokine	NOUN
dpc-3688	67	43	,	,	PUNCT
dpc-3688	67	44	including	include	VERB
dpc-3688	67	45	il-22	il-22	NUM
dpc-3688	67	46	and	and	CCONJ
dpc-3688	67	47	tnf	tnf	PROPN
dpc-3688	67	48	-	-	PUNCT
dpc-3688	67	49	α	α	PROPN
dpc-3688	67	50	,	,	PUNCT
dpc-3688	67	51	strengthening	strengthen	VERB
dpc-3688	67	52	the	the	DET
dpc-3688	67	53	production	production	NOUN
dpc-3688	67	54	of	of	ADP
dpc-3688	67	55	chemokines	chemokine	NOUN
dpc-3688	67	56	,	,	PUNCT
dpc-3688	67	57	figure	figure	NOUN
dpc-3688	67	58	1	1	NUM
dpc-3688	67	59	.	.	PUNCT
dpc-3688	67	60	il-17	il-17	NUM
dpc-3688	67	61	cytokines	cytokine	VERB
dpc-3688	67	62	family	family	NOUN
dpc-3688	67	63	.	.	PUNCT
dpc-3688	68	1	the	the	DET
dpc-3688	68	2	il-17	il-17	NUM
dpc-3688	68	3	cytokine	cytokine	ADJ
dpc-3688	68	4	family	family	NOUN
dpc-3688	68	5	members	member	NOUN
dpc-3688	68	6	signal	signal	VERB
dpc-3688	68	7	through	through	ADP
dpc-3688	68	8	different	different	ADJ
dpc-3688	68	9	dimeric	dimeric	ADJ
dpc-3688	68	10	receptor	receptor	NOUN
dpc-3688	68	11	complexes	complex	NOUN
dpc-3688	68	12	that	that	PRON
dpc-3688	68	13	include	include	VERB
dpc-3688	68	14	five	five	NUM
dpc-3688	68	15	subunits	subunit	NOUN
dpc-3688	68	16	(	(	PUNCT
dpc-3688	68	17	il-17ra	il-17ra	NOUN
dpc-3688	68	18	to	to	ADP
dpc-3688	68	19	il-17re	il-17re	PROPN
dpc-3688	68	20	)	)	PUNCT
dpc-3688	68	21	.	.	PUNCT
dpc-3688	69	1	binding	bind	VERB
dpc-3688	69	2	to	to	ADP
dpc-3688	69	3	receptor	receptor	NOUN
dpc-3688	69	4	complex	complex	NOUN
dpc-3688	69	5	,	,	PUNCT
dpc-3688	69	6	il-17	il-17	NUM
dpc-3688	69	7	cytokines	cytokine	NOUN
dpc-3688	69	8	are	be	AUX
dpc-3688	69	9	able	able	ADJ
dpc-3688	69	10	to	to	PART
dpc-3688	69	11	induce	induce	VERB
dpc-3688	69	12	the	the	DET
dpc-3688	69	13	expression	expression	NOUN
dpc-3688	69	14	of	of	ADP
dpc-3688	69	15	specific	specific	ADJ
dpc-3688	69	16	downstream	downstream	ADJ
dpc-3688	69	17	genes	gene	NOUN
dpc-3688	69	18	,	,	PUNCT
dpc-3688	69	19	mostly	mostly	ADV
dpc-3688	69	20	transducing	transduce	VERB
dpc-3688	69	21	for	for	ADP
dpc-3688	69	22	pro	pro	ADJ
dpc-3688	69	23	-	-	ADJ
dpc-3688	69	24	inflammatory	inflammatory	ADJ
dpc-3688	69	25	mediators	mediator	NOUN
dpc-3688	69	26	.	.	PUNCT
dpc-3688	70	1	ccl	ccl	PROPN
dpc-3688	70	2	,	,	PUNCT
dpc-3688	70	3	cxcl	cxcl	VERB
dpc-3688	70	4	chemokine	chemokine	ADJ
dpc-3688	70	5	ligand	ligand	NOUN
dpc-3688	70	6	;	;	PUNCT
dpc-3688	70	7	il	il	PROPN
dpc-3688	70	8	interleukin	interleukin	NOUN
dpc-3688	70	9	;	;	PUNCT
dpc-3688	70	10	tnf	tnf	PROPN
dpc-3688	70	11	-	-	PUNCT
dpc-3688	70	12	α	α	PROPN
dpc-3688	70	13	=	=	PUNCT
dpc-3688	70	14	tumor	tumor	NOUN
dpc-3688	70	15	necrosis	necrosis	NOUN
dpc-3688	70	16	factor	factor	NOUN
dpc-3688	70	17	alpha	alpha	NOUN
dpc-3688	70	18	.	.	PUNCT
dpc-3688	71	1	4	4	NUM
dpc-3688	71	2	review	review	NOUN
dpc-3688	71	3	|	|	ADV
dpc-3688	71	4	dermatol	dermatol	ADJ
dpc-3688	71	5	pract	pract	NOUN
dpc-3688	71	6	concept	concept	NOUN
dpc-3688	71	7	.	.	PUNCT
dpc-3688	72	1	2023;13(3):e2023245	2023;13(3):e2023245	NUM
dpc-3688	72	2	of	of	ADP
dpc-3688	72	3	its	its	PRON
dpc-3688	72	4	receptor	receptor	NOUN
dpc-3688	72	5	on	on	ADP
dpc-3688	72	6	th17	th17	NOUN
dpc-3688	72	7	cells	cell	NOUN
dpc-3688	72	8	,	,	PUNCT
dpc-3688	72	9	especially	especially	ADV
dpc-3688	72	10	when	when	SCONJ
dpc-3688	72	11	pooled	pool	VERB
dpc-3688	72	12	with	with	ADP
dpc-3688	72	13	il-6	il-6	NOUN
dpc-3688	72	14	,	,	PUNCT
dpc-3688	72	15	tgf	tgf	PROPN
dpc-3688	72	16	-	-	PUNCT
dpc-3688	72	17	β	β	PROPN
dpc-3688	72	18	,	,	PUNCT
dpc-3688	72	19	il-1	il-1	ADP
dpc-3688	72	20	,	,	PUNCT
dpc-3688	72	21	and	and	CCONJ
dpc-3688	72	22	il-23	il-23	NOUN
dpc-3688	73	1	[	[	X
dpc-3688	73	2	36	36	NUM
dpc-3688	73	3	-	-	SYM
dpc-3688	73	4	38	38	NUM
dpc-3688	73	5	]	]	PUNCT
dpc-3688	73	6	.	.	PUNCT
dpc-3688	74	1	there	there	PRON
dpc-3688	74	2	is	be	VERB
dpc-3688	74	3	an	an	DET
dpc-3688	74	4	important	important	ADJ
dpc-3688	74	5	bidirectional	bidirectional	ADJ
dpc-3688	74	6	relationship	relationship	NOUN
dpc-3688	74	7	between	between	ADP
dpc-3688	74	8	il-17a	il-17a	PROPN
dpc-3688	74	9	and	and	CCONJ
dpc-3688	74	10	il-17c	il-17c	PROPN
dpc-3688	74	11	,	,	PUNCT
dpc-3688	74	12	because	because	SCONJ
dpc-3688	74	13	il-17a	il-17a	PROPN
dpc-3688	74	14	is	be	AUX
dpc-3688	74	15	a	a	DET
dpc-3688	74	16	strong	strong	ADJ
dpc-3688	74	17	inducer	inducer	NOUN
dpc-3688	74	18	of	of	ADP
dpc-3688	74	19	il-17c	il-17c	NOUN
dpc-3688	74	20	in	in	ADP
dpc-3688	74	21	keratinocytes	keratinocyte	NOUN
dpc-3688	74	22	and	and	CCONJ
dpc-3688	74	23	il-17c	il-17c	NOUN
dpc-3688	74	24	can	can	AUX
dpc-3688	74	25	induce	induce	VERB
dpc-3688	74	26	high	high	ADJ
dpc-3688	74	27	-	-	PUNCT
dpc-3688	74	28	level	level	NOUN
dpc-3688	74	29	synthesis	synthesis	NOUN
dpc-3688	74	30	of	of	ADP
dpc-3688	74	31	il-17a	il-17a	PROPN
dpc-3688	74	32	in	in	ADP
dpc-3688	74	33	t	t	PROPN
dpc-3688	74	34	lymphocytes	lymphocyte	VERB
dpc-3688	74	35	.	.	PUNCT
dpc-3688	75	1	because	because	SCONJ
dpc-3688	75	2	il-17c	il-17c	NOUN
dpc-3688	75	3	is	be	AUX
dpc-3688	75	4	produced	produce	VERB
dpc-3688	75	5	in	in	ADP
dpc-3688	75	6	massive	massive	ADJ
dpc-3688	75	7	quantities	quantity	NOUN
dpc-3688	75	8	by	by	ADP
dpc-3688	75	9	keratinocytes	keratinocyte	NOUN
dpc-3688	75	10	(	(	PUNCT
dpc-3688	75	11	eg	eg	NOUN
dpc-3688	75	12	,	,	PUNCT
dpc-3688	75	13	production	production	NOUN
dpc-3688	75	14	in	in	ADP
dpc-3688	75	15	psoriasis	psoriasis	NOUN
dpc-3688	75	16	is	be	AUX
dpc-3688	75	17	100	100	NUM
dpc-3688	75	18	-	-	NUM
dpc-3688	75	19	fold	fold	VERB
dpc-3688	75	20	higher	high	ADJ
dpc-3688	75	21	than	than	ADP
dpc-3688	75	22	il-17	il-17	PRON
dpc-3688	75	23	a	a	PRON
dpc-3688	75	24	[	[	X
dpc-3688	75	25	35	35	NUM
dpc-3688	75	26	]	]	PUNCT
dpc-3688	75	27	,	,	PUNCT
dpc-3688	75	28	the	the	DET
dpc-3688	75	29	actions	action	NOUN
dpc-3688	75	30	of	of	ADP
dpc-3688	75	31	this	this	DET
dpc-3688	75	32	cytokine	cytokine	NOUN
dpc-3688	75	33	may	may	AUX
dpc-3688	75	34	come	come	VERB
dpc-3688	75	35	to	to	PART
dpc-3688	75	36	lead	lead	VERB
dpc-3688	75	37	the	the	DET
dpc-3688	75	38	il-17	il-17	NUM
dpc-3688	75	39	response	response	NOUN
dpc-3688	75	40	axis	axis	NOUN
dpc-3688	75	41	in	in	ADP
dpc-3688	75	42	chronic	chronic	ADJ
dpc-3688	75	43	inflammatory	inflammatory	ADJ
dpc-3688	75	44	conditions	condition	NOUN
dpc-3688	75	45	.	.	PUNCT
dpc-3688	76	1	il‐17c	il‐17c	PROPN
dpc-3688	76	2	may	may	AUX
dpc-3688	76	3	thereby	thereby	ADV
dpc-3688	76	4	amplify	amplify	VERB
dpc-3688	76	5	the	the	DET
dpc-3688	76	6	inflammatory	inflammatory	ADJ
dpc-3688	76	7	response	response	NOUN
dpc-3688	76	8	by	by	ADP
dpc-3688	76	9	further	far	ADV
dpc-3688	76	10	enhancing	enhance	VERB
dpc-3688	76	11	the	the	DET
dpc-3688	76	12	production	production	NOUN
dpc-3688	76	13	of	of	ADP
dpc-3688	76	14	inflammatory	inflammatory	ADJ
dpc-3688	76	15	mediators	mediator	NOUN
dpc-3688	76	16	,	,	PUNCT
dpc-3688	76	17	including	include	VERB
dpc-3688	76	18	c‐c	c‐c	NUM
dpc-3688	76	19	motif	motif	NOUN
dpc-3688	76	20	chemokine	chemokine	ADJ
dpc-3688	76	21	ligand	ligand	NOUN
dpc-3688	76	22	20	20	NUM
dpc-3688	76	23	(	(	PUNCT
dpc-3688	76	24	ccl20	ccl20	NOUN
dpc-3688	76	25	)	)	PUNCT
dpc-3688	76	26	,	,	PUNCT
dpc-3688	76	27	which	which	PRON
dpc-3688	76	28	attracts	attract	VERB
dpc-3688	76	29	il‐17‐producing	il‐17‐producing	PROPN
dpc-3688	76	30	t	t	NOUN
dpc-3688	76	31	cells	cell	NOUN
dpc-3688	76	32	.	.	PUNCT
dpc-3688	77	1	additionally	additionally	ADV
dpc-3688	77	2	,	,	PUNCT
dpc-3688	77	3	il‐17c	il‐17c	PROPN
dpc-3688	77	4	was	be	AUX
dpc-3688	77	5	shown	show	VERB
dpc-3688	77	6	directly	directly	ADV
dpc-3688	77	7	to	to	PART
dpc-3688	77	8	induce	induce	VERB
dpc-3688	77	9	expression	expression	NOUN
dpc-3688	77	10	of	of	ADP
dpc-3688	77	11	il‐17a	il‐17a	PROPN
dpc-3688	77	12	and	and	CCONJ
dpc-3688	77	13	il‐17f	il‐17f	VERB
dpc-3688	77	14	in	in	ADP
dpc-3688	77	15	mouse	mouse	NOUN
dpc-3688	77	16	th17	th17	NOUN
dpc-3688	77	17	cells	cell	NOUN
dpc-3688	77	18	[	[	X
dpc-3688	77	19	36	36	NUM
dpc-3688	77	20	]	]	PUNCT
dpc-3688	77	21	.	.	PUNCT
dpc-3688	78	1	therapeutic	therapeutic	ADJ
dpc-3688	78	2	agents	agent	NOUN
dpc-3688	78	3	used	use	VERB
dpc-3688	78	4	in	in	ADP
dpc-3688	78	5	the	the	DET
dpc-3688	78	6	management	management	NOUN
dpc-3688	78	7	of	of	ADP
dpc-3688	78	8	moderate	moderate	ADJ
dpc-3688	78	9	-	-	PUNCT
dpc-3688	78	10	to	to	ADP
dpc-3688	78	11	-	-	PUNCT
dpc-3688	78	12	severe	severe	ADJ
dpc-3688	78	13	plaque	plaque	NOUN
dpc-3688	78	14	psoriasis	psoriasis	NOUN
dpc-3688	78	15	treatment	treatment	NOUN
dpc-3688	78	16	of	of	ADP
dpc-3688	78	17	patients	patient	NOUN
dpc-3688	78	18	affected	affect	VERB
dpc-3688	78	19	by	by	ADP
dpc-3688	78	20	hard	hard	ADJ
dpc-3688	78	21	-	-	PUNCT
dpc-3688	78	22	to	to	PART
dpc-3688	78	23	-	-	PUNCT
dpc-3688	78	24	treat	treat	VERB
dpc-3688	78	25	psoriasis	psoriasis	NOUN
dpc-3688	78	26	is	be	AUX
dpc-3688	78	27	often	often	ADV
dpc-3688	78	28	challenging	challenging	ADJ
dpc-3688	78	29	.	.	PUNCT
dpc-3688	79	1	the	the	DET
dpc-3688	79	2	anatomical	anatomical	ADJ
dpc-3688	79	3	structure	structure	NOUN
dpc-3688	79	4	of	of	ADP
dpc-3688	79	5	affected	affect	VERB
dpc-3688	79	6	sites	site	NOUN
dpc-3688	79	7	may	may	AUX
dpc-3688	79	8	hamper	hamper	VERB
dpc-3688	79	9	the	the	DET
dpc-3688	79	10	application	application	NOUN
dpc-3688	79	11	and	and	CCONJ
dpc-3688	79	12	reduce	reduce	VERB
dpc-3688	79	13	the	the	DET
dpc-3688	79	14	absorption	absorption	NOUN
dpc-3688	79	15	of	of	ADP
dpc-3688	79	16	topical	topical	ADJ
dpc-3688	79	17	treatments	treatment	NOUN
dpc-3688	79	18	[	[	X
dpc-3688	79	19	39,40	39,40	NUM
dpc-3688	79	20	]	]	PUNCT
dpc-3688	79	21	.	.	PUNCT
dpc-3688	80	1	physical	physical	ADJ
dpc-3688	80	2	therapies	therapy	NOUN
dpc-3688	80	3	may	may	AUX
dpc-3688	80	4	be	be	AUX
dpc-3688	80	5	effective	effective	ADJ
dpc-3688	80	6	for	for	ADP
dpc-3688	80	7	palmoplantar	palmoplantar	NOUN
dpc-3688	80	8	areas	area	NOUN
dpc-3688	80	9	,	,	PUNCT
dpc-3688	80	10	but	but	CCONJ
dpc-3688	80	11	time	time	NOUN
dpc-3688	80	12	consuming	consume	VERB
dpc-3688	80	13	.	.	PUNCT
dpc-3688	81	1	traditional	traditional	ADJ
dpc-3688	81	2	therapies	therapy	NOUN
dpc-3688	81	3	(	(	PUNCT
dpc-3688	81	4	cyclosporine	cyclosporine	NOUN
dpc-3688	81	5	,	,	PUNCT
dpc-3688	81	6	methotrexate	methotrexate	NOUN
dpc-3688	81	7	,	,	PUNCT
dpc-3688	81	8	acitretin	acitretin	NOUN
dpc-3688	81	9	,	,	PUNCT
dpc-3688	81	10	dimethyl	dimethyl	NOUN
dpc-3688	81	11	fumarate	fumarate	NOUN
dpc-3688	81	12	)	)	PUNCT
dpc-3688	81	13	can	can	AUX
dpc-3688	81	14	provide	provide	VERB
dpc-3688	81	15	some	some	DET
dpc-3688	81	16	benefits	benefit	NOUN
dpc-3688	81	17	,	,	PUNCT
dpc-3688	81	18	but	but	CCONJ
dpc-3688	81	19	often	often	ADV
dpc-3688	81	20	not	not	PART
dpc-3688	81	21	well	well	ADV
dpc-3688	81	22	tolerated	tolerate	VERB
dpc-3688	81	23	or	or	CCONJ
dpc-3688	81	24	aggravated	aggravate	VERB
dpc-3688	81	25	by	by	ADP
dpc-3688	81	26	side	side	NOUN
dpc-3688	81	27	effects	effect	NOUN
dpc-3688	81	28	.	.	PUNCT
dpc-3688	82	1	a	a	DET
dpc-3688	82	2	new	new	ADJ
dpc-3688	82	3	small	small	ADJ
dpc-3688	82	4	molecule	molecule	NOUN
dpc-3688	82	5	,	,	PUNCT
dpc-3688	82	6	apremilast	apremilast	ADJ
dpc-3688	82	7	,	,	PUNCT
dpc-3688	82	8	demonstrated	demonstrate	VERB
dpc-3688	82	9	to	to	PART
dpc-3688	82	10	be	be	AUX
dpc-3688	82	11	effective	effective	ADJ
dpc-3688	82	12	on	on	ADP
dpc-3688	82	13	psa	psa	NOUN
dpc-3688	82	14	and	and	CCONJ
dpc-3688	82	15	pso	pso	NOUN
dpc-3688	82	16	,	,	PUNCT
dpc-3688	82	17	pro	pro	ADJ
dpc-3688	82	18	-	-	ADJ
dpc-3688	82	19	inflammatory	inflammatory	ADJ
dpc-3688	82	20	cytokines	cytokine	NOUN
dpc-3688	82	21	,	,	PUNCT
dpc-3688	82	22	and	and	CCONJ
dpc-3688	82	23	antimicrobial	antimicrobial	ADJ
dpc-3688	82	24	peptides	peptide	NOUN
dpc-3688	82	25	(	(	PUNCT
dpc-3688	82	26	amps	amp	NOUN
dpc-3688	82	27	)	)	PUNCT
dpc-3688	82	28	.	.	PUNCT
dpc-3688	83	1	they	they	PRON
dpc-3688	83	2	key	key	VERB
dpc-3688	83	3	psoriasis	psoriasis	NOUN
dpc-3688	83	4	-	-	PUNCT
dpc-3688	83	5	signature	signature	NOUN
dpc-3688	83	6	genes	gene	NOUN
dpc-3688	83	7	are	be	AUX
dpc-3688	83	8	mostly	mostly	ADV
dpc-3688	83	9	induced	induce	VERB
dpc-3688	83	10	by	by	ADP
dpc-3688	83	11	il-17	il-17	X
dpc-3688	83	12	stimulation	stimulation	VERB
dpc-3688	83	13	on	on	ADP
dpc-3688	83	14	keratinocytes	keratinocyte	NOUN
dpc-3688	83	15	and	and	CCONJ
dpc-3688	83	16	,	,	PUNCT
dpc-3688	83	17	conversely	conversely	ADV
dpc-3688	83	18	to	to	ADP
dpc-3688	83	19	signals	signal	NOUN
dpc-3688	83	20	mediated	mediate	VERB
dpc-3688	83	21	by	by	ADP
dpc-3688	83	22	other	other	ADJ
dpc-3688	83	23	pivotal	pivotal	ADJ
dpc-3688	83	24	cytokines	cytokine	NOUN
dpc-3688	83	25	,	,	PUNCT
dpc-3688	83	26	il-17a	il-17a	PROPN
dpc-3688	83	27	signal	signal	VERB
dpc-3688	83	28	greatly	greatly	ADV
dpc-3688	83	29	characterizes	characterize	VERB
dpc-3688	83	30	the	the	DET
dpc-3688	83	31	psoriasis	psoriasis	NOUN
dpc-3688	83	32	lesional	lesional	ADJ
dpc-3688	83	33	skin	skin	NOUN
dpc-3688	83	34	transcriptome	transcriptome	NOUN
dpc-3688	84	1	[	[	X
dpc-3688	84	2	28	28	NUM
dpc-3688	84	3	-	-	SYM
dpc-3688	84	4	30	30	NUM
dpc-3688	84	5	]	]	PUNCT
dpc-3688	84	6	.	.	PUNCT
dpc-3688	85	1	similarly	similarly	ADV
dpc-3688	85	2	to	to	ADP
dpc-3688	85	3	il-17a	il-17a	PROPN
dpc-3688	85	4	,	,	PUNCT
dpc-3688	85	5	il‐17f	il‐17f	ADJ
dpc-3688	85	6	and	and	CCONJ
dpc-3688	85	7	il‐17c	il‐17c	PROPN
dpc-3688	85	8	act	act	NOUN
dpc-3688	85	9	in	in	ADP
dpc-3688	85	10	synergy	synergy	NOUN
dpc-3688	85	11	with	with	ADP
dpc-3688	85	12	other	other	ADJ
dpc-3688	85	13	cytokines	cytokine	NOUN
dpc-3688	85	14	,	,	PUNCT
dpc-3688	85	15	such	such	ADJ
dpc-3688	85	16	as	as	ADP
dpc-3688	85	17	tnf	tnf	PROPN
dpc-3688	85	18	-	-	PUNCT
dpc-3688	85	19	α	α	PROPN
dpc-3688	85	20	or	or	CCONJ
dpc-3688	85	21	il‐1	il‐1	NOUN
dpc-3688	85	22	,	,	PUNCT
dpc-3688	85	23	inducing	induce	VERB
dpc-3688	85	24	expression	expression	NOUN
dpc-3688	85	25	of	of	ADP
dpc-3688	85	26	antimicrobial	antimicrobial	ADJ
dpc-3688	85	27	peptides	peptide	NOUN
dpc-3688	85	28	(	(	PUNCT
dpc-3688	85	29	amps	amp	NOUN
dpc-3688	85	30	)	)	PUNCT
dpc-3688	85	31	,	,	PUNCT
dpc-3688	85	32	chemokines	chemokine	NOUN
dpc-3688	85	33	and	and	CCONJ
dpc-3688	85	34	proinflammatory	proinflammatory	ADJ
dpc-3688	85	35	cytokines	cytokine	NOUN
dpc-3688	85	36	,	,	PUNCT
dpc-3688	85	37	which	which	PRON
dpc-3688	85	38	promote	promote	VERB
dpc-3688	85	39	innate	innate	ADJ
dpc-3688	85	40	immune	immune	ADJ
dpc-3688	85	41	responses	response	NOUN
dpc-3688	85	42	,	,	PUNCT
dpc-3688	85	43	the	the	DET
dpc-3688	85	44	recruitment	recruitment	NOUN
dpc-3688	85	45	of	of	ADP
dpc-3688	85	46	inflammatory	inflammatory	ADJ
dpc-3688	85	47	cells	cell	NOUN
dpc-3688	85	48	,	,	PUNCT
dpc-3688	85	49	and	and	CCONJ
dpc-3688	85	50	keratinocyte	keratinocyte	NOUN
dpc-3688	85	51	activation	activation	NOUN
dpc-3688	85	52	and	and	CCONJ
dpc-3688	85	53	proliferation	proliferation	NOUN
dpc-3688	86	1	[	[	X
dpc-3688	86	2	31	31	NUM
dpc-3688	86	3	]	]	PUNCT
dpc-3688	86	4	.	.	PUNCT
dpc-3688	87	1	furthermore	furthermore	ADV
dpc-3688	87	2	,	,	PUNCT
dpc-3688	87	3	an	an	DET
dpc-3688	87	4	interplay	interplay	NOUN
dpc-3688	87	5	between	between	ADP
dpc-3688	87	6	il‐17a	il‐17a	PROPN
dpc-3688	87	7	,	,	PUNCT
dpc-3688	87	8	il‐17f	il‐17f	ADJ
dpc-3688	87	9	and	and	CCONJ
dpc-3688	87	10	il‐17c	il‐17c	NOUN
dpc-3688	87	11	has	have	AUX
dpc-3688	87	12	been	be	AUX
dpc-3688	87	13	described	describe	VERB
dpc-3688	87	14	,	,	PUNCT
dpc-3688	87	15	and	and	CCONJ
dpc-3688	87	16	both	both	PRON
dpc-3688	87	17	il‐17a	il‐17a	X
dpc-3688	87	18	and	and	CCONJ
dpc-3688	87	19	il‐17f	il‐17f	NOUN
dpc-3688	87	20	,	,	PUNCT
dpc-3688	87	21	as	as	ADV
dpc-3688	87	22	well	well	ADV
dpc-3688	87	23	as	as	ADP
dpc-3688	87	24	il‐17c	il‐17c	NOUN
dpc-3688	87	25	,	,	PUNCT
dpc-3688	87	26	acting	act	VERB
dpc-3688	87	27	in	in	ADP
dpc-3688	87	28	autocrine	autocrine	NOUN
dpc-3688	87	29	manner	manner	NOUN
dpc-3688	87	30	,	,	PUNCT
dpc-3688	87	31	are	be	AUX
dpc-3688	87	32	able	able	ADJ
dpc-3688	87	33	to	to	PART
dpc-3688	87	34	induce	induce	VERB
dpc-3688	87	35	the	the	DET
dpc-3688	87	36	expression	expression	NOUN
dpc-3688	87	37	of	of	ADP
dpc-3688	87	38	il‐17c	il‐17c	NOUN
dpc-3688	87	39	in	in	ADP
dpc-3688	87	40	keratinocytes	keratinocyte	NOUN
dpc-3688	87	41	[	[	X
dpc-3688	87	42	32	32	NUM
dpc-3688	87	43	]	]	PUNCT
dpc-3688	87	44	.	.	PUNCT
dpc-3688	88	1	il‐17a	il‐17a	PROPN
dpc-3688	88	2	,	,	PUNCT
dpc-3688	88	3	il‐17a	il‐17a	PROPN
dpc-3688	88	4	/	/	SYM
dpc-3688	88	5	f	f	PROPN
dpc-3688	88	6	and	and	CCONJ
dpc-3688	88	7	il‐17f	il‐17f	CCONJ
dpc-3688	88	8	exert	exert	VERB
dpc-3688	88	9	their	their	PRON
dpc-3688	88	10	effects	effect	NOUN
dpc-3688	88	11	on	on	ADP
dpc-3688	88	12	a	a	DET
dpc-3688	88	13	range	range	NOUN
dpc-3688	88	14	of	of	ADP
dpc-3688	88	15	tissue	tissue	NOUN
dpc-3688	88	16	cells	cell	NOUN
dpc-3688	88	17	,	,	PUNCT
dpc-3688	88	18	of	of	ADP
dpc-3688	88	19	which	which	PRON
dpc-3688	88	20	keratinocytes	keratinocyte	VERB
dpc-3688	88	21	and	and	CCONJ
dpc-3688	88	22	fibroblasts	fibroblast	NOUN
dpc-3688	88	23	are	be	AUX
dpc-3688	88	24	the	the	DET
dpc-3688	88	25	main	main	ADJ
dpc-3688	88	26	target	target	NOUN
dpc-3688	88	27	cells	cell	NOUN
dpc-3688	88	28	in	in	ADP
dpc-3688	88	29	the	the	DET
dpc-3688	88	30	skin	skin	NOUN
dpc-3688	88	31	[	[	X
dpc-3688	88	32	33	33	NUM
dpc-3688	88	33	]	]	PUNCT
dpc-3688	88	34	(	(	PUNCT
dpc-3688	88	35	figure	figure	NOUN
dpc-3688	88	36	2	2	NUM
dpc-3688	88	37	)	)	PUNCT
dpc-3688	88	38	.	.	PUNCT
dpc-3688	89	1	keratinocyte	keratinocyte	NOUN
dpc-3688	89	2	response	response	NOUN
dpc-3688	89	3	to	to	ADP
dpc-3688	89	4	either	either	CCONJ
dpc-3688	89	5	il-17c	il-17c	NOUN
dpc-3688	89	6	or	or	CCONJ
dpc-3688	89	7	il-17a	il-17a	PROPN
dpc-3688	89	8	stimulation	stimulation	NOUN
dpc-3688	89	9	are	be	AUX
dpc-3688	89	10	very	very	ADV
dpc-3688	89	11	similar	similar	ADJ
dpc-3688	89	12	,	,	PUNCT
dpc-3688	89	13	with	with	ADP
dpc-3688	89	14	strong	strong	ADJ
dpc-3688	89	15	induction	induction	NOUN
dpc-3688	89	16	of	of	ADP
dpc-3688	89	17	s100a7	s100a7	ADJ
dpc-3688	89	18	/	/	SYM
dpc-3688	89	19	a9	a9	NOUN
dpc-3688	89	20	proteins	protein	NOUN
dpc-3688	89	21	and	and	CCONJ
dpc-3688	89	22	antimicrobial	antimicrobial	ADJ
dpc-3688	89	23	proteins	protein	NOUN
dpc-3688	89	24	and	and	CCONJ
dpc-3688	89	25	cytokines	cytokine	NOUN
dpc-3688	89	26	or	or	CCONJ
dpc-3688	89	27	chemokines	chemokine	NOUN
dpc-3688	89	28	including	include	VERB
dpc-3688	89	29	cxcl1	cxcl1	NOUN
dpc-3688	89	30	,	,	PUNCT
dpc-3688	89	31	il-1	il-1	ADP
dpc-3688	89	32	,	,	PUNCT
dpc-3688	89	33	il-8	il-8	NOUN
dpc-3688	89	34	,	,	PUNCT
dpc-3688	89	35	ccl20	ccl20	NOUN
dpc-3688	89	36	,	,	PUNCT
dpc-3688	89	37	and	and	CCONJ
dpc-3688	89	38	il-36	il-36	X
dpc-3688	89	39	.	.	PUNCT
dpc-3688	90	1	il-17c	il-17c	AUX
dpc-3688	90	2	also	also	ADV
dpc-3688	90	3	stimulates	stimulate	VERB
dpc-3688	90	4	th17	th17	PROPN
dpc-3688	90	5	t	t	NOUN
dpc-3688	90	6	cells	cell	NOUN
dpc-3688	90	7	to	to	PART
dpc-3688	90	8	increase	increase	VERB
dpc-3688	90	9	synthesis	synthesis	NOUN
dpc-3688	90	10	of	of	ADP
dpc-3688	90	11	il-17a	il-17a	PROPN
dpc-3688	90	12	/	/	SYM
dpc-3688	90	13	f	f	PROPN
dpc-3688	90	14	and	and	CCONJ
dpc-3688	90	15	il-22	il-22	NOUN
dpc-3688	90	16	promoting	promote	VERB
dpc-3688	90	17	an	an	DET
dpc-3688	90	18	autoimmune	autoimmune	ADJ
dpc-3688	90	19	activation	activation	NOUN
dpc-3688	90	20	[	[	X
dpc-3688	90	21	34,35	34,35	NOUN
dpc-3688	90	22	]	]	PUNCT
dpc-3688	90	23	.	.	PUNCT
dpc-3688	91	1	indeed	indeed	ADV
dpc-3688	91	2	the	the	DET
dpc-3688	91	3	il-17ra	il-17ra	PROPN
dpc-3688	91	4	/	/	SYM
dpc-3688	91	5	re	re	NOUN
dpc-3688	91	6	receptor	receptor	NOUN
dpc-3688	91	7	complex	complex	NOUN
dpc-3688	91	8	is	be	AUX
dpc-3688	91	9	expressed	express	VERB
dpc-3688	91	10	on	on	ADP
dpc-3688	91	11	both	both	CCONJ
dpc-3688	91	12	epithelial	epithelial	ADJ
dpc-3688	91	13	and	and	CCONJ
dpc-3688	91	14	th17	th17	NOUN
dpc-3688	91	15	cells	cell	NOUN
dpc-3688	91	16	,	,	PUNCT
dpc-3688	91	17	with	with	ADP
dpc-3688	91	18	il-17c	il-17c	NOUN
dpc-3688	91	19	that	that	PRON
dpc-3688	91	20	amplifies	amplify	VERB
dpc-3688	91	21	its	its	PRON
dpc-3688	91	22	own	own	ADJ
dpc-3688	91	23	signal	signal	NOUN
dpc-3688	91	24	,	,	PUNCT
dpc-3688	91	25	inducing	induce	VERB
dpc-3688	91	26	the	the	DET
dpc-3688	91	27	expression	expression	NOUN
dpc-3688	91	28	figure	figure	NOUN
dpc-3688	91	29	2	2	NUM
dpc-3688	91	30	.	.	PUNCT
dpc-3688	91	31	key	key	ADJ
dpc-3688	91	32	psoriasis	psoriasis	NOUN
dpc-3688	91	33	pathogenic	pathogenic	ADJ
dpc-3688	91	34	circuits	circuit	NOUN
dpc-3688	91	35	mediated	mediate	VERB
dpc-3688	91	36	by	by	ADP
dpc-3688	91	37	il-17	il-17	NOUN
dpc-3688	91	38	cytokines	cytokine	NOUN
dpc-3688	91	39	.	.	PUNCT
dpc-3688	92	1	il‐17a	il‐17a	PROPN
dpc-3688	92	2	strongly	strongly	ADV
dpc-3688	92	3	induces	induce	VERB
dpc-3688	92	4	il-17c	il-17c	NOUN
dpc-3688	92	5	expression	expression	NOUN
dpc-3688	92	6	in	in	ADP
dpc-3688	92	7	keratinocytes	keratinocyte	NOUN
dpc-3688	92	8	.	.	PUNCT
dpc-3688	93	1	il-17c	il-17c	PROPN
dpc-3688	93	2	amplifies	amplify	VERB
dpc-3688	93	3	its	its	PRON
dpc-3688	93	4	own	own	ADJ
dpc-3688	93	5	signal	signal	NOUN
dpc-3688	93	6	through	through	ADP
dpc-3688	93	7	the	the	DET
dpc-3688	93	8	induction	induction	NOUN
dpc-3688	93	9	of	of	ADP
dpc-3688	93	10	il-17c	il-17c	NOUN
dpc-3688	93	11	receptor	receptor	NOUN
dpc-3688	93	12	on	on	ADP
dpc-3688	93	13	th17	th17	PROPN
dpc-3688	93	14	cells	cell	NOUN
dpc-3688	93	15	and	and	CCONJ
dpc-3688	93	16	the	the	DET
dpc-3688	93	17	increase	increase	NOUN
dpc-3688	93	18	of	of	ADP
dpc-3688	93	19	il-17a	il-17a	PROPN
dpc-3688	93	20	synthesis	synthesis	NOUN
dpc-3688	93	21	.	.	PUNCT
dpc-3688	94	1	il-17a	il-17a	PROPN
dpc-3688	94	2	and	and	CCONJ
dpc-3688	94	3	il-17f	il-17f	NOUN
dpc-3688	94	4	exert	exert	VERB
dpc-3688	94	5	their	their	PRON
dpc-3688	94	6	effects	effect	NOUN
dpc-3688	94	7	on	on	ADP
dpc-3688	94	8	other	other	ADJ
dpc-3688	94	9	tissue	tissue	NOUN
dpc-3688	94	10	cells	cell	NOUN
dpc-3688	94	11	,	,	PUNCT
dpc-3688	94	12	such	such	ADJ
dpc-3688	94	13	as	as	ADP
dpc-3688	94	14	fibroblasts	fibroblast	NOUN
dpc-3688	94	15	,	,	PUNCT
dpc-3688	94	16	inducing	induce	VERB
dpc-3688	94	17	the	the	DET
dpc-3688	94	18	production	production	NOUN
dpc-3688	94	19	of	of	ADP
dpc-3688	94	20	several	several	ADJ
dpc-3688	94	21	proinflammatory	proinflammatory	ADJ
dpc-3688	94	22	mediators	mediator	NOUN
dpc-3688	94	23	.	.	PUNCT
dpc-3688	95	1	other	other	ADJ
dpc-3688	95	2	inflammatory	inflammatory	ADJ
dpc-3688	95	3	loops	loop	NOUN
dpc-3688	95	4	result	result	VERB
dpc-3688	95	5	in	in	ADP
dpc-3688	95	6	the	the	DET
dpc-3688	95	7	induction	induction	NOUN
dpc-3688	95	8	of	of	ADP
dpc-3688	95	9	il-17c	il-17c	NOUN
dpc-3688	95	10	on	on	ADP
dpc-3688	95	11	th17	th17	NOUN
dpc-3688	95	12	cells	cell	NOUN
dpc-3688	95	13	.	.	PUNCT
dpc-3688	96	1	il	il	PROPN
dpc-3688	96	2	=	=	NOUN
dpc-3688	96	3	interleukin	interleukin	NOUN
dpc-3688	96	4	.	.	PUNCT
dpc-3688	97	1	review	review	VERB
dpc-3688	97	2	|	|	ADV
dpc-3688	97	3	dermatol	dermatol	ADJ
dpc-3688	97	4	pract	pract	NOUN
dpc-3688	97	5	concept	concept	NOUN
dpc-3688	97	6	.	.	PUNCT
dpc-3688	98	1	2023;13(3):e2023245	2023;13(3):e2023245	NUM
dpc-3688	98	2	5	5	NUM
dpc-3688	98	3	ta	ta	PART
dpc-3688	98	4	b	b	PROPN
dpc-3688	98	5	le	le	ADP
dpc-3688	98	6	1	1	NUM
dpc-3688	98	7	.	.	PUNCT
dpc-3688	99	1	r	r	NOUN
dpc-3688	99	2	es	es	NOUN
dpc-3688	99	3	ul	ul	INTJ
dpc-3688	99	4	ts	ts	X
dpc-3688	99	5	f	f	PROPN
dpc-3688	99	6	ro	ro	INTJ
dpc-3688	99	7	m	m	PROPN
dpc-3688	99	8	c	c	PROPN
dpc-3688	99	9	lin	lin	PROPN
dpc-3688	99	10	ic	ic	PROPN
dpc-3688	99	11	al	al	PROPN
dpc-3688	99	12	t	t	PROPN
dpc-3688	99	13	ri	ri	PROPN
dpc-3688	100	1	al	al	PROPN
dpc-3688	100	2	s	s	PROPN
dpc-3688	100	3	an	an	DET
dpc-3688	100	4	d	d	X
dpc-3688	100	5	re	re	ADP
dpc-3688	100	6	al	al	PROPN
dpc-3688	100	7	-w	-w	PROPN
dpc-3688	100	8	or	or	CCONJ
dpc-3688	100	9	ld	ld	PROPN
dpc-3688	100	10	e	e	X
dpc-3688	100	11	xp	xp	INTJ
dpc-3688	101	1	er	er	INTJ
dpc-3688	101	2	ie	ie	X
dpc-3688	101	3	nc	nc	PROPN
dpc-3688	101	4	es	es	PROPN
dpc-3688	101	5	r	r	PROPN
dpc-3688	101	6	el	el	PROPN
dpc-3688	101	7	at	at	ADP
dpc-3688	101	8	ed	ed	PROPN
dpc-3688	101	9	t	t	PROPN
dpc-3688	101	10	o	o	NOUN
dpc-3688	102	1	br	br	INTJ
dpc-3688	102	2	od	od	PROPN
dpc-3688	102	3	al	al	PROPN
dpc-3688	102	4	um	um	INTJ
dpc-3688	102	5	ab	ab	PROPN
dpc-3688	102	6	e	e	PROPN
dpc-3688	102	7	ffi	ffi	PROPN
dpc-3688	102	8	ca	can	AUX
dpc-3688	102	9	cy	cy	VERB
dpc-3688	102	10	in	in	ADP
dpc-3688	102	11	d	d	PROPN
dpc-3688	102	12	if	if	SCONJ
dpc-3688	102	13	fic	fic	ADJ
dpc-3688	102	14	ul	ul	INTJ
dpc-3688	102	15	tto	tto	NOUN
dpc-3688	102	16	-t	-t	PUNCT
dpc-3688	102	17	re	re	VERB
dpc-3688	102	18	at	at	ADP
dpc-3688	102	19	p	p	NOUN
dpc-3688	102	20	so	so	ADV
dpc-3688	102	21	ri	ri	PROPN
dpc-3688	102	22	as	as	SCONJ
dpc-3688	102	23	is	be	AUX
dpc-3688	102	24	.	.	PUNCT
dpc-3688	103	1	a	a	DET
dpc-3688	103	2	u	u	NOUN
dpc-3688	103	3	th	th	X
dpc-3688	103	4	o	o	NOUN
dpc-3688	103	5	r	r	NOUN
dpc-3688	103	6	d	d	X
dpc-3688	103	7	ru	ru	NOUN
dpc-3688	103	8	g	g	PROPN
dpc-3688	103	9	tr	tr	PROPN
dpc-3688	103	10	ia	ia	PROPN
dpc-3688	103	11	l/	l/	X
dpc-3688	103	12	n	n	ADP
dpc-3688	103	13	c	c	NOUN
dpc-3688	103	14	t	t	X
dpc-3688	103	15	en	en	PROPN
dpc-3688	103	16	d	d	X
dpc-3688	103	17	p	p	X
dpc-3688	103	18	o	o	NOUN
dpc-3688	103	19	in	in	ADP
dpc-3688	103	20	ts	ts	PROPN
dpc-3688	103	21	d	d	PROPN
dpc-3688	103	22	es	es	ADP
dpc-3688	103	23	ig	ig	PROPN
dpc-3688	103	24	n	n	NOUN
dpc-3688	103	25	r	r	NOUN
dpc-3688	103	26	eg	eg	NOUN
dpc-3688	103	27	i	i	PRON
dpc-3688	103	28	m	m	VERB
dpc-3688	103	29	en	en	X
dpc-3688	103	30	/d	/d	PUNCT
dpc-3688	103	31	o	o	X
dpc-3688	103	32	se	se	X
dpc-3688	103	33	n	n	PROPN
dpc-3688	103	34	sp	sp	ADP
dpc-3688	103	35	ec	ec	PROPN
dpc-3688	103	36	ifi	ifi	PROPN
dpc-3688	103	37	c	c	PROPN
dpc-3688	103	38	o	o	PUNCT
dpc-3688	103	39	u	u	X
dpc-3688	104	1	tc	tc	X
dpc-3688	104	2	o	o	NOUN
dpc-3688	104	3	m	m	VERB
dpc-3688	104	4	es	es	VERB
dpc-3688	104	5	fo	fo	ADP
dpc-3688	104	6	r	r	NOUN
dpc-3688	104	7	d	d	NOUN
dpc-3688	105	1	if	if	SCONJ
dpc-3688	105	2	fc	fc	PROPN
dpc-3688	105	3	u	u	NOUN
dpc-3688	105	4	lt	lt	NOUN
dpc-3688	105	5	-t	-t	PROPN
dpc-3688	105	6	o	o	X
dpc-3688	105	7	-t	-t	PUNCT
dpc-3688	105	8	re	re	VERB
dpc-3688	105	9	at	at	ADP
dpc-3688	105	10	ar	ar	PROPN
dpc-3688	105	11	ea	ea	PROPN
dpc-3688	105	12	s	s	PROPN
dpc-3688	105	13	b	b	PROPN
dpc-3688	105	14	as	as	ADP
dpc-3688	105	15	el	el	PROPN
dpc-3688	105	16	in	in	ADP
dpc-3688	105	17	e	e	PROPN
dpc-3688	105	18	se	se	X
dpc-3688	105	19	ve	ve	AUX
dpc-3688	105	20	ri	ri	VERB
dpc-3688	105	21	ty	ty	INTJ
dpc-3688	105	22	in	in	ADP
dpc-3688	105	23	d	d	PROPN
dpc-3688	105	24	if	if	SCONJ
dpc-3688	105	25	fc	fc	PROPN
dpc-3688	105	26	u	u	NOUN
dpc-3688	105	27	lt	lt	NOUN
dpc-3688	106	1	-t	-t	PROPN
dpc-3688	106	2	o	o	X
dpc-3688	106	3	-t	-t	PUNCT
dpc-3688	106	4	re	re	VERB
dpc-3688	106	5	at	at	ADP
dpc-3688	106	6	ar	ar	PROPN
dpc-3688	106	7	ea	ea	PROPN
dpc-3688	106	8	s	s	VERB
dpc-3688	106	9	fo	fo	INTJ
dpc-3688	106	10	llo	llo	INTJ
dpc-3688	106	11	w	w	PROPN
dpc-3688	106	12	-u	-u	PROPN
dpc-3688	106	13	p	p	X
dpc-3688	106	14	e	e	X
dpc-3688	106	15	le	le	X
dpc-3688	106	16	w	w	PROPN
dpc-3688	106	17	sk	sk	INTJ
dpc-3688	106	18	i	i	PROPN
dpc-3688	106	19	,	,	PUNCT
dpc-3688	106	20	j	j	PROPN
dpc-3688	106	21	  	  	SPACE
dpc-3688	107	1	d	d	PROPN
dpc-3688	107	2	er	er	INTJ
dpc-3688	107	3	m	m	VERB
dpc-3688	107	4	at	at	ADP
dpc-3688	107	5	ol	ol	PROPN
dpc-3688	107	6	og	og	PROPN
dpc-3688	107	7	t	t	PROPN
dpc-3688	107	8	re	re	NOUN
dpc-3688	107	9	at	at	ADP
dpc-3688	107	10	2	2	NUM
dpc-3688	107	11	02	02	NUM
dpc-3688	107	12	2	2	NUM
dpc-3688	107	13	b	b	X
dpc-3688	107	14	ro	ro	X
dpc-3688	107	15	da	da	PROPN
dpc-3688	107	16	lu	lu	PROPN
dpc-3688	107	17	m	m	PROPN
dpc-3688	107	18	ab	ab	PROPN
dpc-3688	107	19	,	,	PUNCT
dpc-3688	107	20	pl	pl	PROPN
dpc-3688	107	21	ac	ac	PROPN
dpc-3688	107	22	eb	eb	PROPN
dpc-3688	107	23	o	o	PROPN
dpc-3688	107	24	a	a	DET
dpc-3688	107	25	m	m	NOUN
dpc-3688	107	26	ag	ag	PROPN
dpc-3688	107	27	in	in	ADP
dpc-3688	107	28	e1	e1	PROPN
dpc-3688	107	29	w	w	PROPN
dpc-3688	107	30	12	12	NUM
dpc-3688	107	31	(	(	PUNCT
dpc-3688	107	32	in	in	ADP
dpc-3688	107	33	du	du	PROPN
dpc-3688	107	34	ct	ct	PROPN
dpc-3688	107	35	io	io	PROPN
dpc-3688	107	36	n	n	PROPN
dpc-3688	107	37	pe	pe	INTJ
dpc-3688	107	38	ri	ri	PROPN
dpc-3688	107	39	od	od	ADV
dpc-3688	107	40	)	)	PUNCT
dpc-3688	108	1	r	r	NOUN
dpc-3688	108	2	c	c	NOUN
dpc-3688	108	3	t	t	PROPN
dpc-3688	108	4	b	b	PROPN
dpc-3688	108	5	d	d	X
dpc-3688	108	6	l	l	NOUN
dpc-3688	108	7	21	21	NUM
dpc-3688	108	8	0	0	NUM
dpc-3688	108	9	q	q	PROPN
dpc-3688	108	10	2w	2w	NUM
dpc-3688	108	11	pl	pl	X
dpc-3688	108	12	ac	ac	PROPN
dpc-3688	108	13	eb	eb	PROPN
dpc-3688	108	14	o	o	PROPN
dpc-3688	108	15	q	q	PROPN
dpc-3688	109	1	2w	2w	NUM
dpc-3688	109	2	22	22	NUM
dpc-3688	109	3	2	2	NUM
dpc-3688	109	4	21	21	NUM
dpc-3688	109	5	9	9	NUM
dpc-3688	109	6	ps	ps	NOUN
dpc-3688	109	7	si	si	NOUN
dpc-3688	109	8	75	75	NUM
dpc-3688	109	9	p	p	PROPN
dpc-3688	109	10	ss	ss	PROPN
dpc-3688	109	11	i1	i1	PROPN
dpc-3688	109	12	00	00	PUNCT
dpc-3688	110	1	ps	ps	INTJ
dpc-3688	110	2	si	si	PROPN
dpc-3688	110	3	>	>	X
dpc-3688	110	4	1	1	NUM
dpc-3688	110	5	5	5	NUM
dpc-3688	110	6	(	(	PUNCT
dpc-3688	110	7	o	o	NOUN
dpc-3688	110	8	ut	ut	PROPN
dpc-3688	111	1	o	o	X
dpc-3688	111	2	f	f	PROPN
dpc-3688	112	1	pa	pa	PROPN
dpc-3688	112	2	si	si	PROPN
dpc-3688	112	3	72	72	NUM
dpc-3688	112	4	)	)	PUNCT
dpc-3688	112	5	w	w	ADP
dpc-3688	112	6	12	12	NUM
dpc-3688	112	7	p	p	NOUN
dpc-3688	112	8	a	a	DET
dpc-3688	112	9	si	si	NOUN
dpc-3688	112	10	75	75	NUM
dpc-3688	112	11	in	in	ADP
dpc-3688	112	12	8	8	NUM
dpc-3688	112	13	9	9	NUM
dpc-3688	112	14	%	%	NOUN
dpc-3688	112	15	w	w	NOUN
dpc-3688	112	16	12	12	NUM
dpc-3688	112	17	p	p	NOUN
dpc-3688	112	18	a	a	DET
dpc-3688	112	19	si	si	NOUN
dpc-3688	112	20	10	10	NUM
dpc-3688	112	21	0	0	NUM
dpc-3688	112	22	by	by	ADP
dpc-3688	112	23	6	6	NUM
dpc-3688	112	24	3	3	NUM
dpc-3688	112	25	.	.	NOUN
dpc-3688	112	26	4	4	NUM
dpc-3688	112	27	%	%	NOUN
dpc-3688	112	28	w	w	NOUN
dpc-3688	112	29	12	12	NUM
dpc-3688	112	30	p	p	NOUN
dpc-3688	112	31	a	a	DET
dpc-3688	112	32	si	si	NOUN
dpc-3688	112	33	75	75	NUM
dpc-3688	112	34	b	b	PROPN
dpc-3688	112	35	y	y	PROPN
dpc-3688	112	36	9	9	NUM
dpc-3688	112	37	.	.	X
dpc-3688	112	38	5	5	NUM
dpc-3688	112	39	%	%	NOUN
dpc-3688	112	40	w	w	NOUN
dpc-3688	112	41	12	12	NUM
dpc-3688	112	42	p	p	NOUN
dpc-3688	112	43	a	a	DET
dpc-3688	112	44	si	si	NOUN
dpc-3688	112	45	10	10	NUM
dpc-3688	112	46	0	0	NUM
dpc-3688	112	47	by	by	ADP
dpc-3688	112	48	3	3	NUM
dpc-3688	112	49	.2	.2	NUM
dpc-3688	112	50	n	n	PROPN
dpc-3688	112	51	ak	ak	PROPN
dpc-3688	112	52	ag	ag	PROPN
dpc-3688	112	53	aw	aw	INTJ
dpc-3688	112	54	a	a	PROPN
dpc-3688	112	55	,	,	PUNCT
dpc-3688	112	56	j	j	PROPN
dpc-3688	112	57	  	  	SPACE
dpc-3688	112	58	d	d	PROPN
dpc-3688	112	59	er	er	INTJ
dpc-3688	112	60	m	m	VERB
dpc-3688	112	61	at	at	ADP
dpc-3688	112	62	ol	ol	PROPN
dpc-3688	112	63	s	s	PROPN
dpc-3688	112	64	ci	ci	PROPN
dpc-3688	112	65	.	.	PUNCT
dpc-3688	113	1	20	20	NUM
dpc-3688	113	2	16	16	NUM
dpc-3688	113	3	b	b	X
dpc-3688	113	4	ro	ro	X
dpc-3688	113	5	da	da	PROPN
dpc-3688	113	6	lu	lu	PROPN
dpc-3688	113	7	m	m	VERB
dpc-3688	113	8	ab	ab	PROPN
dpc-3688	113	9	pl	pl	PROPN
dpc-3688	113	10	ac	ac	PROPN
dpc-3688	114	1	eb	eb	PROPN
dpc-3688	114	2	o	o	PROPN
dpc-3688	115	1	n	n	ADP
dpc-3688	115	2	c	c	NOUN
dpc-3688	115	3	t	t	NOUN
dpc-3688	115	4	01	01	NUM
dpc-3688	115	5	74	74	NUM
dpc-3688	115	6	85	85	NUM
dpc-3688	115	7	39	39	NUM
dpc-3688	116	1	w	w	NOUN
dpc-3688	116	2	12	12	NUM
dpc-3688	116	3	r	r	NOUN
dpc-3688	116	4	c	c	NOUN
dpc-3688	116	5	t	t	NOUN
dpc-3688	116	6	b	b	PROPN
dpc-3688	116	7	d	d	X
dpc-3688	116	8	l	l	NOUN
dpc-3688	116	9	2	2	NUM
dpc-3688	116	10	10	10	NUM
dpc-3688	116	11	q	q	NOUN
dpc-3688	116	12	2w	2w	NUM
dpc-3688	116	13	pl	pl	X
dpc-3688	116	14	ac	ac	PROPN
dpc-3688	117	1	eb	eb	PROPN
dpc-3688	118	1	o	o	PROPN
dpc-3688	119	1	37	37	NUM
dpc-3688	119	2	38	38	NUM
dpc-3688	119	3	ps	ps	NOUN
dpc-3688	119	4	si	si	PROPN
dpc-3688	119	5	n	n	ADV
dpc-3688	119	6	a	a	DET
dpc-3688	119	7	ps	ps	X
dpc-3688	119	8	i	i	PRON
dpc-3688	119	9	(	(	PUNCT
dpc-3688	119	10	2	2	NUM
dpc-3688	119	11	2p	2p	NUM
dpc-3688	119	12	ts	ts	ADP
dpc-3688	119	13	)	)	PUNCT
dpc-3688	120	1	d	d	X
dpc-3688	120	2	l	l	NOUN
dpc-3688	120	3	q	q	X
dpc-3688	121	1	i	i	PRON
dpc-3688	121	2	ps	ps	VERB
dpc-3688	121	3	si	si	NOUN
dpc-3688	121	4	4	4	NUM
dpc-3688	121	5	3	3	NUM
dpc-3688	121	6	.	.	NOUN
dpc-3688	121	7	7	7	NUM
dpc-3688	121	8	n	n	PROPN
dpc-3688	121	9	a	a	DET
dpc-3688	121	10	ps	ps	NOUN
dpc-3688	121	11	i	i	PRON
dpc-3688	121	12	6	6	NUM
dpc-3688	121	13	.	.	SYM
dpc-3688	121	14	3	3	NUM
dpc-3688	121	15	d	d	SYM
dpc-3688	121	16	l	l	NOUN
dpc-3688	121	17	q	q	PROPN
dpc-3688	121	18	i1	i1	PROPN
dpc-3688	121	19	0	0	NUM
dpc-3688	121	20	.	.	PROPN
dpc-3688	122	1	7	7	NUM
dpc-3688	122	2	ps	ps	NOUN
dpc-3688	122	3	si	si	NOUN
dpc-3688	122	4	2	2	NUM
dpc-3688	122	5	6	6	NUM
dpc-3688	122	6	.	.	SYM
dpc-3688	122	7	2	2	NUM
dpc-3688	122	8	n	n	PROPN
dpc-3688	122	9	a	a	DET
dpc-3688	122	10	ps	ps	NOUN
dpc-3688	122	11	i7	i7	NOUN
dpc-3688	123	1	.2	.2	NUM
dpc-3688	123	2	d	d	PUNCT
dpc-3688	123	3	l	l	NOUN
dpc-3688	123	4	q	q	NOUN
dpc-3688	123	5	i9	i9	NOUN
dpc-3688	123	6	.4	.4	NUM
dpc-3688	123	7	w	w	NOUN
dpc-3688	123	8	12	12	NUM
dpc-3688	124	1	p	p	NOUN
dpc-3688	124	2	ss	ss	NOUN
dpc-3688	125	1	i	i	PRON
dpc-3688	125	2	-9	-9	PROPN
dpc-3688	125	3	4	4	NUM
dpc-3688	126	1	.	.	NOUN
dpc-3688	126	2	5	5	NUM
dpc-3688	126	3	%	%	NOUN
dpc-3688	126	4	w	w	NOUN
dpc-3688	126	5	12	12	NUM
dpc-3688	126	6	n	n	NOUN
dpc-3688	126	7	a	a	DET
dpc-3688	126	8	ps	ps	NOUN
dpc-3688	126	9	i47	i47	PROPN
dpc-3688	127	1	.6	.6	NUM
dpc-3688	127	2	%	%	NOUN
dpc-3688	127	3	w	w	PROPN
dpc-3688	127	4	12	12	NUM
dpc-3688	127	5	d	d	NOUN
dpc-3688	127	6	l	l	NOUN
dpc-3688	128	1	q	q	NOUN
dpc-3688	129	1	i	i	PRON
dpc-3688	129	2	-9	-9	PROPN
dpc-3688	129	3	w	w	PROPN
dpc-3688	129	4	12	12	NUM
dpc-3688	129	5	p	p	NOUN
dpc-3688	129	6	ss	ss	INTJ
dpc-3688	130	1	i	i	PRON
dpc-3688	130	2	-1	-1	PUNCT
dpc-3688	131	1	2	2	X
dpc-3688	131	2	.	.	NOUN
dpc-3688	131	3	6	6	NUM
dpc-3688	131	4	%	%	NOUN
dpc-3688	131	5	w	w	NOUN
dpc-3688	131	6	12	12	NUM
dpc-3688	131	7	n	n	NOUN
dpc-3688	131	8	a	a	DET
dpc-3688	131	9	ps	ps	NOUN
dpc-3688	132	1	i	i	PRON
dpc-3688	132	2	-7	-7	INTJ
dpc-3688	133	1	.6	.6	NUM
dpc-3688	133	2	%	%	NOUN
dpc-3688	133	3	w	w	PROPN
dpc-3688	133	4	12	12	NUM
dpc-3688	133	5	n	n	NOUN
dpc-3688	133	6	a	a	DET
dpc-3688	133	7	ps	ps	NOUN
dpc-3688	134	1	i	i	PRON
dpc-3688	134	2	-2	-2	NOUN
dpc-3688	135	1	.2	.2	NUM
dpc-3688	135	2	e	e	X
dpc-3688	135	3	le	le	PROPN
dpc-3688	135	4	w	w	PROPN
dpc-3688	135	5	sk	sk	INTJ
dpc-3688	135	6	i	i	PROPN
dpc-3688	135	7	,	,	PUNCT
dpc-3688	135	8	j	j	PROPN
dpc-3688	135	9	  	  	SPACE
dpc-3688	135	10	d	d	PROPN
dpc-3688	135	11	er	er	INTJ
dpc-3688	135	12	m	m	VERB
dpc-3688	135	13	at	at	ADP
dpc-3688	135	14	ol	ol	PROPN
dpc-3688	135	15	og	og	PROPN
dpc-3688	135	16	t	t	PROPN
dpc-3688	135	17	re	re	NOUN
dpc-3688	135	18	at	at	ADP
dpc-3688	135	19	2	2	NUM
dpc-3688	135	20	02	02	NUM
dpc-3688	135	21	2	2	NUM
dpc-3688	135	22	b	b	X
dpc-3688	135	23	ro	ro	X
dpc-3688	135	24	da	da	PROPN
dpc-3688	135	25	lu	lu	PROPN
dpc-3688	135	26	m	m	PROPN
dpc-3688	135	27	ab	ab	PROPN
dpc-3688	135	28	,	,	PUNCT
dpc-3688	135	29	u	u	PROPN
dpc-3688	135	30	st	st	PROPN
dpc-3688	135	31	ek	ek	PROPN
dpc-3688	135	32	in	in	ADP
dpc-3688	135	33	um	um	INTJ
dpc-3688	135	34	ab	ab	PROPN
dpc-3688	135	35	a	a	PROPN
dpc-3688	135	36	m	m	NOUN
dpc-3688	135	37	a	a	DET
dpc-3688	135	38	g	g	NOUN
dpc-3688	135	39	in	in	ADP
dpc-3688	135	40	e	e	PROPN
dpc-3688	135	41	-2	-2	INTJ
dpc-3688	135	42	/3	/3	PUNCT
dpc-3688	136	1	w	w	PROPN
dpc-3688	136	2	12	12	NUM
dpc-3688	136	3	/2	/2	NUM
dpc-3688	136	4	4/	4/	NUM
dpc-3688	137	1	36	36	NUM
dpc-3688	137	2	/5	/5	SYM
dpc-3688	137	3	2	2	NUM
dpc-3688	137	4	r	r	NOUN
dpc-3688	137	5	c	c	NOUN
dpc-3688	137	6	t	t	NOUN
dpc-3688	137	7	b	b	PROPN
dpc-3688	137	8	d	d	X
dpc-3688	137	9	l	l	NOUN
dpc-3688	137	10	21	21	NUM
dpc-3688	137	11	0	0	NUM
dpc-3688	137	12	at	at	ADP
dpc-3688	137	13	w	w	PROPN
dpc-3688	137	14	0	0	NUM
dpc-3688	137	15	,	,	PUNCT
dpc-3688	137	16	w	w	PROPN
dpc-3688	137	17	1	1	NUM
dpc-3688	137	18	,	,	PUNCT
dpc-3688	137	19	w	w	PROPN
dpc-3688	137	20	2	2	NUM
dpc-3688	137	21	,	,	PUNCT
dpc-3688	137	22	t	t	PROPN
dpc-3688	137	23	he	he	PRON
dpc-3688	137	24	n	n	PROPN
dpc-3688	137	25	q	q	PROPN
dpc-3688	137	26	2w	2w	NUM
dpc-3688	137	27	u	u	PROPN
dpc-3688	137	28	st	st	PROPN
dpc-3688	137	29	45	45	NUM
dpc-3688	137	30	/9	/9	NOUN
dpc-3688	137	31	0	0	PUNCT
dpc-3688	138	1	at	at	ADP
dpc-3688	138	2	w	w	PROPN
dpc-3688	138	3	0/	0/	NUM
dpc-3688	138	4	w	w	PROPN
dpc-3688	138	5	4	4	NUM
dpc-3688	138	6	th	th	NUM
dpc-3688	138	7	en	en	ADP
dpc-3688	138	8	q	q	PROPN
dpc-3688	138	9	12	12	NUM
dpc-3688	138	10	w	w	NOUN
dpc-3688	138	11	10	10	NUM
dpc-3688	138	12	4	4	NUM
dpc-3688	138	13	17	17	NUM
dpc-3688	138	14	9	9	NUM
dpc-3688	138	15	n	n	DET
dpc-3688	138	16	a	a	DET
dpc-3688	138	17	ps	ps	NOUN
dpc-3688	138	18	i	i	PRON
dpc-3688	138	19	(	(	PUNCT
dpc-3688	138	20	t	t	PROPN
dpc-3688	138	21	ar	ar	PROPN
dpc-3688	138	22	ge	ge	PROPN
dpc-3688	138	23	t	t	PROPN
dpc-3688	138	24	)	)	PUNCT
dpc-3688	138	25	n	n	CCONJ
dpc-3688	138	26	a	a	DET
dpc-3688	138	27	ps	ps	NOUN
dpc-3688	138	28	i	i	PRON
dpc-3688	138	29	9	9	NUM
dpc-3688	138	30	.	.	NOUN
dpc-3688	138	31	6	6	NUM
dpc-3688	138	32	(	(	PUNCT
dpc-3688	138	33	4	4	NUM
dpc-3688	138	34	)	)	PUNCT
dpc-3688	138	35	n	n	CCONJ
dpc-3688	138	36	a	a	DET
dpc-3688	138	37	ps	ps	NOUN
dpc-3688	138	38	i	i	PRON
dpc-3688	138	39	9	9	NUM
dpc-3688	138	40	.	.	NOUN
dpc-3688	138	41	9	9	NUM
dpc-3688	138	42	(	(	PUNCT
dpc-3688	138	43	3	3	NUM
dpc-3688	138	44	.6	.6	NUM
dpc-3688	138	45	)	)	PUNCT
dpc-3688	138	46	w	w	ADP
dpc-3688	138	47	52	52	NUM
dpc-3688	138	48	n	n	NOUN
dpc-3688	138	49	a	a	DET
dpc-3688	138	50	ps	ps	NOUN
dpc-3688	138	51	i	i	PRON
dpc-3688	138	52	1	1	NUM
dpc-3688	138	53	.	.	NOUN
dpc-3688	139	1	6	6	NUM
dpc-3688	139	2	w	w	NOUN
dpc-3688	139	3	52	52	NUM
dpc-3688	139	4	n	n	NOUN
dpc-3688	139	5	a	a	DET
dpc-3688	139	6	ps	ps	NOUN
dpc-3688	139	7	i	i	NOUN
dpc-3688	139	8	2	2	NUM
dpc-3688	139	9	.	.	X
dpc-3688	139	10	5	5	NUM
dpc-3688	139	11	y	y	NOUN
dpc-3688	139	12	am	be	AUX
dpc-3688	139	13	as	as	ADP
dpc-3688	139	14	ak	ak	PROPN
dpc-3688	139	15	i	i	PROPN
dpc-3688	139	16	,	,	PUNCT
dpc-3688	139	17	b	b	PROPN
dpc-3688	139	18	r	r	PROPN
dpc-3688	139	19	jd	jd	PROPN
dpc-3688	139	20	,	,	PUNCT
dpc-3688	139	21	20	20	NUM
dpc-3688	139	22	17	17	NUM
dpc-3688	139	23	b	b	X
dpc-3688	139	24	ro	ro	X
dpc-3688	139	25	da	da	PROPN
dpc-3688	139	26	lu	lu	PROPN
dpc-3688	139	27	m	m	PROPN
dpc-3688	139	28	ab	ab	PROPN
dpc-3688	139	29	n	n	PROPN
dpc-3688	139	30	c	c	PROPN
dpc-3688	139	31	t	t	NOUN
dpc-3688	139	32	01	01	NUM
dpc-3688	139	33	78	78	NUM
dpc-3688	139	34	29	29	NUM
dpc-3688	139	35	37	37	NUM
dpc-3688	139	36	w	w	NOUN
dpc-3688	139	37	52	52	NUM
dpc-3688	139	38	o	o	NOUN
dpc-3688	139	39	pe	pe	INTJ
dpc-3688	139	40	n	n	PROPN
dpc-3688	139	41	l	l	NOUN
dpc-3688	139	42	ab	ab	PROPN
dpc-3688	139	43	el	el	PROPN
dpc-3688	139	44	b	b	PROPN
dpc-3688	139	45	d	d	PROPN
dpc-3688	139	46	l	l	NOUN
dpc-3688	139	47	2	2	NUM
dpc-3688	139	48	10	10	NUM
dpc-3688	139	49	m	m	NOUN
dpc-3688	139	50	g	g	NOUN
dpc-3688	139	51	g	g	NOUN
dpc-3688	139	52	pp	pp	PROPN
dpc-3688	139	53	12	12	NUM
dpc-3688	139	54	ps	ps	NOUN
dpc-3688	139	55	s	s	NOUN
dpc-3688	139	56	ps	ps	NOUN
dpc-3688	139	57	si	si	PROPN
dpc-3688	139	58	n	n	ADV
dpc-3688	139	59	a	a	DET
dpc-3688	139	60	ps	ps	NOUN
dpc-3688	140	1	i	i	NOUN
dpc-3688	141	1	d	d	PROPN
dpc-3688	141	2	l	l	NOUN
dpc-3688	141	3	q	q	X
dpc-3688	142	1	i	i	PRON
dpc-3688	142	2	ps	ps	PROPN
dpc-3688	142	3	s	s	NOUN
dpc-3688	142	4	4	4	NUM
dpc-3688	142	5	.	.	ADP
dpc-3688	142	6	4	4	NUM
dpc-3688	142	7	ps	ps	NOUN
dpc-3688	142	8	si	si	NOUN
dpc-3688	142	9	1	1	NUM
dpc-3688	142	10	6	6	NUM
dpc-3688	142	11	.	.	NOUN
dpc-3688	142	12	7	7	NUM
dpc-3688	142	13	n	n	PROPN
dpc-3688	142	14	a	a	DET
dpc-3688	142	15	ps	ps	NOUN
dpc-3688	143	1	i	i	PRON
dpc-3688	143	2	10	10	NUM
dpc-3688	143	3	.8	.8	NUM
dpc-3688	144	1	d	d	NOUN
dpc-3688	144	2	q	q	PUNCT
dpc-3688	144	3	l	l	NOUN
dpc-3688	144	4	i	i	PRON
dpc-3688	144	5	7	7	NUM
dpc-3688	144	6	.	.	NOUN
dpc-3688	144	7	9	9	NUM
dpc-3688	144	8	w	w	NOUN
dpc-3688	144	9	52	52	NUM
dpc-3688	144	10	p	p	NOUN
dpc-3688	144	11	ss	ss	NOUN
dpc-3688	144	12	0	0	NUM
dpc-3688	144	13	in	in	ADP
dpc-3688	144	14	9	9	NUM
dpc-3688	144	15	1	1	NUM
dpc-3688	144	16	%	%	NOUN
dpc-3688	144	17	w	w	NOUN
dpc-3688	144	18	52	52	NUM
dpc-3688	144	19	p	p	NOUN
dpc-3688	144	20	ss	ss	NOUN
dpc-3688	144	21	i	i	NOUN
dpc-3688	144	22	-8	-8	NOUN
dpc-3688	144	23	2	2	NUM
dpc-3688	144	24	w	w	PROPN
dpc-3688	144	25	52	52	NUM
dpc-3688	144	26	n	n	NOUN
dpc-3688	144	27	a	a	DET
dpc-3688	144	28	ps	ps	NOUN
dpc-3688	145	1	i	i	PRON
dpc-3688	145	2	-6	-6	PROPN
dpc-3688	145	3	7	7	NUM
dpc-3688	145	4	.	.	SYM
dpc-3688	145	5	5	5	NUM
dpc-3688	145	6	w	w	NOUN
dpc-3688	145	7	52	52	NUM
dpc-3688	145	8	d	d	NOUN
dpc-3688	145	9	l	l	NOUN
dpc-3688	145	10	q	q	NOUN
dpc-3688	146	1	i	i	PRON
dpc-3688	146	2	-5	-5	VERB
dpc-3688	146	3	.5	.5	NUM
dpc-3688	146	4	g	g	NOUN
dpc-3688	146	5	re	re	AUX
dpc-3688	146	6	go	go	VERB
dpc-3688	146	7	ri	ri	PROPN
dpc-3688	146	8	u	u	PROPN
dpc-3688	146	9	,	,	PUNCT
dpc-3688	146	10	j	j	PROPN
dpc-3688	146	11	e	e	PROPN
dpc-3688	146	12	a	a	PROPN
dpc-3688	146	13	d	d	X
dpc-3688	146	14	v	v	NUM
dpc-3688	146	15	20	20	NUM
dpc-3688	146	16	21	21	NUM
dpc-3688	146	17	b	b	X
dpc-3688	146	18	ro	ro	X
dpc-3688	146	19	da	da	PROPN
dpc-3688	146	20	lu	lu	PROPN
dpc-3688	146	21	m	m	PROPN
dpc-3688	146	22	ab	ab	NOUN
dpc-3688	146	23	pr	pr	NOUN
dpc-3688	146	24	os	os	NOUN
dpc-3688	146	25	pop	pop	VERB
dpc-3688	146	26	en	en	ADV
dpc-3688	146	27	,	,	PUNCT
dpc-3688	146	28	w	w	PROPN
dpc-3688	146	29	24	24	NUM
dpc-3688	146	30	b	b	PROPN
dpc-3688	146	31	d	d	PROPN
dpc-3688	146	32	l	l	NOUN
dpc-3688	146	33	2	2	NUM
dpc-3688	146	34	10	10	NUM
dpc-3688	146	35	a	a	DET
dpc-3688	146	36	t	t	NOUN
dpc-3688	146	37	w	w	PROPN
dpc-3688	146	38	0	0	PROPN
dpc-3688	146	39	,	,	PUNCT
dpc-3688	146	40	w	w	PROPN
dpc-3688	146	41	1	1	NUM
dpc-3688	146	42	,	,	PUNCT
dpc-3688	146	43	w	w	NOUN
dpc-3688	146	44	2	2	NUM
dpc-3688	146	45	,	,	PUNCT
dpc-3688	146	46	w	w	PROPN
dpc-3688	146	47	3	3	NUM
dpc-3688	146	48	th	th	NUM
dpc-3688	146	49	en	en	ADP
dpc-3688	146	50	q	q	PROPN
dpc-3688	146	51	2w	2w	NUM
dpc-3688	146	52	30	30	NUM
dpc-3688	146	53	n	n	NOUN
dpc-3688	146	54	a	a	DET
dpc-3688	146	55	ps	ps	NOUN
dpc-3688	146	56	i	i	PRON
dpc-3688	146	57	(	(	PUNCT
dpc-3688	146	58	fi	fi	NOUN
dpc-3688	146	59	ng	ng	PROPN
dpc-3688	146	60	er	er	INTJ
dpc-3688	146	61	)	)	PUNCT
dpc-3688	146	62	n	n	CCONJ
dpc-3688	146	63	a	a	DET
dpc-3688	146	64	ps	ps	NOUN
dpc-3688	147	1	i	i	PRON
dpc-3688	147	2	19	19	NUM
dpc-3688	148	1	.6	.6	NUM
dpc-3688	148	2	d	d	PROPN
dpc-3688	148	3	l	l	NOUN
dpc-3688	148	4	q	q	X
dpc-3688	149	1	i	i	PRON
dpc-3688	149	2	22	22	NUM
dpc-3688	149	3	.8	.8	PROPN
dpc-3688	149	4	w	w	PROPN
dpc-3688	149	5	24	24	NUM
dpc-3688	149	6	n	n	PROPN
dpc-3688	149	7	a	a	DET
dpc-3688	149	8	ps	ps	NOUN
dpc-3688	149	9	i	i	NOUN
dpc-3688	149	10	2	2	NUM
dpc-3688	149	11	.	.	NOUN
dpc-3688	149	12	3	3	NUM
dpc-3688	149	13	w	w	PROPN
dpc-3688	149	14	24	24	NUM
dpc-3688	149	15	d	d	NOUN
dpc-3688	149	16	l	l	NOUN
dpc-3688	149	17	q	q	X
dpc-3688	149	18	i	i	PRON
dpc-3688	149	19	3	3	NUM
dpc-3688	149	20	.	.	NOUN
dpc-3688	149	21	7	7	NUM
dpc-3688	149	22	po	po	NOUN
dpc-3688	149	23	lit	light	VERB
dpc-3688	149	24	ou	ou	PROPN
dpc-3688	149	25	,	,	PUNCT
dpc-3688	149	26	a	a	DET
dpc-3688	149	27	m	m	NOUN
dpc-3688	149	28	a	a	DET
dpc-3688	149	29	ca	ca	NOUN
dpc-3688	150	1	d	d	NOUN
dpc-3688	150	2	d	d	NOUN
dpc-3688	150	3	er	er	INTJ
dpc-3688	150	4	m	m	VERB
dpc-3688	150	5	at	at	ADP
dpc-3688	150	6	ol	ol	PROPN
dpc-3688	150	7	.	.	PUNCT
dpc-3688	151	1	2	2	NUM
dpc-3688	151	2	02	02	NUM
dpc-3688	151	3	0	0	NUM
dpc-3688	151	4	b	b	X
dpc-3688	151	5	ro	ro	X
dpc-3688	151	6	da	da	PROPN
dpc-3688	151	7	lu	lu	PROPN
dpc-3688	151	8	m	m	PROPN
dpc-3688	151	9	ab	ab	PROPN
dpc-3688	151	10	a	a	DET
dpc-3688	151	11	b	b	PROPN
dpc-3688	151	12	st	st	PROPN
dpc-3688	151	13	r	r	PROPN
dpc-3688	151	14	a	a	PROPN
dpc-3688	151	15	c	c	NOUN
dpc-3688	151	16	t	t	PROPN
dpc-3688	151	17	w	w	PROPN
dpc-3688	151	18	12	12	NUM
dpc-3688	151	19	c	c	NOUN
dpc-3688	151	20	as	as	ADP
dpc-3688	151	21	e	e	X
dpc-3688	151	22	re	re	X
dpc-3688	151	23	po	po	PROPN
dpc-3688	151	24	rt	rt	PROPN
dpc-3688	151	25	b	b	PROPN
dpc-3688	151	26	d	d	PROPN
dpc-3688	151	27	l	l	NOUN
dpc-3688	151	28	2	2	NUM
dpc-3688	151	29	10	10	NUM
dpc-3688	151	30	4	4	NUM
dpc-3688	151	31	pp	pp	ADV
dpc-3688	151	32	pg	pg	VERB
dpc-3688	151	33	a	a	DET
dpc-3688	151	34	w	w	NOUN
dpc-3688	151	35	12	12	NUM
dpc-3688	151	36	p	p	NOUN
dpc-3688	151	37	pg	pg	PROPN
dpc-3688	151	38	a	a	DET
dpc-3688	151	39	0	0	NUM
dpc-3688	151	40	n	n	SYM
dpc-3688	151	41	ak	ak	PROPN
dpc-3688	151	42	ao	ao	PROPN
dpc-3688	151	43	,	,	PUNCT
dpc-3688	151	44	e	e	PROPN
dpc-3688	151	45	jd	jd	PROPN
dpc-3688	151	46	,	,	PUNCT
dpc-3688	151	47	2	2	NUM
dpc-3688	151	48	01	01	NUM
dpc-3688	151	49	8	8	NUM
dpc-3688	151	50	b	b	X
dpc-3688	151	51	ro	ro	X
dpc-3688	151	52	da	da	PROPN
dpc-3688	151	53	lu	lu	PROPN
dpc-3688	151	54	m	m	PROPN
dpc-3688	151	55	ab	ab	PROPN
dpc-3688	151	56	c	c	PROPN
dpc-3688	151	57	as	as	ADP
dpc-3688	151	58	e	e	X
dpc-3688	151	59	re	re	X
dpc-3688	151	60	po	po	PROPN
dpc-3688	151	61	rt	rt	PROPN
dpc-3688	151	62	b	b	PROPN
dpc-3688	151	63	d	d	PROPN
dpc-3688	151	64	l	l	NOUN
dpc-3688	151	65	2	2	NUM
dpc-3688	151	66	10	10	NUM
dpc-3688	151	67	m	m	NOUN
dpc-3688	151	68	g	g	NOUN
dpc-3688	151	69	1	1	NUM
dpc-3688	151	70	pp	pp	ADP
dpc-3688	152	1	pa	pa	PROPN
dpc-3688	152	2	si	si	PROPN
dpc-3688	153	1	pp	pp	ADV
dpc-3688	153	2	pa	pa	PROPN
dpc-3688	153	3	si	si	PROPN
dpc-3688	153	4	1	1	NUM
dpc-3688	153	5	3	3	NUM
dpc-3688	153	6	.	.	NOUN
dpc-3688	153	7	2	2	NUM
dpc-3688	153	8	w	w	PROPN
dpc-3688	153	9	24	24	NUM
dpc-3688	153	10	p	p	NOUN
dpc-3688	153	11	pp	pp	ADP
dpc-3688	153	12	a	a	DET
dpc-3688	153	13	si	si	PROPN
dpc-3688	153	14	4	4	NUM
dpc-3688	153	15	.0	.0	NUM
dpc-3688	153	16	pi	pi	NOUN
dpc-3688	153	17	nt	not	PART
dpc-3688	153	18	er	er	INTJ
dpc-3688	153	19	,	,	PUNCT
dpc-3688	153	20	jo	jo	PROPN
dpc-3688	153	21	ur	ur	INTJ
dpc-3688	153	22	na	na	VERB
dpc-3688	153	23	l	l	NOUN
dpc-3688	153	24	f	f	PROPN
dpc-3688	154	1	d	d	X
dpc-3688	154	2	er	er	INTJ
dpc-3688	154	3	m	m	VERB
dpc-3688	154	4	at	at	ADP
dpc-3688	154	5	ol	ol	PROPN
dpc-3688	154	6	og	og	PROPN
dpc-3688	154	7	y	y	PROPN
dpc-3688	154	8	20	20	NUM
dpc-3688	154	9	19	19	NUM
dpc-3688	154	10	b	b	X
dpc-3688	154	11	ro	ro	X
dpc-3688	154	12	da	da	PROPN
dpc-3688	154	13	lu	lu	PROPN
dpc-3688	154	14	m	m	PROPN
dpc-3688	154	15	ab	ab	PROPN
dpc-3688	154	16	c	c	PROPN
dpc-3688	154	17	as	as	ADP
dpc-3688	154	18	e	e	PROPN
dpc-3688	154	19	se	se	X
dpc-3688	154	20	ri	ri	PROPN
dpc-3688	154	21	es	es	X
dpc-3688	154	22	b	b	PROPN
dpc-3688	154	23	d	d	NOUN
dpc-3688	154	24	l	l	NOUN
dpc-3688	154	25	2	2	NUM
dpc-3688	154	26	10	10	NUM
dpc-3688	154	27	m	m	NOUN
dpc-3688	154	28	g	g	ADJ
dpc-3688	154	29	4	4	NUM
dpc-3688	154	30	pp	pp	ADP
dpc-3688	154	31	g	g	PROPN
dpc-3688	154	32	a	a	DET
dpc-3688	154	33	m	m	NOUN
dpc-3688	154	34	ea	ea	NOUN
dpc-3688	154	35	n	n	ADP
dpc-3688	154	36	8	8	NUM
dpc-3688	154	37	e	e	NOUN
dpc-3688	154	38	t	t	PROPN
dpc-3688	154	39	m	m	PROPN
dpc-3688	154	40	ea	ea	PROPN
dpc-3688	154	41	n	n	ADP
dpc-3688	154	42	8	8	NUM
dpc-3688	154	43	o	o	NOUN
dpc-3688	154	44	ku	ku	PROPN
dpc-3688	154	45	bo	bo	PROPN
dpc-3688	154	46	,	,	PUNCT
dpc-3688	154	47	j	j	PROPN
dpc-3688	154	48	ea	ea	PROPN
dpc-3688	155	1	dv	dv	PROPN
dpc-3688	155	2	po	po	PROPN
dpc-3688	155	3	st	st	PROPN
dpc-3688	156	1	er	er	INTJ
dpc-3688	156	2	2	2	NUM
dpc-3688	156	3	02	02	NUM
dpc-3688	156	4	2	2	NUM
dpc-3688	156	5	b	b	X
dpc-3688	156	6	ro	ro	X
dpc-3688	156	7	da	da	PROPN
dpc-3688	156	8	lu	lu	PROPN
dpc-3688	156	9	m	m	PROPN
dpc-3688	156	10	ab	ab	PROPN
dpc-3688	156	11	a	a	DET
dpc-3688	156	12	b	b	PROPN
dpc-3688	156	13	st	st	PROPN
dpc-3688	156	14	r	r	PROPN
dpc-3688	156	15	a	a	PROPN
dpc-3688	156	16	c	c	NOUN
dpc-3688	156	17	t	t	PROPN
dpc-3688	157	1	w	w	PROPN
dpc-3688	158	1	16	16	NUM
dpc-3688	158	2	b	b	PROPN
dpc-3688	158	3	d	d	PROPN
dpc-3688	158	4	l	l	NOUN
dpc-3688	158	5	2	2	NUM
dpc-3688	158	6	10	10	NUM
dpc-3688	158	7	pl	pl	PROPN
dpc-3688	158	8	ac	ac	PROPN
dpc-3688	158	9	eb	eb	PROPN
dpc-3688	158	10	o	o	PROPN
dpc-3688	158	11	12	12	NUM
dpc-3688	158	12	6	6	NUM
dpc-3688	158	13	pp	pp	ADP
dpc-3688	158	14	pa	pa	PROPN
dpc-3688	158	15	si	si	PROPN
dpc-3688	158	16	m	m	PROPN
dpc-3688	158	17	ea	ea	PROPN
dpc-3688	158	18	n	n	NUM
dpc-3688	158	19	ch	ch	NOUN
dpc-3688	158	20	an	an	DET
dpc-3688	158	21	ge	ge	PROPN
dpc-3688	158	22	in	in	ADP
dpc-3688	158	23	pp	pp	PROPN
dpc-3688	158	24	a	a	DET
dpc-3688	158	25	si	si	PROPN
dpc-3688	158	26	t	t	PROPN
dpc-3688	158	27	ot	ot	INTJ
dpc-3688	158	28	al	al	PROPN
dpc-3688	158	29	s	s	PROPN
dpc-3688	158	30	co	co	X
dpc-3688	158	31	re	re	PROPN
dpc-3688	158	32	13	13	NUM
dpc-3688	158	33	.7	.7	NUM
dpc-3688	158	34	3	3	NUM
dpc-3688	158	35	8	8	NUM
dpc-3688	159	1	.	.	PUNCT
dpc-3688	160	1	45	45	NUM
dpc-3688	160	2	b	b	NOUN
dpc-3688	160	3	d	d	NOUN
dpc-3688	160	4	l	l	NOUN
dpc-3688	160	5	=	=	SYM
dpc-3688	160	6	b	b	X
dpc-3688	160	7	ro	ro	X
dpc-3688	160	8	da	da	PROPN
dpc-3688	160	9	lu	lu	PROPN
dpc-3688	160	10	m	m	PROPN
dpc-3688	160	11	ab	ab	NOUN
dpc-3688	160	12	;	;	PUNCT
dpc-3688	160	13	d	d	X
dpc-3688	160	14	l	l	NOUN
dpc-3688	160	15	q	q	X
dpc-3688	161	1	i	i	NOUN
dpc-3688	161	2	=	=	PUNCT
dpc-3688	162	1	d	d	X
dpc-3688	162	2	er	er	INTJ
dpc-3688	162	3	m	m	VERB
dpc-3688	162	4	at	at	ADP
dpc-3688	162	5	ol	ol	PROPN
dpc-3688	162	6	og	og	PROPN
dpc-3688	162	7	y	y	PROPN
dpc-3688	163	1	l	l	NOUN
dpc-3688	163	2	if	if	SCONJ
dpc-3688	163	3	e	e	PROPN
dpc-3688	163	4	q	q	X
dpc-3688	163	5	ua	ua	PROPN
dpc-3688	163	6	lit	light	VERB
dpc-3688	163	7	y	y	PROPN
dpc-3688	163	8	in	in	ADP
dpc-3688	163	9	de	de	PROPN
dpc-3688	163	10	x	x	PROPN
dpc-3688	163	11	;	;	PUNCT
dpc-3688	163	12	n	n	CCONJ
dpc-3688	163	13	a	a	DET
dpc-3688	163	14	ps	ps	NOUN
dpc-3688	164	1	i	i	NOUN
dpc-3688	164	2	=	=	PUNCT
dpc-3688	164	3	n	n	CCONJ
dpc-3688	164	4	ai	ai	VERB
dpc-3688	164	5	l	l	NOUN
dpc-3688	164	6	p	p	NOUN
dpc-3688	165	1	so	so	ADV
dpc-3688	165	2	ri	ri	PROPN
dpc-3688	165	3	as	as	SCONJ
dpc-3688	165	4	is	be	AUX
dpc-3688	165	5	s	s	VERB
dpc-3688	165	6	ev	ev	INTJ
dpc-3688	166	1	er	er	INTJ
dpc-3688	166	2	it	it	PRON
dpc-3688	166	3	y	y	PROPN
dpc-3688	166	4	in	in	ADP
dpc-3688	166	5	de	de	PROPN
dpc-3688	166	6	x	x	PROPN
dpc-3688	166	7	;	;	PUNCT
dpc-3688	167	1	p	p	X
dpc-3688	167	2	g	g	PROPN
dpc-3688	167	3	a	a	DET
dpc-3688	167	4	=	=	X
dpc-3688	167	5	p	p	NOUN
dpc-3688	167	6	hy	hy	NOUN
dpc-3688	167	7	si	si	PROPN
dpc-3688	167	8	ci	ci	PROPN
dpc-3688	167	9	an	an	DET
dpc-3688	167	10	g	g	PROPN
dpc-3688	167	11	lo	lo	PROPN
dpc-3688	167	12	ba	ba	PROPN
dpc-3688	167	13	l	l	NOUN
dpc-3688	168	1	a	a	DET
dpc-3688	168	2	ss	ss	NOUN
dpc-3688	168	3	es	es	X
dpc-3688	168	4	sm	sm	PROPN
dpc-3688	168	5	en	en	PROPN
dpc-3688	168	6	t	t	PROPN
dpc-3688	168	7	;	;	PUNCT
dpc-3688	168	8	p	p	NOUN
dpc-3688	168	9	ss	ss	NOUN
dpc-3688	169	1	=	=	PUNCT
dpc-3688	169	2	p	p	NOUN
dpc-3688	169	3	so	so	ADV
dpc-3688	169	4	ri	ri	PROPN
dpc-3688	169	5	as	as	SCONJ
dpc-3688	169	6	is	be	AUX
dpc-3688	169	7	s	s	PROPN
dpc-3688	169	8	ym	ym	NOUN
dpc-3688	169	9	pt	pt	NOUN
dpc-3688	169	10	om	om	PROPN
dpc-3688	169	11	s	s	PROPN
dpc-3688	169	12	sc	sc	PROPN
dpc-3688	169	13	al	al	PROPN
dpc-3688	169	14	e	e	PROPN
dpc-3688	169	15	;	;	PUNCT
dpc-3688	169	16	p	p	X
dpc-3688	169	17	ss	ss	NOUN
dpc-3688	170	1	i	i	PRON
dpc-3688	170	2	=	=	PUNCT
dpc-3688	170	3	ps	ps	PROPN
dpc-3688	170	4	or	or	CCONJ
dpc-3688	170	5	ia	ia	PROPN
dpc-3688	170	6	si	si	X
dpc-3688	170	7	s	s	PROPN
dpc-3688	170	8	sc	sc	PROPN
dpc-3688	170	9	al	al	PROPN
dpc-3688	170	10	p	p	PROPN
dpc-3688	170	11	se	se	PROPN
dpc-3688	170	12	ve	ve	VERB
dpc-3688	170	13	ri	ri	INTJ
dpc-3688	171	1	ty	ty	INTJ
dpc-3688	171	2	i	i	PRON
dpc-3688	171	3	nd	nd	ADV
dpc-3688	171	4	ex	ex	X
dpc-3688	171	5	;	;	PUNCT
dpc-3688	172	1	pp	pp	ADV
dpc-3688	172	2	pa	pa	PROPN
dpc-3688	172	3	si	si	PROPN
dpc-3688	173	1	=	=	PROPN
dpc-3688	173	2	p	p	PROPN
dpc-3688	173	3	al	al	PROPN
dpc-3688	173	4	m	m	PROPN
dpc-3688	173	5	op	op	NOUN
dpc-3688	173	6	la	la	PROPN
dpc-3688	173	7	nt	not	PART
dpc-3688	173	8	ar	ar	PROPN
dpc-3688	173	9	p	p	PROPN
dpc-3688	173	10	us	us	PROPN
dpc-3688	174	1	tu	tu	INTJ
dpc-3688	174	2	lo	lo	PROPN
dpc-3688	174	3	si	si	PROPN
dpc-3688	174	4	s	s	PROPN
dpc-3688	174	5	ps	ps	NOUN
dpc-3688	174	6	or	or	CCONJ
dpc-3688	174	7	ia	ia	PROPN
dpc-3688	174	8	si	si	X
dpc-3688	174	9	s	s	PROPN
dpc-3688	174	10	a	a	PRON
dpc-3688	174	11	re	re	X
dpc-3688	174	12	a	a	DET
dpc-3688	174	13	an	an	PROPN
dpc-3688	174	14	d	d	X
dpc-3688	174	15	se	se	X
dpc-3688	174	16	ve	ve	VERB
dpc-3688	174	17	ri	ri	INTJ
dpc-3688	175	1	ty	ty	INTJ
dpc-3688	175	2	i	i	PRON
dpc-3688	175	3	nd	nd	ADV
dpc-3688	175	4	ex	ex	NOUN
dpc-3688	175	5	;	;	PUNCT
dpc-3688	175	6	q	q	PROPN
dpc-3688	175	7	2w	2w	NUM
dpc-3688	175	8	=	=	SYM
dpc-3688	175	9	e	e	AUX
dpc-3688	175	10	ve	ve	AUX
dpc-3688	175	11	ry	ry	VERB
dpc-3688	175	12	o	o	NOUN
dpc-3688	175	13	th	th	INTJ
dpc-3688	175	14	er	er	INTJ
dpc-3688	175	15	w	w	PROPN
dpc-3688	175	16	ee	ee	PROPN
dpc-3688	175	17	k	k	PROPN
dpc-3688	175	18	;	;	PUNCT
dpc-3688	175	19	r	r	NOUN
dpc-3688	175	20	c	c	NOUN
dpc-3688	175	21	t	t	NOUN
dpc-3688	175	22	=	=	PUNCT
dpc-3688	175	23	r	r	NOUN
dpc-3688	175	24	an	an	DET
dpc-3688	175	25	do	do	NOUN
dpc-3688	175	26	m	m	NOUN
dpc-3688	175	27	iz	iz	INTJ
dpc-3688	176	1	ed	ed	NOUN
dpc-3688	176	2	c	c	PROPN
dpc-3688	176	3	lin	lin	PROPN
dpc-3688	176	4	ic	ic	PROPN
dpc-3688	176	5	al	al	PROPN
dpc-3688	176	6	t	t	PROPN
dpc-3688	176	7	ri	ri	PROPN
dpc-3688	176	8	al	al	PROPN
dpc-3688	176	9	s.	s.	PROPN
dpc-3688	176	10	6	6	NUM
dpc-3688	176	11	review	review	NOUN
dpc-3688	176	12	|	|	ADV
dpc-3688	176	13	dermatol	dermatol	ADJ
dpc-3688	176	14	pract	pract	NOUN
dpc-3688	176	15	concept	concept	NOUN
dpc-3688	176	16	.	.	PUNCT
dpc-3688	177	1	2023;13(3):e2023245	2023;13(3):e2023245	NUM
dpc-3688	177	2	including	include	VERB
dpc-3688	177	3	difficult	difficult	ADJ
dpc-3688	177	4	areas	area	NOUN
dpc-3688	177	5	including	include	VERB
dpc-3688	177	6	nails	nail	NOUN
dpc-3688	177	7	and	and	CCONJ
dpc-3688	177	8	scalp	scalp	NOUN
dpc-3688	177	9	[	[	X
dpc-3688	177	10	41	41	NUM
dpc-3688	177	11	]	]	PUNCT
dpc-3688	177	12	.	.	PUNCT
dpc-3688	178	1	different	different	ADJ
dpc-3688	178	2	classes	class	NOUN
dpc-3688	178	3	of	of	ADP
dpc-3688	178	4	biologic	biologic	NOUN
dpc-3688	178	5	agents	agent	NOUN
dpc-3688	178	6	have	have	AUX
dpc-3688	178	7	been	be	AUX
dpc-3688	178	8	also	also	ADV
dpc-3688	178	9	approved	approve	VERB
dpc-3688	178	10	for	for	ADP
dpc-3688	178	11	the	the	DET
dpc-3688	178	12	treatment	treatment	NOUN
dpc-3688	178	13	of	of	ADP
dpc-3688	178	14	moderate	moderate	ADJ
dpc-3688	178	15	-	-	PUNCT
dpc-3688	178	16	severe	severe	ADJ
dpc-3688	178	17	psoriasis	psoriasis	NOUN
dpc-3688	178	18	,	,	PUNCT
dpc-3688	178	19	and	and	CCONJ
dpc-3688	178	20	anti	anti	ADJ
dpc-3688	178	21	-	-	ADJ
dpc-3688	178	22	tnfs	tnfs	NOUN
dpc-3688	178	23	represented	represent	VERB
dpc-3688	178	24	the	the	DET
dpc-3688	178	25	first	first	ADJ
dpc-3688	178	26	approved	approve	VERB
dpc-3688	178	27	biologic	biologic	NOUN
dpc-3688	178	28	class	class	NOUN
dpc-3688	178	29	.	.	PUNCT
dpc-3688	179	1	patients	patient	NOUN
dpc-3688	179	2	may	may	AUX
dpc-3688	179	3	experience	experience	VERB
dpc-3688	179	4	beneficial	beneficial	ADJ
dpc-3688	179	5	effects	effect	NOUN
dpc-3688	179	6	through	through	ADP
dpc-3688	179	7	p40il-12/23	p40il-12/23	ADJ
dpc-3688	179	8	inhibition	inhibition	NOUN
dpc-3688	179	9	(	(	PUNCT
dpc-3688	179	10	ustekinumab	ustekinumab	NOUN
dpc-3688	179	11	)	)	PUNCT
dpc-3688	179	12	or	or	CCONJ
dpc-3688	179	13	through	through	ADP
dpc-3688	179	14	il-23	il-23	NOUN
dpc-3688	179	15	blockade	blockade	NOUN
dpc-3688	179	16	(	(	PUNCT
dpc-3688	179	17	guselkumab	guselkumab	NOUN
dpc-3688	179	18	,	,	PUNCT
dpc-3688	179	19	risankizumab	risankizumab	NOUN
dpc-3688	179	20	,	,	PUNCT
dpc-3688	179	21	tildrakizumab	tildrakizumab	NOUN
dpc-3688	179	22	)	)	PUNCT
dpc-3688	179	23	.	.	PUNCT
dpc-3688	180	1	comparative	comparative	ADJ
dpc-3688	180	2	studies	study	NOUN
dpc-3688	180	3	demonstrated	demonstrate	VERB
dpc-3688	180	4	superiority	superiority	NOUN
dpc-3688	180	5	of	of	ADP
dpc-3688	180	6	anti	anti	ADJ
dpc-3688	180	7	-	-	ADJ
dpc-3688	180	8	il-17	il-17	ADJ
dpc-3688	180	9	agents	agent	NOUN
dpc-3688	180	10	compared	compare	VERB
dpc-3688	180	11	with	with	ADP
dpc-3688	180	12	ustekinumab	ustekinumab	NOUN
dpc-3688	180	13	in	in	ADP
dpc-3688	180	14	treating	treat	VERB
dpc-3688	180	15	difficult	difficult	ADJ
dpc-3688	180	16	areas	area	NOUN
dpc-3688	180	17	[	[	X
dpc-3688	180	18	42	42	NUM
dpc-3688	180	19	-	-	SYM
dpc-3688	180	20	48	48	NUM
dpc-3688	180	21	]	]	PUNCT
dpc-3688	180	22	.	.	PUNCT
dpc-3688	181	1	nowadays	nowadays	ADV
dpc-3688	181	2	,	,	PUNCT
dpc-3688	181	3	four	four	NUM
dpc-3688	181	4	anti	anti	ADJ
dpc-3688	181	5	-	-	ADJ
dpc-3688	181	6	il-17	il-17	ADJ
dpc-3688	181	7	agents	agent	NOUN
dpc-3688	181	8	are	be	AUX
dpc-3688	181	9	approved	approve	VERB
dpc-3688	181	10	for	for	ADP
dpc-3688	181	11	the	the	DET
dpc-3688	181	12	treatment	treatment	NOUN
dpc-3688	181	13	of	of	ADP
dpc-3688	181	14	plaque	plaque	NOUN
dpc-3688	181	15	psoriasis	psoriasis	NOUN
dpc-3688	181	16	:	:	PUNCT
dpc-3688	181	17	secukinumab	secukinumab	NOUN
dpc-3688	181	18	and	and	CCONJ
dpc-3688	181	19	ixekizumab	ixekizumab	NOUN
dpc-3688	181	20	are	be	AUX
dpc-3688	181	21	directed	direct	VERB
dpc-3688	181	22	against	against	ADP
dpc-3688	181	23	il-17a	il-17a	PROPN
dpc-3688	181	24	,	,	PUNCT
dpc-3688	181	25	bimekizumab	bimekizumab	X
dpc-3688	181	26	neutralizes	neutralize	VERB
dpc-3688	181	27	both	both	DET
dpc-3688	181	28	il-17a	il-17a	PROPN
dpc-3688	181	29	and	and	CCONJ
dpc-3688	181	30	il-17f	il-17f	NOUN
dpc-3688	181	31	,	,	PUNCT
dpc-3688	181	32	while	while	SCONJ
dpc-3688	181	33	brodalumab	brodalumab	NOUN
dpc-3688	181	34	antagonizes	antagonize	VERB
dpc-3688	181	35	il-17ra	il-17ra	PROPN
dpc-3688	181	36	.	.	PUNCT
dpc-3688	182	1	substantial	substantial	ADJ
dpc-3688	182	2	clinical	clinical	ADJ
dpc-3688	182	3	efficacy	efficacy	NOUN
dpc-3688	182	4	was	be	AUX
dpc-3688	182	5	achieved	achieve	VERB
dpc-3688	182	6	in	in	ADP
dpc-3688	182	7	patients	patient	NOUN
dpc-3688	182	8	treated	treat	VERB
dpc-3688	182	9	with	with	ADP
dpc-3688	182	10	secukinumab	secukinumab	NOUN
dpc-3688	182	11	and	and	CCONJ
dpc-3688	182	12	ixekizumab	ixekizumab	NOUN
dpc-3688	182	13	.	.	PUNCT
dpc-3688	183	1	recently	recently	ADV
dpc-3688	183	2	,	,	PUNCT
dpc-3688	183	3	elevated	elevated	ADJ
dpc-3688	183	4	efficacy	efficacy	NOUN
dpc-3688	183	5	,	,	PUNCT
dpc-3688	183	6	with	with	ADP
dpc-3688	183	7	even	even	ADV
dpc-3688	183	8	higher	high	ADJ
dpc-3688	183	9	response	response	NOUN
dpc-3688	183	10	rates	rate	NOUN
dpc-3688	183	11	compared	compare	VERB
dpc-3688	183	12	to	to	ADP
dpc-3688	183	13	secukinumab	secukinumab	NOUN
dpc-3688	183	14	or	or	CCONJ
dpc-3688	183	15	ixekizumab	ixekizumab	NOUN
dpc-3688	183	16	,	,	PUNCT
dpc-3688	183	17	was	be	AUX
dpc-3688	183	18	demonstrated	demonstrate	VERB
dpc-3688	183	19	in	in	ADP
dpc-3688	183	20	phase	phase	NOUN
dpc-3688	183	21	iii	iii	NUM
dpc-3688	183	22	studies	study	NOUN
dpc-3688	183	23	testing	testing	NOUN
dpc-3688	183	24	bimekizumab	bimekizumab	PROPN
dpc-3688	183	25	,	,	PUNCT
dpc-3688	183	26	indicating	indicate	VERB
dpc-3688	183	27	that	that	SCONJ
dpc-3688	183	28	il‐17f	il‐17f	NOUN
dpc-3688	183	29	also	also	ADV
dpc-3688	183	30	contributes	contribute	VERB
dpc-3688	183	31	to	to	PART
dpc-3688	183	32	drive	drive	VERB
dpc-3688	183	33	skin	skin	NOUN
dpc-3688	183	34	inflammation	inflammation	NOUN
dpc-3688	183	35	in	in	ADP
dpc-3688	183	36	psoriasis	psoriasis	NOUN
dpc-3688	183	37	[	[	X
dpc-3688	183	38	46,47	46,47	NOUN
dpc-3688	183	39	]	]	X
dpc-3688	183	40	.	.	PUNCT
dpc-3688	184	1	moreover	moreover	ADV
dpc-3688	184	2	,	,	PUNCT
dpc-3688	184	3	the	the	DET
dpc-3688	184	4	simultaneous	simultaneous	ADJ
dpc-3688	184	5	inhibition	inhibition	NOUN
dpc-3688	184	6	of	of	ADP
dpc-3688	184	7	several	several	ADJ
dpc-3688	184	8	il‐17	il‐17	ADJ
dpc-3688	184	9	family	family	NOUN
dpc-3688	184	10	cytokines	cytokine	NOUN
dpc-3688	184	11	induced	induce	VERB
dpc-3688	184	12	by	by	ADP
dpc-3688	184	13	brodalumab	brodalumab	NOUN
dpc-3688	184	14	,	,	PUNCT
dpc-3688	184	15	has	have	AUX
dpc-3688	184	16	been	be	AUX
dpc-3688	184	17	shown	show	VERB
dpc-3688	184	18	to	to	PART
dpc-3688	184	19	be	be	AUX
dpc-3688	184	20	efficacious	efficacious	ADJ
dpc-3688	184	21	in	in	ADP
dpc-3688	184	22	the	the	DET
dpc-3688	184	23	treatment	treatment	NOUN
dpc-3688	184	24	of	of	ADP
dpc-3688	184	25	psoriasis	psoriasis	NOUN
dpc-3688	184	26	[	[	X
dpc-3688	184	27	48	48	NUM
dpc-3688	184	28	-	-	SYM
dpc-3688	184	29	49	49	NUM
dpc-3688	184	30	]	]	PUNCT
dpc-3688	184	31	.	.	PUNCT
dpc-3688	185	1	brodalumab	brodalumab	NOUN
dpc-3688	185	2	extensively	extensively	ADV
dpc-3688	185	3	suppresses	suppress	VERB
dpc-3688	185	4	tissue	tissue	NOUN
dpc-3688	185	5	response	response	NOUN
dpc-3688	185	6	to	to	ADP
dpc-3688	185	7	il17	il17	PROPN
dpc-3688	185	8	cytokine	cytokine	VERB
dpc-3688	185	9	impulse	impulse	ADJ
dpc-3688	185	10	,	,	PUNCT
dpc-3688	185	11	normalizing	normalize	VERB
dpc-3688	185	12	the	the	DET
dpc-3688	185	13	expression	expression	NOUN
dpc-3688	185	14	of	of	ADP
dpc-3688	185	15	il-17	il-17	NUM
dpc-3688	185	16	dependent	dependent	ADJ
dpc-3688	185	17	genes	gene	NOUN
dpc-3688	185	18	,	,	PUNCT
dpc-3688	185	19	in	in	ADP
dpc-3688	185	20	tissue	tissue	NOUN
dpc-3688	185	21	cells	cell	NOUN
dpc-3688	185	22	,	,	PUNCT
dpc-3688	185	23	particularly	particularly	ADV
dpc-3688	185	24	keratinocytes	keratinocyte	NOUN
dpc-3688	185	25	.	.	PUNCT
dpc-3688	186	1	this	this	DET
dpc-3688	186	2	modulation	modulation	NOUN
dpc-3688	186	3	is	be	AUX
dpc-3688	186	4	dose	dose	VERB
dpc-3688	186	5	dependent	dependent	ADJ
dpc-3688	186	6	and	and	CCONJ
dpc-3688	186	7	after	after	ADP
dpc-3688	186	8	12	12	NUM
dpc-3688	186	9	weeks	week	NOUN
dpc-3688	186	10	of	of	ADP
dpc-3688	186	11	treatment	treatment	NOUN
dpc-3688	186	12	a	a	DET
dpc-3688	186	13	profound	profound	ADJ
dpc-3688	186	14	molecular	molecular	ADJ
dpc-3688	186	15	response	response	NOUN
dpc-3688	186	16	,	,	PUNCT
dpc-3688	186	17	with	with	SCONJ
dpc-3688	186	18	>	>	X
dpc-3688	186	19	95%-improvement	95%-improvement	NUM
dpc-3688	186	20	in	in	ADP
dpc-3688	186	21	differentially	differentially	ADV
dpc-3688	186	22	expressed	express	VERB
dpc-3688	186	23	psoriasis	psoriasis	NOUN
dpc-3688	186	24	genes	gene	NOUN
dpc-3688	186	25	was	be	AUX
dpc-3688	186	26	obtained	obtain	VERB
dpc-3688	186	27	[	[	X
dpc-3688	186	28	43	43	NUM
dpc-3688	186	29	]	]	PUNCT
dpc-3688	186	30	.	.	PUNCT
dpc-3688	187	1	this	this	DET
dpc-3688	187	2	effect	effect	NOUN
dpc-3688	187	3	is	be	AUX
dpc-3688	187	4	rapidly	rapidly	ADV
dpc-3688	187	5	detected	detect	VERB
dpc-3688	187	6	with	with	ADP
dpc-3688	187	7	greater	great	ADJ
dpc-3688	187	8	magnitude	magnitude	NOUN
dpc-3688	187	9	than	than	ADP
dpc-3688	187	10	with	with	ADP
dpc-3688	187	11	other	other	ADJ
dpc-3688	187	12	biological	biological	ADJ
dpc-3688	187	13	agents	agent	NOUN
dpc-3688	187	14	,	,	PUNCT
dpc-3688	187	15	resulting	result	VERB
dpc-3688	187	16	in	in	ADP
dpc-3688	187	17	a	a	DET
dpc-3688	187	18	lower	low	ADJ
dpc-3688	187	19	residual	residual	ADJ
dpc-3688	187	20	alteration	alteration	NOUN
dpc-3688	187	21	of	of	ADP
dpc-3688	187	22	gene	gene	NOUN
dpc-3688	187	23	expression	expression	NOUN
dpc-3688	187	24	compared	compare	VERB
dpc-3688	187	25	with	with	ADP
dpc-3688	187	26	ustekinumab	ustekinumab	NOUN
dpc-3688	187	27	and	and	CCONJ
dpc-3688	187	28	etanercept	etanercept	VERB
dpc-3688	187	29	[	[	X
dpc-3688	187	30	50	50	NUM
dpc-3688	187	31	]	]	PUNCT
dpc-3688	187	32	.	.	PUNCT
dpc-3688	188	1	the	the	DET
dpc-3688	188	2	distinctive	distinctive	ADJ
dpc-3688	188	3	mechanism	mechanism	NOUN
dpc-3688	188	4	of	of	ADP
dpc-3688	188	5	blocking	block	VERB
dpc-3688	188	6	multiple	multiple	ADJ
dpc-3688	188	7	il-17	il-17	NUM
dpc-3688	188	8	family	family	NOUN
dpc-3688	188	9	cytokines	cytokine	NOUN
dpc-3688	188	10	(	(	PUNCT
dpc-3688	188	11	il-17a	il-17a	PROPN
dpc-3688	188	12	,	,	PUNCT
dpc-3688	188	13	e	e	PROPN
dpc-3688	188	14	,	,	PUNCT
dpc-3688	188	15	f	f	X
dpc-3688	188	16	,	,	PUNCT
dpc-3688	188	17	c	c	X
dpc-3688	188	18	)	)	PUNCT
dpc-3688	188	19	may	may	AUX
dpc-3688	188	20	account	account	VERB
dpc-3688	188	21	for	for	ADP
dpc-3688	188	22	the	the	DET
dpc-3688	188	23	effectiveness	effectiveness	NOUN
dpc-3688	188	24	of	of	ADP
dpc-3688	188	25	brodalumab	brodalumab	NOUN
dpc-3688	188	26	in	in	ADP
dpc-3688	188	27	achieving	achieve	VERB
dpc-3688	188	28	skin	skin	NOUN
dpc-3688	188	29	clearance	clearance	NOUN
dpc-3688	188	30	in	in	ADP
dpc-3688	188	31	psoriasis	psoriasis	NOUN
dpc-3688	188	32	patients	patient	NOUN
dpc-3688	188	33	,	,	PUNCT
dpc-3688	188	34	comprising	comprise	VERB
dpc-3688	188	35	those	those	PRON
dpc-3688	188	36	with	with	ADP
dpc-3688	188	37	inadequate	inadequate	ADJ
dpc-3688	188	38	response	response	NOUN
dpc-3688	188	39	to	to	ADP
dpc-3688	188	40	other	other	ADJ
dpc-3688	188	41	biologics	biologic	NOUN
dpc-3688	188	42	,	,	PUNCT
dpc-3688	188	43	in	in	ADP
dpc-3688	188	44	particular	particular	ADJ
dpc-3688	188	45	the	the	DET
dpc-3688	188	46	anti	anti	NOUN
dpc-3688	188	47	-	-	ADJ
dpc-3688	188	48	il-17	il-17	ADV
dpc-3688	188	49	[	[	X
dpc-3688	188	50	51	51	NUM
dpc-3688	188	51	]	]	PUNCT
dpc-3688	188	52	.	.	PUNCT
dpc-3688	189	1	data	datum	NOUN
dpc-3688	189	2	from	from	ADP
dpc-3688	189	3	rct	rct	PROPN
dpc-3688	189	4	and	and	CCONJ
dpc-3688	189	5	real	real	ADJ
dpc-3688	189	6	-	-	PUNCT
dpc-3688	189	7	world	world	NOUN
dpc-3688	189	8	experiences	experience	NOUN
dpc-3688	189	9	showed	show	VERB
dpc-3688	189	10	efficacy	efficacy	NOUN
dpc-3688	189	11	of	of	ADP
dpc-3688	189	12	brodalumab	brodalumab	NOUN
dpc-3688	189	13	also	also	ADV
dpc-3688	189	14	in	in	ADP
dpc-3688	189	15	treating	treat	VERB
dpc-3688	189	16	difficult	difficult	ADJ
dpc-3688	189	17	areas	area	NOUN
dpc-3688	189	18	and	and	CCONJ
dpc-3688	189	19	severe	severe	ADJ
dpc-3688	189	20	variants	variant	NOUN
dpc-3688	189	21	of	of	ADP
dpc-3688	189	22	psoriasis	psoriasis	NOUN
dpc-3688	189	23	,	,	PUNCT
dpc-3688	189	24	such	such	ADJ
dpc-3688	189	25	as	as	ADP
dpc-3688	189	26	generalized	generalize	VERB
dpc-3688	189	27	pustular	pustular	ADJ
dpc-3688	189	28	and	and	CCONJ
dpc-3688	189	29	erhytrodermic	erhytrodermic	ADJ
dpc-3688	189	30	psoriasis	psoriasis	NOUN
dpc-3688	189	31	.	.	PUNCT
dpc-3688	190	1	data	datum	NOUN
dpc-3688	190	2	from	from	ADP
dpc-3688	190	3	randomized	randomized	ADJ
dpc-3688	190	4	controlled	control	VERB
dpc-3688	190	5	trials	trial	NOUN
dpc-3688	190	6	scalp	scalp	NOUN
dpc-3688	190	7	psoriasis	psoriasis	NOUN
dpc-3688	190	8	brodalumab	brodalumab	NOUN
dpc-3688	190	9	showed	show	VERB
dpc-3688	190	10	to	to	PART
dpc-3688	190	11	be	be	AUX
dpc-3688	190	12	effective	effective	ADJ
dpc-3688	190	13	and	and	CCONJ
dpc-3688	190	14	rapid	rapid	ADJ
dpc-3688	190	15	on	on	ADP
dpc-3688	190	16	scalp	scalp	NOUN
dpc-3688	190	17	psoriasis	psoriasis	NOUN
dpc-3688	190	18	as	as	SCONJ
dpc-3688	190	19	reported	report	VERB
dpc-3688	190	20	in	in	ADP
dpc-3688	190	21	a	a	DET
dpc-3688	190	22	post	post	ADJ
dpc-3688	190	23	-	-	ADJ
dpc-3688	190	24	hoc	hoc	ADJ
dpc-3688	190	25	analysis	analysis	NOUN
dpc-3688	190	26	from	from	ADP
dpc-3688	190	27	the	the	DET
dpc-3688	190	28	phase	phase	NOUN
dpc-3688	190	29	3	3	NUM
dpc-3688	190	30	amagine	amagine	NOUN
dpc-3688	190	31	1	1	NUM
dpc-3688	190	32	study	study	NOUN
dpc-3688	190	33	(	(	PUNCT
dpc-3688	190	34	a	a	DET
dpc-3688	190	35	randomized	randomized	ADJ
dpc-3688	190	36	,	,	PUNCT
dpc-3688	190	37	placebo	placebo	NOUN
dpc-3688	190	38	-	-	PUNCT
dpc-3688	190	39	controlled	control	VERB
dpc-3688	190	40	,	,	PUNCT
dpc-3688	190	41	phase	phase	NOUN
dpc-3688	190	42	3	3	NUM
dpc-3688	190	43	study	study	NOUN
dpc-3688	190	44	,	,	PUNCT
dpc-3688	190	45	nct01708590	nct01708590	NUM
dpc-3688	190	46	)	)	PUNCT
dpc-3688	190	47	which	which	PRON
dpc-3688	190	48	detected	detect	VERB
dpc-3688	190	49	improvement	improvement	NOUN
dpc-3688	190	50	rates	rate	NOUN
dpc-3688	190	51	from	from	ADP
dpc-3688	190	52	baseline	baseline	NOUN
dpc-3688	190	53	in	in	ADP
dpc-3688	190	54	mean	mean	PROPN
dpc-3688	190	55	pssi	pssi	PROPN
dpc-3688	190	56	seen	see	VERB
dpc-3688	190	57	as	as	ADV
dpc-3688	190	58	early	early	ADV
dpc-3688	190	59	as	as	ADP
dpc-3688	190	60	at	at	ADP
dpc-3688	190	61	week	week	NOUN
dpc-3688	190	62	2	2	NUM
dpc-3688	190	63	in	in	ADP
dpc-3688	190	64	patients	patient	NOUN
dpc-3688	190	65	receiving	receive	VERB
dpc-3688	190	66	brodalumab	brodalumab	NOUN
dpc-3688	190	67	versus	versus	ADP
dpc-3688	190	68	placebo	placebo	NOUN
dpc-3688	190	69	(	(	PUNCT
dpc-3688	190	70	pssi	pssi	ADJ
dpc-3688	190	71	:	:	PUNCT
dpc-3688	190	72	67.6	67.6	NUM
dpc-3688	190	73	%	%	NOUN
dpc-3688	190	74	versus	versus	ADP
dpc-3688	190	75	6.7	6.7	NUM
dpc-3688	190	76	%	%	NOUN
dpc-3688	190	77	at	at	ADP
dpc-3688	190	78	week	week	NOUN
dpc-3688	190	79	2	2	NUM
dpc-3688	190	80	)	)	PUNCT
dpc-3688	190	81	.	.	PUNCT
dpc-3688	191	1	treatment	treatment	NOUN
dpc-3688	191	2	response	response	NOUN
dpc-3688	191	3	was	be	AUX
dpc-3688	191	4	maintained	maintain	VERB
dpc-3688	191	5	with	with	ADP
dpc-3688	191	6	further	further	ADJ
dpc-3688	191	7	reduction	reduction	NOUN
dpc-3688	191	8	in	in	ADP
dpc-3688	191	9	pssi	pssi	ADJ
dpc-3688	191	10	through	through	ADP
dpc-3688	191	11	week	week	NOUN
dpc-3688	191	12	12	12	NUM
dpc-3688	191	13	(	(	PUNCT
dpc-3688	191	14	92.8	92.8	NUM
dpc-3688	191	15	%	%	NOUN
dpc-3688	191	16	versus	versus	ADP
dpc-3688	191	17	14.4	14.4	NUM
dpc-3688	191	18	%	%	NOUN
dpc-3688	191	19	;	;	PUNCT
dpc-3688	191	20	p	p	NOUN
dpc-3688	191	21	value	value	NOUN
dpc-3688	191	22	<	<	NOUN
dpc-3688	191	23	0.001	0.001	NUM
dpc-3688	191	24	)	)	PUNCT
dpc-3688	191	25	.	.	PUNCT
dpc-3688	192	1	at	at	ADP
dpc-3688	192	2	week	week	NOUN
dpc-3688	192	3	12	12	NUM
dpc-3688	192	4	,	,	PUNCT
dpc-3688	192	5	pssi75	pssi75	NOUN
dpc-3688	192	6	was	be	AUX
dpc-3688	192	7	achieved	achieve	VERB
dpc-3688	192	8	by	by	ADP
dpc-3688	192	9	89	89	NUM
dpc-3688	192	10	%	%	NOUN
dpc-3688	192	11	of	of	ADP
dpc-3688	192	12	patients	patient	NOUN
dpc-3688	192	13	receiving	receive	VERB
dpc-3688	192	14	brodalumab	brodalumab	NOUN
dpc-3688	192	15	,	,	PUNCT
dpc-3688	192	16	compared	compare	VERB
dpc-3688	192	17	with	with	ADP
dpc-3688	192	18	9.5	9.5	NUM
dpc-3688	192	19	%	%	NOUN
dpc-3688	192	20	of	of	ADP
dpc-3688	192	21	patients	patient	NOUN
dpc-3688	192	22	receiving	receive	VERB
dpc-3688	192	23	placebo	placebo	NOUN
dpc-3688	192	24	,	,	PUNCT
dpc-3688	192	25	while	while	SCONJ
dpc-3688	192	26	pssi100	pssi100	PROPN
dpc-3688	192	27	was	be	AUX
dpc-3688	192	28	observed	observe	VERB
dpc-3688	192	29	in	in	ADP
dpc-3688	192	30	63.4	63.4	NUM
dpc-3688	192	31	%	%	NOUN
dpc-3688	192	32	of	of	ADP
dpc-3688	192	33	brodalumab	brodalumab	NOUN
dpc-3688	192	34	-	-	PUNCT
dpc-3688	192	35	treated	treat	VERB
dpc-3688	192	36	patients	patient	NOUN
dpc-3688	192	37	versus	versus	ADP
dpc-3688	192	38	3.2	3.2	NUM
dpc-3688	192	39	%	%	NOUN
dpc-3688	192	40	of	of	ADP
dpc-3688	192	41	the	the	DET
dpc-3688	192	42	placebo	placebo	NOUN
dpc-3688	192	43	group	group	NOUN
dpc-3688	193	1	[	[	X
dpc-3688	193	2	48,52	48,52	NUM
dpc-3688	193	3	]	]	PUNCT
dpc-3688	193	4	.	.	PUNCT
dpc-3688	194	1	brodalumab	brodalumab	NOUN
dpc-3688	194	2	effectiveness	effectiveness	NOUN
dpc-3688	194	3	was	be	AUX
dpc-3688	194	4	also	also	ADV
dpc-3688	194	5	confirmed	confirm	VERB
dpc-3688	194	6	in	in	ADP
dpc-3688	194	7	a	a	DET
dpc-3688	194	8	subanalysis	subanalysis	NOUN
dpc-3688	194	9	of	of	ADP
dpc-3688	194	10	a	a	DET
dpc-3688	194	11	phase	phase	NOUN
dpc-3688	194	12	2	2	NUM
dpc-3688	194	13	,	,	PUNCT
dpc-3688	194	14	randomized	randomize	VERB
dpc-3688	194	15	,	,	PUNCT
dpc-3688	194	16	placebo	placebo	NOUN
dpc-3688	194	17	-	-	PUNCT
dpc-3688	194	18	controlled	control	VERB
dpc-3688	194	19	trial	trial	NOUN
dpc-3688	194	20	(	(	PUNCT
dpc-3688	194	21	nct01748539	nct01748539	NOUN
dpc-3688	194	22	)	)	PUNCT
dpc-3688	194	23	reporting	report	VERB
dpc-3688	194	24	a	a	DET
dpc-3688	194	25	mean	mean	NOUN
dpc-3688	194	26	pssi	pssi	ADJ
dpc-3688	194	27	improvement	improvement	NOUN
dpc-3688	194	28	rate	rate	NOUN
dpc-3688	194	29	of	of	ADP
dpc-3688	194	30	94.5	94.5	NUM
dpc-3688	194	31	%	%	NOUN
dpc-3688	194	32	after	after	ADP
dpc-3688	194	33	12	12	NUM
dpc-3688	194	34	weeks	week	NOUN
dpc-3688	194	35	of	of	ADP
dpc-3688	194	36	therapy	therapy	NOUN
dpc-3688	194	37	with	with	ADP
dpc-3688	194	38	brodalumab	brodalumab	NOUN
dpc-3688	194	39	210	210	NUM
dpc-3688	194	40	mg	mg	NOUN
dpc-3688	194	41	q2w	q2w	NOUN
dpc-3688	194	42	from	from	ADP
dpc-3688	194	43	baseline	baseline	NOUN
dpc-3688	194	44	,	,	PUNCT
dpc-3688	194	45	versus	versus	ADP
dpc-3688	194	46	12.6	12.6	NUM
dpc-3688	194	47	%	%	NOUN
dpc-3688	194	48	of	of	ADP
dpc-3688	194	49	placebo	placebo	NOUN
dpc-3688	194	50	-	-	PUNCT
dpc-3688	194	51	treated	treat	VERB
dpc-3688	194	52	patients	patient	NOUN
dpc-3688	194	53	(	(	PUNCT
dpc-3688	194	54	p	p	X
dpc-3688	194	55	=	=	NOUN
dpc-3688	194	56	0.001	0.001	NUM
dpc-3688	194	57	)	)	PUNCT
dpc-3688	195	1	[	[	X
dpc-3688	195	2	53	53	NUM
dpc-3688	195	3	]	]	PUNCT
dpc-3688	195	4	.	.	PUNCT
dpc-3688	196	1	data	datum	NOUN
dpc-3688	196	2	deriving	derive	VERB
dpc-3688	196	3	from	from	ADP
dpc-3688	196	4	another	another	DET
dpc-3688	196	5	study	study	NOUN
dpc-3688	196	6	conducted	conduct	VERB
dpc-3688	196	7	on	on	ADP
dpc-3688	196	8	patients	patient	NOUN
dpc-3688	196	9	affected	affect	VERB
dpc-3688	196	10	by	by	ADP
dpc-3688	196	11	severe	severe	ADJ
dpc-3688	196	12	forms	form	NOUN
dpc-3688	196	13	of	of	ADP
dpc-3688	196	14	psoriasis	psoriasis	NOUN
dpc-3688	196	15	,	,	PUNCT
dpc-3688	196	16	namely	namely	ADV
dpc-3688	196	17	generalized	generalize	VERB
dpc-3688	196	18	pustular	pustular	ADJ
dpc-3688	196	19	(	(	PUNCT
dpc-3688	196	20	gpp	gpp	NOUN
dpc-3688	196	21	)	)	PUNCT
dpc-3688	196	22	and	and	CCONJ
dpc-3688	196	23	erythrodermic	erythrodermic	ADJ
dpc-3688	196	24	(	(	PUNCT
dpc-3688	196	25	pse	pse	NOUN
dpc-3688	196	26	)	)	PUNCT
dpc-3688	196	27	,	,	PUNCT
dpc-3688	196	28	also	also	ADV
dpc-3688	196	29	revealed	reveal	VERB
dpc-3688	196	30	great	great	ADJ
dpc-3688	196	31	efficacy	efficacy	NOUN
dpc-3688	196	32	of	of	ADP
dpc-3688	196	33	brodalumab	brodalumab	NOUN
dpc-3688	196	34	therapy	therapy	NOUN
dpc-3688	196	35	in	in	ADP
dpc-3688	196	36	reducing	reduce	VERB
dpc-3688	196	37	skin	skin	NOUN
dpc-3688	196	38	manifestations	manifestation	NOUN
dpc-3688	196	39	,	,	PUNCT
dpc-3688	196	40	including	include	VERB
dpc-3688	196	41	scalp	scalp	NOUN
dpc-3688	196	42	psoriasis	psoriasis	NOUN
dpc-3688	196	43	lesions	lesion	NOUN
dpc-3688	196	44	,	,	PUNCT
dpc-3688	196	45	with	with	ADP
dpc-3688	196	46	improvements	improvement	NOUN
dpc-3688	196	47	in	in	ADP
dpc-3688	196	48	pssi	pssi	ADJ
dpc-3688	196	49	score	score	NOUN
dpc-3688	196	50	occurring	occur	VERB
dpc-3688	196	51	in	in	ADP
dpc-3688	196	52	80.9	80.9	NUM
dpc-3688	196	53	%	%	NOUN
dpc-3688	196	54	of	of	ADP
dpc-3688	196	55	all	all	DET
dpc-3688	196	56	treated	treat	VERB
dpc-3688	196	57	patients	patient	NOUN
dpc-3688	196	58	(	(	PUNCT
dpc-3688	196	59	including	include	VERB
dpc-3688	196	60	gpp	gpp	NOUN
dpc-3688	196	61	and	and	CCONJ
dpc-3688	196	62	pse	pse	NOUN
dpc-3688	196	63	)	)	PUNCT
dpc-3688	196	64	at	at	ADP
dpc-3688	196	65	week	week	NOUN
dpc-3688	196	66	12	12	NUM
dpc-3688	196	67	and	and	CCONJ
dpc-3688	196	68	in	in	ADP
dpc-3688	196	69	90	90	NUM
dpc-3688	196	70	%	%	NOUN
dpc-3688	196	71	of	of	ADP
dpc-3688	196	72	all	all	DET
dpc-3688	196	73	patients	patient	NOUN
dpc-3688	196	74	after	after	ADP
dpc-3688	196	75	52	52	NUM
dpc-3688	196	76	weeks	week	NOUN
dpc-3688	196	77	of	of	ADP
dpc-3688	196	78	treatment	treatment	NOUN
dpc-3688	196	79	,	,	PUNCT
dpc-3688	196	80	concurrently	concurrently	ADV
dpc-3688	196	81	with	with	ADP
dpc-3688	196	82	dermatology	dermatology	NOUN
dpc-3688	196	83	life	life	NOUN
dpc-3688	196	84	quality	quality	NOUN
dpc-3688	196	85	index	index	NOUN
dpc-3688	196	86	(	(	PUNCT
dpc-3688	196	87	dlqi	dlqi	ADJ
dpc-3688	196	88	)	)	PUNCT
dpc-3688	196	89	ameliorations	amelioration	NOUN
dpc-3688	196	90	throughout	throughout	ADP
dpc-3688	196	91	the	the	DET
dpc-3688	196	92	observation	observation	NOUN
dpc-3688	196	93	period	period	NOUN
dpc-3688	196	94	(	(	PUNCT
dpc-3688	196	95	dlqi	dlqi	VERB
dpc-3688	196	96	scoring	scoring	NOUN
dpc-3688	196	97	0	0	NUM
dpc-3688	196	98	or	or	CCONJ
dpc-3688	196	99	1	1	NUM
dpc-3688	196	100	was	be	AUX
dpc-3688	196	101	achieved	achieve	VERB
dpc-3688	196	102	by	by	ADP
dpc-3688	196	103	80	80	NUM
dpc-3688	196	104	%	%	NOUN
dpc-3688	196	105	of	of	ADP
dpc-3688	196	106	patients	patient	NOUN
dpc-3688	196	107	at	at	ADP
dpc-3688	196	108	week	week	NOUN
dpc-3688	196	109	52	52	NUM
dpc-3688	196	110	)	)	PUNCT
dpc-3688	197	1	[	[	X
dpc-3688	197	2	54	54	NUM
dpc-3688	197	3	]	]	PUNCT
dpc-3688	197	4	.	.	PUNCT
dpc-3688	198	1	nail	nail	NOUN
dpc-3688	198	2	psoriasis	psoriasis	NOUN
dpc-3688	198	3	brodalumab	brodalumab	NOUN
dpc-3688	198	4	effects	effect	NOUN
dpc-3688	198	5	on	on	ADP
dpc-3688	198	6	psoriatic	psoriatic	ADJ
dpc-3688	198	7	nails	nail	NOUN
dpc-3688	198	8	were	be	AUX
dpc-3688	198	9	assessed	assess	VERB
dpc-3688	198	10	in	in	ADP
dpc-3688	198	11	two	two	NUM
dpc-3688	198	12	trials	trial	NOUN
dpc-3688	198	13	.	.	PUNCT
dpc-3688	199	1	head	head	NOUN
dpc-3688	199	2	-	-	PUNCT
dpc-3688	199	3	to	to	ADP
dpc-3688	199	4	-	-	PUNCT
dpc-3688	199	5	head	head	NOUN
dpc-3688	199	6	trials	trial	NOUN
dpc-3688	199	7	,	,	PUNCT
dpc-3688	199	8	amagine-2	amagine-2	NUM
dpc-3688	199	9	and	and	CCONJ
dpc-3688	199	10	amagine	amagine	ADJ
dpc-3688	199	11	3	3	NUM
dpc-3688	199	12	trials	trial	NOUN
dpc-3688	199	13	,	,	PUNCT
dpc-3688	199	14	comparing	compare	VERB
dpc-3688	199	15	brodalumab	brodalumab	NOUN
dpc-3688	199	16	with	with	ADP
dpc-3688	199	17	ustekinumab	ustekinumab	NOUN
dpc-3688	199	18	,	,	PUNCT
dpc-3688	199	19	included	include	VERB
dpc-3688	199	20	283	283	NUM
dpc-3688	199	21	patients	patient	NOUN
dpc-3688	199	22	with	with	ADP
dpc-3688	199	23	nail	nail	NOUN
dpc-3688	199	24	involvement	involvement	NOUN
dpc-3688	199	25	[	[	X
dpc-3688	199	26	52	52	NUM
dpc-3688	199	27	]	]	PUNCT
dpc-3688	199	28	.	.	PUNCT
dpc-3688	200	1	patients	patient	NOUN
dpc-3688	200	2	randomized	randomize	VERB
dpc-3688	200	3	to	to	PART
dpc-3688	200	4	brodalumab	brodalumab	VERB
dpc-3688	200	5	210	210	NUM
dpc-3688	200	6	mg	mg	NOUN
dpc-3688	200	7	every	every	DET
dpc-3688	200	8	two	two	NUM
dpc-3688	200	9	weeks	week	NOUN
dpc-3688	200	10	(	(	PUNCT
dpc-3688	200	11	bld210	bld210	PROPN
dpc-3688	200	12	q2w	q2w	PROPN
dpc-3688	200	13	)	)	PUNCT
dpc-3688	200	14	had	have	VERB
dpc-3688	200	15	a	a	DET
dpc-3688	200	16	greater	great	ADJ
dpc-3688	200	17	reduction	reduction	NOUN
dpc-3688	200	18	in	in	ADP
dpc-3688	200	19	mean	mean	ADJ
dpc-3688	200	20	nail	nail	NOUN
dpc-3688	200	21	-	-	PUNCT
dpc-3688	200	22	target	target	NOUN
dpc-3688	200	23	napsi	napsi	NOUN
dpc-3688	200	24	score	score	NOUN
dpc-3688	200	25	compared	compare	VERB
dpc-3688	200	26	with	with	ADP
dpc-3688	200	27	those	those	PRON
dpc-3688	200	28	randomized	randomize	VERB
dpc-3688	200	29	to	to	ADP
dpc-3688	200	30	ustekinumab	ustekinumab	NOUN
dpc-3688	200	31	45/90	45/90	NUM
dpc-3688	200	32	mg	mg	NOUN
dpc-3688	200	33	every	every	DET
dpc-3688	200	34	12	12	NUM
dpc-3688	200	35	weeks	week	NOUN
dpc-3688	200	36	(	(	PUNCT
dpc-3688	200	37	ust45/90	ust45/90	NOUN
dpc-3688	200	38	q12w	q12w	NOUN
dpc-3688	200	39	)	)	PUNCT
dpc-3688	200	40	,	,	PUNCT
dpc-3688	200	41	at	at	ADP
dpc-3688	200	42	week	week	NOUN
dpc-3688	200	43	12	12	NUM
dpc-3688	200	44	(	(	PUNCT
dpc-3688	200	45	43.7	43.7	NUM
dpc-3688	200	46	%	%	NOUN
dpc-3688	200	47	versus	versus	ADP
dpc-3688	200	48	31.8	31.8	NUM
dpc-3688	200	49	%	%	NOUN
dpc-3688	200	50	,	,	PUNCT
dpc-3688	200	51	p	p	X
dpc-3688	200	52	<	<	X
dpc-3688	200	53	0.05	0.05	NUM
dpc-3688	200	54	)	)	PUNCT
dpc-3688	200	55	,	,	PUNCT
dpc-3688	200	56	with	with	ADP
dpc-3688	200	57	further	further	ADJ
dpc-3688	200	58	improvements	improvement	NOUN
dpc-3688	200	59	at	at	ADP
dpc-3688	200	60	week	week	NOUN
dpc-3688	200	61	24	24	NUM
dpc-3688	200	62	(	(	PUNCT
dpc-3688	200	63	76.9	76.9	NUM
dpc-3688	200	64	%	%	NOUN
dpc-3688	200	65	versus	versus	ADP
dpc-3688	200	66	58.9	58.9	NUM
dpc-3688	200	67	%	%	NOUN
dpc-3688	200	68	,	,	PUNCT
dpc-3688	200	69	p	p	X
dpc-3688	200	70	<	<	X
dpc-3688	200	71	0.05	0.05	NUM
dpc-3688	200	72	)	)	PUNCT
dpc-3688	200	73	,	,	PUNCT
dpc-3688	200	74	and	and	CCONJ
dpc-3688	200	75	at	at	ADP
dpc-3688	200	76	week	week	NOUN
dpc-3688	200	77	36	36	NUM
dpc-3688	200	78	(	(	PUNCT
dpc-3688	200	79	82.4	82.4	NUM
dpc-3688	200	80	%	%	NOUN
dpc-3688	200	81	versus	versus	ADP
dpc-3688	200	82	69.0	69.0	NUM
dpc-3688	200	83	%	%	NOUN
dpc-3688	200	84	,	,	PUNCT
dpc-3688	200	85	p	p	X
dpc-3688	200	86	<	<	X
dpc-3688	200	87	0.05	0.05	NUM
dpc-3688	200	88	)	)	PUNCT
dpc-3688	200	89	.	.	PUNCT
dpc-3688	201	1	a	a	DET
dpc-3688	201	2	greater	great	ADJ
dpc-3688	201	3	amelioration	amelioration	NOUN
dpc-3688	201	4	was	be	AUX
dpc-3688	201	5	also	also	ADV
dpc-3688	201	6	seen	see	VERB
dpc-3688	201	7	at	at	ADP
dpc-3688	201	8	week	week	NOUN
dpc-3688	201	9	52	52	NUM
dpc-3688	201	10	in	in	ADP
dpc-3688	201	11	the	the	DET
dpc-3688	201	12	brodalumab	brodalumab	NOUN
dpc-3688	201	13	arm	arm	NOUN
dpc-3688	201	14	(	(	PUNCT
dpc-3688	201	15	83.1	83.1	NUM
dpc-3688	201	16	%	%	NOUN
dpc-3688	201	17	versus	versus	ADP
dpc-3688	201	18	75.0	75.0	NUM
dpc-3688	201	19	%	%	NOUN
dpc-3688	201	20	)	)	PUNCT
dpc-3688	201	21	,	,	PUNCT
dpc-3688	201	22	although	although	SCONJ
dpc-3688	201	23	statistical	statistical	ADJ
dpc-3688	201	24	significance	significance	NOUN
dpc-3688	201	25	was	be	AUX
dpc-3688	201	26	not	not	PART
dpc-3688	201	27	reported	report	VERB
dpc-3688	201	28	.	.	PUNCT
dpc-3688	202	1	at	at	ADP
dpc-3688	202	2	week	week	NOUN
dpc-3688	202	3	24	24	NUM
dpc-3688	202	4	,	,	PUNCT
dpc-3688	202	5	31.6	31.6	NUM
dpc-3688	202	6	%	%	NOUN
dpc-3688	202	7	of	of	ADP
dpc-3688	202	8	patients	patient	NOUN
dpc-3688	202	9	achieved	achieve	VERB
dpc-3688	202	10	a	a	DET
dpc-3688	202	11	complete	complete	ADJ
dpc-3688	202	12	resolution	resolution	NOUN
dpc-3688	202	13	of	of	ADP
dpc-3688	202	14	nail	nail	NOUN
dpc-3688	202	15	psoriasis	psoriasis	NOUN
dpc-3688	202	16	(	(	PUNCT
dpc-3688	202	17	napsi100	napsi100	PROPN
dpc-3688	202	18	)	)	PUNCT
dpc-3688	202	19	in	in	ADP
dpc-3688	202	20	the	the	DET
dpc-3688	202	21	brodalumab	brodalumab	NOUN
dpc-3688	202	22	arm	arm	NOUN
dpc-3688	202	23	compared	compare	VERB
dpc-3688	202	24	with	with	ADP
dpc-3688	202	25	18.8	18.8	NUM
dpc-3688	202	26	%	%	NOUN
dpc-3688	202	27	in	in	ADP
dpc-3688	202	28	ustekinumab	ustekinumab	NOUN
dpc-3688	202	29	subcohort	subcohort	NOUN
dpc-3688	202	30	(	(	PUNCT
dpc-3688	202	31	p	p	X
dpc-3688	202	32	<	<	X
dpc-3688	202	33	0.05	0.05	NUM
dpc-3688	202	34	)	)	PUNCT
dpc-3688	202	35	.	.	PUNCT
dpc-3688	203	1	at	at	ADP
dpc-3688	203	2	week	week	NOUN
dpc-3688	203	3	52	52	NUM
dpc-3688	203	4	,	,	PUNCT
dpc-3688	203	5	63.8	63.8	NUM
dpc-3688	203	6	%	%	NOUN
dpc-3688	203	7	of	of	ADP
dpc-3688	203	8	brodalumab	brodalumab	NOUN
dpc-3688	203	9	-	-	PUNCT
dpc-3688	203	10	treated	treat	VERB
dpc-3688	203	11	and	and	CCONJ
dpc-3688	203	12	39.1	39.1	NUM
dpc-3688	203	13	%	%	NOUN
dpc-3688	203	14	of	of	ADP
dpc-3688	203	15	ustekinumab	ustekinumab	NOUN
dpc-3688	203	16	-	-	PUNCT
dpc-3688	203	17	treated	treat	VERB
dpc-3688	203	18	patients	patient	NOUN
dpc-3688	203	19	achieved	achieve	VERB
dpc-3688	203	20	napsi100	napsi100	PROPN
dpc-3688	203	21	(	(	PUNCT
dpc-3688	203	22	p	p	X
dpc-3688	203	23	<	<	X
dpc-3688	203	24	0.05	0.05	NUM
dpc-3688	203	25	)	)	PUNCT
dpc-3688	203	26	,	,	PUNCT
dpc-3688	203	27	respectively	respectively	ADV
dpc-3688	203	28	.	.	PUNCT
dpc-3688	204	1	safety	safety	NOUN
dpc-3688	204	2	was	be	AUX
dpc-3688	204	3	comparable	comparable	ADJ
dpc-3688	204	4	between	between	ADP
dpc-3688	204	5	brodalumab	brodalumab	NOUN
dpc-3688	204	6	and	and	CCONJ
dpc-3688	204	7	ustekinumab	ustekinumab	NOUN
dpc-3688	204	8	treatment	treatment	NOUN
dpc-3688	204	9	groups	group	NOUN
dpc-3688	204	10	(	(	PUNCT
dpc-3688	204	11	adverse	adverse	ADJ
dpc-3688	204	12	events	event	NOUN
dpc-3688	204	13	:	:	PUNCT
dpc-3688	204	14	57.3	57.3	NUM
dpc-3688	204	15	%	%	NOUN
dpc-3688	204	16	versus	versus	ADP
dpc-3688	204	17	56.3	56.3	NUM
dpc-3688	204	18	%	%	NOUN
dpc-3688	204	19	;	;	PUNCT
dpc-3688	204	20	severe	severe	ADJ
dpc-3688	204	21	adverse	adverse	ADJ
dpc-3688	204	22	events	event	NOUN
dpc-3688	204	23	1.2	1.2	NUM
dpc-3688	204	24	%	%	NOUN
dpc-3688	204	25	versus	versus	ADP
dpc-3688	204	26	1.0	1.0	NUM
dpc-3688	204	27	%	%	NOUN
dpc-3688	204	28	)	)	PUNCT
dpc-3688	205	1	[	[	X
dpc-3688	205	2	52	52	NUM
dpc-3688	205	3	]	]	PUNCT
dpc-3688	205	4	.	.	PUNCT
dpc-3688	206	1	improvement	improvement	NOUN
dpc-3688	206	2	of	of	ADP
dpc-3688	206	3	nail	nail	NOUN
dpc-3688	206	4	psoriasis	psoriasis	NOUN
dpc-3688	206	5	has	have	AUX
dpc-3688	206	6	also	also	ADV
dpc-3688	206	7	been	be	AUX
dpc-3688	206	8	reported	report	VERB
dpc-3688	206	9	in	in	ADP
dpc-3688	206	10	the	the	DET
dpc-3688	206	11	japanese	japanese	ADJ
dpc-3688	206	12	trial	trial	NOUN
dpc-3688	206	13	(	(	PUNCT
dpc-3688	206	14	nct01748539	nct01748539	NOUN
dpc-3688	206	15	)	)	PUNCT
dpc-3688	206	16	on	on	ADP
dpc-3688	206	17	22	22	NUM
dpc-3688	206	18	patients	patient	NOUN
dpc-3688	206	19	(	(	PUNCT
dpc-3688	206	20	out	out	ADP
dpc-3688	206	21	of	of	ADP
dpc-3688	206	22	38	38	NUM
dpc-3688	206	23	)	)	PUNCT
dpc-3688	206	24	treated	treat	VERB
dpc-3688	206	25	using	use	VERB
dpc-3688	206	26	210	210	NUM
dpc-3688	206	27	mg	mg	PROPN
dpc-3688	206	28	brodalumab	brodalumab	NOUN
dpc-3688	206	29	with	with	ADP
dpc-3688	206	30	total	total	ADJ
dpc-3688	206	31	napsi	napsi	NOUN
dpc-3688	206	32	score	score	NOUN
dpc-3688	206	33	reduction	reduction	NOUN
dpc-3688	206	34	of	of	ADP
dpc-3688	206	35	47.6	47.6	NUM
dpc-3688	206	36	%	%	NOUN
dpc-3688	206	37	after	after	ADP
dpc-3688	206	38	12	12	NUM
dpc-3688	206	39	weeks	week	NOUN
dpc-3688	206	40	(	(	PUNCT
dpc-3688	206	41	mean	mean	VERB
dpc-3688	206	42	napsi	napsi	NOUN
dpc-3688	206	43	change	change	NOUN
dpc-3688	206	44	from	from	ADP
dpc-3688	206	45	baseline	baseline	NOUN
dpc-3688	206	46	in	in	ADP
dpc-3688	206	47	the	the	DET
dpc-3688	206	48	placebo	placebo	NOUN
dpc-3688	206	49	group	group	NOUN
dpc-3688	206	50	was	be	AUX
dpc-3688	206	51	9.6	9.6	NUM
dpc-3688	206	52	%	%	NOUN
dpc-3688	206	53	at	at	ADP
dpc-3688	206	54	week12	week12	NOUN
dpc-3688	206	55	)	)	PUNCT
dpc-3688	207	1	[	[	X
dpc-3688	207	2	53	53	NUM
dpc-3688	207	3	]	]	PUNCT
dpc-3688	207	4	.	.	PUNCT
dpc-3688	208	1	review	review	VERB
dpc-3688	208	2	|	|	ADV
dpc-3688	208	3	dermatol	dermatol	ADJ
dpc-3688	208	4	pract	pract	NOUN
dpc-3688	208	5	concept	concept	NOUN
dpc-3688	208	6	.	.	PUNCT
dpc-3688	209	1	2023;13(3):e2023245	2023;13(3):e2023245	NUM
dpc-3688	209	2	7	7	NUM
dpc-3688	209	3	in	in	ADP
dpc-3688	209	4	a	a	DET
dpc-3688	209	5	prospective	prospective	ADJ
dpc-3688	209	6	open	open	ADJ
dpc-3688	209	7	-	-	PUNCT
dpc-3688	209	8	label	label	NOUN
dpc-3688	209	9	trial	trial	NOUN
dpc-3688	209	10	with	with	ADP
dpc-3688	209	11	30	30	NUM
dpc-3688	209	12	patients	patient	NOUN
dpc-3688	209	13	affected	affect	VERB
dpc-3688	209	14	by	by	ADP
dpc-3688	209	15	nail	nail	NOUN
dpc-3688	209	16	psoriasis	psoriasis	NOUN
dpc-3688	209	17	treated	treat	VERB
dpc-3688	209	18	with	with	ADP
dpc-3688	209	19	brodalumab	brodalumab	NOUN
dpc-3688	209	20	210	210	NUM
dpc-3688	209	21	mg	mg	PROPN
dpc-3688	209	22	q2w	q2w	PROPN
dpc-3688	209	23	,	,	PUNCT
dpc-3688	209	24	a	a	DET
dpc-3688	209	25	significant	significant	ADJ
dpc-3688	209	26	improvement	improvement	NOUN
dpc-3688	209	27	was	be	AUX
dpc-3688	209	28	observed	observe	VERB
dpc-3688	209	29	after	after	ADP
dpc-3688	209	30	12	12	NUM
dpc-3688	209	31	and	and	CCONJ
dpc-3688	209	32	24	24	NUM
dpc-3688	209	33	weeks	week	NOUN
dpc-3688	209	34	of	of	ADP
dpc-3688	209	35	treatment	treatment	NOUN
dpc-3688	209	36	compared	compare	VERB
dpc-3688	209	37	with	with	ADP
dpc-3688	209	38	baseline	baseline	NOUN
dpc-3688	209	39	(	(	PUNCT
dpc-3688	209	40	p	p	X
dpc-3688	209	41	<	<	X
dpc-3688	209	42	0.001	0.001	NUM
dpc-3688	209	43	:	:	PUNCT
dpc-3688	209	44	mean	mean	VERB
dpc-3688	209	45	finger	finger	NOUN
dpc-3688	209	46	absolute	absolute	ADJ
dpc-3688	209	47	napsi	napsi	NOUN
dpc-3688	209	48	score	score	NOUN
dpc-3688	209	49	at	at	ADP
dpc-3688	209	50	the	the	DET
dpc-3688	209	51	bl	bl	PROPN
dpc-3688	209	52	:	:	PUNCT
dpc-3688	209	53	19.6	19.6	NUM
dpc-3688	209	54	,	,	PUNCT
dpc-3688	209	55	w12	w12	NOUN
dpc-3688	209	56	:	:	PUNCT
dpc-3688	209	57	9.6	9.6	NUM
dpc-3688	209	58	,	,	PUNCT
dpc-3688	209	59	w24	w24	PROPN
dpc-3688	209	60	:	:	PUNCT
dpc-3688	209	61	2.63	2.63	NUM
dpc-3688	209	62	;	;	PUNCT
dpc-3688	209	63	mean	mean	VERB
dpc-3688	209	64	toes	toe	NOUN
dpc-3688	209	65	absolute	absolute	ADJ
dpc-3688	209	66	napsi	napsi	NOUN
dpc-3688	209	67	at	at	ADP
dpc-3688	209	68	the	the	DET
dpc-3688	209	69	bl	bl	PROPN
dpc-3688	209	70	24.9	24.9	NUM
dpc-3688	209	71	;	;	PUNCT
dpc-3688	209	72	w12	w12	NOUN
dpc-3688	209	73	:	:	PUNCT
dpc-3688	209	74	16.1	16.1	NUM
dpc-3688	209	75	;	;	PUNCT
dpc-3688	209	76	w24	w24	NUM
dpc-3688	209	77	:	:	PUNCT
dpc-3688	210	1	7.2)54	7.2)54	NOUN
dpc-3688	210	2	.	.	PUNCT
dpc-3688	211	1	napsi	napsi	NOUN
dpc-3688	211	2	improvement	improvement	NOUN
dpc-3688	211	3	was	be	AUX
dpc-3688	211	4	also	also	ADV
dpc-3688	211	5	associated	associate	VERB
dpc-3688	211	6	with	with	ADP
dpc-3688	211	7	a	a	DET
dpc-3688	211	8	decrease	decrease	NOUN
dpc-3688	211	9	of	of	ADP
dpc-3688	211	10	dlqi	dlqi	NOUN
dpc-3688	211	11	,	,	PUNCT
dpc-3688	211	12	from	from	ADP
dpc-3688	211	13	a	a	DET
dpc-3688	211	14	mean	mean	ADJ
dpc-3688	211	15	value	value	NOUN
dpc-3688	211	16	of	of	ADP
dpc-3688	211	17	22.8	22.8	NUM
dpc-3688	211	18	,	,	PUNCT
dpc-3688	211	19	to	to	ADP
dpc-3688	211	20	a	a	DET
dpc-3688	211	21	mean	mean	ADJ
dpc-3688	211	22	value	value	NOUN
dpc-3688	211	23	of	of	ADP
dpc-3688	211	24	3.7	3.7	NUM
dpc-3688	211	25	,	,	PUNCT
dpc-3688	211	26	after	after	ADP
dpc-3688	211	27	24	24	NUM
dpc-3688	211	28	weeks	week	NOUN
dpc-3688	211	29	of	of	ADP
dpc-3688	211	30	treatment	treatment	NOUN
dpc-3688	211	31	.	.	PUNCT
dpc-3688	212	1	adverse	adverse	ADJ
dpc-3688	212	2	events	event	NOUN
dpc-3688	212	3	(	(	PUNCT
dpc-3688	212	4	ae	ae	PROPN
dpc-3688	212	5	)	)	PUNCT
dpc-3688	212	6	incidence	incidence	NOUN
dpc-3688	212	7	(	(	PUNCT
dpc-3688	212	8	10.0	10.0	NUM
dpc-3688	212	9	%	%	NOUN
dpc-3688	212	10	)	)	PUNCT
dpc-3688	212	11	was	be	AUX
dpc-3688	212	12	low	low	ADJ
dpc-3688	212	13	,	,	PUNCT
dpc-3688	212	14	and	and	CCONJ
dpc-3688	212	15	no	no	DET
dpc-3688	212	16	seriousaes	seriousaes	NOUN
dpc-3688	212	17	occurred	occur	VERB
dpc-3688	212	18	.	.	PUNCT
dpc-3688	213	1	a	a	DET
dpc-3688	213	2	recent	recent	ADJ
dpc-3688	213	3	network	network	NOUN
dpc-3688	213	4	meta	meta	NOUN
dpc-3688	213	5	-	-	PUNCT
dpc-3688	213	6	analysis	analysis	NOUN
dpc-3688	213	7	of	of	ADP
dpc-3688	213	8	head	head	NOUN
dpc-3688	213	9	-	-	PUNCT
dpc-3688	213	10	to	to	ADP
dpc-3688	213	11	-	-	PUNCT
dpc-3688	213	12	head	head	NOUN
dpc-3688	213	13	trials	trial	NOUN
dpc-3688	213	14	investigating	investigate	VERB
dpc-3688	213	15	the	the	DET
dpc-3688	213	16	complete	complete	ADJ
dpc-3688	213	17	resolution	resolution	NOUN
dpc-3688	213	18	of	of	ADP
dpc-3688	213	19	nail	nail	NOUN
dpc-3688	213	20	psoriasis	psoriasis	NOUN
dpc-3688	213	21	identified	identify	VERB
dpc-3688	213	22	ixekizumab	ixekizumab	NOUN
dpc-3688	213	23	as	as	ADP
dpc-3688	213	24	the	the	DET
dpc-3688	213	25	biologic	biologic	ADJ
dpc-3688	213	26	agent	agent	NOUN
dpc-3688	213	27	with	with	ADP
dpc-3688	213	28	the	the	DET
dpc-3688	213	29	highest	high	ADJ
dpc-3688	213	30	response	response	NOUN
dpc-3688	213	31	rate	rate	NOUN
dpc-3688	213	32	(	(	PUNCT
dpc-3688	213	33	rr	rr	NOUN
dpc-3688	213	34	:	:	PUNCT
dpc-3688	213	35	1.4	1.4	NUM
dpc-3688	213	36	,	,	PUNCT
dpc-3688	213	37	95%ci=	95%ci=	NUM
dpc-3688	213	38	0.73	0.73	NUM
dpc-3688	213	39	-	-	SYM
dpc-3688	213	40	3.1	3.1	NUM
dpc-3688	213	41	)	)	PUNCT
dpc-3688	213	42	resulting	result	VERB
dpc-3688	213	43	superior	superior	ADJ
dpc-3688	213	44	to	to	ADP
dpc-3688	213	45	brodalumab	brodalumab	NOUN
dpc-3688	213	46	(	(	PUNCT
dpc-3688	213	47	rr	rr	NOUN
dpc-3688	213	48	:	:	PUNCT
dpc-3688	213	49	0.92	0.92	NUM
dpc-3688	213	50	,	,	PUNCT
dpc-3688	213	51	95%ci=	95%ci=	NUM
dpc-3688	213	52	0.14	0.14	NUM
dpc-3688	213	53	-	-	SYM
dpc-3688	213	54	7.4	7.4	NUM
dpc-3688	213	55	)	)	PUNCT
dpc-3688	213	56	,	,	PUNCT
dpc-3688	213	57	guselkumab	guselkumab	NOUN
dpc-3688	213	58	(	(	PUNCT
dpc-3688	213	59	rr	rr	NOUN
dpc-3688	213	60	:	:	PUNCT
dpc-3688	213	61	0.81	0.81	NUM
dpc-3688	213	62	,	,	PUNCT
dpc-3688	213	63	95%ci=	95%ci=	NUM
dpc-3688	213	64	0.40	0.40	NUM
dpc-3688	213	65	-	-	SYM
dpc-3688	213	66	1.8	1.8	NUM
dpc-3688	213	67	)	)	PUNCT
dpc-3688	213	68	,	,	PUNCT
dpc-3688	213	69	infliximab	infliximab	PROPN
dpc-3688	213	70	(	(	PUNCT
dpc-3688	213	71	rr	rr	NOUN
dpc-3688	213	72	:	:	PUNCT
dpc-3688	213	73	0.90	0.90	NUM
dpc-3688	213	74	,	,	PUNCT
dpc-3688	213	75	95%ci=	95%ci=	NUM
dpc-3688	213	76	0.19	0.19	NUM
dpc-3688	213	77	-	-	SYM
dpc-3688	213	78	4.6	4.6	NUM
dpc-3688	213	79	)	)	PUNCT
dpc-3688	213	80	and	and	CCONJ
dpc-3688	213	81	ustekinumab	ustekinumab	NOUN
dpc-3688	213	82	(	(	PUNCT
dpc-3688	213	83	rr	rr	NOUN
dpc-3688	213	84	:	:	PUNCT
dpc-3688	213	85	0.33	0.33	NUM
dpc-3688	213	86	,	,	PUNCT
dpc-3688	213	87	95	95	NUM
dpc-3688	213	88	%	%	NOUN
dpc-3688	213	89	ci=	ci=	PROPN
dpc-3688	213	90	0.083	0.083	NUM
dpc-3688	213	91	-	-	SYM
dpc-3688	213	92	1.6	1.6	NUM
dpc-3688	213	93	)	)	PUNCT
dpc-3688	213	94	,	,	PUNCT
dpc-3688	213	95	using	use	VERB
dpc-3688	213	96	adalimumab	adalimumab	NOUN
dpc-3688	213	97	as	as	ADP
dpc-3688	213	98	reference	reference	NOUN
dpc-3688	213	99	[	[	X
dpc-3688	213	100	55	55	NUM
dpc-3688	213	101	]	]	PUNCT
dpc-3688	213	102	.	.	PUNCT
dpc-3688	214	1	palmoplantar	palmoplantar	NOUN
dpc-3688	214	2	psoriasis	psoriasis	NOUN
dpc-3688	214	3	preliminary	preliminary	ADJ
dpc-3688	214	4	results	result	NOUN
dpc-3688	214	5	of	of	ADP
dpc-3688	214	6	a	a	DET
dpc-3688	214	7	multicenter	multicenter	NOUN
dpc-3688	214	8	,	,	PUNCT
dpc-3688	214	9	randomized	randomize	VERB
dpc-3688	214	10	,	,	PUNCT
dpc-3688	214	11	double	double	ADV
dpc-3688	214	12	blind	blind	ADJ
dpc-3688	214	13	,	,	PUNCT
dpc-3688	214	14	placebo	placebo	NOUN
dpc-3688	214	15	-	-	PUNCT
dpc-3688	214	16	controlled	control	VERB
dpc-3688	214	17	phase	phase	NOUN
dpc-3688	214	18	3	3	NUM
dpc-3688	214	19	,	,	PUNCT
dpc-3688	214	20	japanese	japanese	ADJ
dpc-3688	214	21	study	study	NOUN
dpc-3688	214	22	on	on	ADP
dpc-3688	214	23	126	126	NUM
dpc-3688	214	24	  	  	SPACE
dpc-3688	214	25	patients	patient	NOUN
dpc-3688	214	26	affected	affect	VERB
dpc-3688	214	27	by	by	ADP
dpc-3688	214	28	palmoplantar	palmoplantar	NOUN
dpc-3688	214	29	pustulosis	pustulosis	NOUN
dpc-3688	214	30	showed	show	VERB
dpc-3688	214	31	great	great	ADJ
dpc-3688	214	32	improvement	improvement	NOUN
dpc-3688	214	33	in	in	ADP
dpc-3688	214	34	the	the	DET
dpc-3688	214	35	brodalumab	brodalumab	NOUN
dpc-3688	214	36	-	-	PUNCT
dpc-3688	214	37	treated	treat	VERB
dpc-3688	214	38	group	group	NOUN
dpc-3688	214	39	.	.	PUNCT
dpc-3688	215	1	after	after	ADP
dpc-3688	215	2	16	16	NUM
dpc-3688	215	3	weeks	week	NOUN
dpc-3688	215	4	of	of	ADP
dpc-3688	215	5	treatment	treatment	NOUN
dpc-3688	215	6	,	,	PUNCT
dpc-3688	215	7	total	total	ADJ
dpc-3688	215	8	pppasi	pppasi	NOUN
dpc-3688	215	9	score	score	NOUN
dpc-3688	215	10	change	change	NOUN
dpc-3688	215	11	from	from	ADP
dpc-3688	215	12	baseline	baseline	PROPN
dpc-3688	215	13	was	be	AUX
dpc-3688	215	14	significantly	significantly	ADV
dpc-3688	215	15	higher	high	ADJ
dpc-3688	215	16	with	with	ADP
dpc-3688	215	17	brodalumab	brodalumab	NOUN
dpc-3688	215	18	:	:	PUNCT
dpc-3688	215	19	13.73	13.73	NUM
dpc-3688	215	20	versus	versus	ADP
dpc-3688	215	21	placebo	placebo	NOUN
dpc-3688	215	22	8.45	8.45	NUM
dpc-3688	215	23	%	%	NOUN
dpc-3688	215	24	(	(	PUNCT
dpc-3688	215	25	p	p	NOUN
dpc-3688	215	26	=	=	NOUN
dpc-3688	215	27	0,0049	0,0049	NOUN
dpc-3688	215	28	)	)	PUNCT
dpc-3688	215	29	with	with	ADP
dpc-3688	215	30	16.0	16.0	NUM
dpc-3688	215	31	%	%	NOUN
dpc-3688	215	32	of	of	ADP
dpc-3688	215	33	patients	patient	NOUN
dpc-3688	215	34	treated	treat	VERB
dpc-3688	215	35	with	with	ADP
dpc-3688	215	36	brodalumab	brodalumab	NOUN
dpc-3688	215	37	who	who	PRON
dpc-3688	215	38	achieved	achieve	VERB
dpc-3688	215	39	pppasi-90	pppasi-90	ADJ
dpc-3688	215	40	response	response	NOUN
dpc-3688	215	41	compared	compare	VERB
dpc-3688	215	42	with	with	ADP
dpc-3688	215	43	versus	versus	ADP
dpc-3688	215	44	0.0	0.0	NUM
dpc-3688	215	45	%	%	NOUN
dpc-3688	215	46	of	of	ADP
dpc-3688	215	47	placebo	placebo	NOUN
dpc-3688	215	48	[	[	X
dpc-3688	215	49	56	56	NUM
dpc-3688	215	50	]	]	PUNCT
dpc-3688	215	51	.	.	PUNCT
dpc-3688	216	1	results	result	NOUN
dpc-3688	216	2	from	from	ADP
dpc-3688	216	3	a	a	DET
dpc-3688	216	4	phase	phase	NOUN
dpc-3688	216	5	4	4	NUM
dpc-3688	216	6	clinical	clinical	ADJ
dpc-3688	216	7	trial	trial	NOUN
dpc-3688	216	8	investigating	investigate	VERB
dpc-3688	216	9	efficacy	efficacy	NOUN
dpc-3688	216	10	of	of	ADP
dpc-3688	216	11	brodalumab	brodalumab	NOUN
dpc-3688	216	12	in	in	ADP
dpc-3688	216	13	the	the	DET
dpc-3688	216	14	treatment	treatment	NOUN
dpc-3688	216	15	of	of	ADP
dpc-3688	216	16	palmoplantar	palmoplantar	NOUN
dpc-3688	216	17	psoriasis	psoriasis	NOUN
dpc-3688	216	18	have	have	AUX
dpc-3688	216	19	not	not	PART
dpc-3688	216	20	been	be	AUX
dpc-3688	216	21	published	publish	VERB
dpc-3688	216	22	yet	yet	ADV
dpc-3688	216	23	(	(	PUNCT
dpc-3688	216	24	nct04622033	nct04622033	ADJ
dpc-3688	216	25	)	)	PUNCT
dpc-3688	216	26	.	.	PUNCT
dpc-3688	217	1	rare	rare	ADJ
dpc-3688	217	2	and	and	CCONJ
dpc-3688	217	3	severe	severe	ADJ
dpc-3688	217	4	forms	form	NOUN
dpc-3688	217	5	of	of	ADP
dpc-3688	217	6	psoriasis	psoriasis	NOUN
dpc-3688	217	7	an	an	DET
dpc-3688	217	8	open	open	ADJ
dpc-3688	217	9	-	-	PUNCT
dpc-3688	217	10	label	label	NOUN
dpc-3688	217	11	,	,	PUNCT
dpc-3688	217	12	multicenter	multicenter	NOUN
dpc-3688	217	13	,	,	PUNCT
dpc-3688	217	14	long	long	ADJ
dpc-3688	217	15	-	-	PUNCT
dpc-3688	217	16	term	term	NOUN
dpc-3688	217	17	phase	phase	NOUN
dpc-3688	217	18	iii	iii	NUM
dpc-3688	217	19	study	study	NOUN
dpc-3688	217	20	in	in	ADP
dpc-3688	217	21	japanese	japanese	ADJ
dpc-3688	217	22	patients	patient	NOUN
dpc-3688	217	23	affected	affect	VERB
dpc-3688	217	24	by	by	ADP
dpc-3688	217	25	rare	rare	ADJ
dpc-3688	217	26	and	and	CCONJ
dpc-3688	217	27	severe	severe	ADJ
dpc-3688	217	28	form	form	NOUN
dpc-3688	217	29	of	of	ADP
dpc-3688	217	30	psoriasis	psoriasis	NOUN
dpc-3688	217	31	has	have	AUX
dpc-3688	217	32	been	be	AUX
dpc-3688	217	33	conducted	conduct	VERB
dpc-3688	217	34	[	[	PUNCT
dpc-3688	217	35	57	57	NUM
dpc-3688	217	36	]	]	PUNCT
dpc-3688	217	37	.	.	PUNCT
dpc-3688	218	1	out	out	ADP
dpc-3688	218	2	of	of	ADP
dpc-3688	218	3	30	30	NUM
dpc-3688	218	4	patients	patient	NOUN
dpc-3688	218	5	treated	treat	VERB
dpc-3688	218	6	with	with	ADP
dpc-3688	218	7	210	210	NUM
dpc-3688	218	8	mg	mg	PROPN
dpc-3688	218	9	brodalumab	brodalumab	NOUN
dpc-3688	218	10	,	,	PUNCT
dpc-3688	218	11	12	12	NUM
dpc-3688	218	12	were	be	AUX
dpc-3688	218	13	affected	affect	VERB
dpc-3688	218	14	by	by	ADP
dpc-3688	218	15	gpp	gpp	NOUN
dpc-3688	218	16	and	and	CCONJ
dpc-3688	218	17	18	18	NUM
dpc-3688	218	18	patients	patient	NOUN
dpc-3688	218	19	by	by	ADP
dpc-3688	218	20	erythrodermic	erythrodermic	ADJ
dpc-3688	218	21	psoriasis	psoriasis	NOUN
dpc-3688	218	22	.	.	PUNCT
dpc-3688	219	1	the	the	DET
dpc-3688	219	2	primary	primary	ADJ
dpc-3688	219	3	endpoint	endpoint	NOUN
dpc-3688	219	4	was	be	AUX
dpc-3688	219	5	the	the	DET
dpc-3688	219	6	clinical	clinical	ADJ
dpc-3688	219	7	global	global	ADJ
dpc-3688	219	8	impression	impression	NOUN
dpc-3688	219	9	of	of	ADP
dpc-3688	219	10	improvement	improvement	NOUN
dpc-3688	219	11	(	(	PUNCT
dpc-3688	219	12	cgi	cgi	NOUN
dpc-3688	219	13	)	)	PUNCT
dpc-3688	219	14	.	.	PUNCT
dpc-3688	220	1	ten	ten	NUM
dpc-3688	220	2	patients	patient	NOUN
dpc-3688	220	3	with	with	ADP
dpc-3688	220	4	gpp	gpp	NOUN
dpc-3688	220	5	and	and	CCONJ
dpc-3688	220	6	16	16	NUM
dpc-3688	220	7	with	with	ADP
dpc-3688	220	8	erythrodermic	erythrodermic	ADJ
dpc-3688	220	9	psoriasis	psoriasis	NOUN
dpc-3688	220	10	completed	complete	VERB
dpc-3688	220	11	the	the	DET
dpc-3688	220	12	study	study	NOUN
dpc-3688	220	13	and	and	CCONJ
dpc-3688	220	14	cgi	cgi	NOUN
dpc-3688	220	15	was	be	AUX
dpc-3688	220	16	achieved	achieve	VERB
dpc-3688	220	17	in	in	ADP
dpc-3688	220	18	11	11	NUM
dpc-3688	220	19	patients	patient	NOUN
dpc-3688	220	20	with	with	ADP
dpc-3688	220	21	gpp	gpp	NOUN
dpc-3688	220	22	and	and	CCONJ
dpc-3688	220	23	18	18	NUM
dpc-3688	220	24	with	with	ADP
dpc-3688	220	25	erythrodermic	erythrodermic	ADJ
dpc-3688	220	26	psoriasis	psoriasis	NOUN
dpc-3688	220	27	after	after	ADP
dpc-3688	220	28	a	a	DET
dpc-3688	220	29	52	52	NUM
dpc-3688	220	30	-	-	PUNCT
dpc-3688	220	31	week	week	NOUN
dpc-3688	220	32	treatment	treatment	NOUN
dpc-3688	220	33	(	(	PUNCT
dpc-3688	220	34	last	last	ADJ
dpc-3688	220	35	observation	observation	NOUN
dpc-3688	220	36	carried	carry	VERB
dpc-3688	220	37	forward	forward	ADV
dpc-3688	220	38	)	)	PUNCT
dpc-3688	220	39	.	.	PUNCT
dpc-3688	221	1	the	the	DET
dpc-3688	221	2	most	most	ADV
dpc-3688	221	3	commonly	commonly	ADV
dpc-3688	221	4	reported	report	VERB
dpc-3688	221	5	adverse	adverse	ADJ
dpc-3688	221	6	event	event	NOUN
dpc-3688	221	7	was	be	AUX
dpc-3688	221	8	nasopharyngitis	nasopharyngitis	ADJ
dpc-3688	221	9	(	(	PUNCT
dpc-3688	221	10	33.3	33.3	NUM
dpc-3688	221	11	%	%	NOUN
dpc-3688	221	12	)	)	PUNCT
dpc-3688	221	13	and	and	CCONJ
dpc-3688	221	14	five	five	NUM
dpc-3688	221	15	serious	serious	ADJ
dpc-3688	221	16	adverse	adverse	ADJ
dpc-3688	221	17	events	event	NOUN
dpc-3688	221	18	occurred	occur	VERB
dpc-3688	221	19	during	during	ADP
dpc-3688	221	20	the	the	DET
dpc-3688	221	21	study	study	NOUN
dpc-3688	221	22	;	;	PUNCT
dpc-3688	221	23	none	none	NOUN
dpc-3688	221	24	of	of	ADP
dpc-3688	221	25	the	the	DET
dpc-3688	221	26	serious	serious	ADJ
dpc-3688	221	27	adverse	adverse	ADJ
dpc-3688	221	28	events	event	NOUN
dpc-3688	221	29	was	be	AUX
dpc-3688	221	30	considered	consider	VERB
dpc-3688	221	31	related	related	ADJ
dpc-3688	221	32	to	to	ADP
dpc-3688	221	33	treatment	treatment	NOUN
dpc-3688	221	34	.	.	PUNCT
dpc-3688	222	1	overall	overall	ADJ
dpc-3688	222	2	brodalumab	brodalumab	NOUN
dpc-3688	222	3	demonstrated	demonstrate	VERB
dpc-3688	222	4	to	to	PART
dpc-3688	222	5	be	be	AUX
dpc-3688	222	6	safe	safe	ADJ
dpc-3688	222	7	and	and	CCONJ
dpc-3688	222	8	significantly	significantly	ADV
dpc-3688	222	9	improved	improve	VERB
dpc-3688	222	10	symptoms	symptom	NOUN
dpc-3688	222	11	of	of	ADP
dpc-3688	222	12	patients	patient	NOUN
dpc-3688	222	13	with	with	ADP
dpc-3688	222	14	either	either	CCONJ
dpc-3688	222	15	gpp	gpp	NOUN
dpc-3688	222	16	or	or	CCONJ
dpc-3688	222	17	erythrodermic	erythrodermic	ADJ
dpc-3688	222	18	psoriasis	psoriasis	NOUN
dpc-3688	222	19	throughout	throughout	ADP
dpc-3688	222	20	the	the	DET
dpc-3688	222	21	52	52	NUM
dpc-3688	222	22	-	-	PUNCT
dpc-3688	222	23	week	week	NOUN
dpc-3688	222	24	observation	observation	NOUN
dpc-3688	222	25	period	period	NOUN
dpc-3688	222	26	[	[	X
dpc-3688	222	27	57	57	NUM
dpc-3688	222	28	]	]	PUNCT
dpc-3688	222	29	.	.	PUNCT
dpc-3688	223	1	real	real	ADJ
dpc-3688	223	2	-	-	PUNCT
dpc-3688	223	3	world	world	NOUN
dpc-3688	223	4	data	datum	NOUN
dpc-3688	223	5	on	on	ADP
dpc-3688	223	6	brodalumab	brodalumab	NOUN
dpc-3688	223	7	effectiveness	effectiveness	NOUN
dpc-3688	223	8	and	and	CCONJ
dpc-3688	223	9	safety	safety	NOUN
dpc-3688	223	10	for	for	ADP
dpc-3688	223	11	hard	hard	ADJ
dpc-3688	223	12	-	-	PUNCT
dpc-3688	223	13	to	to	PART
dpc-3688	223	14	-	-	PUNCT
dpc-3688	223	15	treat	treat	VERB
dpc-3688	223	16	psoriasis	psoriasis	NOUN
dpc-3688	223	17	areas	area	NOUN
dpc-3688	223	18	real	real	ADJ
dpc-3688	223	19	-	-	PUNCT
dpc-3688	223	20	world	world	NOUN
dpc-3688	223	21	data	datum	NOUN
dpc-3688	223	22	reported	report	VERB
dpc-3688	223	23	in	in	ADP
dpc-3688	223	24	a	a	DET
dpc-3688	223	25	retrospective	retrospective	ADJ
dpc-3688	223	26	longitudinal	longitudinal	ADJ
dpc-3688	223	27	study	study	NOUN
dpc-3688	223	28	on	on	ADP
dpc-3688	223	29	90	90	NUM
dpc-3688	223	30	patients	patient	NOUN
dpc-3688	223	31	with	with	ADP
dpc-3688	223	32	moderate	moderate	ADJ
dpc-3688	223	33	-	-	PUNCT
dpc-3688	223	34	to	to	ADP
dpc-3688	223	35	-	-	PUNCT
dpc-3688	223	36	severe	severe	ADJ
dpc-3688	223	37	plaque	plaque	NOUN
dpc-3688	223	38	psoriasis	psoriasis	NOUN
dpc-3688	223	39	treated	treat	VERB
dpc-3688	223	40	for	for	ADP
dpc-3688	223	41	12	12	NUM
dpc-3688	223	42	months	month	NOUN
dpc-3688	223	43	,	,	PUNCT
dpc-3688	223	44	demonstrated	demonstrate	VERB
dpc-3688	223	45	complete	complete	ADJ
dpc-3688	223	46	clearance	clearance	NOUN
dpc-3688	223	47	of	of	ADP
dpc-3688	223	48	scalp	scalp	NOUN
dpc-3688	223	49	,	,	PUNCT
dpc-3688	223	50	nails	nail	NOUN
dpc-3688	223	51	,	,	PUNCT
dpc-3688	223	52	palmo	palmo	NOUN
dpc-3688	223	53	-	-	PUNCT
dpc-3688	223	54	plantar	plantar	NOUN
dpc-3688	223	55	areas	area	NOUN
dpc-3688	223	56	and	and	CCONJ
dpc-3688	223	57	genitalia	genitalia	NOUN
dpc-3688	224	1	[	[	X
dpc-3688	224	2	58	58	NUM
dpc-3688	224	3	]	]	PUNCT
dpc-3688	224	4	.	.	PUNCT
dpc-3688	225	1	efficacy	efficacy	NOUN
dpc-3688	225	2	of	of	ADP
dpc-3688	225	3	brodalumab	brodalumab	NOUN
dpc-3688	225	4	on	on	ADP
dpc-3688	225	5	palmoplantar	palmoplantar	NOUN
dpc-3688	225	6	psoriasis	psoriasis	NOUN
dpc-3688	225	7	was	be	AUX
dpc-3688	225	8	also	also	ADV
dpc-3688	225	9	described	describe	VERB
dpc-3688	225	10	in	in	ADP
dpc-3688	225	11	case	case	NOUN
dpc-3688	225	12	reports	report	NOUN
dpc-3688	225	13	or	or	CCONJ
dpc-3688	225	14	case	case	NOUN
dpc-3688	225	15	series	series	NOUN
dpc-3688	225	16	[	[	X
dpc-3688	225	17	59	59	NUM
dpc-3688	225	18	]	]	PUNCT
dpc-3688	225	19	.	.	PUNCT
dpc-3688	226	1	politou	politou	PROPN
dpc-3688	226	2	et	et	PROPN
dpc-3688	226	3	al	al	PROPN
dpc-3688	226	4	reported	report	VERB
dpc-3688	226	5	successfully	successfully	ADV
dpc-3688	226	6	response	response	NOUN
dpc-3688	226	7	to	to	PART
dpc-3688	226	8	brodalumab	brodalumab	VERB
dpc-3688	226	9	in	in	ADP
dpc-3688	226	10	4	4	NUM
dpc-3688	226	11	patients	patient	NOUN
dpc-3688	226	12	,	,	PUNCT
dpc-3688	226	13	obtaining	obtain	VERB
dpc-3688	226	14	pppga	pppga	NOUN
dpc-3688	226	15	score	score	NOUN
dpc-3688	226	16	0	0	NUM
dpc-3688	226	17	at	at	ADP
dpc-3688	226	18	week	week	NOUN
dpc-3688	226	19	16	16	NUM
dpc-3688	226	20	,	,	PUNCT
dpc-3688	226	21	after	after	ADP
dpc-3688	226	22	secukinumab	secukinumab	NOUN
dpc-3688	226	23	failure	failure	NOUN
dpc-3688	226	24	[	[	X
dpc-3688	226	25	60	60	NUM
dpc-3688	226	26	]	]	PUNCT
dpc-3688	226	27	.	.	PUNCT
dpc-3688	227	1	in	in	ADP
dpc-3688	227	2	a	a	DET
dpc-3688	227	3	case	case	NOUN
dpc-3688	227	4	report	report	NOUN
dpc-3688	227	5	,	,	PUNCT
dpc-3688	227	6	a	a	DET
dpc-3688	227	7	patient	patient	NOUN
dpc-3688	227	8	suffering	suffering	NOUN
dpc-3688	227	9	from	from	ADP
dpc-3688	227	10	pso	pso	NOUN
dpc-3688	227	11	and	and	CCONJ
dpc-3688	227	12	ppp	ppp	PROPN
dpc-3688	227	13	,	,	PUNCT
dpc-3688	227	14	who	who	PRON
dpc-3688	227	15	previously	previously	ADV
dpc-3688	227	16	failed	fail	VERB
dpc-3688	227	17	adalimumab	adalimumab	NOUN
dpc-3688	227	18	and	and	CCONJ
dpc-3688	227	19	secukinumab	secukinumab	NOUN
dpc-3688	227	20	,	,	PUNCT
dpc-3688	227	21	was	be	AUX
dpc-3688	227	22	successfully	successfully	ADV
dpc-3688	227	23	treated	treat	VERB
dpc-3688	227	24	with	with	ADP
dpc-3688	227	25	brodalumab	brodalumab	NOUN
dpc-3688	227	26	,	,	PUNCT
dpc-3688	227	27	with	with	ADP
dpc-3688	227	28	clinical	clinical	ADJ
dpc-3688	227	29	improvement	improvement	NOUN
dpc-3688	227	30	observed	observe	VERB
dpc-3688	227	31	after	after	ADP
dpc-3688	227	32	2	2	NUM
dpc-3688	227	33	weeks	week	NOUN
dpc-3688	227	34	and	and	CCONJ
dpc-3688	227	35	the	the	DET
dpc-3688	227	36	complete	complete	ADJ
dpc-3688	227	37	clearance	clearance	NOUN
dpc-3688	227	38	after	after	ADP
dpc-3688	227	39	6	6	NUM
dpc-3688	227	40	months	month	NOUN
dpc-3688	227	41	[	[	X
dpc-3688	227	42	61	61	NUM
dpc-3688	227	43	]	]	PUNCT
dpc-3688	227	44	.	.	PUNCT
dpc-3688	228	1	contrasting	contrast	VERB
dpc-3688	228	2	findings	finding	NOUN
dpc-3688	228	3	were	be	AUX
dpc-3688	228	4	described	describe	VERB
dpc-3688	228	5	in	in	ADP
dpc-3688	228	6	a	a	DET
dpc-3688	228	7	case	case	NOUN
dpc-3688	228	8	series	series	NOUN
dpc-3688	228	9	consisting	consist	VERB
dpc-3688	228	10	of	of	ADP
dpc-3688	228	11	four	four	NUM
dpc-3688	228	12	patients	patient	NOUN
dpc-3688	228	13	treated	treat	VERB
dpc-3688	228	14	for	for	ADP
dpc-3688	228	15	ppp	ppp	NOUN
dpc-3688	228	16	,	,	PUNCT
dpc-3688	228	17	obtaining	obtain	VERB
dpc-3688	228	18	partial	partial	ADJ
dpc-3688	228	19	response	response	NOUN
dpc-3688	228	20	only	only	ADV
dpc-3688	228	21	in	in	ADP
dpc-3688	228	22	one	one	NUM
dpc-3688	228	23	patient	patient	NOUN
dpc-3688	228	24	,	,	PUNCT
dpc-3688	228	25	while	while	SCONJ
dpc-3688	228	26	the	the	DET
dpc-3688	228	27	three	three	NUM
dpc-3688	228	28	other	other	ADJ
dpc-3688	228	29	patients	patient	NOUN
dpc-3688	228	30	had	have	VERB
dpc-3688	228	31	no	no	DET
dpc-3688	228	32	response	response	NOUN
dpc-3688	228	33	or	or	CCONJ
dpc-3688	228	34	worsening	worsening	NOUN
dpc-3688	228	35	of	of	ADP
dpc-3688	228	36	ppp	ppp	NOUN
dpc-3688	228	37	.	.	PUNCT
dpc-3688	229	1	one	one	NUM
dpc-3688	229	2	patient	patient	NOUN
dpc-3688	229	3	had	have	VERB
dpc-3688	229	4	a	a	DET
dpc-3688	229	5	partial	partial	ADJ
dpc-3688	229	6	response	response	NOUN
dpc-3688	229	7	and	and	CCONJ
dpc-3688	229	8	after	after	ADP
dpc-3688	229	9	7	7	NUM
dpc-3688	229	10	months	month	NOUN
dpc-3688	229	11	,	,	PUNCT
dpc-3688	229	12	due	due	ADJ
dpc-3688	229	13	to	to	ADP
dpc-3688	229	14	worsening	worsen	VERB
dpc-3688	229	15	of	of	ADP
dpc-3688	229	16	arthralgia	arthralgia	NOUN
dpc-3688	229	17	and	and	CCONJ
dpc-3688	229	18	bad	bad	ADJ
dpc-3688	229	19	tongue	tongue	NOUN
dpc-3688	229	20	symptoms	symptom	NOUN
dpc-3688	229	21	,	,	PUNCT
dpc-3688	229	22	brodalumab	brodalumab	NOUN
dpc-3688	229	23	was	be	AUX
dpc-3688	229	24	stopped	stop	VERB
dpc-3688	229	25	[	[	PUNCT
dpc-3688	229	26	62	62	NUM
dpc-3688	229	27	]	]	PUNCT
dpc-3688	229	28	.	.	PUNCT
dpc-3688	230	1	conclusions	conclusion	NOUN
dpc-3688	230	2	the	the	DET
dpc-3688	230	3	successful	successful	ADJ
dpc-3688	230	4	management	management	NOUN
dpc-3688	230	5	of	of	ADP
dpc-3688	230	6	patients	patient	NOUN
dpc-3688	230	7	affected	affect	VERB
dpc-3688	230	8	by	by	ADP
dpc-3688	230	9	psoriasis	psoriasis	NOUN
dpc-3688	230	10	in	in	ADP
dpc-3688	230	11	difficult	difficult	ADJ
dpc-3688	230	12	-	-	PUNCT
dpc-3688	230	13	to	to	ADP
dpc-3688	230	14	-	-	PUNCT
dpc-3688	230	15	treat	treat	NOUN
dpc-3688	230	16	areas	area	NOUN
dpc-3688	230	17	still	still	ADV
dpc-3688	230	18	represents	represent	VERB
dpc-3688	230	19	an	an	DET
dpc-3688	230	20	unmet	unmet	NOUN
dpc-3688	230	21	therapeutic	therapeutic	ADJ
dpc-3688	230	22	need	need	NOUN
dpc-3688	230	23	that	that	PRON
dpc-3688	230	24	has	have	AUX
dpc-3688	230	25	been	be	AUX
dpc-3688	230	26	partially	partially	ADV
dpc-3688	230	27	covered	cover	VERB
dpc-3688	230	28	by	by	ADP
dpc-3688	230	29	currently	currently	ADV
dpc-3688	230	30	available	available	ADJ
dpc-3688	230	31	therapeutic	therapeutic	ADJ
dpc-3688	230	32	options	option	NOUN
dpc-3688	230	33	.	.	PUNCT
dpc-3688	231	1	brodalumab	brodalumab	NOUN
dpc-3688	231	2	,	,	PUNCT
dpc-3688	231	3	combining	combine	VERB
dpc-3688	231	4	rapid	rapid	ADJ
dpc-3688	231	5	and	and	CCONJ
dpc-3688	231	6	sustained	sustained	ADJ
dpc-3688	231	7	efficacy	efficacy	NOUN
dpc-3688	231	8	with	with	ADP
dpc-3688	231	9	a	a	DET
dpc-3688	231	10	favorable	favorable	ADJ
dpc-3688	231	11	safety	safety	NOUN
dpc-3688	231	12	profile	profile	NOUN
dpc-3688	231	13	,	,	PUNCT
dpc-3688	231	14	may	may	AUX
dpc-3688	231	15	be	be	AUX
dpc-3688	231	16	a	a	DET
dpc-3688	231	17	valid	valid	ADJ
dpc-3688	231	18	therapeutic	therapeutic	ADJ
dpc-3688	231	19	option	option	NOUN
dpc-3688	231	20	not	not	PART
dpc-3688	231	21	only	only	ADV
dpc-3688	231	22	for	for	ADP
dpc-3688	231	23	plaque	plaque	NOUN
dpc-3688	231	24	psoriasis	psoriasis	NOUN
dpc-3688	231	25	but	but	CCONJ
dpc-3688	231	26	also	also	ADV
dpc-3688	231	27	for	for	ADP
dpc-3688	231	28	severe	severe	ADJ
dpc-3688	231	29	variants	variant	NOUN
dpc-3688	231	30	of	of	ADP
dpc-3688	231	31	psoriasis	psoriasis	NOUN
dpc-3688	231	32	as	as	ADV
dpc-3688	231	33	well	well	ADV
dpc-3688	231	34	as	as	ADP
dpc-3688	231	35	for	for	ADP
dpc-3688	231	36	psoriasis	psoriasis	NOUN
dpc-3688	231	37	localized	localize	VERB
dpc-3688	231	38	in	in	ADP
dpc-3688	231	39	difficult	difficult	ADJ
dpc-3688	231	40	-	-	PUNCT
dpc-3688	231	41	to	to	ADP
dpc-3688	231	42	-	-	PUNCT
dpc-3688	231	43	treat	treat	NOUN
dpc-3688	231	44	areas	area	NOUN
dpc-3688	231	45	.	.	PUNCT
dpc-3688	232	1	an	an	DET
dpc-3688	232	2	expert	expert	NOUN
dpc-3688	232	3	panel	panel	NOUN
dpc-3688	232	4	recently	recently	ADV
dpc-3688	232	5	sought	seek	VERB
dpc-3688	232	6	to	to	PART
dpc-3688	232	7	define	define	VERB
dpc-3688	232	8	the	the	DET
dpc-3688	232	9	best	good	ADJ
dpc-3688	232	10	areas	area	NOUN
dpc-3688	232	11	of	of	ADP
dpc-3688	232	12	action	action	NOUN
dpc-3688	232	13	for	for	ADP
dpc-3688	232	14	brodalumab	brodalumab	NOUN
dpc-3688	232	15	,	,	PUNCT
dpc-3688	232	16	clarifying	clarify	VERB
dpc-3688	232	17	the	the	DET
dpc-3688	232	18	optimal	optimal	ADJ
dpc-3688	232	19	place	place	NOUN
dpc-3688	232	20	-	-	PUNCT
dpc-3688	232	21	intherapy	intherapy	NOUN
dpc-3688	232	22	for	for	ADP
dpc-3688	232	23	this	this	DET
dpc-3688	232	24	drug	drug	NOUN
dpc-3688	232	25	.	.	PUNCT
dpc-3688	233	1	through	through	ADP
dpc-3688	233	2	a	a	DET
dpc-3688	233	3	delphi	delphi	NOUN
dpc-3688	233	4	methodology	methodology	NOUN
dpc-3688	233	5	,	,	PUNCT
dpc-3688	233	6	the	the	DET
dpc-3688	233	7	expert	expert	NOUN
dpc-3688	233	8	panel	panel	NOUN
dpc-3688	233	9	agreed	agree	VERB
dpc-3688	233	10	in	in	ADP
dpc-3688	233	11	considering	consider	VERB
dpc-3688	233	12	brodalumab	brodalumab	NOUN
dpc-3688	233	13	an	an	DET
dpc-3688	233	14	appropriate	appropriate	ADJ
dpc-3688	233	15	therapeutic	therapeutic	ADJ
dpc-3688	233	16	choice	choice	NOUN
dpc-3688	233	17	when	when	SCONJ
dpc-3688	233	18	there	there	PRON
dpc-3688	233	19	is	be	VERB
dpc-3688	233	20	involvement	involvement	NOUN
dpc-3688	233	21	of	of	ADP
dpc-3688	233	22	difficult	difficult	ADJ
dpc-3688	233	23	to	to	PART
dpc-3688	233	24	-	-	PUNCT
dpc-3688	233	25	treat	treat	NOUN
dpc-3688	233	26	areas	area	NOUN
dpc-3688	233	27	,	,	PUNCT
dpc-3688	233	28	such	such	ADJ
dpc-3688	233	29	as	as	ADP
dpc-3688	233	30	scalp	scalp	NOUN
dpc-3688	233	31	/	/	SYM
dpc-3688	233	32	nails	nail	NOUN
dpc-3688	233	33	or	or	CCONJ
dpc-3688	233	34	palmo	palmo	NOUN
dpc-3688	233	35	-	-	PUNCT
dpc-3688	233	36	plantar	plantar	NOUN
dpc-3688	233	37	area	area	NOUN
dpc-3688	233	38	[	[	X
dpc-3688	233	39	17	17	NUM
dpc-3688	233	40	]	]	PUNCT
dpc-3688	233	41	.	.	PUNCT
dpc-3688	234	1	moreover	moreover	ADV
dpc-3688	234	2	,	,	PUNCT
dpc-3688	234	3	the	the	DET
dpc-3688	234	4	expert	expert	NOUN
dpc-3688	234	5	panel	panel	NOUN
dpc-3688	234	6	highlighted	highlight	VERB
dpc-3688	234	7	the	the	DET
dpc-3688	234	8	benefits	benefit	NOUN
dpc-3688	234	9	of	of	ADP
dpc-3688	234	10	brodalumab	brodalumab	NOUN
dpc-3688	234	11	in	in	ADP
dpc-3688	234	12	treating	treat	VERB
dpc-3688	234	13	psoriasis	psoriasis	NOUN
dpc-3688	234	14	in	in	ADP
dpc-3688	234	15	difficult	difficult	ADJ
dpc-3688	234	16	-	-	PUNCT
dpc-3688	234	17	to	to	ADP
dpc-3688	234	18	-	-	PUNCT
dpc-3688	234	19	treat	treat	NOUN
dpc-3688	234	20	areas	area	NOUN
dpc-3688	234	21	,	,	PUNCT
dpc-3688	234	22	including	include	VERB
dpc-3688	234	23	the	the	DET
dpc-3688	234	24	amelioration	amelioration	NOUN
dpc-3688	234	25	obtained	obtain	VERB
dpc-3688	234	26	on	on	ADP
dpc-3688	234	27	pruritus	pruritus	PROPN
dpc-3688	234	28	.	.	PUNCT
dpc-3688	235	1	in	in	ADP
dpc-3688	235	2	addition	addition	NOUN
dpc-3688	235	3	,	,	PUNCT
dpc-3688	235	4	the	the	DET
dpc-3688	235	5	expert	expert	NOUN
dpc-3688	235	6	panel	panel	NOUN
dpc-3688	235	7	noted	note	VERB
dpc-3688	235	8	that	that	SCONJ
dpc-3688	235	9	the	the	DET
dpc-3688	235	10	scalp	scalp	NOUN
dpc-3688	235	11	tends	tend	VERB
dpc-3688	235	12	to	to	PART
dpc-3688	235	13	be	be	AUX
dpc-3688	235	14	the	the	DET
dpc-3688	235	15	first	first	ADJ
dpc-3688	235	16	site	site	NOUN
dpc-3688	235	17	to	to	PART
dpc-3688	235	18	clear	clear	VERB
dpc-3688	235	19	from	from	ADP
dpc-3688	235	20	psoriasis	psoriasis	NOUN
dpc-3688	235	21	as	as	ADV
dpc-3688	235	22	well	well	ADV
dpc-3688	235	23	as	as	ADP
dpc-3688	235	24	the	the	DET
dpc-3688	235	25	first	first	ADJ
dpc-3688	235	26	site	site	NOUN
dpc-3688	235	27	where	where	SCONJ
dpc-3688	235	28	the	the	DET
dpc-3688	235	29	disease	disease	NOUN
dpc-3688	235	30	recurs	recur	VERB
dpc-3688	235	31	whether	whether	SCONJ
dpc-3688	235	32	brodalumab	brodalumab	NOUN
dpc-3688	235	33	fails	fail	VERB
dpc-3688	235	34	.	.	PUNCT
dpc-3688	236	1	the	the	DET
dpc-3688	236	2	advantage	advantage	NOUN
dpc-3688	236	3	of	of	ADP
dpc-3688	236	4	brodalumab	brodalumab	NOUN
dpc-3688	236	5	in	in	ADP
dpc-3688	236	6	inhibiting	inhibit	VERB
dpc-3688	236	7	multiple	multiple	ADJ
dpc-3688	236	8	pathogenic	pathogenic	ADJ
dpc-3688	236	9	il-17	il-17	NUM
dpc-3688	236	10	cytokines	cytokine	NOUN
dpc-3688	236	11	through	through	ADP
dpc-3688	236	12	17ra	17ra	ADJ
dpc-3688	236	13	blockade	blockade	NOUN
dpc-3688	236	14	,	,	PUNCT
dpc-3688	236	15	is	be	AUX
dpc-3688	236	16	clinically	clinically	ADV
dpc-3688	236	17	reflected	reflect	VERB
dpc-3688	236	18	by	by	ADP
dpc-3688	236	19	a	a	DET
dpc-3688	236	20	rapid	rapid	ADJ
dpc-3688	236	21	response	response	NOUN
dpc-3688	236	22	and	and	CCONJ
dpc-3688	236	23	high	high	ADJ
dpc-3688	236	24	rate	rate	NOUN
dpc-3688	236	25	of	of	ADP
dpc-3688	236	26	skin	skin	NOUN
dpc-3688	236	27	clearance	clearance	NOUN
dpc-3688	236	28	,	,	PUNCT
dpc-3688	236	29	even	even	ADV
dpc-3688	236	30	in	in	ADP
dpc-3688	236	31	the	the	DET
dpc-3688	236	32	treatment	treatment	NOUN
dpc-3688	236	33	of	of	ADP
dpc-3688	236	34	psoriasis	psoriasis	NOUN
dpc-3688	236	35	localized	localize	VERB
dpc-3688	236	36	in	in	ADP
dpc-3688	236	37	difficult	difficult	ADJ
dpc-3688	236	38	to	to	PART
dpc-3688	236	39	-	-	PUNCT
dpc-3688	236	40	treat	treat	VERB
dpc-3688	236	41	areas	area	NOUN
dpc-3688	236	42	.	.	PUNCT
dpc-3688	237	1	nevertheless	nevertheless	ADV
dpc-3688	237	2	,	,	PUNCT
dpc-3688	237	3	having	have	VERB
dpc-3688	237	4	limited	limit	VERB
dpc-3688	237	5	data	datum	NOUN
dpc-3688	237	6	deriving	derive	VERB
dpc-3688	237	7	from	from	ADP
dpc-3688	237	8	both	both	DET
dpc-3688	237	9	trials	trial	NOUN
dpc-3688	237	10	and	and	CCONJ
dpc-3688	237	11	real	real	ADJ
dpc-3688	237	12	-	-	PUNCT
dpc-3688	237	13	world	world	NOUN
dpc-3688	237	14	studies	study	NOUN
dpc-3688	237	15	,	,	PUNCT
dpc-3688	237	16	further	further	ADJ
dpc-3688	237	17	evidence	evidence	NOUN
dpc-3688	237	18	is	be	AUX
dpc-3688	237	19	8	8	NUM
dpc-3688	237	20	review	review	NOUN
dpc-3688	237	21	|	|	ADV
dpc-3688	237	22	dermatol	dermatol	ADJ
dpc-3688	237	23	pract	pract	NOUN
dpc-3688	237	24	concept	concept	NOUN
dpc-3688	237	25	.	.	PUNCT
dpc-3688	238	1	2023;13(3):e2023245	2023;13(3):e2023245	NUM
dpc-3688	238	2	european	european	PROPN
dpc-3688	238	3	medicines	medicine	NOUN
dpc-3688	238	4	agency	agency	NOUN
dpc-3688	238	5	.	.	PUNCT
dpc-3688	239	1	kyntheum	kyntheum	NOUN
dpc-3688	239	2	(	(	PUNCT
dpc-3688	239	3	brodalumab	brodalumab	NOUN
dpc-3688	239	4	)	)	PUNCT
dpc-3688	239	5	210	210	NUM
dpc-3688	239	6	mg	mg	NOUN
dpc-3688	239	7	solution	solution	NOUN
dpc-3688	239	8	for	for	ADP
dpc-3688	239	9	injection	injection	NOUN
dpc-3688	239	10	in	in	ADP
dpc-3688	239	11	pre	pre	ADJ
dpc-3688	239	12	-	-	ADJ
dpc-3688	239	13	filled	filled	ADJ
dpc-3688	239	14	syringe	syringe	NOUN
dpc-3688	239	15	:	:	PUNCT
dpc-3688	239	16	summary	summary	NOUN
dpc-3688	239	17	of	of	ADP
dpc-3688	239	18	product	product	NOUN
dpc-3688	239	19	characteristics	characteristic	NOUN
dpc-3688	239	20	.	.	PUNCT
dpc-3688	240	1	date	date	NOUN
dpc-3688	240	2	of	of	ADP
dpc-3688	240	3	first	first	ADJ
dpc-3688	240	4	authorisation:17	authorisation:17	VERB
dpc-3688	240	5	july	july	PROPN
dpc-3688	240	6	2017	2017	NUM
dpc-3688	240	7	availabre	availabre	NOUN
dpc-3688	240	8	from	from	ADP
dpc-3688	240	9	from	from	ADP
dpc-3688	240	10	:	:	PUNCT
dpc-3688	240	11	https://www.ema.europa.eu	https://www.ema.europa.eu	X
dpc-3688	240	12	/	/	SYM
dpc-3688	240	13	en	en	NOUN
dpc-3688	240	14	/	/	SYM
dpc-3688	240	15	documents	document	NOUN
dpc-3688	240	16	/product	/product	NOUN
dpc-3688	240	17	-	-	PUNCT
dpc-3688	240	18	information	information	NOUN
dpc-3688	240	19	/	/	SYM
dpc-3688	240	20	kyntheum	kyntheum	NOUN
dpc-3688	240	21	-	-	PUNCT
dpc-3688	240	22	epar	epar	NOUN
dpc-3688	240	23	-	-	PUNCT
dpc-3688	240	24	product	product	NOUN
dpc-3688	240	25	-	-	PUNCT
dpc-3688	240	26	information	information	NOUN
dpc-3688	240	27	_	_	PUNCT
dpc-3688	241	1	en.pdf	en.pdf	PROPN
dpc-3688	241	2	.	.	PROPN
dpc-3688	241	3	accessed	access	VERB
dpc-3688	241	4	on	on	ADP
dpc-3688	241	5	28	28	NUM
dpc-3688	241	6	july	july	PROPN
dpc-3688	241	7	2023	2023	NUM
dpc-3688	241	8	.	.	PUNCT
dpc-3688	242	1	14	14	NUM
dpc-3688	242	2	.	.	X
dpc-3688	243	1	leopharma	leopharma	PROPN
dpc-3688	243	2	a	a	PROPN
dpc-3688	243	3	/	/	SYM
dpc-3688	243	4	s.	s.	PROPN
dpc-3688	243	5	siliqtm	siliqtm	PROPN
dpc-3688	243	6	(	(	PUNCT
dpc-3688	243	7	brodalumab	brodalumab	NOUN
dpc-3688	243	8	)	)	PUNCT
dpc-3688	243	9	injection	injection	NOUN
dpc-3688	243	10	,	,	PUNCT
dpc-3688	243	11	for	for	ADP
dpc-3688	243	12	subcutaneous	subcutaneous	ADJ
dpc-3688	243	13	use	use	NOUN
dpc-3688	243	14	.	.	PUNCT
dpc-3688	244	1	initial	initial	ADJ
dpc-3688	244	2	u.s	u.s	PROPN
dpc-3688	244	3	.	.	PROPN
dpc-3688	244	4	approval	approval	NOUN
dpc-3688	244	5	:	:	PUNCT
dpc-3688	245	1	2017.available	2017.available	NUM
dpc-3688	245	2	from	from	ADP
dpc-3688	245	3	:	:	PUNCT
dpc-3688	245	4	https://www	https://www	PROPN
dpc-3688	245	5	.accessdata.fda.gov	.accessdata.fda.gov	PUNCT
dpc-3688	245	6	/	/	SYM
dpc-3688	245	7	drugsatfda_docs	drugsatfda_docs	PROPN
dpc-3688	245	8	/	/	SYM
dpc-3688	245	9	label/2017/761032lbl.pdf	label/2017/761032lbl.pdf	PROPN
dpc-3688	245	10	.	.	PROPN
dpc-3688	245	11	accessed	access	VERB
dpc-3688	245	12	on	on	ADP
dpc-3688	245	13	28	28	NUM
dpc-3688	245	14	july	july	PROPN
dpc-3688	245	15	2023	2023	NUM
dpc-3688	245	16	.	.	PUNCT
dpc-3688	246	1	15	15	NUM
dpc-3688	246	2	.	.	PUNCT
dpc-3688	246	3	papp	papp	PROPN
dpc-3688	246	4	ka	ka	PROPN
dpc-3688	246	5	,	,	PUNCT
dpc-3688	246	6	reich	reich	PROPN
dpc-3688	246	7	k	k	PROPN
dpc-3688	246	8	,	,	PUNCT
dpc-3688	246	9	paul	paul	PROPN
dpc-3688	246	10	c	c	PROPN
dpc-3688	246	11	,	,	PUNCT
dpc-3688	246	12	et	et	PROPN
dpc-3688	246	13	al	al	PROPN
dpc-3688	246	14	.	.	PUNCT
dpc-3688	247	1	a	a	DET
dpc-3688	247	2	prospective	prospective	ADJ
dpc-3688	247	3	phase	phase	NOUN
dpc-3688	247	4	iii	iii	NOUN
dpc-3688	247	5	,	,	PUNCT
dpc-3688	247	6	randomized	randomize	VERB
dpc-3688	247	7	,	,	PUNCT
dpc-3688	247	8	double	double	ADJ
dpc-3688	247	9	-	-	PUNCT
dpc-3688	247	10	blind	blind	ADJ
dpc-3688	247	11	,	,	PUNCT
dpc-3688	247	12	placebo	placebo	NOUN
dpc-3688	247	13	-	-	PUNCT
dpc-3688	247	14	controlled	control	VERB
dpc-3688	247	15	study	study	NOUN
dpc-3688	247	16	of	of	ADP
dpc-3688	247	17	brodalumab	brodalumab	NOUN
dpc-3688	247	18	in	in	ADP
dpc-3688	247	19	patients	patient	NOUN
dpc-3688	247	20	with	with	ADP
dpc-3688	247	21	moderate	moderate	ADJ
dpc-3688	247	22	-	-	PUNCT
dpc-3688	247	23	to	to	ADP
dpc-3688	247	24	-	-	PUNCT
dpc-3688	247	25	severe	severe	ADJ
dpc-3688	247	26	plaque	plaque	NOUN
dpc-3688	247	27	psoriasis	psoriasis	NOUN
dpc-3688	247	28	.	.	PUNCT
dpc-3688	248	1	br	br	PROPN
dpc-3688	248	2	j	j	PROPN
dpc-3688	248	3	dermatol	dermatol	NOUN
dpc-3688	248	4	.	.	PUNCT
dpc-3688	249	1	2016;175(2):273	2016;175(2):273	NUM
dpc-3688	249	2	-	-	SYM
dpc-3688	249	3	286	286	NUM
dpc-3688	249	4	.	.	PUNCT
dpc-3688	250	1	doi	doi	NOUN
dpc-3688	250	2	:	:	PUNCT
dpc-3688	250	3	10.1111	10.1111	NUM
dpc-3688	250	4	/	/	SYM
dpc-3688	250	5	bjd.14493	bjd.14493	NOUN
dpc-3688	250	6	.	.	PUNCT
dpc-3688	251	1	pmid	pmid	NOUN
dpc-3688	251	2	:	:	PUNCT
dpc-3688	251	3	26914406	26914406	NUM
dpc-3688	251	4	.	.	PUNCT
dpc-3688	252	1	16	16	NUM
dpc-3688	252	2	.	.	PUNCT
dpc-3688	253	1	fargnoli	fargnoli	PROPN
dpc-3688	253	2	mc	mc	PROPN
dpc-3688	253	3	,	,	PUNCT
dpc-3688	253	4	bardazzi	bardazzi	PROPN
dpc-3688	253	5	f	f	PROPN
dpc-3688	253	6	,	,	PUNCT
dpc-3688	253	7	bianchi	bianchi	PROPN
dpc-3688	253	8	l	l	PROPN
dpc-3688	253	9	,	,	PUNCT
dpc-3688	253	10	et	et	PROPN
dpc-3688	253	11	al	al	PROPN
dpc-3688	253	12	.	.	PROPN
dpc-3688	253	13	brodalumab	brodalumab	PROPN
dpc-3688	253	14	for	for	ADP
dpc-3688	253	15	the	the	DET
dpc-3688	253	16	treatment	treatment	NOUN
dpc-3688	253	17	of	of	ADP
dpc-3688	253	18	moderate	moderate	ADJ
dpc-3688	253	19	-	-	PUNCT
dpc-3688	253	20	to	to	ADP
dpc-3688	253	21	-	-	PUNCT
dpc-3688	253	22	severe	severe	ADJ
dpc-3688	253	23	psoriasis	psoriasis	NOUN
dpc-3688	253	24	:	:	PUNCT
dpc-3688	253	25	an	an	DET
dpc-3688	253	26	expert	expert	ADJ
dpc-3688	253	27	delphi	delphi	NOUN
dpc-3688	253	28	consensus	consensus	NOUN
dpc-3688	253	29	statement	statement	NOUN
dpc-3688	253	30	.	.	PUNCT
dpc-3688	254	1	j	j	PROPN
dpc-3688	254	2	clin	clin	PROPN
dpc-3688	254	3	med	med	PROPN
dpc-3688	254	4	.	.	PUNCT
dpc-3688	255	1	2023;12(10):3545	2023;12(10):3545	X
dpc-3688	255	2	.	.	PUNCT
dpc-3688	256	1	doi	doi	NOUN
dpc-3688	256	2	:	:	PUNCT
dpc-3688	256	3	10.3390	10.3390	NUM
dpc-3688	256	4	/	/	SYM
dpc-3688	256	5	jcm12103545	jcm12103545	NOUN
dpc-3688	256	6	.	.	PUNCT
dpc-3688	257	1	pmid	pmid	NOUN
dpc-3688	257	2	:	:	PUNCT
dpc-3688	257	3	37240650	37240650	NUM
dpc-3688	257	4	.	.	PUNCT
dpc-3688	258	1	pmcid	pmcid	NOUN
dpc-3688	258	2	:	:	PUNCT
dpc-3688	258	3	pmc10219103	pmc10219103	ADJ
dpc-3688	258	4	.	.	PUNCT
dpc-3688	259	1	17	17	NUM
dpc-3688	259	2	.	.	PUNCT
dpc-3688	260	1	mcmichael	mcmichael	PROPN
dpc-3688	260	2	a	a	PROPN
dpc-3688	260	3	,	,	PUNCT
dpc-3688	260	4	desai	desai	PROPN
dpc-3688	260	5	sr	sr	PROPN
dpc-3688	260	6	,	,	PUNCT
dpc-3688	260	7	qureshi	qureshi	PROPN
dpc-3688	260	8	a	a	PROPN
dpc-3688	260	9	,	,	PUNCT
dpc-3688	260	10	rastogi	rastogi	PROPN
dpc-3688	260	11	s	s	PROPN
dpc-3688	260	12	,	,	PUNCT
dpc-3688	260	13	alexis	alexis	PROPN
dpc-3688	260	14	af	af	PROPN
dpc-3688	260	15	.	.	PROPN
dpc-3688	260	16	efficacy	efficacy	NOUN
dpc-3688	260	17	and	and	CCONJ
dpc-3688	260	18	safety	safety	NOUN
dpc-3688	260	19	of	of	ADP
dpc-3688	260	20	brodalumab	brodalumab	NOUN
dpc-3688	260	21	in	in	ADP
dpc-3688	260	22	patients	patient	NOUN
dpc-3688	260	23	with	with	ADP
dpc-3688	260	24	moderate	moderate	ADJ
dpc-3688	260	25	-	-	PUNCT
dpc-3688	260	26	to	to	ADP
dpc-3688	260	27	severe	severe	ADJ
dpc-3688	260	28	plaque	plaque	NOUN
dpc-3688	260	29	psoriasis	psoriasis	NOUN
dpc-3688	260	30	and	and	CCONJ
dpc-3688	260	31	skin	skin	NOUN
dpc-3688	260	32	of	of	ADP
dpc-3688	260	33	color	color	NOUN
dpc-3688	260	34	:	:	PUNCT
dpc-3688	260	35	results	result	NOUN
dpc-3688	260	36	from	from	ADP
dpc-3688	260	37	the	the	DET
dpc-3688	260	38	pooled	pooled	ADJ
dpc-3688	260	39	amagine-2/-3	amagine-2/-3	NOUN
dpc-3688	260	40	randomized	randomize	VERB
dpc-3688	260	41	trials	trial	NOUN
dpc-3688	260	42	.	.	PUNCT
dpc-3688	261	1	am	be	AUX
dpc-3688	261	2	j	j	PROPN
dpc-3688	261	3	clin	clin	PROPN
dpc-3688	261	4	dermatol	dermatol	NOUN
dpc-3688	261	5	.	.	PUNCT
dpc-3688	262	1	2019;20(2):267	2019;20(2):267	NUM
dpc-3688	262	2	-	-	PUNCT
dpc-3688	262	3	276	276	NUM
dpc-3688	262	4	.	.	PUNCT
dpc-3688	263	1	doi	doi	NOUN
dpc-3688	263	2	:	:	PUNCT
dpc-3688	263	3	10.1007	10.1007	NUM
dpc-3688	263	4	/	/	SYM
dpc-3688	263	5	s40257	s40257	NOUN
dpc-3688	263	6	-	-	PUNCT
dpc-3688	263	7	018	018	NUM
dpc-3688	263	8	-	-	PUNCT
dpc-3688	263	9	0408	0408	NUM
dpc-3688	263	10	-	-	PUNCT
dpc-3688	263	11	z.	z.	NOUN
dpc-3688	263	12	pmid	pmid	PROPN
dpc-3688	263	13	:	:	PUNCT
dpc-3688	263	14	30471012	30471012	NUM
dpc-3688	263	15	.	.	PUNCT
dpc-3688	264	1	18	18	NUM
dpc-3688	264	2	.	.	PUNCT
dpc-3688	264	3	blauvelt	blauvelt	VERB
dpc-3688	264	4	a	a	DET
dpc-3688	264	5	,	,	PUNCT
dpc-3688	264	6	chiricozzi	chiricozzi	NOUN
dpc-3688	264	7	a.	a.	NOUN
dpc-3688	264	8	the	the	DET
dpc-3688	264	9	immunologic	immunologic	ADJ
dpc-3688	264	10	role	role	NOUN
dpc-3688	264	11	of	of	ADP
dpc-3688	264	12	il-17	il-17	X
dpc-3688	264	13	in	in	ADP
dpc-3688	264	14	psoriasis	psoriasis	NOUN
dpc-3688	264	15	and	and	CCONJ
dpc-3688	264	16	psoriatic	psoriatic	ADJ
dpc-3688	264	17	arthritis	arthritis	NOUN
dpc-3688	264	18	pathogenesis	pathogenesis	NOUN
dpc-3688	264	19	.	.	PUNCT
dpc-3688	265	1	clin	clin	PROPN
dpc-3688	265	2	rev	rev	PROPN
dpc-3688	265	3	allergy	allergy	PROPN
dpc-3688	265	4	immunol	immunol	NOUN
dpc-3688	265	5	.	.	PUNCT
dpc-3688	266	1	2018;55(3):379	2018;55(3):379	NUM
dpc-3688	266	2	-	-	SYM
dpc-3688	266	3	390	390	NUM
dpc-3688	266	4	.	.	PUNCT
dpc-3688	267	1	doi	doi	NOUN
dpc-3688	267	2	:	:	PUNCT
dpc-3688	267	3	10.1007	10.1007	NUM
dpc-3688	267	4	/	/	SYM
dpc-3688	267	5	s12016	s12016	PROPN
dpc-3688	267	6	-	-	PUNCT
dpc-3688	267	7	018	018	NUM
dpc-3688	267	8	-	-	PUNCT
dpc-3688	267	9	8702	8702	NUM
dpc-3688	267	10	-	-	SYM
dpc-3688	267	11	3	3	NUM
dpc-3688	267	12	.	.	PUNCT
dpc-3688	268	1	pmid	pmid	NOUN
dpc-3688	268	2	:	:	PUNCT
dpc-3688	268	3	30109481	30109481	NUM
dpc-3688	268	4	.	.	PUNCT
dpc-3688	269	1	pmcid	pmcid	ADJ
dpc-3688	269	2	:	:	PUNCT
dpc-3688	269	3	pmc6244934	pmc6244934	NOUN
dpc-3688	269	4	.	.	PUNCT
dpc-3688	270	1	19	19	NUM
dpc-3688	270	2	.	.	X
dpc-3688	270	3	di	di	PROPN
dpc-3688	270	4	cesare	cesare	PROPN
dpc-3688	270	5	a	a	PROPN
dpc-3688	270	6	,	,	PUNCT
dpc-3688	270	7	di	di	NOUN
dpc-3688	270	8	meglio	meglio	NOUN
dpc-3688	270	9	p	p	X
dpc-3688	270	10	,	,	PUNCT
dpc-3688	270	11	nestle	nestle	PROPN
dpc-3688	270	12	fo	fo	PROPN
dpc-3688	270	13	.	.	PUNCT
dpc-3688	271	1	the	the	DET
dpc-3688	271	2	il-23	il-23	NOUN
dpc-3688	271	3	/	/	SYM
dpc-3688	271	4	th17	th17	PROPN
dpc-3688	271	5	axis	axis	NOUN
dpc-3688	271	6	in	in	ADP
dpc-3688	271	7	the	the	DET
dpc-3688	271	8	immunopathogenesis	immunopathogenesis	NOUN
dpc-3688	271	9	of	of	ADP
dpc-3688	271	10	psoriasis	psoriasis	NOUN
dpc-3688	271	11	.	.	PUNCT
dpc-3688	272	1	j	j	PROPN
dpc-3688	272	2	invest	invest	VERB
dpc-3688	272	3	dermatol	dermatol	NOUN
dpc-3688	272	4	.	.	PUNCT
dpc-3688	273	1	2009;129(6):1339	2009;129(6):1339	NUM
dpc-3688	273	2	-	-	SYM
dpc-3688	273	3	1350	1350	NUM
dpc-3688	273	4	.	.	PUNCT
dpc-3688	274	1	doi	doi	NOUN
dpc-3688	274	2	:	:	PUNCT
dpc-3688	274	3	10.1038	10.1038	NUM
dpc-3688	274	4	/	/	SYM
dpc-3688	274	5	jid.2009.59	jid.2009.59	PROPN
dpc-3688	274	6	.	.	PUNCT
dpc-3688	275	1	pmid	pmid	NOUN
dpc-3688	275	2	:	:	PUNCT
dpc-3688	275	3	19322214	19322214	NUM
dpc-3688	275	4	.	.	PUNCT
dpc-3688	276	1	20	20	NUM
dpc-3688	276	2	.	.	PUNCT
dpc-3688	277	1	martin	martin	PROPN
dpc-3688	277	2	da	da	PROPN
dpc-3688	277	3	,	,	PUNCT
dpc-3688	277	4	towne	towne	PROPN
dpc-3688	277	5	je	je	PROPN
dpc-3688	277	6	,	,	PUNCT
dpc-3688	277	7	kricorian	kricorian	PROPN
dpc-3688	277	8	g	g	PROPN
dpc-3688	277	9	,	,	PUNCT
dpc-3688	277	10	et	et	PROPN
dpc-3688	277	11	al	al	PROPN
dpc-3688	277	12	.	.	PUNCT
dpc-3688	278	1	the	the	DET
dpc-3688	278	2	emerging	emerge	VERB
dpc-3688	278	3	role	role	NOUN
dpc-3688	278	4	of	of	ADP
dpc-3688	278	5	il-17	il-17	NUM
dpc-3688	278	6	in	in	ADP
dpc-3688	278	7	the	the	DET
dpc-3688	278	8	pathogenesis	pathogenesis	NOUN
dpc-3688	278	9	of	of	ADP
dpc-3688	278	10	psoriasis	psoriasis	NOUN
dpc-3688	278	11	:	:	PUNCT
dpc-3688	278	12	preclinical	preclinical	ADJ
dpc-3688	278	13	and	and	CCONJ
dpc-3688	278	14	clinical	clinical	ADJ
dpc-3688	278	15	findings	finding	NOUN
dpc-3688	278	16	.	.	PUNCT
dpc-3688	279	1	j	j	PROPN
dpc-3688	279	2	invest	invest	VERB
dpc-3688	279	3	dermatol	dermatol	NOUN
dpc-3688	279	4	.	.	PUNCT
dpc-3688	280	1	2013;133(1):17	2013;133(1):17	VERB
dpc-3688	280	2	-	-	PUNCT
dpc-3688	280	3	26	26	NUM
dpc-3688	280	4	.	.	PUNCT
dpc-3688	281	1	doi	doi	NOUN
dpc-3688	281	2	:	:	PUNCT
dpc-3688	281	3	10.1038	10.1038	NUM
dpc-3688	281	4	/jid.2012.194	/jid.2012.194	X
dpc-3688	281	5	.	.	PUNCT
dpc-3688	282	1	pmid	pmid	NOUN
dpc-3688	282	2	:	:	PUNCT
dpc-3688	282	3	22673731	22673731	NUM
dpc-3688	282	4	;	;	PUNCT
dpc-3688	282	5	pmcid	pmcid	NOUN
dpc-3688	282	6	:	:	PUNCT
dpc-3688	282	7	pmc3568997	pmc3568997	NOUN
dpc-3688	282	8	.	.	PUNCT
dpc-3688	283	1	21	21	NUM
dpc-3688	283	2	.	.	PUNCT
dpc-3688	284	1	johansen	johansen	PROPN
dpc-3688	284	2	c	c	PROPN
dpc-3688	284	3	,	,	PUNCT
dpc-3688	284	4	usher	usher	PROPN
dpc-3688	284	5	pa	pa	PROPN
dpc-3688	284	6	,	,	PUNCT
dpc-3688	284	7	kjellerup	kjellerup	PROPN
dpc-3688	284	8	rb	rb	PROPN
dpc-3688	284	9	,	,	PUNCT
dpc-3688	284	10	lundsgaard	lundsgaard	ADJ
dpc-3688	284	11	d	d	NOUN
dpc-3688	284	12	,	,	PUNCT
dpc-3688	284	13	iversen	iversen	PROPN
dpc-3688	284	14	l	l	PROPN
dpc-3688	284	15	,	,	PUNCT
dpc-3688	284	16	kragballe	kragballe	PROPN
dpc-3688	284	17	k.	k.	PROPN
dpc-3688	284	18	characterization	characterization	NOUN
dpc-3688	284	19	of	of	ADP
dpc-3688	284	20	the	the	DET
dpc-3688	284	21	interleukin-17	interleukin-17	PROPN
dpc-3688	284	22	isoforms	isoform	NOUN
dpc-3688	284	23	and	and	CCONJ
dpc-3688	284	24	receptors	receptor	NOUN
dpc-3688	284	25	in	in	ADP
dpc-3688	284	26	lesional	lesional	ADJ
dpc-3688	284	27	psoriatic	psoriatic	ADJ
dpc-3688	284	28	skin	skin	NOUN
dpc-3688	284	29	.	.	PUNCT
dpc-3688	285	1	br	br	PROPN
dpc-3688	285	2	j	j	PROPN
dpc-3688	285	3	dermatol	dermatol	NOUN
dpc-3688	285	4	.	.	PUNCT
dpc-3688	286	1	2009	2009	NUM
dpc-3688	286	2	;	;	PUNCT
dpc-3688	286	3	160(2):319	160(2):319	NUM
dpc-3688	286	4	-	-	PUNCT
dpc-3688	286	5	324	324	NUM
dpc-3688	286	6	.	.	PUNCT
dpc-3688	287	1	doi	doi	NOUN
dpc-3688	287	2	:	:	PUNCT
dpc-3688	287	3	10.1111	10.1111	NUM
dpc-3688	287	4	/	/	SYM
dpc-3688	287	5	j.1365	j.1365	NOUN
dpc-3688	287	6	-	-	PUNCT
dpc-3688	287	7	2133.2008.08902.x	2133.2008.08902.x	NUM
dpc-3688	287	8	.	.	PUNCT
dpc-3688	288	1	pmid	pmid	NOUN
dpc-3688	288	2	:	:	PUNCT
dpc-3688	288	3	19016708	19016708	NUM
dpc-3688	288	4	.	.	PUNCT
dpc-3688	289	1	22	22	NUM
dpc-3688	289	2	.	.	PUNCT
dpc-3688	289	3	moseley	moseley	PROPN
dpc-3688	289	4	ta	ta	PROPN
dpc-3688	289	5	,	,	PUNCT
dpc-3688	289	6	haudenschild	haudenschild	PROPN
dpc-3688	289	7	dr	dr	PROPN
dpc-3688	289	8	,	,	PUNCT
dpc-3688	289	9	rose	rise	VERB
dpc-3688	289	10	l	l	NOUN
dpc-3688	289	11	,	,	PUNCT
dpc-3688	289	12	reddi	reddi	NOUN
dpc-3688	289	13	ah	ah	INTJ
dpc-3688	289	14	.	.	PUNCT
dpc-3688	290	1	interleukin	interleukin	NOUN
dpc-3688	290	2	17	17	NUM
dpc-3688	290	3	family	family	NOUN
dpc-3688	290	4	and	and	CCONJ
dpc-3688	290	5	il-17	il-17	NUM
dpc-3688	290	6	receptors	receptor	NOUN
dpc-3688	290	7	.	.	PUNCT
dpc-3688	291	1	cytokine	cytokine	ADJ
dpc-3688	291	2	growth	growth	NOUN
dpc-3688	291	3	factor	factor	NOUN
dpc-3688	291	4	rev	rev	VERB
dpc-3688	291	5	.	.	PROPN
dpc-3688	291	6	2003;14(2):155	2003;14(2):155	PROPN
dpc-3688	291	7	-	-	SYM
dpc-3688	291	8	174	174	NUM
dpc-3688	291	9	.	.	PUNCT
dpc-3688	292	1	doi	doi	NOUN
dpc-3688	292	2	:	:	PUNCT
dpc-3688	292	3	10.1016	10.1016	NUM
dpc-3688	292	4	/	/	SYM
dpc-3688	292	5	s1359	s1359	CCONJ
dpc-3688	292	6	-	-	PUNCT
dpc-3688	292	7	6101(03)00002	6101(03)00002	NUM
dpc-3688	292	8	-	-	PUNCT
dpc-3688	292	9	9	9	NUM
dpc-3688	292	10	.	.	PUNCT
dpc-3688	293	1	pmid	pmid	NOUN
dpc-3688	293	2	:	:	PUNCT
dpc-3688	293	3	12651226	12651226	NUM
dpc-3688	293	4	.	.	PUNCT
dpc-3688	294	1	23	23	NUM
dpc-3688	294	2	.	.	PUNCT
dpc-3688	295	1	chiricozzi	chiricozzi	PROPN
dpc-3688	295	2	a	a	PRON
dpc-3688	295	3	,	,	PUNCT
dpc-3688	295	4	suárez	suárez	NOUN
dpc-3688	295	5	-	-	PUNCT
dpc-3688	295	6	fariñas	fariñas	NOUN
dpc-3688	295	7	m	m	PROPN
dpc-3688	295	8	,	,	PUNCT
dpc-3688	295	9	fuentes	fuentes	PROPN
dpc-3688	295	10	-	-	PUNCT
dpc-3688	295	11	duculan	duculan	PROPN
dpc-3688	295	12	j	j	PROPN
dpc-3688	295	13	,	,	PUNCT
dpc-3688	295	14	et	et	PROPN
dpc-3688	295	15	al	al	PROPN
dpc-3688	295	16	.	.	PROPN
dpc-3688	295	17	increased	increase	VERB
dpc-3688	295	18	expression	expression	NOUN
dpc-3688	295	19	of	of	ADP
dpc-3688	295	20	interleukin-17	interleukin-17	PROPN
dpc-3688	295	21	pathway	pathway	NOUN
dpc-3688	295	22	genes	gene	NOUN
dpc-3688	295	23	in	in	ADP
dpc-3688	295	24	nonlesional	nonlesional	ADJ
dpc-3688	295	25	skin	skin	NOUN
dpc-3688	295	26	of	of	ADP
dpc-3688	295	27	moderate	moderate	ADJ
dpc-3688	295	28	-	-	PUNCT
dpc-3688	295	29	to	to	ADP
dpc-3688	295	30	-	-	PUNCT
dpc-3688	295	31	severe	severe	ADJ
dpc-3688	295	32	psoriasis	psoriasis	NOUN
dpc-3688	295	33	vulgaris	vulgaris	NOUN
dpc-3688	295	34	.	.	PUNCT
dpc-3688	296	1	br	br	PROPN
dpc-3688	296	2	j	j	PROPN
dpc-3688	296	3	dermatol	dermatol	NOUN
dpc-3688	296	4	.	.	PUNCT
dpc-3688	297	1	2016;174(1):136	2016;174(1):136	NUM
dpc-3688	297	2	-	-	SYM
dpc-3688	297	3	145	145	NUM
dpc-3688	297	4	.	.	PUNCT
dpc-3688	298	1	doi	doi	NOUN
dpc-3688	298	2	:	:	PUNCT
dpc-3688	298	3	10.1111	10.1111	NUM
dpc-3688	298	4	/	/	SYM
dpc-3688	298	5	bjd.14034	bjd.14034	NOUN
dpc-3688	298	6	.	.	PUNCT
dpc-3688	299	1	pmid	pmid	NOUN
dpc-3688	299	2	:	:	PUNCT
dpc-3688	299	3	26189551	26189551	NUM
dpc-3688	299	4	.	.	PUNCT
dpc-3688	300	1	pmcid	pmcid	NOUN
dpc-3688	300	2	:	:	PUNCT
dpc-3688	300	3	pmc4720589	pmc4720589	ADJ
dpc-3688	300	4	.	.	PUNCT
dpc-3688	301	1	24	24	NUM
dpc-3688	301	2	.	.	PUNCT
dpc-3688	302	1	krueger	krueger	PROPN
dpc-3688	302	2	jg	jg	PROPN
dpc-3688	302	3	,	,	PUNCT
dpc-3688	302	4	fretzin	fretzin	PROPN
dpc-3688	302	5	s	s	PROPN
dpc-3688	302	6	,	,	PUNCT
dpc-3688	302	7	suárez	suárez	NOUN
dpc-3688	302	8	-	-	PUNCT
dpc-3688	302	9	fariñas	fariñas	NOUN
dpc-3688	302	10	m	m	PROPN
dpc-3688	302	11	,	,	PUNCT
dpc-3688	302	12	et	et	PROPN
dpc-3688	302	13	al	al	PROPN
dpc-3688	302	14	.	.	PROPN
dpc-3688	303	1	il-17a	il-17a	PROPN
dpc-3688	303	2	is	be	AUX
dpc-3688	303	3	essential	essential	ADJ
dpc-3688	303	4	for	for	ADP
dpc-3688	303	5	cell	cell	NOUN
dpc-3688	303	6	activation	activation	NOUN
dpc-3688	303	7	and	and	CCONJ
dpc-3688	303	8	inflammatory	inflammatory	ADJ
dpc-3688	303	9	gene	gene	NOUN
dpc-3688	303	10	circuits	circuit	NOUN
dpc-3688	303	11	in	in	ADP
dpc-3688	303	12	subjects	subject	NOUN
dpc-3688	303	13	with	with	ADP
dpc-3688	303	14	psoriasis	psoriasis	NOUN
dpc-3688	303	15	.	.	PUNCT
dpc-3688	304	1	j	j	PROPN
dpc-3688	304	2	allergy	allergy	PROPN
dpc-3688	304	3	clin	clin	PROPN
dpc-3688	304	4	immunol	immunol	PROPN
dpc-3688	304	5	.	.	PUNCT
dpc-3688	305	1	2012;130(1):145	2012;130(1):145	NUM
dpc-3688	305	2	-	-	SYM
dpc-3688	305	3	154.e9	154.e9	NUM
dpc-3688	305	4	.	.	PUNCT
dpc-3688	306	1	doi	doi	NOUN
dpc-3688	306	2	:	:	PUNCT
dpc-3688	306	3	10.1016	10.1016	NUM
dpc-3688	306	4	/	/	SYM
dpc-3688	306	5	j.jaci.2012.04.024	j.jaci.2012.04.024	NUM
dpc-3688	306	6	.	.	PUNCT
dpc-3688	307	1	pmid	pmid	NOUN
dpc-3688	307	2	:	:	PUNCT
dpc-3688	307	3	22677045	22677045	NUM
dpc-3688	307	4	.	.	PUNCT
dpc-3688	308	1	pmcid	pmcid	ADJ
dpc-3688	308	2	:	:	PUNCT
dpc-3688	308	3	pmc3470466	pmc3470466	NOUN
dpc-3688	308	4	.	.	PUNCT
dpc-3688	309	1	25	25	NUM
dpc-3688	309	2	.	.	PUNCT
dpc-3688	309	3	su	su	PROPN
dpc-3688	309	4	y	y	PROPN
dpc-3688	309	5	,	,	PUNCT
dpc-3688	309	6	huang	huang	PROPN
dpc-3688	309	7	j	j	PROPN
dpc-3688	309	8	,	,	PUNCT
dpc-3688	309	9	zhao	zhao	PROPN
dpc-3688	309	10	x	x	PROPN
dpc-3688	309	11	,	,	PUNCT
dpc-3688	309	12	et	et	PROPN
dpc-3688	309	13	al	al	PROPN
dpc-3688	309	14	.	.	PUNCT
dpc-3688	310	1	interleukin-17	interleukin-17	DET
dpc-3688	310	2	receptor	receptor	NOUN
dpc-3688	310	3	d	d	NOUN
dpc-3688	310	4	constitutes	constitute	VERB
dpc-3688	310	5	an	an	DET
dpc-3688	310	6	alternative	alternative	ADJ
dpc-3688	310	7	receptor	receptor	NOUN
dpc-3688	310	8	for	for	ADP
dpc-3688	310	9	interleukin-17a	interleukin-17a	PROPN
dpc-3688	310	10	important	important	ADJ
dpc-3688	310	11	in	in	ADP
dpc-3688	310	12	psoriasis	psoriasis	NOUN
dpc-3688	310	13	necessary	necessary	ADJ
dpc-3688	310	14	to	to	PART
dpc-3688	310	15	support	support	VERB
dpc-3688	310	16	the	the	DET
dpc-3688	310	17	beneficial	beneficial	ADJ
dpc-3688	310	18	effects	effect	NOUN
dpc-3688	310	19	of	of	ADP
dpc-3688	310	20	brodalumab	brodalumab	NOUN
dpc-3688	310	21	in	in	ADP
dpc-3688	310	22	these	these	DET
dpc-3688	310	23	peculiar	peculiar	ADJ
dpc-3688	310	24	forms	form	NOUN
dpc-3688	310	25	of	of	ADP
dpc-3688	310	26	psoriasis	psoriasis	NOUN
dpc-3688	310	27	.	.	PUNCT
dpc-3688	311	1	references	reference	NOUN
dpc-3688	311	2	1	1	NUM
dpc-3688	311	3	.	.	PUNCT
dpc-3688	311	4	griffiths	griffiths	PROPN
dpc-3688	311	5	cem	cem	PROPN
dpc-3688	311	6	,	,	PUNCT
dpc-3688	311	7	armstrong	armstrong	PROPN
dpc-3688	311	8	aw	aw	INTJ
dpc-3688	311	9	,	,	PUNCT
dpc-3688	311	10	gudjonsson	gudjonsson	PROPN
dpc-3688	311	11	je	je	PROPN
dpc-3688	311	12	,	,	PUNCT
dpc-3688	311	13	barker	barker	PROPN
dpc-3688	311	14	jnwn	jnwn	PROPN
dpc-3688	311	15	.	.	PUNCT
dpc-3688	312	1	psoriasis	psoriasis	NOUN
dpc-3688	312	2	.	.	PUNCT
dpc-3688	313	1	lancet	lancet	PROPN
dpc-3688	313	2	.	.	PUNCT
dpc-3688	314	1	2021;397(10281):1301	2021;397(10281):1301	NUM
dpc-3688	314	2	-	-	SYM
dpc-3688	314	3	1315	1315	NUM
dpc-3688	314	4	.	.	PUNCT
dpc-3688	315	1	doi	doi	NOUN
dpc-3688	315	2	:	:	PUNCT
dpc-3688	315	3	10.1016	10.1016	NUM
dpc-3688	315	4	/s0140	/s0140	PROPN
dpc-3688	315	5	-	-	PUNCT
dpc-3688	315	6	6736(20)32549	6736(20)32549	NUM
dpc-3688	315	7	-	-	PUNCT
dpc-3688	315	8	6	6	NUM
dpc-3688	315	9	.	.	PUNCT
dpc-3688	316	1	pmid	pmid	NOUN
dpc-3688	316	2	:	:	PUNCT
dpc-3688	316	3	33812489	33812489	NUM
dpc-3688	316	4	.	.	PUNCT
dpc-3688	317	1	2	2	X
dpc-3688	317	2	.	.	PUNCT
dpc-3688	317	3	parisi	parisi	PROPN
dpc-3688	317	4	r	r	PROPN
dpc-3688	317	5	,	,	PUNCT
dpc-3688	317	6	symmons	symmon	NOUN
dpc-3688	317	7	dp	dp	PROPN
dpc-3688	317	8	,	,	PUNCT
dpc-3688	317	9	griffiths	griffiths	PROPN
dpc-3688	317	10	ce	ce	PROPN
dpc-3688	317	11	,	,	PUNCT
dpc-3688	317	12	ashcroft	ashcroft	PROPN
dpc-3688	317	13	dm	dm	PROPN
dpc-3688	317	14	;	;	PUNCT
dpc-3688	317	15	identification	identification	NOUN
dpc-3688	317	16	and	and	CCONJ
dpc-3688	317	17	management	management	NOUN
dpc-3688	317	18	of	of	ADP
dpc-3688	317	19	psoriasis	psoriasis	NOUN
dpc-3688	317	20	and	and	CCONJ
dpc-3688	317	21	associated	associate	VERB
dpc-3688	317	22	comorbidity	comorbidity	NOUN
dpc-3688	317	23	(	(	PUNCT
dpc-3688	317	24	impact	impact	NOUN
dpc-3688	317	25	)	)	PUNCT
dpc-3688	317	26	project	project	NOUN
dpc-3688	317	27	team	team	NOUN
dpc-3688	317	28	.	.	PUNCT
dpc-3688	318	1	global	global	ADJ
dpc-3688	318	2	epidemiology	epidemiology	NOUN
dpc-3688	318	3	of	of	ADP
dpc-3688	318	4	psoriasis	psoriasis	NOUN
dpc-3688	318	5	:	:	PUNCT
dpc-3688	318	6	a	a	DET
dpc-3688	318	7	systematic	systematic	ADJ
dpc-3688	318	8	review	review	NOUN
dpc-3688	318	9	of	of	ADP
dpc-3688	318	10	incidence	incidence	NOUN
dpc-3688	318	11	and	and	CCONJ
dpc-3688	318	12	prevalence	prevalence	NOUN
dpc-3688	318	13	.	.	PUNCT
dpc-3688	319	1	j	j	PROPN
dpc-3688	319	2	invest	invest	VERB
dpc-3688	319	3	dermatol	dermatol	NOUN
dpc-3688	319	4	.	.	PUNCT
dpc-3688	320	1	2013;133(2):377	2013;133(2):377	NUM
dpc-3688	320	2	-	-	SYM
dpc-3688	320	3	385	385	NUM
dpc-3688	320	4	.	.	PUNCT
dpc-3688	321	1	doi	doi	NOUN
dpc-3688	321	2	:	:	PUNCT
dpc-3688	321	3	10.1038	10.1038	NUM
dpc-3688	321	4	/	/	SYM
dpc-3688	321	5	jid.2012.339	jid.2012.339	PROPN
dpc-3688	321	6	.	.	PUNCT
dpc-3688	322	1	pmid	pmid	NOUN
dpc-3688	322	2	:	:	PUNCT
dpc-3688	322	3	23014338	23014338	NUM
dpc-3688	322	4	.	.	PUNCT
dpc-3688	323	1	3	3	X
dpc-3688	323	2	.	.	X
dpc-3688	323	3	lewis	lewis	PROPN
dpc-3688	323	4	-	-	PUNCT
dpc-3688	323	5	beck	beck	PROPN
dpc-3688	323	6	c	c	PROPN
dpc-3688	323	7	,	,	PUNCT
dpc-3688	323	8	abouzaid	abouzaid	VERB
dpc-3688	323	9	s	s	PROPN
dpc-3688	323	10	,	,	PUNCT
dpc-3688	323	11	xie	xie	PROPN
dpc-3688	323	12	l	l	PROPN
dpc-3688	323	13	,	,	PUNCT
dpc-3688	323	14	baser	baser	ADJ
dpc-3688	323	15	o	o	NOUN
dpc-3688	323	16	,	,	PUNCT
dpc-3688	323	17	kim	kim	PROPN
dpc-3688	323	18	e.	e.	PROPN
dpc-3688	323	19	analysis	analysis	NOUN
dpc-3688	323	20	of	of	ADP
dpc-3688	323	21	the	the	DET
dpc-3688	323	22	relationship	relationship	NOUN
dpc-3688	323	23	between	between	ADP
dpc-3688	323	24	psoriasis	psoriasis	NOUN
dpc-3688	323	25	symptom	symptom	NOUN
dpc-3688	323	26	severity	severity	NOUN
dpc-3688	323	27	and	and	CCONJ
dpc-3688	323	28	quality	quality	NOUN
dpc-3688	323	29	of	of	ADP
dpc-3688	323	30	life	life	NOUN
dpc-3688	323	31	,	,	PUNCT
dpc-3688	323	32	work	work	NOUN
dpc-3688	323	33	productivity	productivity	NOUN
dpc-3688	323	34	,	,	PUNCT
dpc-3688	323	35	and	and	CCONJ
dpc-3688	323	36	activity	activity	NOUN
dpc-3688	323	37	impairment	impairment	NOUN
dpc-3688	323	38	among	among	ADP
dpc-3688	323	39	patients	patient	NOUN
dpc-3688	323	40	with	with	ADP
dpc-3688	323	41	moderate	moderate	ADJ
dpc-3688	323	42	-	-	PUNCT
dpc-3688	323	43	to	to	ADP
dpc-3688	323	44	-	-	PUNCT
dpc-3688	323	45	severe	severe	ADJ
dpc-3688	323	46	psoriasis	psoriasis	NOUN
dpc-3688	323	47	using	use	VERB
dpc-3688	323	48	structural	structural	ADJ
dpc-3688	323	49	equation	equation	NOUN
dpc-3688	323	50	modeling	modeling	NOUN
dpc-3688	323	51	.	.	PUNCT
dpc-3688	324	1	patient	patient	ADJ
dpc-3688	324	2	prefer	prefer	NOUN
dpc-3688	324	3	adherence	adherence	NOUN
dpc-3688	324	4	.	.	PUNCT
dpc-3688	325	1	2013;7:199	2013;7:199	NUM
dpc-3688	325	2	-	-	SYM
dpc-3688	325	3	205	205	NUM
dpc-3688	325	4	.	.	PUNCT
dpc-3688	326	1	doi	doi	NOUN
dpc-3688	326	2	:	:	PUNCT
dpc-3688	326	3	10.2147	10.2147	NUM
dpc-3688	326	4	/ppa.s39887	/ppa.s39887	NUM
dpc-3688	326	5	.	.	PUNCT
dpc-3688	327	1	pmid	pmid	NOUN
dpc-3688	327	2	:	:	PUNCT
dpc-3688	327	3	23508007	23508007	NUM
dpc-3688	327	4	.	.	PUNCT
dpc-3688	328	1	pmcid	pmcid	NOUN
dpc-3688	328	2	:	:	PUNCT
dpc-3688	328	3	pmc3597339	pmc3597339	NOUN
dpc-3688	328	4	.	.	PUNCT
dpc-3688	329	1	4	4	X
dpc-3688	329	2	.	.	X
dpc-3688	329	3	armstrong	armstrong	PROPN
dpc-3688	329	4	aw	aw	PROPN
dpc-3688	329	5	,	,	PUNCT
dpc-3688	329	6	read	read	VERB
dpc-3688	329	7	c.	c.	PROPN
dpc-3688	329	8	pathophysiology	pathophysiology	NOUN
dpc-3688	329	9	,	,	PUNCT
dpc-3688	329	10	clinical	clinical	ADJ
dpc-3688	329	11	presentation	presentation	NOUN
dpc-3688	329	12	,	,	PUNCT
dpc-3688	329	13	and	and	CCONJ
dpc-3688	329	14	treatment	treatment	NOUN
dpc-3688	329	15	of	of	ADP
dpc-3688	329	16	psoriasis	psoriasis	NOUN
dpc-3688	329	17	:	:	PUNCT
dpc-3688	329	18	a	a	DET
dpc-3688	329	19	review	review	NOUN
dpc-3688	329	20	.	.	PUNCT
dpc-3688	330	1	jama	jama	PROPN
dpc-3688	330	2	.	.	PUNCT
dpc-3688	331	1	2020;323(19):19451960	2020;323(19):19451960	X
dpc-3688	331	2	.	.	PUNCT
dpc-3688	332	1	doi	doi	NOUN
dpc-3688	332	2	:	:	PUNCT
dpc-3688	332	3	10.1001	10.1001	NUM
dpc-3688	332	4	/	/	SYM
dpc-3688	332	5	jama.2020.4006	jama.2020.4006	PROPN
dpc-3688	332	6	.	.	PUNCT
dpc-3688	333	1	pmid	pmid	NOUN
dpc-3688	333	2	:	:	PUNCT
dpc-3688	333	3	32427307	32427307	NUM
dpc-3688	333	4	.	.	PUNCT
dpc-3688	334	1	5	5	X
dpc-3688	334	2	.	.	NOUN
dpc-3688	334	3	wozel	wozel	PROPN
dpc-3688	334	4	g.	g.	PROPN
dpc-3688	334	5	psoriasis	psoriasis	NOUN
dpc-3688	334	6	treatment	treatment	NOUN
dpc-3688	334	7	in	in	ADP
dpc-3688	334	8	difficult	difficult	ADJ
dpc-3688	334	9	locations	location	NOUN
dpc-3688	334	10	:	:	PUNCT
dpc-3688	334	11	scalp	scalp	NOUN
dpc-3688	334	12	,	,	PUNCT
dpc-3688	334	13	nails	nail	NOUN
dpc-3688	334	14	,	,	PUNCT
dpc-3688	334	15	and	and	CCONJ
dpc-3688	334	16	intertriginous	intertriginous	ADJ
dpc-3688	334	17	areas	area	NOUN
dpc-3688	334	18	.	.	PUNCT
dpc-3688	335	1	clin	clin	PROPN
dpc-3688	335	2	dermatol	dermatol	NOUN
dpc-3688	335	3	.	.	PUNCT
dpc-3688	336	1	2008;26(5):448	2008;26(5):448	X
dpc-3688	336	2	-	-	SYM
dpc-3688	336	3	459	459	NUM
dpc-3688	336	4	.	.	PUNCT
dpc-3688	337	1	doi	doi	NOUN
dpc-3688	337	2	:	:	PUNCT
dpc-3688	337	3	10.1016	10.1016	NUM
dpc-3688	337	4	/	/	SYM
dpc-3688	337	5	j.clindermatol.2007.10.026	j.clindermatol.2007.10.026	PROPN
dpc-3688	337	6	.	.	PUNCT
dpc-3688	338	1	pmid	pmid	NOUN
dpc-3688	338	2	:	:	PUNCT
dpc-3688	338	3	18755363	18755363	NUM
dpc-3688	338	4	.	.	PUNCT
dpc-3688	339	1	6	6	NUM
dpc-3688	339	2	.	.	PUNCT
dpc-3688	339	3	handa	handa	PROPN
dpc-3688	339	4	s.	s.	PROPN
dpc-3688	339	5	newer	new	ADJ
dpc-3688	339	6	trends	trend	NOUN
dpc-3688	339	7	in	in	ADP
dpc-3688	339	8	the	the	DET
dpc-3688	339	9	management	management	NOUN
dpc-3688	339	10	of	of	ADP
dpc-3688	339	11	psoriasis	psoriasis	NOUN
dpc-3688	339	12	at	at	ADP
dpc-3688	339	13	difficult	difficult	ADJ
dpc-3688	339	14	to	to	PART
dpc-3688	339	15	treat	treat	VERB
dpc-3688	339	16	locations	location	NOUN
dpc-3688	339	17	:	:	PUNCT
dpc-3688	339	18	scalp	scalp	NOUN
dpc-3688	339	19	,	,	PUNCT
dpc-3688	339	20	palmoplantar	palmoplantar	NOUN
dpc-3688	339	21	disease	disease	NOUN
dpc-3688	339	22	and	and	CCONJ
dpc-3688	339	23	nails	nail	NOUN
dpc-3688	339	24	.	.	PUNCT
dpc-3688	340	1	indian	indian	PROPN
dpc-3688	340	2	j	j	PROPN
dpc-3688	340	3	dermatol	dermatol	PROPN
dpc-3688	340	4	venereol	venereol	ADJ
dpc-3688	340	5	leprol	leprol	NOUN
dpc-3688	340	6	.	.	PUNCT
dpc-3688	341	1	2010;76(6):634	2010;76(6):634	PROPN
dpc-3688	341	2	-	-	PUNCT
dpc-3688	341	3	644	644	NUM
dpc-3688	341	4	.	.	PUNCT
dpc-3688	342	1	doi	doi	NOUN
dpc-3688	342	2	:	:	PUNCT
dpc-3688	342	3	10.4103/0378	10.4103/0378	NUM
dpc-3688	342	4	-	-	PUNCT
dpc-3688	342	5	6323.72455	6323.72455	NOUN
dpc-3688	342	6	.	.	PUNCT
dpc-3688	343	1	pmid	pmid	NOUN
dpc-3688	343	2	:	:	PUNCT
dpc-3688	343	3	21079306	21079306	NUM
dpc-3688	343	4	.	.	PUNCT
dpc-3688	344	1	7	7	X
dpc-3688	344	2	.	.	X
dpc-3688	344	3	chan	chan	PROPN
dpc-3688	344	4	cs	cs	PROPN
dpc-3688	344	5	,	,	PUNCT
dpc-3688	344	6	van	van	PROPN
dpc-3688	344	7	voorhees	voorhees	PROPN
dpc-3688	344	8	as	as	ADP
dpc-3688	344	9	,	,	PUNCT
dpc-3688	344	10	lebwohl	lebwohl	VERB
dpc-3688	344	11	mg	mg	PROPN
dpc-3688	344	12	,	,	PUNCT
dpc-3688	344	13	et	et	PROPN
dpc-3688	344	14	al	al	PROPN
dpc-3688	344	15	.	.	PROPN
dpc-3688	344	16	treatment	treatment	NOUN
dpc-3688	344	17	of	of	ADP
dpc-3688	344	18	severe	severe	ADJ
dpc-3688	344	19	scalp	scalp	NOUN
dpc-3688	344	20	psoriasis	psoriasis	NOUN
dpc-3688	344	21	:	:	PUNCT
dpc-3688	344	22	from	from	ADP
dpc-3688	344	23	the	the	DET
dpc-3688	344	24	medical	medical	ADJ
dpc-3688	344	25	board	board	NOUN
dpc-3688	344	26	of	of	ADP
dpc-3688	344	27	the	the	DET
dpc-3688	344	28	national	national	ADJ
dpc-3688	344	29	psoriasis	psoriasis	NOUN
dpc-3688	344	30	foundation	foundation	NOUN
dpc-3688	344	31	.	.	PUNCT
dpc-3688	345	1	j	j	PROPN
dpc-3688	345	2	am	be	AUX
dpc-3688	345	3	acad	acad	ADJ
dpc-3688	345	4	dermatol	dermatol	NOUN
dpc-3688	345	5	.	.	PUNCT
dpc-3688	346	1	2009;60(6	2009;60(6	NUM
dpc-3688	346	2	):	):	PUNCT
dpc-3688	346	3	962	962	NUM
dpc-3688	346	4	-	-	SYM
dpc-3688	346	5	971	971	NUM
dpc-3688	346	6	.	.	PUNCT
dpc-3688	347	1	doi	doi	NOUN
dpc-3688	347	2	:	:	PUNCT
dpc-3688	347	3	10.1016	10.1016	NUM
dpc-3688	347	4	/	/	SYM
dpc-3688	347	5	j.jaad.2008.11.890	j.jaad.2008.11.890	PROPN
dpc-3688	347	6	.	.	PUNCT
dpc-3688	348	1	pmid	pmid	NOUN
dpc-3688	348	2	:	:	PUNCT
dpc-3688	348	3	19375191	19375191	NUM
dpc-3688	348	4	.	.	PUNCT
dpc-3688	349	1	8	8	X
dpc-3688	349	2	.	.	PUNCT
dpc-3688	350	1	van	van	PROPN
dpc-3688	350	2	de	de	X
dpc-3688	350	3	kerkhof	kerkhof	PROPN
dpc-3688	350	4	pc	pc	NOUN
dpc-3688	350	5	,	,	PUNCT
dpc-3688	350	6	franssen	franssen	VERB
dpc-3688	350	7	me	i	PRON
dpc-3688	350	8	.	.	PUNCT
dpc-3688	351	1	psoriasis	psoriasis	NOUN
dpc-3688	351	2	of	of	ADP
dpc-3688	351	3	the	the	DET
dpc-3688	351	4	scalp	scalp	NOUN
dpc-3688	351	5	.	.	PUNCT
dpc-3688	352	1	diagnosis	diagnosis	NOUN
dpc-3688	352	2	and	and	CCONJ
dpc-3688	352	3	management	management	NOUN
dpc-3688	352	4	.	.	PUNCT
dpc-3688	353	1	am	be	AUX
dpc-3688	353	2	j	j	PROPN
dpc-3688	353	3	clin	clin	PROPN
dpc-3688	353	4	dermatol	dermatol	NOUN
dpc-3688	353	5	.	.	PUNCT
dpc-3688	354	1	2001;2(3):159	2001;2(3):159	NUM
dpc-3688	354	2	-	-	SYM
dpc-3688	354	3	165	165	NUM
dpc-3688	354	4	.	.	PUNCT
dpc-3688	354	5	doi	doi	NOUN
dpc-3688	354	6	:	:	PUNCT
dpc-3688	354	7	10.2165/00128071	10.2165/00128071	NUM
dpc-3688	354	8	-	-	SYM
dpc-3688	354	9	200102030	200102030	NUM
dpc-3688	354	10	-	-	SYM
dpc-3688	354	11	00005	00005	NUM
dpc-3688	354	12	.	.	PUNCT
dpc-3688	355	1	pmid	pmid	NOUN
dpc-3688	355	2	:	:	PUNCT
dpc-3688	355	3	11705093	11705093	NUM
dpc-3688	355	4	.	.	PUNCT
dpc-3688	356	1	9	9	X
dpc-3688	356	2	.	.	X
dpc-3688	356	3	zampieron	zampieron	PROPN
dpc-3688	356	4	a	a	PRON
dpc-3688	356	5	,	,	PUNCT
dpc-3688	356	6	buja	buja	NOUN
dpc-3688	356	7	a	a	X
dpc-3688	356	8	,	,	PUNCT
dpc-3688	356	9	fusco	fusco	PROPN
dpc-3688	356	10	m	m	PROPN
dpc-3688	356	11	,	,	PUNCT
dpc-3688	356	12	et	et	PROPN
dpc-3688	356	13	al	al	PROPN
dpc-3688	356	14	.	.	PUNCT
dpc-3688	356	15	quality	quality	NOUN
dpc-3688	356	16	of	of	ADP
dpc-3688	356	17	life	life	NOUN
dpc-3688	356	18	in	in	ADP
dpc-3688	356	19	patients	patient	NOUN
dpc-3688	356	20	with	with	ADP
dpc-3688	356	21	scalp	scalp	NOUN
dpc-3688	356	22	psoriasis	psoriasis	NOUN
dpc-3688	356	23	.	.	PUNCT
dpc-3688	357	1	g	g	ADP
dpc-3688	357	2	ital	ital	ADJ
dpc-3688	357	3	dermatol	dermatol	NOUN
dpc-3688	357	4	venereol	venereol	NOUN
dpc-3688	357	5	.	.	PUNCT
dpc-3688	358	1	2015;150(3	2015;150(3	NOUN
dpc-3688	358	2	):	):	PUNCT
dpc-3688	358	3	309	309	NUM
dpc-3688	358	4	-	-	SYM
dpc-3688	358	5	316	316	NUM
dpc-3688	358	6	.	.	PUNCT
dpc-3688	359	1	pmid	pmid	NOUN
dpc-3688	359	2	:	:	PUNCT
dpc-3688	359	3	25236315	25236315	NUM
dpc-3688	359	4	.	.	PUNCT
dpc-3688	360	1	10	10	NUM
dpc-3688	360	2	.	.	X
dpc-3688	360	3	nicolescu	nicolescu	PROPN
dpc-3688	360	4	ac	ac	PROPN
dpc-3688	360	5	,	,	PUNCT
dpc-3688	360	6	ionescu	ionescu	PROPN
dpc-3688	360	7	ma	ma	PROPN
dpc-3688	360	8	,	,	PUNCT
dpc-3688	360	9	constantin	constantin	PROPN
dpc-3688	360	10	mm	mm	PROPN
dpc-3688	360	11	,	,	PUNCT
dpc-3688	360	12	et	et	PROPN
dpc-3688	360	13	al	al	PROPN
dpc-3688	360	14	.	.	PUNCT
dpc-3688	360	15	psoriasis	psoriasis	NOUN
dpc-3688	360	16	management	management	NOUN
dpc-3688	360	17	challenges	challenge	NOUN
dpc-3688	360	18	regarding	regard	VERB
dpc-3688	360	19	difficult	difficult	ADJ
dpc-3688	360	20	-	-	PUNCT
dpc-3688	360	21	to	to	ADP
dpc-3688	360	22	-	-	PUNCT
dpc-3688	360	23	treat	treat	NOUN
dpc-3688	360	24	areas	area	NOUN
dpc-3688	360	25	:	:	PUNCT
dpc-3688	360	26	therapeutic	therapeutic	ADJ
dpc-3688	360	27	decision	decision	NOUN
dpc-3688	360	28	and	and	CCONJ
dpc-3688	360	29	effectiveness	effectiveness	NOUN
dpc-3688	360	30	.	.	PUNCT
dpc-3688	361	1	life	life	NOUN
dpc-3688	361	2	(	(	PUNCT
dpc-3688	361	3	basel	basel	PROPN
dpc-3688	361	4	)	)	PUNCT
dpc-3688	361	5	.	.	PUNCT
dpc-3688	362	1	2022;12(12):2050	2022;12(12):2050	X
dpc-3688	362	2	.	.	X
dpc-3688	362	3	doi	doi	NOUN
dpc-3688	362	4	:	:	PUNCT
dpc-3688	362	5	10.3390	10.3390	NUM
dpc-3688	362	6	/	/	SYM
dpc-3688	362	7	life12122050	life12122050	PROPN
dpc-3688	362	8	.	.	PUNCT
dpc-3688	363	1	pmid	pmid	NOUN
dpc-3688	363	2	:	:	PUNCT
dpc-3688	363	3	36556415	36556415	NUM
dpc-3688	363	4	.	.	PUNCT
dpc-3688	364	1	pmcid	pmcid	NOUN
dpc-3688	364	2	:	:	PUNCT
dpc-3688	364	3	pmc9785802	pmc9785802	ADJ
dpc-3688	364	4	.	.	PUNCT
dpc-3688	365	1	11	11	NUM
dpc-3688	365	2	.	.	PUNCT
dpc-3688	365	3	bardazzi	bardazzi	PROPN
dpc-3688	365	4	f	f	PROPN
dpc-3688	365	5	,	,	PUNCT
dpc-3688	365	6	starace	starace	PROPN
dpc-3688	365	7	m	m	PROPN
dpc-3688	365	8	,	,	PUNCT
dpc-3688	365	9	bruni	bruni	PROPN
dpc-3688	365	10	f	f	PROPN
dpc-3688	365	11	,	,	PUNCT
dpc-3688	365	12	magnano	magnano	PROPN
dpc-3688	365	13	m	m	PROPN
dpc-3688	365	14	,	,	PUNCT
dpc-3688	365	15	piraccini	piraccini	PROPN
dpc-3688	365	16	bm	bm	PROPN
dpc-3688	365	17	,	,	PUNCT
dpc-3688	365	18	alessandrini	alessandrini	PROPN
dpc-3688	365	19	a.	a.	NOUN
dpc-3688	365	20	nail	nail	NOUN
dpc-3688	365	21	psoriasis	psoriasis	NOUN
dpc-3688	365	22	:	:	PUNCT
dpc-3688	365	23	an	an	DET
dpc-3688	365	24	updated	update	VERB
dpc-3688	365	25	review	review	NOUN
dpc-3688	365	26	and	and	CCONJ
dpc-3688	365	27	expert	expert	ADJ
dpc-3688	365	28	opinion	opinion	NOUN
dpc-3688	365	29	on	on	ADP
dpc-3688	365	30	available	available	ADJ
dpc-3688	365	31	treatments	treatment	NOUN
dpc-3688	365	32	,	,	PUNCT
dpc-3688	365	33	including	include	VERB
dpc-3688	365	34	biologics	biologic	NOUN
dpc-3688	365	35	.	.	PUNCT
dpc-3688	366	1	acta	acta	PROPN
dpc-3688	366	2	derm	derm	PROPN
dpc-3688	366	3	venereol	venereol	NOUN
dpc-3688	366	4	.	.	PUNCT
dpc-3688	367	1	2019;99(6):516	2019;99(6):516	NUM
dpc-3688	367	2	-	-	PUNCT
dpc-3688	367	3	523	523	NUM
dpc-3688	367	4	.	.	PUNCT
dpc-3688	368	1	doi	doi	NOUN
dpc-3688	368	2	:	:	PUNCT
dpc-3688	368	3	10.2340/00015555	10.2340/00015555	NUM
dpc-3688	368	4	-	-	SYM
dpc-3688	368	5	3098	3098	NUM
dpc-3688	368	6	.	.	PUNCT
dpc-3688	369	1	pmid	pmid	NOUN
dpc-3688	369	2	:	:	PUNCT
dpc-3688	369	3	30521057	30521057	NUM
dpc-3688	369	4	.	.	PUNCT
dpc-3688	370	1	12	12	NUM
dpc-3688	370	2	.	.	PUNCT
dpc-3688	371	1	stewart	stewart	PROPN
dpc-3688	371	2	cr	cr	PROPN
dpc-3688	371	3	,	,	PUNCT
dpc-3688	371	4	algu	algu	PROPN
dpc-3688	371	5	l	l	PROPN
dpc-3688	371	6	,	,	PUNCT
dpc-3688	371	7	kamran	kamran	PROPN
dpc-3688	371	8	r	r	PROPN
dpc-3688	371	9	,	,	PUNCT
dpc-3688	371	10	et	et	PROPN
dpc-3688	371	11	al	al	PROPN
dpc-3688	371	12	.	.	PUNCT
dpc-3688	372	1	the	the	DET
dpc-3688	372	2	impact	impact	NOUN
dpc-3688	372	3	of	of	ADP
dpc-3688	372	4	nail	nail	NOUN
dpc-3688	372	5	psoriasis	psoriasis	NOUN
dpc-3688	372	6	and	and	CCONJ
dpc-3688	372	7	treatment	treatment	NOUN
dpc-3688	372	8	on	on	ADP
dpc-3688	372	9	quality	quality	NOUN
dpc-3688	372	10	of	of	ADP
dpc-3688	372	11	life	life	NOUN
dpc-3688	372	12	:	:	PUNCT
dpc-3688	372	13	a	a	DET
dpc-3688	372	14	systematic	systematic	ADJ
dpc-3688	372	15	review	review	NOUN
dpc-3688	372	16	.	.	PUNCT
dpc-3688	373	1	skin	skin	NOUN
dpc-3688	373	2	appendage	appendage	NOUN
dpc-3688	373	3	disord	disord	NOUN
dpc-3688	373	4	.	.	PUNCT
dpc-3688	374	1	2021;7(2):83	2021;7(2):83	NUM
dpc-3688	374	2	-	-	SYM
dpc-3688	374	3	89	89	NUM
dpc-3688	374	4	.	.	PUNCT
dpc-3688	374	5	doi	doi	NOUN
dpc-3688	374	6	:	:	PUNCT
dpc-3688	374	7	10.1159/000512688	10.1159/000512688	NUM
dpc-3688	374	8	.	.	PUNCT
dpc-3688	375	1	pmid	pmid	NOUN
dpc-3688	375	2	:	:	PUNCT
dpc-3688	375	3	33796553	33796553	NUM
dpc-3688	375	4	.	.	PUNCT
dpc-3688	376	1	pmcid	pmcid	NOUN
dpc-3688	376	2	:	:	PUNCT
dpc-3688	376	3	pmc7991285	pmc7991285	NOUN
dpc-3688	376	4	.	.	PUNCT
dpc-3688	377	1	13	13	NUM
dpc-3688	377	2	.	.	PUNCT
dpc-3688	378	1	chung	chung	PROPN
dpc-3688	378	2	j	j	PROPN
dpc-3688	378	3	,	,	PUNCT
dpc-3688	378	4	callis	calli	VERB
dpc-3688	378	5	duffin	duffin	PROPN
dpc-3688	378	6	k	k	PROPN
dpc-3688	378	7	,	,	PUNCT
dpc-3688	378	8	takeshita	takeshita	PROPN
dpc-3688	378	9	j	j	PROPN
dpc-3688	378	10	,	,	PUNCT
dpc-3688	378	11	et	et	PROPN
dpc-3688	378	12	al	al	PROPN
dpc-3688	378	13	.	.	PROPN
dpc-3688	379	1	palmoplantar	palmoplantar	PROPN
dpc-3688	379	2	psoriasis	psoriasis	NOUN
dpc-3688	379	3	is	be	AUX
dpc-3688	379	4	associated	associate	VERB
dpc-3688	379	5	with	with	ADP
dpc-3688	379	6	greater	great	ADJ
dpc-3688	379	7	impairment	impairment	NOUN
dpc-3688	379	8	of	of	ADP
dpc-3688	379	9	health	health	NOUN
dpc-3688	379	10	-	-	PUNCT
dpc-3688	379	11	related	relate	VERB
dpc-3688	379	12	quality	quality	NOUN
dpc-3688	379	13	of	of	ADP
dpc-3688	379	14	life	life	NOUN
dpc-3688	379	15	compared	compare	VERB
dpc-3688	379	16	with	with	ADP
dpc-3688	379	17	moderate	moderate	ADJ
dpc-3688	379	18	to	to	ADP
dpc-3688	379	19	severe	severe	ADJ
dpc-3688	379	20	plaque	plaque	NOUN
dpc-3688	379	21	psoriasis	psoriasis	NOUN
dpc-3688	379	22	.	.	PUNCT
dpc-3688	380	1	j	j	PROPN
dpc-3688	380	2	am	be	AUX
dpc-3688	380	3	acad	acad	ADJ
dpc-3688	380	4	dermatol	dermatol	NOUN
dpc-3688	380	5	.	.	PUNCT
dpc-3688	381	1	2014;71(4):623	2014;71(4):623	NUM
dpc-3688	381	2	-	-	PUNCT
dpc-3688	381	3	632	632	NUM
dpc-3688	381	4	.	.	PUNCT
dpc-3688	382	1	doi	doi	NOUN
dpc-3688	382	2	:	:	PUNCT
dpc-3688	382	3	10.1016	10.1016	NUM
dpc-3688	382	4	/	/	SYM
dpc-3688	382	5	j	j	PROPN
dpc-3688	382	6	.jaad.2014.04.063	.jaad.2014.04.063	PUNCT
dpc-3688	382	7	.	.	PUNCT
dpc-3688	383	1	pmid	pmid	NOUN
dpc-3688	383	2	:	:	PUNCT
dpc-3688	383	3	24894455	24894455	NUM
dpc-3688	383	4	.	.	PUNCT
dpc-3688	384	1	pmcid	pmcid	NOUN
dpc-3688	384	2	:	:	PUNCT
dpc-3688	384	3	pmc4165651	pmc4165651	ADJ
dpc-3688	384	4	.	.	PUNCT
dpc-3688	385	1	review	review	VERB
dpc-3688	385	2	|	|	ADV
dpc-3688	385	3	dermatol	dermatol	ADJ
dpc-3688	385	4	pract	pract	NOUN
dpc-3688	385	5	concept	concept	NOUN
dpc-3688	385	6	.	.	PUNCT
dpc-3688	386	1	2023;13(3):e2023245	2023;13(3):e2023245	NUM
dpc-3688	386	2	9	9	NUM
dpc-3688	386	3	39	39	NUM
dpc-3688	386	4	.	.	PUNCT
dpc-3688	387	1	menter	menter	PROPN
dpc-3688	387	2	a	a	PRON
dpc-3688	387	3	,	,	PUNCT
dpc-3688	387	4	bhutani	bhutani	NOUN
dpc-3688	387	5	t	t	PROPN
dpc-3688	387	6	,	,	PUNCT
dpc-3688	387	7	ehst	ehst	NOUN
dpc-3688	387	8	b	b	NOUN
dpc-3688	387	9	,	,	PUNCT
dpc-3688	387	10	elewski	elewski	NOUN
dpc-3688	387	11	b	b	PROPN
dpc-3688	387	12	,	,	PUNCT
dpc-3688	387	13	jacobson	jacobson	PROPN
dpc-3688	387	14	a.	a.	PROPN
dpc-3688	387	15	narrative	narrative	PROPN
dpc-3688	387	16	review	review	NOUN
dpc-3688	387	17	of	of	ADP
dpc-3688	387	18	the	the	DET
dpc-3688	387	19	emerging	emerge	VERB
dpc-3688	387	20	therapeutic	therapeutic	ADJ
dpc-3688	387	21	role	role	NOUN
dpc-3688	387	22	of	of	ADP
dpc-3688	387	23	brodalumab	brodalumab	NOUN
dpc-3688	387	24	in	in	ADP
dpc-3688	387	25	difficult	difficult	ADJ
dpc-3688	387	26	-	-	PUNCT
dpc-3688	387	27	to	to	ADP
dpc-3688	387	28	-	-	PUNCT
dpc-3688	387	29	treat	treat	VERB
dpc-3688	387	30	psoriasis	psoriasis	NOUN
dpc-3688	387	31	.	.	PUNCT
dpc-3688	388	1	dermatol	dermatol	NOUN
dpc-3688	388	2	ther	ther	ADV
dpc-3688	388	3	(	(	PUNCT
dpc-3688	388	4	heidelb	heidelb	NOUN
dpc-3688	388	5	)	)	PUNCT
dpc-3688	388	6	.	.	PUNCT
dpc-3688	389	1	2022;12(6):1289	2022;12(6):1289	NUM
dpc-3688	389	2	-	-	SYM
dpc-3688	389	3	1302	1302	NUM
dpc-3688	389	4	.	.	PUNCT
dpc-3688	390	1	doi	doi	NOUN
dpc-3688	390	2	:	:	PUNCT
dpc-3688	390	3	10.1007	10.1007	NUM
dpc-3688	390	4	/	/	SYM
dpc-3688	390	5	s13555	s13555	PROPN
dpc-3688	390	6	-	-	PUNCT
dpc-3688	390	7	022	022	NUM
dpc-3688	390	8	-	-	PUNCT
dpc-3688	390	9	00746	00746	NUM
dpc-3688	390	10	-	-	SYM
dpc-3688	390	11	6	6	NUM
dpc-3688	390	12	.	.	PUNCT
dpc-3688	391	1	pmid	pmid	NOUN
dpc-3688	391	2	:	:	PUNCT
dpc-3688	391	3	35672564	35672564	NUM
dpc-3688	391	4	.	.	PUNCT
dpc-3688	392	1	pmcid	pmcid	ADJ
dpc-3688	392	2	:	:	PUNCT
dpc-3688	392	3	pmc9209590	pmc9209590	NOUN
dpc-3688	392	4	.	.	PUNCT
dpc-3688	393	1	40	40	NUM
dpc-3688	393	2	.	.	PUNCT
dpc-3688	394	1	rich	rich	ADJ
dpc-3688	394	2	p	p	NOUN
dpc-3688	394	3	,	,	PUNCT
dpc-3688	394	4	gooderham	gooderham	PROPN
dpc-3688	394	5	m	m	PROPN
dpc-3688	394	6	,	,	PUNCT
dpc-3688	394	7	bachelez	bachelez	PROPN
dpc-3688	394	8	h	h	NOUN
dpc-3688	394	9	,	,	PUNCT
dpc-3688	394	10	et	et	PROPN
dpc-3688	394	11	al	al	PROPN
dpc-3688	394	12	.	.	PROPN
dpc-3688	395	1	apremilast	apremilast	PROPN
dpc-3688	395	2	,	,	PUNCT
dpc-3688	395	3	an	an	DET
dpc-3688	395	4	oral	oral	ADJ
dpc-3688	395	5	phosphodiesterase	phosphodiesterase	NOUN
dpc-3688	395	6	4	4	NUM
dpc-3688	395	7	inhibitor	inhibitor	NOUN
dpc-3688	395	8	,	,	PUNCT
dpc-3688	395	9	in	in	ADP
dpc-3688	395	10	patients	patient	NOUN
dpc-3688	395	11	with	with	ADP
dpc-3688	395	12	difficult	difficult	ADJ
dpc-3688	395	13	-	-	PUNCT
dpc-3688	395	14	to	to	AUX
dpc-3688	395	15	-	-	PUNCT
dpc-3688	395	16	treat	treat	VERB
dpc-3688	395	17	nail	nail	NOUN
dpc-3688	395	18	and	and	CCONJ
dpc-3688	395	19	scalp	scalp	NOUN
dpc-3688	395	20	psoriasis	psoriasis	NOUN
dpc-3688	395	21	:	:	PUNCT
dpc-3688	395	22	results	result	NOUN
dpc-3688	395	23	of	of	ADP
dpc-3688	395	24	2	2	NUM
dpc-3688	395	25	phase	phase	NOUN
dpc-3688	395	26	iii	iii	NOUN
dpc-3688	395	27	randomized	randomize	VERB
dpc-3688	395	28	,	,	PUNCT
dpc-3688	395	29	controlled	control	VERB
dpc-3688	395	30	trials	trial	NOUN
dpc-3688	395	31	(	(	PUNCT
dpc-3688	395	32	esteem	esteem	NOUN
dpc-3688	395	33	1	1	NUM
dpc-3688	395	34	and	and	CCONJ
dpc-3688	395	35	esteem	esteem	VERB
dpc-3688	395	36	2	2	NUM
dpc-3688	395	37	)	)	PUNCT
dpc-3688	395	38	.	.	PUNCT
dpc-3688	396	1	j	j	PROPN
dpc-3688	396	2	am	be	AUX
dpc-3688	396	3	acad	acad	ADJ
dpc-3688	396	4	dermatol	dermatol	NOUN
dpc-3688	396	5	.	.	PUNCT
dpc-3688	397	1	2016;74(1):134	2016;74(1):134	NUM
dpc-3688	397	2	-	-	SYM
dpc-3688	397	3	142	142	NUM
dpc-3688	397	4	.	.	PUNCT
dpc-3688	398	1	doi	doi	NOUN
dpc-3688	398	2	:	:	PUNCT
dpc-3688	398	3	10.1016	10.1016	NUM
dpc-3688	398	4	/	/	SYM
dpc-3688	398	5	j.jaad.2015.09.001	j.jaad.2015.09.001	PROPN
dpc-3688	398	6	.	.	PUNCT
dpc-3688	399	1	pmid	pmid	NOUN
dpc-3688	399	2	:	:	PUNCT
dpc-3688	399	3	26549249	26549249	NUM
dpc-3688	399	4	.	.	PUNCT
dpc-3688	400	1	41	41	NUM
dpc-3688	400	2	.	.	NOUN
dpc-3688	401	1	ten	ten	NUM
dpc-3688	401	2	bergen	bergen	PROPN
dpc-3688	401	3	ll	ll	NOUN
dpc-3688	401	4	,	,	PUNCT
dpc-3688	401	5	petrovic	petrovic	PROPN
dpc-3688	401	6	a	a	PROPN
dpc-3688	401	7	,	,	PUNCT
dpc-3688	401	8	krogh	krogh	PROPN
dpc-3688	401	9	aarebrot	aarebrot	VERB
dpc-3688	401	10	a	a	PRON
dpc-3688	401	11	,	,	PUNCT
dpc-3688	401	12	appel	appel	PROPN
dpc-3688	401	13	s.	s.	PROPN
dpc-3688	401	14	the	the	DET
dpc-3688	401	15	tnf/	tnf/	NOUN
dpc-3688	401	16	il-23	il-23	NOUN
dpc-3688	401	17	/	/	SYM
dpc-3688	401	18	il-17	il-17	ADV
dpc-3688	401	19	axis	axis	ADJ
dpc-3688	401	20	-	-	PUNCT
dpc-3688	401	21	head	head	NOUN
dpc-3688	401	22	-	-	PUNCT
dpc-3688	401	23	to	to	ADP
dpc-3688	401	24	-	-	PUNCT
dpc-3688	401	25	head	head	NOUN
dpc-3688	401	26	trials	trial	NOUN
dpc-3688	401	27	comparing	compare	VERB
dpc-3688	401	28	different	different	ADJ
dpc-3688	401	29	biologics	biologic	NOUN
dpc-3688	401	30	in	in	ADP
dpc-3688	401	31	psoriasis	psoriasis	NOUN
dpc-3688	401	32	treatment	treatment	NOUN
dpc-3688	401	33	.	.	PUNCT
dpc-3688	402	1	scand	scand	PROPN
dpc-3688	402	2	j	j	PROPN
dpc-3688	402	3	immunol	immunol	NOUN
dpc-3688	402	4	.	.	PUNCT
dpc-3688	403	1	2020;92(4):e12946	2020;92(4):e12946	NUM
dpc-3688	403	2	.	.	PUNCT
dpc-3688	403	3	doi	doi	NOUN
dpc-3688	403	4	:	:	PUNCT
dpc-3688	403	5	10.1111	10.1111	NUM
dpc-3688	403	6	/	/	SYM
dpc-3688	403	7	sji.12946	sji.12946	NOUN
dpc-3688	403	8	.	.	PUNCT
dpc-3688	404	1	pmid	pmid	NOUN
dpc-3688	404	2	:	:	PUNCT
dpc-3688	404	3	32697374	32697374	NUM
dpc-3688	404	4	.	.	PUNCT
dpc-3688	405	1	42	42	NUM
dpc-3688	405	2	.	.	PUNCT
dpc-3688	406	1	tomalin	tomalin	PROPN
dpc-3688	406	2	le	le	PROPN
dpc-3688	406	3	,	,	PUNCT
dpc-3688	406	4	russell	russell	PROPN
dpc-3688	406	5	cb	cb	PROPN
dpc-3688	406	6	,	,	PUNCT
dpc-3688	406	7	garcet	garcet	NOUN
dpc-3688	406	8	s	s	PROPN
dpc-3688	406	9	,	,	PUNCT
dpc-3688	406	10	et	et	PROPN
dpc-3688	406	11	al	al	PROPN
dpc-3688	406	12	.	.	PUNCT
dpc-3688	406	13	short	short	ADJ
dpc-3688	406	14	-	-	PUNCT
dpc-3688	406	15	term	term	NOUN
dpc-3688	406	16	transcriptional	transcriptional	ADJ
dpc-3688	406	17	response	response	NOUN
dpc-3688	406	18	to	to	ADP
dpc-3688	406	19	il-17	il-17	ADV
dpc-3688	406	20	receptor	receptor	VERB
dpc-3688	406	21	-	-	PUNCT
dpc-3688	406	22	a	a	DET
dpc-3688	406	23	antagonism	antagonism	NOUN
dpc-3688	406	24	in	in	ADP
dpc-3688	406	25	the	the	DET
dpc-3688	406	26	treatment	treatment	NOUN
dpc-3688	406	27	of	of	ADP
dpc-3688	406	28	psoriasis	psoriasis	NOUN
dpc-3688	406	29	.	.	PUNCT
dpc-3688	407	1	j	j	PROPN
dpc-3688	407	2	allergy	allergy	PROPN
dpc-3688	407	3	clin	clin	PROPN
dpc-3688	407	4	immunol	immunol	NOUN
dpc-3688	407	5	.	.	PUNCT
dpc-3688	408	1	2020;145(3):922	2020;145(3):922	NUM
dpc-3688	408	2	-	-	SYM
dpc-3688	408	3	932	932	NUM
dpc-3688	408	4	.	.	PUNCT
dpc-3688	408	5	doi	doi	NOUN
dpc-3688	408	6	:	:	PUNCT
dpc-3688	408	7	10.1016	10.1016	NUM
dpc-3688	408	8	/	/	SYM
dpc-3688	408	9	j.jaci.2019.10.041	j.jaci.2019.10.041	PROPN
dpc-3688	408	10	.	.	PUNCT
dpc-3688	409	1	pmid	pmid	NOUN
dpc-3688	409	2	:	:	PUNCT
dpc-3688	409	3	31883845	31883845	NUM
dpc-3688	409	4	.	.	PUNCT
dpc-3688	410	1	43	43	NUM
dpc-3688	410	2	.	.	PUNCT
dpc-3688	411	1	langley	langley	PROPN
dpc-3688	411	2	rg	rg	PROPN
dpc-3688	411	3	,	,	PUNCT
dpc-3688	411	4	elewski	elewski	PROPN
dpc-3688	411	5	be	be	AUX
dpc-3688	411	6	,	,	PUNCT
dpc-3688	411	7	lebwohl	lebwohl	PROPN
dpc-3688	411	8	m	m	PROPN
dpc-3688	411	9	,	,	PUNCT
dpc-3688	411	10	et	et	PROPN
dpc-3688	411	11	al	al	PROPN
dpc-3688	411	12	.	.	PROPN
dpc-3688	411	13	secukinumab	secukinumab	PROPN
dpc-3688	411	14	in	in	ADP
dpc-3688	411	15	plaque	plaque	NOUN
dpc-3688	411	16	psoriasis	psoriasis	NOUN
dpc-3688	411	17	--	--	PUNCT
dpc-3688	411	18	results	result	NOUN
dpc-3688	411	19	of	of	ADP
dpc-3688	411	20	two	two	NUM
dpc-3688	411	21	phase	phase	NOUN
dpc-3688	411	22	3	3	NUM
dpc-3688	411	23	trials	trial	NOUN
dpc-3688	411	24	.	.	PUNCT
dpc-3688	412	1	n	n	PROPN
dpc-3688	412	2	engl	engl	PROPN
dpc-3688	412	3	j	j	PROPN
dpc-3688	412	4	med	med	PROPN
dpc-3688	412	5	.	.	PUNCT
dpc-3688	413	1	2014;371(4):326	2014;371(4):326	NUM
dpc-3688	413	2	-	-	SYM
dpc-3688	413	3	338	338	NUM
dpc-3688	413	4	.	.	PUNCT
dpc-3688	414	1	doi	doi	NOUN
dpc-3688	414	2	:	:	PUNCT
dpc-3688	414	3	10.1056	10.1056	NUM
dpc-3688	414	4	/	/	SYM
dpc-3688	414	5	nejmoa1314258	nejmoa1314258	PROPN
dpc-3688	414	6	.	.	PUNCT
dpc-3688	415	1	pmid	pmid	NOUN
dpc-3688	415	2	:	:	PUNCT
dpc-3688	415	3	25007392	25007392	NUM
dpc-3688	415	4	.	.	PUNCT
dpc-3688	416	1	44	44	NUM
dpc-3688	416	2	.	.	PUNCT
dpc-3688	416	3	griffiths	griffiths	PROPN
dpc-3688	416	4	ce	ce	PROPN
dpc-3688	416	5	,	,	PUNCT
dpc-3688	416	6	reich	reich	PROPN
dpc-3688	416	7	k	k	PROPN
dpc-3688	416	8	,	,	PUNCT
dpc-3688	416	9	lebwohl	lebwohl	PROPN
dpc-3688	416	10	m	m	PROPN
dpc-3688	416	11	,	,	PUNCT
dpc-3688	416	12	et	et	PROPN
dpc-3688	416	13	al	al	PROPN
dpc-3688	416	14	.	.	PROPN
dpc-3688	416	15	comparison	comparison	NOUN
dpc-3688	416	16	of	of	ADP
dpc-3688	416	17	ixekizumab	ixekizumab	NOUN
dpc-3688	416	18	with	with	ADP
dpc-3688	416	19	etanercept	etanercept	NOUN
dpc-3688	416	20	or	or	CCONJ
dpc-3688	416	21	placebo	placebo	NOUN
dpc-3688	416	22	in	in	ADP
dpc-3688	416	23	moderate	moderate	ADJ
dpc-3688	416	24	-	-	PUNCT
dpc-3688	416	25	to	to	ADP
dpc-3688	416	26	-	-	PUNCT
dpc-3688	416	27	severe	severe	ADJ
dpc-3688	416	28	psoriasis	psoriasis	NOUN
dpc-3688	416	29	(	(	PUNCT
dpc-3688	416	30	uncover-2	uncover-2	NUM
dpc-3688	416	31	and	and	CCONJ
dpc-3688	416	32	uncover-3	uncover-3	NUM
dpc-3688	416	33	):	):	PUNCT
dpc-3688	416	34	results	result	NOUN
dpc-3688	416	35	from	from	ADP
dpc-3688	416	36	two	two	NUM
dpc-3688	416	37	phase	phase	NOUN
dpc-3688	416	38	3	3	NUM
dpc-3688	416	39	randomised	randomise	VERB
dpc-3688	416	40	trials	trial	NOUN
dpc-3688	416	41	.	.	PUNCT
dpc-3688	417	1	lancet	lancet	VERB
dpc-3688	417	2	.	.	PUNCT
dpc-3688	418	1	2015;386(9993):541	2015;386(9993):541	NUM
dpc-3688	418	2	-	-	SYM
dpc-3688	418	3	551	551	NUM
dpc-3688	418	4	.	.	PUNCT
dpc-3688	419	1	doi	doi	NOUN
dpc-3688	419	2	:	:	PUNCT
dpc-3688	419	3	10.1016	10.1016	NUM
dpc-3688	419	4	/	/	SYM
dpc-3688	419	5	s0140	s0140	PROPN
dpc-3688	419	6	-	-	PUNCT
dpc-3688	419	7	6736(15)60125	6736(15)60125	NUM
dpc-3688	419	8	-	-	PUNCT
dpc-3688	419	9	8	8	NUM
dpc-3688	419	10	.	.	PUNCT
dpc-3688	420	1	pmid	pmid	NOUN
dpc-3688	420	2	:	:	PUNCT
dpc-3688	420	3	26072109	26072109	NUM
dpc-3688	420	4	.	.	PUNCT
dpc-3688	421	1	45	45	NUM
dpc-3688	421	2	.	.	PUNCT
dpc-3688	422	1	gordon	gordon	PROPN
dpc-3688	422	2	kb	kb	PROPN
dpc-3688	422	3	,	,	PUNCT
dpc-3688	422	4	foley	foley	PROPN
dpc-3688	422	5	p	p	PROPN
dpc-3688	422	6	,	,	PUNCT
dpc-3688	422	7	krueger	krueger	PROPN
dpc-3688	422	8	jg	jg	PROPN
dpc-3688	422	9	,	,	PUNCT
dpc-3688	422	10	et	et	PROPN
dpc-3688	422	11	al	al	PROPN
dpc-3688	422	12	.	.	PROPN
dpc-3688	422	13	bimekizumab	bimekizumab	PROPN
dpc-3688	422	14	efficacy	efficacy	PROPN
dpc-3688	422	15	and	and	CCONJ
dpc-3688	422	16	safety	safety	NOUN
dpc-3688	422	17	in	in	ADP
dpc-3688	422	18	moderate	moderate	ADJ
dpc-3688	422	19	to	to	ADP
dpc-3688	422	20	severe	severe	ADJ
dpc-3688	422	21	plaque	plaque	NOUN
dpc-3688	422	22	psoriasis	psoriasis	NOUN
dpc-3688	422	23	(	(	PUNCT
dpc-3688	422	24	be	be	AUX
dpc-3688	422	25	ready	ready	ADJ
dpc-3688	422	26	):	):	PUNCT
dpc-3688	422	27	a	a	DET
dpc-3688	422	28	multicentre	multicentre	NOUN
dpc-3688	422	29	,	,	PUNCT
dpc-3688	422	30	double	double	ADJ
dpc-3688	422	31	-	-	PUNCT
dpc-3688	422	32	blind	blind	ADJ
dpc-3688	422	33	,	,	PUNCT
dpc-3688	422	34	placebo	placebo	NOUN
dpc-3688	422	35	-	-	PUNCT
dpc-3688	422	36	controlled	control	VERB
dpc-3688	422	37	,	,	PUNCT
dpc-3688	422	38	randomised	randomise	VERB
dpc-3688	422	39	withdrawal	withdrawal	NOUN
dpc-3688	422	40	phase	phase	NOUN
dpc-3688	422	41	3	3	NUM
dpc-3688	422	42	trial	trial	NOUN
dpc-3688	422	43	.	.	PUNCT
dpc-3688	423	1	lancet	lancet	NOUN
dpc-3688	423	2	.	.	PUNCT
dpc-3688	424	1	2021;397(10273):475	2021;397(10273):475	NUM
dpc-3688	424	2	-	-	SYM
dpc-3688	424	3	486	486	NUM
dpc-3688	424	4	.	.	PUNCT
dpc-3688	425	1	doi	doi	NOUN
dpc-3688	425	2	:	:	PUNCT
dpc-3688	425	3	10.1016	10.1016	NUM
dpc-3688	425	4	/	/	SYM
dpc-3688	425	5	s0140	s0140	PROPN
dpc-3688	425	6	-	-	PUNCT
dpc-3688	425	7	6736(21)00126	6736(21)00126	NUM
dpc-3688	425	8	-	-	PUNCT
dpc-3688	425	9	4	4	NUM
dpc-3688	425	10	.	.	PUNCT
dpc-3688	426	1	lancet	lancet	NOUN
dpc-3688	426	2	.	.	PUNCT
dpc-3688	427	1	2021;397(10280	2021;397(10280	NUM
dpc-3688	427	2	):	):	PUNCT
dpc-3688	427	3	1182	1182	NUM
dpc-3688	427	4	.	.	PUNCT
dpc-3688	428	1	pmid	pmid	NOUN
dpc-3688	428	2	:	:	PUNCT
dpc-3688	428	3	33549192	33549192	NUM
dpc-3688	428	4	.	.	PUNCT
dpc-3688	429	1	46	46	NUM
dpc-3688	429	2	.	.	PUNCT
dpc-3688	430	1	reich	reich	PROPN
dpc-3688	430	2	k	k	PROPN
dpc-3688	430	3	,	,	PUNCT
dpc-3688	430	4	papp	papp	PROPN
dpc-3688	430	5	ka	ka	PROPN
dpc-3688	430	6	,	,	PUNCT
dpc-3688	430	7	blauvelt	blauvelt	VERB
dpc-3688	430	8	a	a	PRON
dpc-3688	430	9	,	,	PUNCT
dpc-3688	430	10	et	et	PROPN
dpc-3688	430	11	al	al	PROPN
dpc-3688	430	12	.	.	PROPN
dpc-3688	430	13	bimekizumab	bimekizumab	PROPN
dpc-3688	430	14	versus	versus	ADP
dpc-3688	430	15	ustekinumab	ustekinumab	NOUN
dpc-3688	430	16	for	for	ADP
dpc-3688	430	17	the	the	DET
dpc-3688	430	18	treatment	treatment	NOUN
dpc-3688	430	19	of	of	ADP
dpc-3688	430	20	moderate	moderate	ADJ
dpc-3688	430	21	to	to	ADP
dpc-3688	430	22	severe	severe	ADJ
dpc-3688	430	23	plaque	plaque	NOUN
dpc-3688	430	24	psoriasis	psoriasis	NOUN
dpc-3688	430	25	(	(	PUNCT
dpc-3688	430	26	be	be	AUX
dpc-3688	430	27	vivid	vivid	ADJ
dpc-3688	430	28	):	):	PUNCT
dpc-3688	430	29	efficacy	efficacy	NOUN
dpc-3688	430	30	and	and	CCONJ
dpc-3688	430	31	safety	safety	NOUN
dpc-3688	430	32	from	from	ADP
dpc-3688	430	33	a	a	DET
dpc-3688	430	34	52	52	NUM
dpc-3688	430	35	-	-	PUNCT
dpc-3688	430	36	week	week	NOUN
dpc-3688	430	37	,	,	PUNCT
dpc-3688	430	38	multicentre	multicentre	NOUN
dpc-3688	430	39	,	,	PUNCT
dpc-3688	430	40	double	double	ADJ
dpc-3688	430	41	-	-	PUNCT
dpc-3688	430	42	blind	blind	ADJ
dpc-3688	430	43	,	,	PUNCT
dpc-3688	430	44	active	active	ADJ
dpc-3688	430	45	comparator	comparator	NOUN
dpc-3688	430	46	and	and	CCONJ
dpc-3688	430	47	placebo	placebo	NOUN
dpc-3688	430	48	controlled	control	VERB
dpc-3688	430	49	phase	phase	NOUN
dpc-3688	430	50	3	3	NUM
dpc-3688	430	51	trial	trial	NOUN
dpc-3688	430	52	.	.	PUNCT
dpc-3688	431	1	lancet	lancet	NOUN
dpc-3688	431	2	.	.	PUNCT
dpc-3688	432	1	2021;397(10273):487	2021;397(10273):487	NUM
dpc-3688	432	2	-	-	SYM
dpc-3688	432	3	498	498	NUM
dpc-3688	432	4	.	.	PUNCT
dpc-3688	433	1	doi	doi	NOUN
dpc-3688	433	2	:	:	PUNCT
dpc-3688	433	3	10.1016	10.1016	NUM
dpc-3688	433	4	/	/	SYM
dpc-3688	433	5	s0140	s0140	PROPN
dpc-3688	433	6	-6736(21)00125	-6736(21)00125	NOUN
dpc-3688	433	7	-	-	PUNCT
dpc-3688	433	8	2	2	NUM
dpc-3688	433	9	.	.	PUNCT
dpc-3688	434	1	pmid	pmid	NOUN
dpc-3688	434	2	:	:	PUNCT
dpc-3688	434	3	33549193	33549193	NUM
dpc-3688	434	4	.	.	PUNCT
dpc-3688	435	1	47	47	NUM
dpc-3688	435	2	.	.	PUNCT
dpc-3688	436	1	lebwohl	lebwohl	PROPN
dpc-3688	436	2	m	m	PROPN
dpc-3688	436	3	,	,	PUNCT
dpc-3688	436	4	strober	strober	ADV
dpc-3688	436	5	b	b	NUM
dpc-3688	436	6	,	,	PUNCT
dpc-3688	436	7	menter	menter	X
dpc-3688	436	8	a	a	NOUN
dpc-3688	436	9	,	,	PUNCT
dpc-3688	436	10	et	et	PROPN
dpc-3688	436	11	al	al	PROPN
dpc-3688	436	12	.	.	PROPN
dpc-3688	436	13	phase	phase	NOUN
dpc-3688	436	14	3	3	NUM
dpc-3688	436	15	studies	study	NOUN
dpc-3688	436	16	comparing	compare	VERB
dpc-3688	436	17	brodalumab	brodalumab	NOUN
dpc-3688	436	18	with	with	ADP
dpc-3688	436	19	ustekinumab	ustekinumab	NOUN
dpc-3688	436	20	in	in	ADP
dpc-3688	436	21	psoriasis	psoriasis	NOUN
dpc-3688	436	22	.	.	PUNCT
dpc-3688	437	1	n	n	CCONJ
dpc-3688	437	2	engl	engl	PROPN
dpc-3688	437	3	j	j	PROPN
dpc-3688	437	4	med	med	PROPN
dpc-3688	437	5	.	.	PUNCT
dpc-3688	438	1	2015;373(14):1318	2015;373(14):1318	X
dpc-3688	438	2	-	-	SYM
dpc-3688	438	3	1328	1328	NUM
dpc-3688	438	4	.	.	PUNCT
dpc-3688	439	1	doi	doi	NOUN
dpc-3688	439	2	:	:	PUNCT
dpc-3688	439	3	10.1056	10.1056	NUM
dpc-3688	439	4	/	/	SYM
dpc-3688	439	5	nejmoa1503824	nejmoa1503824	PROPN
dpc-3688	439	6	.	.	PUNCT
dpc-3688	440	1	pmid	pmid	NOUN
dpc-3688	440	2	:	:	PUNCT
dpc-3688	440	3	26422722	26422722	NUM
dpc-3688	440	4	.	.	PUNCT
dpc-3688	441	1	48	48	NUM
dpc-3688	441	2	.	.	PUNCT
dpc-3688	441	3	papp	papp	PROPN
dpc-3688	441	4	ka	ka	PROPN
dpc-3688	441	5	,	,	PUNCT
dpc-3688	441	6	reich	reich	PROPN
dpc-3688	441	7	k	k	PROPN
dpc-3688	441	8	,	,	PUNCT
dpc-3688	441	9	paul	paul	PROPN
dpc-3688	441	10	c	c	PROPN
dpc-3688	441	11	,	,	PUNCT
dpc-3688	441	12	et	et	PROPN
dpc-3688	441	13	al	al	PROPN
dpc-3688	441	14	.	.	PUNCT
dpc-3688	442	1	a	a	DET
dpc-3688	442	2	prospective	prospective	ADJ
dpc-3688	442	3	phase	phase	NOUN
dpc-3688	442	4	iii	iii	NOUN
dpc-3688	442	5	,	,	PUNCT
dpc-3688	442	6	randomized	randomize	VERB
dpc-3688	442	7	,	,	PUNCT
dpc-3688	442	8	double	double	ADJ
dpc-3688	442	9	-	-	PUNCT
dpc-3688	442	10	blind	blind	ADJ
dpc-3688	442	11	,	,	PUNCT
dpc-3688	442	12	placebo	placebo	NOUN
dpc-3688	442	13	-	-	PUNCT
dpc-3688	442	14	controlled	control	VERB
dpc-3688	442	15	study	study	NOUN
dpc-3688	442	16	of	of	ADP
dpc-3688	442	17	brodalumab	brodalumab	NOUN
dpc-3688	442	18	in	in	ADP
dpc-3688	442	19	patients	patient	NOUN
dpc-3688	442	20	with	with	ADP
dpc-3688	442	21	moderate	moderate	ADJ
dpc-3688	442	22	-	-	PUNCT
dpc-3688	442	23	to	to	ADP
dpc-3688	442	24	-	-	PUNCT
dpc-3688	442	25	severe	severe	ADJ
dpc-3688	442	26	plaque	plaque	NOUN
dpc-3688	442	27	psoriasis	psoriasis	NOUN
dpc-3688	442	28	.	.	PUNCT
dpc-3688	443	1	br	br	PROPN
dpc-3688	443	2	j	j	PROPN
dpc-3688	443	3	dermatol	dermatol	NOUN
dpc-3688	443	4	.	.	PUNCT
dpc-3688	444	1	2016;175(2):273	2016;175(2):273	NUM
dpc-3688	444	2	-	-	SYM
dpc-3688	444	3	286	286	NUM
dpc-3688	444	4	.	.	PUNCT
dpc-3688	445	1	doi	doi	NOUN
dpc-3688	445	2	:	:	PUNCT
dpc-3688	445	3	10.1111	10.1111	NUM
dpc-3688	445	4	/	/	SYM
dpc-3688	445	5	bjd.14493	bjd.14493	NOUN
dpc-3688	445	6	.	.	PUNCT
dpc-3688	446	1	pmid	pmid	NOUN
dpc-3688	446	2	:	:	PUNCT
dpc-3688	446	3	26914406	26914406	NUM
dpc-3688	446	4	.	.	PUNCT
dpc-3688	447	1	49	49	NUM
dpc-3688	447	2	.	.	PUNCT
dpc-3688	448	1	gallais	gallais	PROPN
dpc-3688	448	2	sérézal	sérézal	PROPN
dpc-3688	448	3	i	i	PROPN
dpc-3688	448	4	,	,	PUNCT
dpc-3688	448	5	classon	classon	PROPN
dpc-3688	448	6	c	c	AUX
dpc-3688	448	7	,	,	PUNCT
dpc-3688	448	8	cheuk	cheuk	NOUN
dpc-3688	448	9	s	s	PART
dpc-3688	448	10	,	,	PUNCT
dpc-3688	448	11	et	et	PROPN
dpc-3688	448	12	al	al	PROPN
dpc-3688	448	13	.	.	PROPN
dpc-3688	448	14	resident	resident	PROPN
dpc-3688	448	15	t	t	PROPN
dpc-3688	448	16	cells	cell	NOUN
dpc-3688	448	17	in	in	ADP
dpc-3688	448	18	resolved	resolve	VERB
dpc-3688	448	19	psoriasis	psoriasis	NOUN
dpc-3688	448	20	steer	steer	NOUN
dpc-3688	448	21	tissue	tissue	NOUN
dpc-3688	448	22	responses	response	NOUN
dpc-3688	448	23	that	that	PRON
dpc-3688	448	24	stratify	stratify	VERB
dpc-3688	448	25	clinical	clinical	ADJ
dpc-3688	448	26	outcome	outcome	NOUN
dpc-3688	448	27	.	.	PUNCT
dpc-3688	449	1	j	j	PROPN
dpc-3688	449	2	invest	invest	VERB
dpc-3688	449	3	dermatol	dermatol	NOUN
dpc-3688	449	4	.	.	PUNCT
dpc-3688	450	1	2018;138(8):1754	2018;138(8):1754	NUM
dpc-3688	450	2	-	-	SYM
dpc-3688	450	3	1763	1763	NUM
dpc-3688	450	4	.	.	PUNCT
dpc-3688	451	1	doi	doi	NOUN
dpc-3688	451	2	:	:	PUNCT
dpc-3688	451	3	10.1016	10.1016	NUM
dpc-3688	451	4	/	/	SYM
dpc-3688	451	5	j.jid.2018.02.030	j.jid.2018.02.030	PROPN
dpc-3688	451	6	.	.	PUNCT
dpc-3688	452	1	pmid	pmid	NOUN
dpc-3688	452	2	:	:	PUNCT
dpc-3688	452	3	29510191	29510191	NUM
dpc-3688	452	4	.	.	PUNCT
dpc-3688	453	1	50	50	NUM
dpc-3688	453	2	.	.	PUNCT
dpc-3688	453	3	.russell	.russell	PUNCT
dpc-3688	454	1	cb	cb	PROPN
dpc-3688	454	2	,	,	PUNCT
dpc-3688	454	3	rand	rand	NOUN
dpc-3688	454	4	h	h	NOUN
dpc-3688	454	5	,	,	PUNCT
dpc-3688	454	6	bigler	bigler	PROPN
dpc-3688	454	7	j	j	PROPN
dpc-3688	454	8	,	,	PUNCT
dpc-3688	454	9	et	et	PROPN
dpc-3688	454	10	al	al	PROPN
dpc-3688	454	11	.	.	PROPN
dpc-3688	455	1	gene	gene	NOUN
dpc-3688	455	2	expression	expression	NOUN
dpc-3688	455	3	profiles	profile	NOUN
dpc-3688	455	4	normalized	normalize	VERB
dpc-3688	455	5	in	in	ADP
dpc-3688	455	6	psoriatic	psoriatic	ADJ
dpc-3688	455	7	skin	skin	NOUN
dpc-3688	455	8	by	by	ADP
dpc-3688	455	9	treatment	treatment	NOUN
dpc-3688	455	10	with	with	ADP
dpc-3688	455	11	brodalumab	brodalumab	NOUN
dpc-3688	455	12	,	,	PUNCT
dpc-3688	455	13	a	a	DET
dpc-3688	455	14	human	human	ADJ
dpc-3688	455	15	anti	anti	ADJ
dpc-3688	455	16	-	-	ADJ
dpc-3688	455	17	il-17	il-17	ADV
dpc-3688	455	18	receptor	receptor	NOUN
dpc-3688	455	19	monoclonal	monoclonal	NOUN
dpc-3688	455	20	antibody	antibody	NOUN
dpc-3688	455	21	.	.	PUNCT
dpc-3688	456	1	j	j	PROPN
dpc-3688	456	2	immunol	immunol	NOUN
dpc-3688	456	3	.	.	PUNCT
dpc-3688	457	1	2014;192(8):3828	2014;192(8):3828	NUM
dpc-3688	457	2	-	-	SYM
dpc-3688	457	3	3836	3836	NUM
dpc-3688	457	4	.	.	PUNCT
dpc-3688	458	1	doi	doi	NOUN
dpc-3688	458	2	:	:	PUNCT
dpc-3688	458	3	10.4049	10.4049	NUM
dpc-3688	458	4	/	/	SYM
dpc-3688	458	5	jimmunol.1301737	jimmunol.1301737	PROPN
dpc-3688	458	6	.	.	PUNCT
dpc-3688	458	7	pmid	pmid	NOUN
dpc-3688	458	8	:	:	PUNCT
dpc-3688	458	9	24646743	24646743	NUM
dpc-3688	458	10	.	.	PUNCT
dpc-3688	459	1	51	51	NUM
dpc-3688	459	2	.	.	PUNCT
dpc-3688	459	3	elewski	elewski	PROPN
dpc-3688	459	4	b	b	PROPN
dpc-3688	459	5	,	,	PUNCT
dpc-3688	459	6	rich	rich	ADJ
dpc-3688	459	7	p	p	NOUN
dpc-3688	459	8	,	,	PUNCT
dpc-3688	459	9	lain	lain	PROPN
dpc-3688	459	10	e	e	NOUN
dpc-3688	459	11	,	,	PUNCT
dpc-3688	459	12	soung	soung	PROPN
dpc-3688	459	13	j	j	PROPN
dpc-3688	459	14	,	,	PUNCT
dpc-3688	459	15	lewitt	lewitt	PROPN
dpc-3688	459	16	gm	gm	PROPN
dpc-3688	459	17	,	,	PUNCT
dpc-3688	459	18	jacobson	jacobson	PROPN
dpc-3688	459	19	a.	a.	PROPN
dpc-3688	459	20	efficacy	efficacy	PROPN
dpc-3688	459	21	of	of	ADP
dpc-3688	459	22	brodalumab	brodalumab	NOUN
dpc-3688	459	23	in	in	ADP
dpc-3688	459	24	the	the	DET
dpc-3688	459	25	treatment	treatment	NOUN
dpc-3688	459	26	of	of	ADP
dpc-3688	459	27	scalp	scalp	NOUN
dpc-3688	459	28	and	and	CCONJ
dpc-3688	459	29	nail	nail	NOUN
dpc-3688	459	30	like	like	ADP
dpc-3688	459	31	skin	skin	NOUN
dpc-3688	459	32	inflammation	inflammation	NOUN
dpc-3688	459	33	.	.	PUNCT
dpc-3688	460	1	sci	sci	PROPN
dpc-3688	460	2	immunol	immunol	NOUN
dpc-3688	460	3	.	.	PUNCT
dpc-3688	461	1	2019;4(36):eaau9657	2019;4(36):eaau9657	X
dpc-3688	461	2	.	.	PUNCT
dpc-3688	462	1	doi	doi	NOUN
dpc-3688	462	2	:	:	PUNCT
dpc-3688	462	3	10.1126	10.1126	NUM
dpc-3688	462	4	/	/	SYM
dpc-3688	462	5	sciimmunol.aau9657	sciimmunol.aau9657	X
dpc-3688	462	6	.	.	PUNCT
dpc-3688	463	1	pmid	pmid	NOUN
dpc-3688	463	2	:	:	PUNCT
dpc-3688	463	3	31175175	31175175	NUM
dpc-3688	463	4	.	.	PUNCT
dpc-3688	464	1	26	26	NUM
dpc-3688	464	2	.	.	PUNCT
dpc-3688	465	1	facheris	facheris	PROPN
dpc-3688	465	2	p	p	PROPN
dpc-3688	465	3	,	,	PUNCT
dpc-3688	465	4	valenti	valenti	PROPN
dpc-3688	465	5	m	m	PROPN
dpc-3688	465	6	,	,	PUNCT
dpc-3688	465	7	pavia	pavia	PROPN
dpc-3688	465	8	g	g	NOUN
dpc-3688	465	9	,	,	PUNCT
dpc-3688	465	10	et	et	PROPN
dpc-3688	465	11	al	al	PROPN
dpc-3688	465	12	.	.	PUNCT
dpc-3688	465	13	brodalumab	brodalumab	PROPN
dpc-3688	465	14	:	:	PUNCT
dpc-3688	465	15	a	a	DET
dpc-3688	465	16	new	new	ADJ
dpc-3688	465	17	way	way	NOUN
dpc-3688	465	18	to	to	PART
dpc-3688	465	19	inhibit	inhibit	VERB
dpc-3688	465	20	il-17	il-17	ADV
dpc-3688	465	21	in	in	ADP
dpc-3688	465	22	psoriasis	psoriasis	NOUN
dpc-3688	465	23	.	.	PUNCT
dpc-3688	466	1	dermatol	dermatol	NOUN
dpc-3688	466	2	ther	ther	ADV
dpc-3688	466	3	.	.	PUNCT
dpc-3688	467	1	2020;33(3):e13403	2020;33(3):e13403	X
dpc-3688	467	2	.	.	PUNCT
dpc-3688	467	3	doi	doi	NOUN
dpc-3688	467	4	:	:	PUNCT
dpc-3688	467	5	10.1111	10.1111	NUM
dpc-3688	467	6	/	/	SYM
dpc-3688	467	7	dth.13403	dth.13403	PROPN
dpc-3688	467	8	.	.	PUNCT
dpc-3688	468	1	pmid	pmid	NOUN
dpc-3688	468	2	:	:	PUNCT
dpc-3688	468	3	32285564	32285564	NUM
dpc-3688	468	4	.	.	PUNCT
dpc-3688	469	1	27	27	NUM
dpc-3688	469	2	.	.	PUNCT
dpc-3688	470	1	kirkham	kirkham	PROPN
dpc-3688	470	2	bw	bw	PROPN
dpc-3688	470	3	,	,	PUNCT
dpc-3688	470	4	kavanaugh	kavanaugh	PROPN
dpc-3688	470	5	a	a	PROPN
dpc-3688	470	6	,	,	PUNCT
dpc-3688	470	7	reich	reich	PROPN
dpc-3688	470	8	k.	k.	PROPN
dpc-3688	470	9	interleukin-17a	interleukin-17a	PROPN
dpc-3688	470	10	:	:	PUNCT
dpc-3688	470	11	a	a	DET
dpc-3688	470	12	unique	unique	ADJ
dpc-3688	470	13	pathway	pathway	NOUN
dpc-3688	470	14	in	in	ADP
dpc-3688	470	15	immune	immune	NOUN
dpc-3688	470	16	-	-	PUNCT
dpc-3688	470	17	mediated	mediate	VERB
dpc-3688	470	18	diseases	disease	NOUN
dpc-3688	470	19	:	:	PUNCT
dpc-3688	470	20	psoriasis	psoriasis	NOUN
dpc-3688	470	21	,	,	PUNCT
dpc-3688	470	22	psoriatic	psoriatic	ADJ
dpc-3688	470	23	arthritis	arthritis	NOUN
dpc-3688	470	24	and	and	CCONJ
dpc-3688	470	25	rheumatoid	rheumatoid	VERB
dpc-3688	470	26	arthritis	arthritis	NOUN
dpc-3688	470	27	.	.	PUNCT
dpc-3688	471	1	immunology	immunology	NOUN
dpc-3688	471	2	.	.	PUNCT
dpc-3688	472	1	2014;141(2):133142	2014;141(2):133142	NUM
dpc-3688	472	2	.	.	PUNCT
dpc-3688	473	1	doi	doi	NOUN
dpc-3688	473	2	:	:	PUNCT
dpc-3688	473	3	10.1111	10.1111	NUM
dpc-3688	473	4	/	/	SYM
dpc-3688	473	5	imm.12142	imm.12142	X
dpc-3688	473	6	.	.	PUNCT
dpc-3688	474	1	pmid	pmid	NOUN
dpc-3688	474	2	:	:	PUNCT
dpc-3688	474	3	23819583	23819583	NUM
dpc-3688	474	4	.	.	PUNCT
dpc-3688	475	1	pmcid	pmcid	ADJ
dpc-3688	475	2	:	:	PUNCT
dpc-3688	475	3	pmc3904234	pmc3904234	ADJ
dpc-3688	475	4	.	.	PUNCT
dpc-3688	476	1	28	28	NUM
dpc-3688	476	2	.	.	PUNCT
dpc-3688	477	1	chiricozzi	chiricozzi	PROPN
dpc-3688	477	2	a	a	NOUN
dpc-3688	477	3	,	,	PUNCT
dpc-3688	477	4	romanelli	romanelli	ADV
dpc-3688	477	5	p	p	X
dpc-3688	477	6	,	,	PUNCT
dpc-3688	477	7	volpe	volpe	PROPN
dpc-3688	477	8	e	e	PROPN
dpc-3688	477	9	,	,	PUNCT
dpc-3688	477	10	borsellino	borsellino	VERB
dpc-3688	477	11	g	g	NOUN
dpc-3688	477	12	,	,	PUNCT
dpc-3688	477	13	romanelli	romanelli	ADJ
dpc-3688	477	14	m.	m.	NOUN
dpc-3688	477	15	scanning	scan	VERB
dpc-3688	477	16	the	the	DET
dpc-3688	477	17	immunopathogenesis	immunopathogenesis	NOUN
dpc-3688	477	18	of	of	ADP
dpc-3688	477	19	psoriasis	psoriasis	NOUN
dpc-3688	477	20	.	.	PUNCT
dpc-3688	478	1	int	int	PROPN
dpc-3688	478	2	j	j	PROPN
dpc-3688	478	3	mol	mol	ADP
dpc-3688	478	4	sci	sci	PROPN
dpc-3688	478	5	.	.	PUNCT
dpc-3688	479	1	2018;19(1):179	2018;19(1):179	NOUN
dpc-3688	479	2	.	.	PUNCT
dpc-3688	480	1	doi	doi	NOUN
dpc-3688	480	2	:	:	PUNCT
dpc-3688	480	3	10.3390	10.3390	NUM
dpc-3688	480	4	/	/	SYM
dpc-3688	480	5	ijms19010179	ijms19010179	PROPN
dpc-3688	480	6	.	.	PUNCT
dpc-3688	481	1	pmid	pmid	NOUN
dpc-3688	481	2	:	:	PUNCT
dpc-3688	481	3	29316717	29316717	NUM
dpc-3688	481	4	.	.	PUNCT
dpc-3688	482	1	pmcid	pmcid	NOUN
dpc-3688	482	2	:	:	PUNCT
dpc-3688	482	3	pmc5796128	pmc5796128	ADJ
dpc-3688	482	4	.	.	PUNCT
dpc-3688	483	1	29	29	NUM
dpc-3688	483	2	.	.	PUNCT
dpc-3688	484	1	chiricozzi	chiricozzi	PROPN
dpc-3688	484	2	a	a	PRON
dpc-3688	484	3	,	,	PUNCT
dpc-3688	484	4	nograles	nograle	NOUN
dpc-3688	484	5	ke	ke	NOUN
dpc-3688	484	6	,	,	PUNCT
dpc-3688	484	7	johnson	johnson	PROPN
dpc-3688	484	8	-	-	PUNCT
dpc-3688	484	9	huang	huang	PROPN
dpc-3688	484	10	lm	lm	PROPN
dpc-3688	484	11	,	,	PUNCT
dpc-3688	484	12	et	et	PROPN
dpc-3688	484	13	al	al	PROPN
dpc-3688	484	14	.	.	PROPN
dpc-3688	484	15	il-17	il-17	X
dpc-3688	484	16	induces	induce	VERB
dpc-3688	484	17	an	an	DET
dpc-3688	484	18	expanded	expand	VERB
dpc-3688	484	19	range	range	NOUN
dpc-3688	484	20	of	of	ADP
dpc-3688	484	21	downstream	downstream	ADJ
dpc-3688	484	22	genes	gene	NOUN
dpc-3688	484	23	in	in	ADP
dpc-3688	484	24	reconstituted	reconstitute	VERB
dpc-3688	484	25	human	human	ADJ
dpc-3688	484	26	epidermis	epidermis	NOUN
dpc-3688	484	27	model	model	NOUN
dpc-3688	484	28	.	.	PUNCT
dpc-3688	485	1	plos	plos	PROPN
dpc-3688	485	2	one	one	NUM
dpc-3688	485	3	.	.	PUNCT
dpc-3688	486	1	2014;9(2):e90284	2014;9(2):e90284	NUM
dpc-3688	486	2	.	.	PUNCT
dpc-3688	487	1	doi	doi	NOUN
dpc-3688	487	2	:	:	PUNCT
dpc-3688	487	3	10.1371	10.1371	NUM
dpc-3688	487	4	/	/	SYM
dpc-3688	487	5	journal.pone.0090284	journal.pone.0090284	NOUN
dpc-3688	487	6	.	.	PUNCT
dpc-3688	488	1	pmid	pmid	NOUN
dpc-3688	488	2	:	:	PUNCT
dpc-3688	488	3	24587313	24587313	NUM
dpc-3688	488	4	.	.	PUNCT
dpc-3688	489	1	pmcid	pmcid	NOUN
dpc-3688	489	2	:	:	PUNCT
dpc-3688	489	3	pmc3938679	pmc3938679	PROPN
dpc-3688	489	4	.	.	PUNCT
dpc-3688	490	1	30	30	NUM
dpc-3688	490	2	.	.	X
dpc-3688	491	1	tollenaere	tollenaere	NUM
dpc-3688	491	2	max	max	PROPN
dpc-3688	491	3	,	,	PUNCT
dpc-3688	491	4	hebsgaard	hebsgaard	PROPN
dpc-3688	491	5	j	j	PROPN
dpc-3688	491	6	,	,	PUNCT
dpc-3688	491	7	ewald	ewald	PROPN
dpc-3688	491	8	da	da	PROPN
dpc-3688	491	9	,	,	PUNCT
dpc-3688	491	10	et	et	PROPN
dpc-3688	491	11	al	al	PROPN
dpc-3688	491	12	.	.	PUNCT
dpc-3688	492	1	signalling	signal	VERB
dpc-3688	492	2	of	of	ADP
dpc-3688	492	3	multiple	multiple	ADJ
dpc-3688	492	4	interleukin	interleukin	NOUN
dpc-3688	492	5	(	(	PUNCT
dpc-3688	492	6	il)-17	il)-17	ADP
dpc-3688	492	7	family	family	NOUN
dpc-3688	492	8	cytokines	cytokine	VERB
dpc-3688	492	9	via	via	ADP
dpc-3688	492	10	il-17	il-17	NUM
dpc-3688	492	11	receptor	receptor	VERB
dpc-3688	492	12	a	a	DET
dpc-3688	492	13	drives	drive	NOUN
dpc-3688	492	14	psoriasis	psoriasis	NOUN
dpc-3688	492	15	-	-	PUNCT
dpc-3688	492	16	related	relate	VERB
dpc-3688	492	17	inflammatory	inflammatory	ADJ
dpc-3688	492	18	pathways	pathway	NOUN
dpc-3688	492	19	.	.	PUNCT
dpc-3688	493	1	br	br	PROPN
dpc-3688	493	2	j	j	PROPN
dpc-3688	493	3	dermatol	dermatol	NOUN
dpc-3688	493	4	.	.	PUNCT
dpc-3688	494	1	2021;185(3):585	2021;185(3):585	NUM
dpc-3688	494	2	-	-	SYM
dpc-3688	494	3	594	594	NUM
dpc-3688	494	4	.	.	PUNCT
dpc-3688	494	5	doi	doi	NOUN
dpc-3688	494	6	:	:	PUNCT
dpc-3688	494	7	10.1111	10.1111	NUM
dpc-3688	494	8	/	/	SYM
dpc-3688	494	9	bjd.20090	bjd.20090	NOUN
dpc-3688	494	10	.	.	PUNCT
dpc-3688	495	1	pmid	pmid	NOUN
dpc-3688	495	2	:	:	PUNCT
dpc-3688	495	3	33792895	33792895	NUM
dpc-3688	495	4	.	.	PUNCT
dpc-3688	496	1	pmcid	pmcid	NOUN
dpc-3688	496	2	:	:	PUNCT
dpc-3688	496	3	pmc8453543	pmc8453543	ADJ
dpc-3688	496	4	.	.	PUNCT
dpc-3688	497	1	31	31	NUM
dpc-3688	497	2	.	.	PUNCT
dpc-3688	498	1	ramirez	ramirez	NOUN
dpc-3688	498	2	-	-	PUNCT
dpc-3688	498	3	carrozzi	carrozzi	PROPN
dpc-3688	498	4	v	v	NOUN
dpc-3688	498	5	,	,	PUNCT
dpc-3688	498	6	sambandam	sambandam	NOUN
dpc-3688	498	7	a	a	PRON
dpc-3688	498	8	,	,	PUNCT
dpc-3688	498	9	luis	luis	PROPN
dpc-3688	498	10	e	e	PROPN
dpc-3688	498	11	,	,	PUNCT
dpc-3688	498	12	et	et	PROPN
dpc-3688	498	13	al	al	PROPN
dpc-3688	498	14	.	.	PROPN
dpc-3688	498	15	il-17c	il-17c	PROPN
dpc-3688	498	16	regulates	regulate	VERB
dpc-3688	498	17	the	the	DET
dpc-3688	498	18	innate	innate	ADJ
dpc-3688	498	19	immune	immune	ADJ
dpc-3688	498	20	function	function	NOUN
dpc-3688	498	21	of	of	ADP
dpc-3688	498	22	epithelial	epithelial	ADJ
dpc-3688	498	23	cells	cell	NOUN
dpc-3688	498	24	in	in	ADP
dpc-3688	498	25	an	an	DET
dpc-3688	498	26	autocrine	autocrine	NOUN
dpc-3688	498	27	manner	manner	NOUN
dpc-3688	498	28	.	.	PUNCT
dpc-3688	499	1	nat	nat	PROPN
dpc-3688	499	2	immunol	immunol	NOUN
dpc-3688	499	3	.	.	PUNCT
dpc-3688	500	1	2011;12(12):1159	2011;12(12):1159	NUM
dpc-3688	500	2	-	-	SYM
dpc-3688	500	3	1166	1166	NUM
dpc-3688	500	4	.	.	PUNCT
dpc-3688	501	1	doi	doi	NOUN
dpc-3688	501	2	:	:	PUNCT
dpc-3688	501	3	10.1038	10.1038	NUM
dpc-3688	501	4	/	/	SYM
dpc-3688	501	5	ni.2156	ni.2156	PROPN
dpc-3688	501	6	.	.	PUNCT
dpc-3688	502	1	pmid	pmid	NOUN
dpc-3688	502	2	:	:	PUNCT
dpc-3688	502	3	21993848	21993848	NUM
dpc-3688	502	4	.	.	PUNCT
dpc-3688	503	1	32	32	NUM
dpc-3688	503	2	.	.	PUNCT
dpc-3688	504	1	krueger	krueger	PROPN
dpc-3688	504	2	jg	jg	PROPN
dpc-3688	504	3	,	,	PUNCT
dpc-3688	504	4	brunner	brunner	PROPN
dpc-3688	504	5	pm	pm	PROPN
dpc-3688	504	6	.	.	PUNCT
dpc-3688	505	1	interleukin-17	interleukin-17	PROPN
dpc-3688	505	2	alters	alter	VERB
dpc-3688	505	3	the	the	DET
dpc-3688	505	4	biology	biology	NOUN
dpc-3688	505	5	of	of	ADP
dpc-3688	505	6	many	many	ADJ
dpc-3688	505	7	cell	cell	NOUN
dpc-3688	505	8	types	type	NOUN
dpc-3688	505	9	involved	involve	VERB
dpc-3688	505	10	in	in	ADP
dpc-3688	505	11	the	the	DET
dpc-3688	505	12	genesis	genesis	NOUN
dpc-3688	505	13	of	of	ADP
dpc-3688	505	14	psoriasis	psoriasis	NOUN
dpc-3688	505	15	,	,	PUNCT
dpc-3688	505	16	systemic	systemic	ADJ
dpc-3688	505	17	inflammation	inflammation	NOUN
dpc-3688	505	18	and	and	CCONJ
dpc-3688	505	19	associated	associated	ADJ
dpc-3688	505	20	comorbidities	comorbiditie	NOUN
dpc-3688	505	21	.	.	PUNCT
dpc-3688	506	1	exp	exp	NOUN
dpc-3688	506	2	dermatol	dermatol	NOUN
dpc-3688	506	3	.	.	PUNCT
dpc-3688	507	1	2018;27(2):115	2018;27(2):115	NUM
dpc-3688	507	2	-	-	SYM
dpc-3688	507	3	123	123	NUM
dpc-3688	507	4	.	.	PUNCT
dpc-3688	508	1	doi	doi	NOUN
dpc-3688	508	2	:	:	PUNCT
dpc-3688	508	3	10.1111	10.1111	NUM
dpc-3688	508	4	/	/	SYM
dpc-3688	508	5	exd.13467	exd.13467	PROPN
dpc-3688	508	6	.	.	PUNCT
dpc-3688	509	1	pmid	pmid	NOUN
dpc-3688	509	2	:	:	PUNCT
dpc-3688	509	3	29152791	29152791	NUM
dpc-3688	509	4	.	.	PUNCT
dpc-3688	510	1	33	33	NUM
dpc-3688	510	2	.	.	PUNCT
dpc-3688	510	3	lauffer	lauffer	PROPN
dpc-3688	510	4	f	f	PROPN
dpc-3688	510	5	,	,	PUNCT
dpc-3688	510	6	jargosch	jargosch	PROPN
dpc-3688	510	7	m	m	PROPN
dpc-3688	510	8	,	,	PUNCT
dpc-3688	510	9	baghin	baghin	VERB
dpc-3688	510	10	v	v	ADP
dpc-3688	510	11	,	,	PUNCT
dpc-3688	510	12	et	et	PROPN
dpc-3688	510	13	al	al	PROPN
dpc-3688	510	14	.	.	PROPN
dpc-3688	510	15	il-17c	il-17c	PROPN
dpc-3688	510	16	amplifies	amplify	VERB
dpc-3688	510	17	epithelial	epithelial	ADJ
dpc-3688	510	18	inflammation	inflammation	NOUN
dpc-3688	510	19	in	in	ADP
dpc-3688	510	20	human	human	ADJ
dpc-3688	510	21	psoriasis	psoriasis	NOUN
dpc-3688	510	22	and	and	CCONJ
dpc-3688	510	23	atopic	atopic	NOUN
dpc-3688	510	24	eczema	eczema	NOUN
dpc-3688	510	25	.	.	PUNCT
dpc-3688	511	1	j	j	PROPN
dpc-3688	511	2	eur	eur	PROPN
dpc-3688	511	3	acad	acad	PROPN
dpc-3688	511	4	dermatol	dermatol	NOUN
dpc-3688	511	5	venereol	venereol	NOUN
dpc-3688	511	6	.	.	PUNCT
dpc-3688	512	1	2020;34(4):800	2020;34(4):800	NUM
dpc-3688	512	2	-	-	SYM
dpc-3688	512	3	809	809	NUM
dpc-3688	512	4	.	.	PUNCT
dpc-3688	513	1	doi	doi	NOUN
dpc-3688	513	2	:	:	PUNCT
dpc-3688	513	3	10.1111	10.1111	NUM
dpc-3688	513	4	/jdv.16126	/jdv.16126	NOUN
dpc-3688	513	5	.	.	PUNCT
dpc-3688	514	1	pmid	pmid	NOUN
dpc-3688	514	2	:	:	PUNCT
dpc-3688	514	3	31793105	31793105	NUM
dpc-3688	514	4	.	.	PUNCT
dpc-3688	515	1	34	34	NUM
dpc-3688	515	2	.	.	PUNCT
dpc-3688	515	3	doi	doi	NOUN
dpc-3688	515	4	:	:	PUNCT
dpc-3688	515	5	10.4049	10.4049	NUM
dpc-3688	515	6	/	/	SYM
dpc-3688	515	7	jimmunol.1201505	jimmunol.1201505	PROPN
dpc-3688	515	8	.	.	PUNCT
dpc-3688	516	1	johnston	johnston	PROPN
dpc-3688	516	2	a	a	PROPN
dpc-3688	516	3	,	,	PUNCT
dpc-3688	516	4	fritz	fritz	PROPN
dpc-3688	516	5	y	y	PROPN
dpc-3688	516	6	,	,	PUNCT
dpc-3688	516	7	dawes	dawes	X
dpc-3688	516	8	sm	sm	PROPN
dpc-3688	516	9	,	,	PUNCT
dpc-3688	516	10	et	et	PROPN
dpc-3688	516	11	al	al	PROPN
dpc-3688	516	12	.	.	PROPN
dpc-3688	516	13	keratinocyte	keratinocyte	PROPN
dpc-3688	516	14	overexpression	overexpression	NOUN
dpc-3688	516	15	of	of	ADP
dpc-3688	516	16	il-17c	il-17c	NOUN
dpc-3688	516	17	promotes	promote	VERB
dpc-3688	516	18	psoriasiform	psoriasiform	NOUN
dpc-3688	516	19	skin	skin	NOUN
dpc-3688	516	20	inflammation	inflammation	NOUN
dpc-3688	516	21	.	.	PUNCT
dpc-3688	517	1	j	j	PROPN
dpc-3688	517	2	immunol	immunol	NOUN
dpc-3688	517	3	.	.	PUNCT
dpc-3688	518	1	2013;190(5):22522262	2013;190(5):22522262	NUM
dpc-3688	518	2	.	.	X
dpc-3688	518	3	doi	doi	NOUN
dpc-3688	518	4	:	:	PUNCT
dpc-3688	518	5	10.4049	10.4049	NUM
dpc-3688	518	6	/	/	SYM
dpc-3688	518	7	jimmunol.1201505	jimmunol.1201505	PROPN
dpc-3688	518	8	.	.	PUNCT
dpc-3688	519	1	pmid	pmid	NOUN
dpc-3688	519	2	:	:	PUNCT
dpc-3688	519	3	23359500	23359500	NUM
dpc-3688	519	4	.	.	PUNCT
dpc-3688	520	1	pmcid	pmcid	ADJ
dpc-3688	520	2	:	:	PUNCT
dpc-3688	520	3	pmc3577967	pmc3577967	ADJ
dpc-3688	520	4	.	.	PUNCT
dpc-3688	521	1	35	35	NUM
dpc-3688	521	2	.	.	PUNCT
dpc-3688	522	1	guttman	guttman	ADJ
dpc-3688	522	2	-	-	PUNCT
dpc-3688	522	3	yassky	yassky	NOUN
dpc-3688	522	4	e	e	NOUN
dpc-3688	522	5	,	,	PUNCT
dpc-3688	523	1	krueger	krueger	PROPN
dpc-3688	523	2	jg	jg	PROPN
dpc-3688	523	3	.	.	PROPN
dpc-3688	523	4	il-17c	il-17c	PROPN
dpc-3688	523	5	:	:	PUNCT
dpc-3688	523	6	a	a	DET
dpc-3688	523	7	unique	unique	ADJ
dpc-3688	523	8	epithelial	epithelial	ADJ
dpc-3688	523	9	cytokine	cytokine	NOUN
dpc-3688	523	10	with	with	ADP
dpc-3688	523	11	potential	potential	NOUN
dpc-3688	523	12	for	for	ADP
dpc-3688	523	13	targeting	target	VERB
dpc-3688	523	14	across	across	ADP
dpc-3688	523	15	the	the	DET
dpc-3688	523	16	spectrum	spectrum	NOUN
dpc-3688	523	17	of	of	ADP
dpc-3688	523	18	atopic	atopic	NOUN
dpc-3688	523	19	dermatitis	dermatitis	NOUN
dpc-3688	523	20	and	and	CCONJ
dpc-3688	523	21	psoriasis	psoriasis	NOUN
dpc-3688	523	22	.	.	PUNCT
dpc-3688	524	1	j	j	PROPN
dpc-3688	524	2	invest	invest	VERB
dpc-3688	524	3	dermatol	dermatol	NOUN
dpc-3688	524	4	.	.	PUNCT
dpc-3688	525	1	2018;138(7):14671469	2018;138(7):14671469	NUM
dpc-3688	525	2	.	.	X
dpc-3688	525	3	doi	doi	NOUN
dpc-3688	525	4	:	:	PUNCT
dpc-3688	525	5	10.1016	10.1016	NUM
dpc-3688	525	6	/	/	SYM
dpc-3688	525	7	j.jid.2018.02.037	j.jid.2018.02.037	NOUN
dpc-3688	525	8	.	.	PUNCT
dpc-3688	526	1	pmid	pmid	NOUN
dpc-3688	526	2	:	:	PUNCT
dpc-3688	526	3	29941097	29941097	NUM
dpc-3688	526	4	.	.	PUNCT
dpc-3688	527	1	36	36	NUM
dpc-3688	527	2	.	.	X
dpc-3688	528	1	chang	chang	PROPN
dpc-3688	528	2	sh	sh	PROPN
dpc-3688	528	3	,	,	PUNCT
dpc-3688	528	4	reynolds	reynolds	PROPN
dpc-3688	528	5	jm	jm	PROPN
dpc-3688	528	6	,	,	PUNCT
dpc-3688	528	7	pappu	pappu	PROPN
dpc-3688	528	8	bp	bp	PROPN
dpc-3688	528	9	,	,	PUNCT
dpc-3688	528	10	chen	chen	PROPN
dpc-3688	528	11	g	g	PROPN
dpc-3688	528	12	,	,	PUNCT
dpc-3688	528	13	martinez	martinez	PROPN
dpc-3688	528	14	gj	gj	PROPN
dpc-3688	528	15	,	,	PUNCT
dpc-3688	528	16	dong	dong	PROPN
dpc-3688	528	17	c.	c.	PROPN
dpc-3688	528	18	interleukin-17c	interleukin-17c	PROPN
dpc-3688	528	19	promotes	promote	VERB
dpc-3688	528	20	th17	th17	PROPN
dpc-3688	528	21	cell	cell	NOUN
dpc-3688	528	22	responses	response	NOUN
dpc-3688	528	23	and	and	CCONJ
dpc-3688	528	24	autoimmune	autoimmune	ADJ
dpc-3688	528	25	disease	disease	NOUN
dpc-3688	528	26	via	via	ADP
dpc-3688	528	27	interleukin-17	interleukin-17	PRON
dpc-3688	528	28	receptor	receptor	NOUN
dpc-3688	528	29	e.	e.	PROPN
dpc-3688	528	30	immunity	immunity	PROPN
dpc-3688	528	31	.	.	PUNCT
dpc-3688	529	1	2011;35(4	2011;35(4	NUM
dpc-3688	529	2	):	):	PUNCT
dpc-3688	529	3	611	611	NUM
dpc-3688	529	4	-	-	SYM
dpc-3688	529	5	621	621	NUM
dpc-3688	529	6	.	.	PUNCT
dpc-3688	530	1	doi	doi	NOUN
dpc-3688	530	2	:	:	PUNCT
dpc-3688	530	3	10.1016	10.1016	NUM
dpc-3688	530	4	/	/	SYM
dpc-3688	530	5	j.immuni.2011.09.010	j.immuni.2011.09.010	PROPN
dpc-3688	530	6	.	.	PUNCT
dpc-3688	531	1	pmid	pmid	NOUN
dpc-3688	531	2	:	:	PUNCT
dpc-3688	531	3	21982598	21982598	NUM
dpc-3688	531	4	.	.	PUNCT
dpc-3688	532	1	pmcid	pmcid	NOUN
dpc-3688	532	2	:	:	PUNCT
dpc-3688	532	3	pmc5800502	pmc5800502	VERB
dpc-3688	532	4	.	.	PUNCT
dpc-3688	533	1	37	37	NUM
dpc-3688	533	2	.	.	PUNCT
dpc-3688	533	3	nies	nies	PROPN
dpc-3688	533	4	jf	jf	PROPN
dpc-3688	533	5	,	,	PUNCT
dpc-3688	533	6	panzer	panzer	PROPN
dpc-3688	533	7	u.	u.	PROPN
dpc-3688	533	8	il-17c	il-17c	PROPN
dpc-3688	533	9	/	/	SYM
dpc-3688	533	10	il-17re	il-17re	PROPN
dpc-3688	533	11	:	:	PUNCT
dpc-3688	533	12	emergence	emergence	NOUN
dpc-3688	533	13	of	of	ADP
dpc-3688	533	14	a	a	DET
dpc-3688	533	15	unique	unique	ADJ
dpc-3688	533	16	axis	axis	NOUN
dpc-3688	533	17	in	in	ADP
dpc-3688	533	18	th17	th17	NOUN
dpc-3688	533	19	biology	biology	NOUN
dpc-3688	533	20	.	.	PUNCT
dpc-3688	534	1	front	front	ADJ
dpc-3688	534	2	immunol	immunol	NOUN
dpc-3688	534	3	.	.	PUNCT
dpc-3688	535	1	2020;11:341	2020;11:341	NUM
dpc-3688	535	2	.	.	PUNCT
dpc-3688	535	3	doi	doi	PROPN
dpc-3688	535	4	:	:	PUNCT
dpc-3688	535	5	10.3389	10.3389	NUM
dpc-3688	535	6	/fimmu.2020.00341	/fimmu.2020.00341	PUNCT
dpc-3688	535	7	.	.	PUNCT
dpc-3688	536	1	pmid	pmid	NOUN
dpc-3688	536	2	:	:	PUNCT
dpc-3688	536	3	32174926	32174926	NUM
dpc-3688	536	4	.	.	PUNCT
dpc-3688	537	1	pmcid	pmcid	NOUN
dpc-3688	537	2	:	:	PUNCT
dpc-3688	537	3	pmc7054382	pmc7054382	NOUN
dpc-3688	537	4	.	.	PUNCT
dpc-3688	538	1	38	38	NUM
dpc-3688	538	2	.	.	PUNCT
dpc-3688	539	1	merola	merola	PROPN
dpc-3688	539	2	jf	jf	PROPN
dpc-3688	539	3	,	,	PUNCT
dpc-3688	539	4	qureshi	qureshi	PROPN
dpc-3688	539	5	a	a	PROPN
dpc-3688	539	6	,	,	PUNCT
dpc-3688	539	7	husni	husni	VERB
dpc-3688	539	8	me	i	PRON
dpc-3688	539	9	.	.	PUNCT
dpc-3688	540	1	underdiagnosed	underdiagnose	VERB
dpc-3688	540	2	and	and	CCONJ
dpc-3688	540	3	undertreated	undertreate	VERB
dpc-3688	540	4	psoriasis	psoriasis	NOUN
dpc-3688	540	5	:	:	PUNCT
dpc-3688	540	6	nuances	nuance	NOUN
dpc-3688	540	7	of	of	ADP
dpc-3688	540	8	treating	treat	VERB
dpc-3688	540	9	psoriasis	psoriasis	NOUN
dpc-3688	540	10	affecting	affect	VERB
dpc-3688	540	11	the	the	DET
dpc-3688	540	12	scalp	scalp	NOUN
dpc-3688	540	13	,	,	PUNCT
dpc-3688	540	14	face	face	NOUN
dpc-3688	540	15	,	,	PUNCT
dpc-3688	540	16	intertriginous	intertriginous	ADJ
dpc-3688	540	17	areas	area	NOUN
dpc-3688	540	18	,	,	PUNCT
dpc-3688	540	19	genitals	genital	NOUN
dpc-3688	540	20	,	,	PUNCT
dpc-3688	540	21	hands	hand	NOUN
dpc-3688	540	22	,	,	PUNCT
dpc-3688	540	23	feet	foot	NOUN
dpc-3688	540	24	,	,	PUNCT
dpc-3688	540	25	and	and	CCONJ
dpc-3688	540	26	nails	nail	NOUN
dpc-3688	540	27	.	.	PUNCT
dpc-3688	541	1	dermatol	dermatol	NOUN
dpc-3688	541	2	ther	ther	ADV
dpc-3688	541	3	.	.	PUNCT
dpc-3688	542	1	2018;31(3):e12589	2018;31(3):e12589	X
dpc-3688	542	2	.	.	PUNCT
dpc-3688	543	1	doi	doi	NOUN
dpc-3688	543	2	:	:	PUNCT
dpc-3688	543	3	10.1111	10.1111	NUM
dpc-3688	543	4	/	/	SYM
dpc-3688	543	5	dth.12589	dth.12589	NOUN
dpc-3688	543	6	.	.	PUNCT
dpc-3688	544	1	pmid	pmid	NOUN
dpc-3688	544	2	:	:	PUNCT
dpc-3688	544	3	29512290	29512290	NUM
dpc-3688	544	4	.	.	PUNCT
dpc-3688	545	1	pmcid	pmcid	NOUN
dpc-3688	545	2	:	:	PUNCT
dpc-3688	545	3	pmc6901032	pmc6901032	NOUN
dpc-3688	545	4	.	.	PUNCT
dpc-3688	546	1	10	10	NUM
dpc-3688	546	2	review	review	NOUN
dpc-3688	546	3	|	|	ADV
dpc-3688	546	4	dermatol	dermatol	ADJ
dpc-3688	546	5	pract	pract	NOUN
dpc-3688	546	6	concept	concept	NOUN
dpc-3688	546	7	.	.	PUNCT
dpc-3688	547	1	2023;13(3):e2023245	2023;13(3):e2023245	NUM
dpc-3688	547	2	57	57	NUM
dpc-3688	547	3	.	.	PUNCT
dpc-3688	548	1	galluzzo	galluzzo	NOUN
dpc-3688	548	2	m	m	PROPN
dpc-3688	548	3	,	,	PUNCT
dpc-3688	548	4	d'adamio	d'adamio	PROPN
dpc-3688	548	5	s	s	PROPN
dpc-3688	548	6	,	,	PUNCT
dpc-3688	548	7	bianchi	bianchi	PROPN
dpc-3688	548	8	l	l	PROPN
dpc-3688	548	9	,	,	PUNCT
dpc-3688	548	10	talamonti	talamonti	ADJ
dpc-3688	548	11	m.	m.	NOUN
dpc-3688	548	12	brodalumab	brodalumab	NOUN
dpc-3688	548	13	for	for	ADP
dpc-3688	548	14	the	the	DET
dpc-3688	548	15	treatment	treatment	NOUN
dpc-3688	548	16	of	of	ADP
dpc-3688	548	17	psoriasis	psoriasis	NOUN
dpc-3688	548	18	.	.	PUNCT
dpc-3688	549	1	expert	expert	NOUN
dpc-3688	549	2	rev	rev	VERB
dpc-3688	549	3	clin	clin	PROPN
dpc-3688	549	4	immunol	immunol	NOUN
dpc-3688	549	5	.	.	PUNCT
dpc-3688	550	1	2016;12(12):1255	2016;12(12):1255	NUM
dpc-3688	550	2	-	-	SYM
dpc-3688	550	3	1271	1271	NUM
dpc-3688	550	4	.	.	PUNCT
dpc-3688	551	1	doi	doi	NOUN
dpc-3688	551	2	:	:	PUNCT
dpc-3688	551	3	10.1080/1744666x	10.1080/1744666x	NUM
dpc-3688	551	4	.2016.1246957	.2016.1246957	NOUN
dpc-3688	551	5	.	.	PUNCT
dpc-3688	552	1	pmid	pmid	NOUN
dpc-3688	552	2	:	:	PUNCT
dpc-3688	552	3	27718760	27718760	NUM
dpc-3688	552	4	.	.	PUNCT
dpc-3688	553	1	58	58	NUM
dpc-3688	553	2	.	.	PUNCT
dpc-3688	554	1	pinter	pinter	PROPN
dpc-3688	554	2	a	a	PRON
dpc-3688	554	3	,	,	PUNCT
dpc-3688	554	4	bonnekoh	bonnekoh	NOUN
dpc-3688	554	5	b	b	NOUN
dpc-3688	554	6	,	,	PUNCT
dpc-3688	554	7	hadshiew	hadshiew	VERB
dpc-3688	554	8	i	i	PRON
dpc-3688	554	9	m	m	PROPN
dpc-3688	554	10	,	,	PUNCT
dpc-3688	554	11	zimmer	zimmer	PROPN
dpc-3688	554	12	s.	s.	PROPN
dpc-3688	554	13	brodalumab	brodalumab	PROPN
dpc-3688	554	14	for	for	ADP
dpc-3688	554	15	the	the	DET
dpc-3688	554	16	treatment	treatment	NOUN
dpc-3688	554	17	of	of	ADP
dpc-3688	554	18	moderate	moderate	ADJ
dpc-3688	554	19	-	-	PUNCT
dpc-3688	554	20	to	to	ADP
dpc-3688	554	21	-	-	PUNCT
dpc-3688	554	22	severe	severe	ADJ
dpc-3688	554	23	psoriasis	psoriasis	NOUN
dpc-3688	554	24	:	:	PUNCT
dpc-3688	554	25	case	case	NOUN
dpc-3688	554	26	series	series	NOUN
dpc-3688	554	27	and	and	CCONJ
dpc-3688	554	28	literature	literature	PROPN
dpc-3688	554	29	review	review	PROPN
dpc-3688	554	30	.	.	PUNCT
dpc-3688	555	1	clin	clin	PROPN
dpc-3688	555	2	cosmet	cosmet	PROPN
dpc-3688	555	3	investig	investig	NOUN
dpc-3688	555	4	dermatol	dermatol	NOUN
dpc-3688	555	5	.	.	PUNCT
dpc-3688	556	1	2019;12:509517	2019;12:509517	X
dpc-3688	556	2	.	.	PUNCT
dpc-3688	556	3	doi	doi	NOUN
dpc-3688	556	4	:	:	PUNCT
dpc-3688	556	5	10.2147	10.2147	NUM
dpc-3688	556	6	/	/	SYM
dpc-3688	556	7	ccid.s211938	ccid.s211938	NOUN
dpc-3688	556	8	.	.	PUNCT
dpc-3688	557	1	pmid	pmid	NOUN
dpc-3688	557	2	:	:	PUNCT
dpc-3688	557	3	31372022	31372022	NUM
dpc-3688	557	4	.	.	PUNCT
dpc-3688	558	1	pmcid	pmcid	NOUN
dpc-3688	558	2	:	:	PUNCT
dpc-3688	558	3	pmc6628099	pmc6628099	NOUN
dpc-3688	558	4	.	.	PUNCT
dpc-3688	559	1	59	59	NUM
dpc-3688	559	2	.	.	PUNCT
dpc-3688	559	3	politou	politou	PROPN
dpc-3688	559	4	m	m	PROPN
dpc-3688	559	5	,	,	PUNCT
dpc-3688	559	6	pompou	pompou	ADP
dpc-3688	559	7	m	m	PROPN
dpc-3688	559	8	,	,	PUNCT
dpc-3688	559	9	afroditi	afroditi	INTJ
dpc-3688	559	10	ki	ki	INTJ
dpc-3688	559	11	,	,	PUNCT
dpc-3688	559	12	giannoukos	giannoukos	PROPN
dpc-3688	559	13	a	a	X
dpc-3688	559	14	,	,	PUNCT
dpc-3688	559	15	nikolaos	nikolaos	PROPN
dpc-3688	559	16	f.	f.	PROPN
dpc-3688	559	17	twenty	twenty	NUM
dpc-3688	559	18	patients	patient	NOUN
dpc-3688	559	19	with	with	ADP
dpc-3688	559	20	moderate	moderate	ADJ
dpc-3688	559	21	to	to	ADP
dpc-3688	559	22	severe	severe	ADJ
dpc-3688	559	23	psoriasis	psoriasis	NOUN
dpc-3688	559	24	successfully	successfully	ADV
dpc-3688	559	25	treated	treat	VERB
dpc-3688	559	26	with	with	ADP
dpc-3688	559	27	brodalumab	brodalumab	NOUN
dpc-3688	559	28	after	after	ADP
dpc-3688	559	29	a	a	DET
dpc-3688	559	30	failed	fail	VERB
dpc-3688	559	31	treatment	treatment	NOUN
dpc-3688	559	32	with	with	ADP
dpc-3688	559	33	secukinumab	secukinumab	NOUN
dpc-3688	559	34	.	.	PUNCT
dpc-3688	560	1	j	j	PROPN
dpc-3688	560	2	am	be	AUX
dpc-3688	560	3	acad	acad	ADJ
dpc-3688	560	4	dermatol	dermatol	NOUN
dpc-3688	560	5	.	.	PUNCT
dpc-3688	561	1	2020;83(6	2020;83(6	NUM
dpc-3688	561	2	suppl	suppl	ADJ
dpc-3688	561	3	):	):	PUNCT
dpc-3688	561	4	ab214	ab214	PROPN
dpc-3688	561	5	.	.	PUNCT
dpc-3688	562	1	60	60	NUM
dpc-3688	562	2	.	.	PUNCT
dpc-3688	563	1	nakao	nakao	PROPN
dpc-3688	563	2	m	m	PROPN
dpc-3688	563	3	,	,	PUNCT
dpc-3688	563	4	asano	asano	PROPN
dpc-3688	563	5	y	y	PROPN
dpc-3688	563	6	,	,	PUNCT
dpc-3688	563	7	kamata	kamata	PROPN
dpc-3688	563	8	m	m	PROPN
dpc-3688	563	9	,	,	PUNCT
dpc-3688	563	10	yoshizaki	yoshizaki	VERB
dpc-3688	563	11	a	a	PRON
dpc-3688	563	12	,	,	PUNCT
dpc-3688	563	13	sato	sato	PROPN
dpc-3688	563	14	s.	s.	PROPN
dpc-3688	563	15	successful	successful	ADJ
dpc-3688	563	16	treatment	treatment	NOUN
dpc-3688	563	17	of	of	ADP
dpc-3688	563	18	palmoplantar	palmoplantar	NOUN
dpc-3688	563	19	pustular	pustular	ADJ
dpc-3688	563	20	psoriasis	psoriasis	NOUN
dpc-3688	563	21	with	with	ADP
dpc-3688	563	22	brodalumab	brodalumab	NOUN
dpc-3688	563	23	.	.	PUNCT
dpc-3688	564	1	eur	eur	PROPN
dpc-3688	564	2	j	j	PROPN
dpc-3688	564	3	dermatol	dermatol	NOUN
dpc-3688	564	4	.	.	PUNCT
dpc-3688	565	1	2018;28(4):538	2018;28(4):538	NUM
dpc-3688	565	2	-	-	PUNCT
dpc-3688	565	3	539	539	NUM
dpc-3688	565	4	.	.	PUNCT
dpc-3688	566	1	doi	doi	NOUN
dpc-3688	566	2	:	:	PUNCT
dpc-3688	566	3	10.1684	10.1684	NUM
dpc-3688	566	4	/ejd.2018.3325	/ejd.2018.3325	PROPN
dpc-3688	566	5	.	.	PUNCT
dpc-3688	567	1	pmid	pmid	NOUN
dpc-3688	567	2	:	:	PUNCT
dpc-3688	567	3	30129522	30129522	NUM
dpc-3688	567	4	.	.	PUNCT
dpc-3688	568	1	61	61	NUM
dpc-3688	568	2	.	.	PUNCT
dpc-3688	569	1	pinter	pinter	PROPN
dpc-3688	569	2	a	a	PRON
dpc-3688	569	3	,	,	PUNCT
dpc-3688	569	4	wilsmann	wilsmann	PROPN
dpc-3688	569	5	-	-	PUNCT
dpc-3688	569	6	theis	theis	PROPN
dpc-3688	569	7	d	d	NOUN
dpc-3688	569	8	,	,	PUNCT
dpc-3688	569	9	peitsch	peitsch	PROPN
dpc-3688	569	10	wk	wk	INTJ
dpc-3688	569	11	,	,	PUNCT
dpc-3688	569	12	mössner	mössner	PROPN
dpc-3688	569	13	r.	r.	PROPN
dpc-3688	569	14	interleukin-17	interleukin-17	PROPN
dpc-3688	569	15	receptor	receptor	VERB
dpc-3688	569	16	a	a	DET
dpc-3688	569	17	blockade	blockade	NOUN
dpc-3688	569	18	with	with	ADP
dpc-3688	569	19	brodalumab	brodalumab	NOUN
dpc-3688	569	20	in	in	ADP
dpc-3688	569	21	palmoplantar	palmoplantar	NOUN
dpc-3688	569	22	pustular	pustular	ADJ
dpc-3688	569	23	psoriasis	psoriasis	NOUN
dpc-3688	569	24	:	:	PUNCT
dpc-3688	569	25	report	report	NOUN
dpc-3688	569	26	on	on	ADP
dpc-3688	569	27	four	four	NUM
dpc-3688	569	28	cases	case	NOUN
dpc-3688	569	29	.	.	PUNCT
dpc-3688	570	1	j	j	PROPN
dpc-3688	570	2	dermatol	dermatol	NOUN
dpc-3688	570	3	.	.	PUNCT
dpc-3688	571	1	2019;46(5):426	2019;46(5):426	NUM
dpc-3688	571	2	-	-	SYM
dpc-3688	571	3	430	430	NUM
dpc-3688	571	4	.	.	PUNCT
dpc-3688	572	1	doi	doi	NOUN
dpc-3688	572	2	:	:	PUNCT
dpc-3688	572	3	10.1111/1346	10.1111/1346	NUM
dpc-3688	572	4	-	-	SYM
dpc-3688	572	5	8138.14815	8138.14815	NOUN
dpc-3688	572	6	.	.	PUNCT
dpc-3688	573	1	pmid	pmid	NOUN
dpc-3688	573	2	:	:	PUNCT
dpc-3688	573	3	30786053	30786053	NUM
dpc-3688	573	4	.	.	PUNCT
dpc-3688	574	1	62	62	NUM
dpc-3688	574	2	.	.	PUNCT
dpc-3688	575	1	pinter	pinter	PROPN
dpc-3688	575	2	a	a	PRON
dpc-3688	575	3	,	,	PUNCT
dpc-3688	575	4	wilsmann	wilsmann	PROPN
dpc-3688	575	5	-	-	PUNCT
dpc-3688	575	6	theis	theis	PROPN
dpc-3688	575	7	d	d	NOUN
dpc-3688	575	8	,	,	PUNCT
dpc-3688	575	9	peitsch	peitsch	PROPN
dpc-3688	575	10	wk	wk	INTJ
dpc-3688	575	11	,	,	PUNCT
dpc-3688	575	12	mössner	mössner	PROPN
dpc-3688	575	13	r.	r.	PROPN
dpc-3688	575	14	interleukin-17	interleukin-17	PROPN
dpc-3688	575	15	receptor	receptor	VERB
dpc-3688	575	16	a	a	DET
dpc-3688	575	17	blockade	blockade	NOUN
dpc-3688	575	18	with	with	ADP
dpc-3688	575	19	brodalumab	brodalumab	NOUN
dpc-3688	575	20	in	in	ADP
dpc-3688	575	21	palmoplantar	palmoplantar	NOUN
dpc-3688	575	22	pustular	pustular	ADJ
dpc-3688	575	23	psoriasis	psoriasis	NOUN
dpc-3688	575	24	:	:	PUNCT
dpc-3688	575	25	report	report	NOUN
dpc-3688	575	26	on	on	ADP
dpc-3688	575	27	four	four	NUM
dpc-3688	575	28	cases	case	NOUN
dpc-3688	575	29	.	.	PUNCT
dpc-3688	576	1	j	j	PROPN
dpc-3688	576	2	dermatol	dermatol	NOUN
dpc-3688	576	3	.	.	PUNCT
dpc-3688	577	1	2019;46(5):426	2019;46(5):426	NUM
dpc-3688	577	2	-	-	SYM
dpc-3688	577	3	430	430	NUM
dpc-3688	577	4	.	.	PUNCT
dpc-3688	578	1	doi	doi	NOUN
dpc-3688	578	2	:	:	PUNCT
dpc-3688	578	3	10.1111/1346	10.1111/1346	NUM
dpc-3688	578	4	-	-	SYM
dpc-3688	578	5	8138.14815	8138.14815	NOUN
dpc-3688	578	6	.	.	PUNCT
dpc-3688	579	1	pmid	pmid	NOUN
dpc-3688	579	2	:	:	PUNCT
dpc-3688	579	3	30786053	30786053	NUM
dpc-3688	579	4	.	.	PUNCT
dpc-3688	580	1	psoriasis	psoriasis	NOUN
dpc-3688	580	2	:	:	PUNCT
dpc-3688	580	3	results	result	VERB
dpc-3688	580	4	from	from	ADP
dpc-3688	580	5	three	three	NUM
dpc-3688	580	6	phase	phase	NOUN
dpc-3688	580	7	3	3	NUM
dpc-3688	580	8	trials	trial	NOUN
dpc-3688	580	9	.	.	PUNCT
dpc-3688	581	1	j	j	PROPN
dpc-3688	581	2	dermatolog	dermatolog	PROPN
dpc-3688	581	3	treat	treat	NOUN
dpc-3688	581	4	.	.	PUNCT
dpc-3688	582	1	2022;33(1):261	2022;33(1):261	NUM
dpc-3688	582	2	-	-	SYM
dpc-3688	582	3	265	265	NUM
dpc-3688	582	4	.	.	PUNCT
dpc-3688	583	1	doi	doi	NOUN
dpc-3688	583	2	:	:	PUNCT
dpc-3688	583	3	10.1080/09546634.2020.1749546	10.1080/09546634.2020.1749546	NUM
dpc-3688	583	4	.	.	X
dpc-3688	584	1	pmid	pmid	NOUN
dpc-3688	584	2	:	:	PUNCT
dpc-3688	584	3	32250714	32250714	NUM
dpc-3688	584	4	.	.	PUNCT
dpc-3688	585	1	52	52	NUM
dpc-3688	585	2	.	.	PUNCT
dpc-3688	586	1	nakagawa	nakagawa	PROPN
dpc-3688	586	2	h	h	PROPN
dpc-3688	586	3	,	,	PUNCT
dpc-3688	586	4	niiro	niiro	NOUN
dpc-3688	586	5	h	h	NOUN
dpc-3688	586	6	,	,	PUNCT
dpc-3688	586	7	ootaki	ootaki	PROPN
dpc-3688	586	8	k	k	NOUN
dpc-3688	586	9	;	;	PUNCT
dpc-3688	586	10	japanese	japanese	ADJ
dpc-3688	586	11	brodalumab	brodalumab	NOUN
dpc-3688	586	12	study	study	PROPN
dpc-3688	586	13	group	group	NOUN
dpc-3688	586	14	.	.	PUNCT
dpc-3688	587	1	brodalumab	brodalumab	NOUN
dpc-3688	587	2	,	,	PUNCT
dpc-3688	587	3	a	a	DET
dpc-3688	587	4	human	human	ADJ
dpc-3688	587	5	anti	anti	ADJ
dpc-3688	587	6	-	-	ADJ
dpc-3688	587	7	interleukin-17	interleukin-17	ADJ
dpc-3688	587	8	-	-	PUNCT
dpc-3688	587	9	receptor	receptor	NOUN
dpc-3688	587	10	antibody	antibody	NOUN
dpc-3688	587	11	in	in	ADP
dpc-3688	587	12	the	the	DET
dpc-3688	587	13	treatment	treatment	NOUN
dpc-3688	587	14	of	of	ADP
dpc-3688	587	15	japanese	japanese	ADJ
dpc-3688	587	16	patients	patient	NOUN
dpc-3688	587	17	with	with	ADP
dpc-3688	587	18	moderate	moderate	ADJ
dpc-3688	587	19	-	-	PUNCT
dpc-3688	587	20	to	to	ADP
dpc-3688	587	21	severe	severe	ADJ
dpc-3688	587	22	plaque	plaque	NOUN
dpc-3688	587	23	psoriasis	psoriasis	NOUN
dpc-3688	587	24	:	:	PUNCT
dpc-3688	587	25	efficacy	efficacy	NOUN
dpc-3688	587	26	and	and	CCONJ
dpc-3688	587	27	safety	safety	NOUN
dpc-3688	587	28	results	result	NOUN
dpc-3688	587	29	from	from	ADP
dpc-3688	587	30	a	a	DET
dpc-3688	587	31	phase	phase	NOUN
dpc-3688	587	32	ii	ii	NOUN
dpc-3688	587	33	randomized	randomize	VERB
dpc-3688	587	34	controlled	control	VERB
dpc-3688	587	35	study	study	NOUN
dpc-3688	587	36	.	.	PUNCT
dpc-3688	588	1	j	j	PROPN
dpc-3688	588	2	dermatol	dermatol	NOUN
dpc-3688	588	3	sci	sci	PROPN
dpc-3688	588	4	.	.	PROPN
dpc-3688	589	1	2016;81(1	2016;81(1	NUM
dpc-3688	589	2	):	):	PUNCT
dpc-3688	589	3	44	44	NUM
dpc-3688	589	4	-	-	SYM
dpc-3688	589	5	52	52	NUM
dpc-3688	589	6	.	.	PUNCT
dpc-3688	590	1	doi	doi	NOUN
dpc-3688	590	2	:	:	PUNCT
dpc-3688	590	3	10.1016	10.1016	NUM
dpc-3688	590	4	/	/	SYM
dpc-3688	590	5	j.jdermsci.2015.10.009	j.jdermsci.2015.10.009	PROPN
dpc-3688	590	6	.	.	PUNCT
dpc-3688	591	1	pmid	pmid	NOUN
dpc-3688	591	2	:	:	PUNCT
dpc-3688	591	3	26547109	26547109	NUM
dpc-3688	591	4	.	.	PUNCT
dpc-3688	592	1	53	53	NUM
dpc-3688	592	2	.	.	PUNCT
dpc-3688	593	1	gregoriou	gregoriou	PROPN
dpc-3688	593	2	s	s	PROPN
dpc-3688	593	3	,	,	PUNCT
dpc-3688	593	4	tsiogka	tsiogka	ADV
dpc-3688	593	5	a	a	PRON
dpc-3688	593	6	,	,	PUNCT
dpc-3688	593	7	tsimpidakis	tsimpidakis	PROPN
dpc-3688	593	8	a	a	PROPN
dpc-3688	593	9	,	,	PUNCT
dpc-3688	593	10	nicolaidou	nicolaidou	PROPN
dpc-3688	593	11	e	e	PROPN
dpc-3688	593	12	,	,	PUNCT
dpc-3688	593	13	kontochristopoulos	kontochristopoulos	PROPN
dpc-3688	593	14	g	g	PROPN
dpc-3688	593	15	,	,	PUNCT
dpc-3688	593	16	rigopoulos	rigopoulos	PROPN
dpc-3688	593	17	d.	d.	PROPN
dpc-3688	593	18	treatment	treatment	NOUN
dpc-3688	593	19	of	of	ADP
dpc-3688	593	20	nail	nail	NOUN
dpc-3688	593	21	psoriasis	psoriasis	NOUN
dpc-3688	593	22	with	with	ADP
dpc-3688	593	23	brodalumab	brodalumab	NOUN
dpc-3688	593	24	:	:	PUNCT
dpc-3688	593	25	an	an	DET
dpc-3688	593	26	open	open	ADJ
dpc-3688	593	27	-	-	PUNCT
dpc-3688	593	28	label	label	NOUN
dpc-3688	593	29	unblinded	unblinded	ADJ
dpc-3688	593	30	study	study	NOUN
dpc-3688	593	31	.	.	PUNCT
dpc-3688	594	1	j	j	PROPN
dpc-3688	594	2	eur	eur	PROPN
dpc-3688	594	3	acad	acad	PROPN
dpc-3688	594	4	dermatol	dermatol	NOUN
dpc-3688	594	5	venereol	venereol	NOUN
dpc-3688	594	6	.	.	PUNCT
dpc-3688	595	1	2021;35(4):e299	2021;35(4):e299	X
dpc-3688	595	2	-	-	PUNCT
dpc-3688	595	3	e301	e301	PROPN
dpc-3688	595	4	.	.	PUNCT
dpc-3688	595	5	doi	doi	PROPN
dpc-3688	595	6	:	:	PUNCT
dpc-3688	595	7	10.1111	10.1111	NUM
dpc-3688	595	8	/jdv.17055	/jdv.17055	X
dpc-3688	595	9	.	.	PUNCT
dpc-3688	596	1	pmid	pmid	NOUN
dpc-3688	596	2	:	:	PUNCT
dpc-3688	596	3	33269501	33269501	NUM
dpc-3688	596	4	.	.	PUNCT
dpc-3688	597	1	54	54	NUM
dpc-3688	597	2	.	.	X
dpc-3688	597	3	husein	husein	NOUN
dpc-3688	597	4	-	-	PUNCT
dpc-3688	597	5	elahmed	elahme	VERB
dpc-3688	597	6	h	h	NOUN
dpc-3688	597	7	,	,	PUNCT
dpc-3688	597	8	husein	husein	NOUN
dpc-3688	597	9	-	-	PUNCT
dpc-3688	597	10	elahmed	elahme	VERB
dpc-3688	597	11	s.	s.	PROPN
dpc-3688	597	12	bayesian	bayesian	PROPN
dpc-3688	597	13	network	network	NOUN
dpc-3688	597	14	meta	meta	VERB
dpc-3688	597	15	analysis	analysis	NOUN
dpc-3688	597	16	of	of	ADP
dpc-3688	597	17	head	head	NOUN
dpc-3688	597	18	-	-	PUNCT
dpc-3688	597	19	to	to	ADP
dpc-3688	597	20	-	-	PUNCT
dpc-3688	597	21	head	head	NOUN
dpc-3688	597	22	trials	trial	NOUN
dpc-3688	597	23	for	for	ADP
dpc-3688	597	24	complete	complete	ADJ
dpc-3688	597	25	resolution	resolution	NOUN
dpc-3688	597	26	of	of	ADP
dpc-3688	597	27	nail	nail	NOUN
dpc-3688	597	28	psoriasis	psoriasis	NOUN
dpc-3688	597	29	.	.	PUNCT
dpc-3688	598	1	clin	clin	PROPN
dpc-3688	598	2	exp	exp	NOUN
dpc-3688	598	3	dermatol	dermatol	NOUN
dpc-3688	598	4	.	.	PUNCT
dpc-3688	599	1	2023	2023	NUM
dpc-3688	599	2	:	:	PUNCT
dpc-3688	599	3	llad136	llad136	PROPN
dpc-3688	599	4	.	.	PUNCT
dpc-3688	599	5	doi	doi	PROPN
dpc-3688	599	6	:	:	PUNCT
dpc-3688	599	7	10.1093	10.1093	NUM
dpc-3688	599	8	/	/	SYM
dpc-3688	599	9	ced	ce	VERB
dpc-3688	599	10	/llad136	/llad136	X
dpc-3688	599	11	.	.	PUNCT
dpc-3688	600	1	pmid	pmid	NOUN
dpc-3688	600	2	:	:	PUNCT
dpc-3688	600	3	37052062	37052062	NUM
dpc-3688	600	4	.	.	PUNCT
dpc-3688	601	1	55	55	NUM
dpc-3688	601	2	.	.	PUNCT
dpc-3688	602	1	yukari	yukari	PROPN
dpc-3688	602	2	okubo	okubo	VERB
dpc-3688	602	3	y	y	PROPN
dpc-3688	602	4	et	et	PROPN
dpc-3688	602	5	al	al	PROPN
dpc-3688	602	6	.	.	PROPN
dpc-3688	602	7	efficacy	efficacy	NOUN
dpc-3688	602	8	and	and	CCONJ
dpc-3688	602	9	safety	safety	NOUN
dpc-3688	602	10	of	of	ADP
dpc-3688	602	11	brodalumab	brodalumab	NOUN
dpc-3688	602	12	,	,	PUNCT
dpc-3688	602	13	an	an	DET
dpc-3688	602	14	anti	anti	ADJ
dpc-3688	602	15	-	-	ADJ
dpc-3688	602	16	interleukin-17	interleukin-17	ADJ
dpc-3688	602	17	receptor	receptor	NOUN
dpc-3688	602	18	a	a	DET
dpc-3688	602	19	monoclonal	monoclonal	NOUN
dpc-3688	602	20	antibody	antibody	NOUN
dpc-3688	602	21	,	,	PUNCT
dpc-3688	602	22	in	in	ADP
dpc-3688	602	23	japanese	japanese	ADJ
dpc-3688	602	24	patients	patient	NOUN
dpc-3688	602	25	with	with	ADP
dpc-3688	602	26	palmoplantar	palmoplantar	NOUN
dpc-3688	602	27	pustulosis	pustulosis	NOUN
dpc-3688	602	28	:	:	PUNCT
dpc-3688	602	29	a	a	DET
dpc-3688	602	30	16	16	NUM
dpc-3688	602	31	week	week	NOUN
dpc-3688	602	32	results	result	NOUN
dpc-3688	602	33	of	of	ADP
dpc-3688	602	34	a	a	DET
dpc-3688	602	35	phase	phase	NOUN
dpc-3688	602	36	3	3	NUM
dpc-3688	602	37	,	,	PUNCT
dpc-3688	602	38	multicenter	multicenter	NOUN
dpc-3688	602	39	,	,	PUNCT
dpc-3688	602	40	randomized	randomize	VERB
dpc-3688	602	41	,	,	PUNCT
dpc-3688	602	42	double	double	ADJ
dpc-3688	602	43	-	-	PUNCT
dpc-3688	602	44	blind	blind	ADJ
dpc-3688	602	45	,	,	PUNCT
dpc-3688	602	46	placebo	placebo	NOUN
dpc-3688	602	47	controlled	control	VERB
dpc-3688	602	48	study	study	NOUN
dpc-3688	602	49	.	.	PUNCT
dpc-3688	603	1	abstract	abstract	ADJ
dpc-3688	603	2	85	85	NUM
dpc-3688	603	3	.	.	PUNCT
dpc-3688	604	1	eadv	eadv	ADJ
dpc-3688	604	2	2022	2022	NUM
dpc-3688	604	3	.	.	PUNCT
dpc-3688	605	1	56	56	NUM
dpc-3688	605	2	.	.	PUNCT
dpc-3688	606	1	yukari	yukari	PROPN
dpc-3688	606	2	okubo	okubo	VERB
dpc-3688	606	3	y	y	PROPN
dpc-3688	606	4	et	et	PROPN
dpc-3688	606	5	al	al	PROPN
dpc-3688	606	6	.	.	PROPN
dpc-3688	606	7	efficacy	efficacy	NOUN
dpc-3688	606	8	and	and	CCONJ
dpc-3688	606	9	safety	safety	NOUN
dpc-3688	606	10	of	of	ADP
dpc-3688	606	11	brodalumab	brodalumab	NOUN
dpc-3688	606	12	,	,	PUNCT
dpc-3688	606	13	an	an	DET
dpc-3688	606	14	anti	anti	ADJ
dpc-3688	606	15	-	-	ADJ
dpc-3688	606	16	interleukin-17	interleukin-17	ADJ
dpc-3688	606	17	receptor	receptor	NOUN
dpc-3688	606	18	a	a	DET
dpc-3688	606	19	monoclonal	monoclonal	NOUN
dpc-3688	606	20	antibody	antibody	NOUN
dpc-3688	606	21	,	,	PUNCT
dpc-3688	606	22	in	in	ADP
dpc-3688	606	23	japanese	japanese	ADJ
dpc-3688	606	24	patients	patient	NOUN
dpc-3688	606	25	with	with	ADP
dpc-3688	606	26	palmoplantar	palmoplantar	NOUN
dpc-3688	606	27	pustulosis	pustulosis	NOUN
dpc-3688	606	28	:	:	PUNCT
dpc-3688	606	29	a	a	DET
dpc-3688	606	30	16	16	NUM
dpc-3688	606	31	week	week	NOUN
dpc-3688	606	32	results	result	NOUN
dpc-3688	606	33	of	of	ADP
dpc-3688	606	34	a	a	DET
dpc-3688	606	35	phase	phase	NOUN
dpc-3688	606	36	3	3	NUM
dpc-3688	606	37	,	,	PUNCT
dpc-3688	606	38	multicenter	multicenter	NOUN
dpc-3688	606	39	,	,	PUNCT
dpc-3688	606	40	randomized	randomize	VERB
dpc-3688	606	41	,	,	PUNCT
dpc-3688	606	42	double	double	ADJ
dpc-3688	606	43	-	-	PUNCT
dpc-3688	606	44	blind	blind	ADJ
dpc-3688	606	45	,	,	PUNCT
dpc-3688	606	46	placebo	placebo	NOUN
dpc-3688	606	47	-	-	PUNCT
dpc-3688	606	48	controlled	control	VERB
dpc-3688	606	49	study	study	NOUN
dpc-3688	606	50	.	.	PUNCT
dpc-3688	607	1	abstract	abstract	ADJ
dpc-3688	607	2	85	85	NUM
dpc-3688	607	3	.	.	PUNCT
dpc-3688	608	1	eadv	eadv	ADJ
dpc-3688	608	2	2022	2022	NUM
dpc-3688	608	3	.	.	PUNCT
dpc-3688	609	1	[	[	X
dpc-3688	609	2	https://medfyle.com/	https://medfyle.com/	ADJ
dpc-3688	609	3	articles	article	NOUN
dpc-3688	609	4	/	/	SYM
dpc-3688	609	5	p11	p11	NOUN
dpc-3688	609	6	-	-	PUNCT
dpc-3688	609	7	brodalumab	brodalumab	NOUN
dpc-3688	609	8	-	-	PUNCT
dpc-3688	609	9	in	in	ADP
dpc-3688	609	10	-	-	PUNCT
dpc-3688	609	11	ppp	ppp	NOUN
dpc-3688	609	12	.	.	PUNCT
dpc-3688	609	13	accessed	access	VERB
dpc-3688	609	14	on	on	ADP
dpc-3688	609	15	28	28	NUM
dpc-3688	609	16	july	july	PROPN
dpc-3688	609	17	2023	2023	NUM
dpc-3688	609	18	]	]	PUNCT
dpc-3688	609	19	.	.	PUNCT